

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * Welcome to STN International * * * * *
```

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAY 01	New CAS web site launched
NEWS	3	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	7	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	8	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	9	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	10	JUN 29	STN Viewer now available
NEWS	11	JUN 29	STN Express, Version 8.2, now available
NEWS	12	JUL 02	LEMBASE coverage updated
NEWS	13	JUL 02	LMEDLINE coverage updated
NEWS	14	JUL 02	SCISEARCH enhanced with complete author names
NEWS	15	JUL 02	CHEMCATS accession numbers revised
NEWS	16	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	17	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	18	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	20	JUL 30	USGENE now available on STN
NEWS	21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	22	AUG 06	BEILSTEIN updated with new compounds
NEWS	23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	24	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	25	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	27	AUG 27	USPATOLD now available on STN
NEWS	28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:49:07 ON 05 SEP 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:49:20 ON 05 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2

DICTIONARY FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10540330\6.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11
ring/chain nodes :
13
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact bonds :
1-2 1-5 2-3 3-4 4-5
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 :

G1:Cb,Ak


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 13:CLASS 15:CLASS 16:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 11:49:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58873 TO ITERATE

3.4% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **COMPLETE**
 PROJECTED ITERATIONS: 1162995 TO 1191925
 PROJECTED ANSWERS: 74549 TO 82053

L2 50 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10540330\7.str



chain nodes :

12 13 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19

chain bonds :

12-13 13-14

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 14-15 14-19 15-16
 16-17 17-18 18-19

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 12-13 13-14

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 14-15 14-19 15-16 16-17 17-18 18-19


G1:Cb,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:CLASS 21:Atom 23:Atom

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



G1 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 13
SAMPLE SEARCH INITIATED 11:51:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 36831 TO ITERATE

5.4% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 725152 TO 748088
PROJECTED ANSWERS: 16945 TO 20621

L4 50 SEA SSS SAM L3


=> d scan

L4 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2,5-Cyclohexadien-1-one, 4-[[4-(acetyloxy)-3,5-bis(1,1-dimethylethyl)phenyl][4-(3-thienyl)phenyl]methylene]-2,6-bis(1,1-dimethylethyl)-, polymer with 3-hexylthiophene (9CI)
 MF (C41 H50 O3 S . C10 H16 S)x
 CI PMS

CM 1




CM 2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Thieno[2,3-b]pyridine-3-methanaminium, 5-(ethoxycarbonyl)-4,7-dihydro-2-(4-methoxyphenyl)-7-[(2-methoxyphenyl)methyl]-N,N-dimethyl-4-oxo-N-(phenylmethyl)- (9CI)
 MF C35 H37 N2 O5 S
 CI CCM



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L4 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 3-Thiophenecarboxylic acid, 2-[[3-[2-[(4-bromophenyl)methoxy]-3-methoxyphenyl]-2-cyano-1-oxo-2-propen-1-yl]amino]-4-phenyl-, methyl ester
 MF C30 H23 Br N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 3-Thiophenecarboxylic acid, 2-[[3-[2-[(4-bromo-2-[(2,4-dichlorophenyl)methoxy]phenyl]-2-cyano-1-oxo-2-propen-1-yl]amino]-4-phenyl-, ethyl ester
 MF C30 H21 Br Cl2 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 11:49:07 ON 05 SEP 2007)

FILE 'REGISTRY' ENTERED AT 11:49:20 ON 05 SEP 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3

=> s 13 full

FULL SEARCH INITIATED 11:52:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 741628 TO ITERATE


100.0% PROCESSED 741628 ITERATIONS
SEARCH TIME: 00.00.08

21110 ANSWERS

L5 21110 SEA SSS FUL L3

=>

Uploading C:\Program Files\Stnexp\Queries\10540330\8.str



chain nodes :

12 19 24

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18

chain bonds :

12-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15

15-16 16-17 17-18

exact/norm bonds :

12-13

exact bonds :

1-2 1-5 2-3 3-4 4-5

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 :

G1:Cb,Ak


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:Atom 22:Atom 24:CLASS 25:Atom

L6 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10540330\9.str



chain nodes :

12 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18

ring/chain nodes :

24

chain bonds :

12-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15

15-16 16-17 17-18

exact/norm bonds :

12-13

exact bonds :

1-2 1-5 2-3 3-4 4-5

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 :

G1:Cb,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:Atom 22:Atom 24:CLASS 25:Atom

L7 STRUCTURE UPLOADED

=> d

L7 HAS NO ANSWERS

L7 STR



G1 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 17 full sub=L5

FULL SUBSET SEARCH INITIATED 11:53:36 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 17105 TO ITERATE

100.0% PROCESSED 17105 ITERATIONS

12969 ANSWERS

SEARCH TIME: 00.00.01

L8 12969 SEA SUB=L5 SSS FUL L7

=>

Uploading C:\Program Files\Stnexp\Queries\10540330\10.str



chain nodes :

12 19 26

ring nodes :

```

1  2  3  4  5  6  7  8  9  10  11  13  14  15  16  17  18
ring/chain nodes :
24
chain bonds :
12-13  12-26
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-7  6-11  7-8  8-9  9-10  10-11  13-14  13-18  14-15
15-16  16-17  17-18
exact/norm bonds :
12-13  12-26
exact bonds :
1-2  1-5  2-3  3-4  4-5
normalized bonds :
6-7  6-11  7-8  8-9  9-10  10-11  13-14  13-18  14-15  15-16  16-17  17-18
isolated ring systems :
containing 1 : 6 : 13 :
```

G1:Cb,Ak

Match level :


```

1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:Atom 22:Atom 24:CLASS 25:Atom 26:CLASS
```

L9 STRUCTURE UPLOADED

```

=> d
L9 HAS NO ANSWERS
L9 STR
```



G1 Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

```

=> s 19 full sub=L8
FULL SUBSET SEARCH INITIATED 11:55:28 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 12969 TO ITERATE
```

10/540,330

04/08/2008


100.0% PROCESSED 12969 ITERATIONS
SEARCH TIME: 00.00.01

12463 ANSWERS

L10 12463 SEA SUB=L8 SSS FUL L9

=> d scan

L10 12463 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Thiophenecarboxylic acid, 5-methyl-2-[[2-(2-methyl-4-
nitrophenoxy)acetyl]amino]-4-phenyl-, ethyl ester
MF C23 H22 N2 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10540330\12.str



```

chain nodes :
12 19 23 27 28 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18
ring/chain nodes :
24
chain bonds :
2-27 3-28 4-30 5-7 12-13 12-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
2-27 3-28 4-30 12-13 12-23
exact bonds :
1-2 1-5 2-3 3-4 4-5 5-7
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 6 : 13 :

```

G1:Cb,Ak

G2:H, [*1]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:Atom 23:CLASS 24:CLASS 27:CLASS 28:CLASS 30:CLASS

```

L11 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10540330\11.str



```

chain nodes :
12 19 23 27 28 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18
ring/chain nodes :
24
chain bonds :
2-27 3-28 4-8 5-30 12-13 12-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
2-27 3-28 5-30 12-13 12-23
exact bonds :
1-2 1-5 2-3 3-4 4-5 4-8
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 6 : 13 :
```

G1:Cb,Ak

G2:H, [*1]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:Atom 23:CLASS 24:CLASS 27:CLASS 28:CLASS 30:CLASS


L12 STRUCTURE UPLOADED

=> d

L12 HAS NO ANSWERS

L12 STR

1



G1 Cb,Ak

G2 H, [@1]


Structure attributes must be viewed using STN Express query preparation.

=> d l11

L11 HAS NO ANSWERS

L11 STR

1



G1 Cb,Ak

G2 H, [01]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l11 full sub=L10
FULL SUBSET SEARCH INITIATED 12:00:09 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      2559 TO ITERATE

100.0% PROCESSED      2559 ITERATIONS          937 ANSWERS
SEARCH TIME: 00.00.01

L13      937 SEA SUB=L10 SSS FUL L11

=> s l12 full sub=L10
FULL SUBSET SEARCH INITIATED 12:00:18 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    10195 TO ITERATE


100.0% PROCESSED    10195 ITERATIONS          428 ANSWERS
SEARCH TIME: 00.00.01

L14      428 SEA SUB=L10 SSS FUL L12

=> d scan
```

L14 428 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-(4-phenyl-5-propyl-2-thienyl)-
 MF C27 H32 O4 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L14 428 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Acetamide, N-(2-ethoxyphenyl)-2-[[5-(5-methyl-4-phenyl-3-thienyl)-4-(2-propen-1-yl)-4H-1,2,4-triazol-3-yl]thio]-
 MF C26 H26 N4 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L14 428 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 3-Thiophenecarboxylic acid, 5-methyl-4-(4-methylphenyl)-,
 2-[[4-(4-ethoxyphenyl)amino]thioxomethyl]hydrazide
 MF C22 H23 N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 11:49:07 ON 05 SEP 2007)

FILE 'REGISTRY' ENTERED AT 11:49:20 ON 05 SEP 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3
L5 21110 S L3 FULL
L6 STRUCTURE UPLOADED
L7 STRUCTURE UPLOADED
L8 12969 S L7 FULL SUB=L5
L9 STRUCTURE UPLOADED
L10 12463 S L9 FULL SUB=L8
L11 STRUCTURE UPLOADED
L12 STRUCTURE UPLOADED
L13 937 S L11 FULL SUB=L10
L14 428 S L12 FULL SUB=L10

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	343.70	343.91

FILE 'CAPLUS' ENTERED AT 12:01:42 ON 05 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2007 VOL 147 ISS 11

FILE LAST UPDATED: 4 Sep 2007 (20070904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l13

L15 246 L13

=> s l14

L16 88 L14

=> s l15 or l16
L17 262 L15 OR L16

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.17	349.08

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:08:18 ON 05 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 13:28:30 ON 05 SEP 2007
FILE 'CAPLUS' ENTERED AT 13:28:30 ON 05 SEP 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.17	349.08

=> d his

(FILE 'HOME' ENTERED AT 11:49:07 ON 05 SEP 2007)

FILE 'REGISTRY' ENTERED AT 11:49:20 ON 05 SEP 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3
L5 21110 S L3 FULL
L6 STRUCTURE UPLOADED
L7 STRUCTURE UPLOADED
L8 12969 S L7 FULL SUB=L5
L9 STRUCTURE UPLOADED
L10 12463 S L9 FULL SUB=L8
L11 STRUCTURE UPLOADED
L12 STRUCTURE UPLOADED
L13 937 S L11 FULL SUB=L10
L14 428 S L12 FULL SUB=L10

FILE 'CAPLUS' ENTERED AT 12:01:42 ON 05 SEP 2007

L15 246 S L13
L16 88 S L14

L17 262 S L15 OR L16

=> s l17 and ppar
 9692 PPAR

L18 12 L17 AND PPAR

=> d ibib abs hitstr 1-12

L18 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:705845 CAPLUS
DOCUMENT NUMBER: 147:118032
TITLE: Preparation of cyclic alkenyl compounds as PPAR.delta. activators for treating various disease including diabetes and obesity
INVENTOR(S): Sauerberg, Per; Pihera, Pavel; Polivka, Zdenek; Havranek, Miroslav; Pettersson, Ingrid; Mogensen, John
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 216pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007071766	A2	2007-01-28	WO 2006-EP70096	20061221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HA, HE, HK, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IL, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: EP 2005-112758 A 20051222
EP 2006-115631 A 20060619

OTHER SOURCE(S): MARPAT 147:118032
SI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Novel compds. of the general formula I (wherein the "large X" is a double bond, X1 is heterocyclyl, aryl, heteroaryl, etc.; X2 is (un)substituted arylene or heteroarylene; X3 is (un)substituted aryl or heteroaryl; Ar is (un)substituted arylene; Y1 is O or S; and Y2 is O, S or CH2; and Z is -(CH2)n- wherein n = 1-3; and R1 = H, halo, etc.) the use of these compds. as pharmaceuticals, pharmaceutical compns. comprising the compds. and methods of treatment employing these compds. and compns. are claimed. The present compds. are activators of PPAR.delta. and should be

L18 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 942595-11-1P 942595-12-2P, Methyl (E)-[2-methyl-4-[[3-[4-(5-methylthiophen-2-yl)phenyl]-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]phenoxy]acetate 942595-27-9P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl, heteroaryl, and heterocyclic compds. as PPAR delta activators for treating various disease including diabetes and obesity)
RN 942595-11-1 CAPLUS
CN Acetic acid,
2-[4-[[[(2E)-3-(4-iodophenyl)-3-[4-(5-methyl-2-thienyl)phenyl]-2-propen-1-yl]oxy]-2-methylphenoxy]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 942595-12-2 CAPLUS
CN Acetic acid,
2-[2-methyl-4-[[[(2E)-3-[4-(5-methyl-2-thienyl)phenyl]-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.

L18 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
useful for treating conditions mediated by the same, such as diabetes, impaired glucose tolerance, insulin resistance, cardiovascular disease, etc.; no biol. data is given in the patent. Example compd. II was prepd. by reacting Me
(Z)-[4-[3-(4-iodophenyl)-3-(4-trifluoromethylphenyl)allyloxy]phenyl]-2-methylphenoxy]acetate with 2-ethynylpyridine and converting the ester
obtained to the acid.
IT 942595-09-7P 942595-26-8P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl, heteroaryl, and heterocyclic compds. as PPAR.delta. activators for treating various disease including diabetes and obesity)
RN 942595-09-7 CAPLUS
CN Acetic acid,
2-[2-methyl-4-[[[(2E)-3-[4-(5-methyl-2-thienyl)phenyl]-3-[4-[3-(4-morpholinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.



RN 942595-26-8 CAPLUS
CN Acetic acid,
2-[2-methyl-4-[[[(2E)-3-[4-(5-methyl-2-thienyl)phenyl]-3-[4-[3-(1-pyrrolidinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]- (CA INDEX NAME)


Double bond geometry as shown.

L18 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 942595-27-9 CAPLUS
CN Acetic acid,
2-[2-methyl-4-[[[(2E)-3-[4-(5-methyl-2-thienyl)phenyl]-3-[4-[3-(1-pyrrolidinyl)-1-propyn-1-yl]phenyl]-2-propen-1-yl]oxy]phenoxy]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.




L18 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1272380 CAPLUS
 DOCUMENT NUMBER: 146:100309
 TITLE: Insights into the mechanism of the site-selective sequential palladium-catalyzed cross-coupling reactions of dibromothiophenes/dibromothiazoles and arylboronic acids. Synthesis of PPAR β/δ agonists
 AUTHOR(S): Pereira, Raquel; Furst, Audrey; Iglesias, Beatriz; Germain, Pierre; Gronemeyer, Heinrich; de Lera, Angel R.
 CORPORATE SOURCE: Departamento de Quimica Organica, Universidade de Vigo, Vigo, 36310, Spain
 SOURCE: Organic & Biomolecular Chemistry (2006), 4(24), 4514-4525
 CODEN: OBCRAK; ISSN: 1477-0520
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:100309
 AB A reactivity study, aided by NMR spectroscopy, allowed a mechanistic rationale to be postulated for the palladium-catalyzed regioselective coupling of arylboronic acid and arylstannane where feasible) at the position next to the sulfur atom in functionalized dibromothiophenes and dibromothiazoles. The anal. of the NMR spectra (using 19F from the boronic acid CF3 group and 31P from the phosphine of the catalyst as probes) of the entire reaction starting from the dibromoheterocycles allowed the qual. proposal that the transmetalation is the rate-limiting step for both sequential substitution processes. The extremely facile oxidative addition at the C-Br bond next to the sulfur atom of the heterocycle instead det. the positional selectivity. An addnl. Still reaction then replaced the second halogen, providing the trisubstituted heterocyclic scaffolds of PPAR ligands, which displayed PPAR. β agonist activity, as revealed by reporter assays in living cells.
 IT 918164-59-7 P 918164-60-OP 918164-61-1P
 918164-62-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reagent or reagent)
 hydrolysis; mechanism of the site-selective sequential Pd-catalyzed cross-coupling reactions of dibromothiophenes/dibromothiazoles and arylboronic acids and synthesis of PPAR. β agonists)
 RN 918164-59-7 CAPLUS
 Acetic acid, 2-[2-methyl-4-[[[4-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]-, methyl ester (CA INDEX NAME)


L18 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 918164-60-0 CAPLUS
 CN Acetic acid, 2-[2-methyl-4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]-, methyl ester (CA INDEX NAME)




RN 918164-61-1 CAPLUS
 CN Acetic acid, 2-[4-[[[4-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]-, methyl ester (CA INDEX NAME)




RN 918164-62-2 CAPLUS
 CN Acetic acid, 2-[4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]-, methyl ester (CA INDEX NAME)


L18 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 476154-13-9P 918164-63-3P 918164-64-4P
 918164-65-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target PPAR. β agonist; mechanism of the site-selective sequential Pd-catalyzed cross-coupling reactions of dibromothiophenes/dibromothiazoles and arylboronic acids and synthesis of PPAR. β agonists)
 RN 476154-13-9 CAPLUS
 CN Acetic acid, 2-[2-methyl-4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (CA INDEX NAME)




RN 918164-63-3 CAPLUS
 CN Acetic acid, 2-[2-methyl-4-[[[4-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (CA INDEX NAME)




RN 918164-64-4 CAPLUS
 CN Acetic acid, 2-[4-[[[4-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (CA INDEX NAME)

L18 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 918164-65-5 CAPLUS
 CN Acetic acid, 2-[4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 110 THERE ARE 110 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L18 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:494373 CAPLUS
 DOCUMENT NUMBER: 145:8033
 TITLE: Biaryl compounds as selective modulators of PPAR.gamma., their preparation, pharmaceutical and cosmetic compositions, and use in therapy
 INVENTOR(S): Boiteau, Jean-Guy; Clary, Laurence; Millois Barbuiss, Corinne
 PATENT ASSIGNEE(S): Galderma Research & Development, S.N.C., Fr.
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006053791	A2	20060526	WO 2005-EP13533	20051117
WO 2006053791	A3	20060628		

W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

FR 2878247 A1 20060526 FR 2004-12326 20041119
 AU 2005305969 A1 20060526 AU 2005-305969 20051117
 CA 2587545 A1 20060526 CA 2005-2587545 20051117
 EP 1814871 A2 20070808 EP 2005-817959 20051117

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPL. INFO.: FR 2004-12326 A 20041119
 US 2004-631989P P 20041201
 WO 2005-EP13533 W 20051117

OTHER SOURCE(S): MARPAT 145:8033
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to biaryl compds. of general formula I (Ar1-Ar2), which are modulators of peroxisome proliferator-activated receptor subtype


L18 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 y (PPAR.gamma.). In compds. I, Ar1 and Ar2 are independently selected from Ph, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, isothiazolyl, thiazolyl, thiadiazolyl, furanyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, and triazolyl, where Ar2 is substituted with a 3-oxopropyl or 3-oxopropenyl moiety. The invention also relates to the prepn. of I, pharmaceutical or cosmetic compns. comprising, in a physiol. acceptable support, at least one compd. of formula I, as well as to the use of the compns. in human or veterinary medicine, or in cosmetic compns. Me 3-hydroxy-4-iodobenzoate was alkylated with 1-iodobutane, reduced with LiBH4, and oxidized with MnO2 giving 3-butoxy-4-iodobenzaldehyde, which underwent Wittig olefination with Me (triphenylphosphoranylidene)acetate, resulting in the formation of acrylate II. Reductive amination of 4-bromothiophene-2-carboxaldehyde with methylamine followed by N-protection and borination with pinacol diborane gave boronate III, which underwent Suzuki coupling with acrylate II, hydrogenation, deprotection, acylation with octanoyl chloride, and ester hydrolysis to give compd. IV. Several compds. of the invention are selective modulators of PPAR.gamma., e.g., compd. IV expresses Kd app value of 2 nM to PPAR.gamma., but is not active towards either PPAR.alpha. or PPAR.delta..

IT 887832-03-3P, 3-[5-[3-[N'-(4-Butoxyphenyl)-N-ethylureido]phenyl]thien-2-yl]propanoic acid 887921-69-9P, 3-[3-Butoxy-4-[5-[N-(4-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]propanoic acid 887921-71-3P, 3-[3-Butoxy-4-[5-[N-(3-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]propanoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of biaryl compds. as PPAR.gamma. modulators)

RN 887832-03-3 CAPLUS
 CN 2-Thiophenepropanoic acid,
 5-[3-[[[(4-butoxyphenyl)amino]carbonyl]ethylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 887921-69-9 CAPLUS
 CN Benzenepropanoic acid,
 3-butoxy-4-[5-[N-(4-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 887921-71-3 CAPLUS
 CN Benzenepropanoic acid,
 3-butoxy-4-[5-[N-(4-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 887921-70-2P, Methyl 3-[3-butoxy-4-[5-[N-(4-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]propionate 887921-72-4P, Methyl 3-[3-butoxy-4-[5-[N-(3-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]propionate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of biaryl compds. as PPAR.gamma. modulators)

RN 887921-70-2 CAPLUS
 CN Benzenepropanoic acid,
 3-butoxy-4-[5-[N-(4-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 887921-72-4 CAPLUS
 CN Benzenepropanoic acid,
 3-butoxy-4-[5-[N-(4-methoxybenzoyl)-N-methylamino]methyl]thien-3-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:493925 CAPLUS
 DOCUMENT NUMBER: 145:8180
 TITLE: Preparation of substituted hetero/aryl propanoic acid derivatives, as PPAR.gamma. activators, and their use in cosmetic and pharmaceutical compositions
 INVENTOR(S): Boiteau, Jean Guy; Clary, Laurence; Barbuis, Corinne
 PATENT ASSIGNEE(S): Galderma Research & Development, Fr.
 SOURCE: Fr. Demande, 55 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2878247	A1	20060526	FR 2005-12326	20041119
AU 2005305969	A1	20060526	AU 2005-305969	20051117
CA 2587545	A1	20060526	CA 2005-2587545	20051117
WO 2006053791	A2	20060526	WO 2005-EP13533	20051117
WO 2006053791	A3	20060629		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1814871 A2 20070808 EP 2005-817959 20051117

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR



PRIORITY APPLN. INFO.: FR 2004-12326 A 20041119

US 2004-631989P P 20041201

WO 2005-EP13533 W 20051117

OTHER SOURCE(S): MARPAT 145:8180
 GI

L18 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I [R1 = CH2CH2COR5; CH:CH-COR5; R5 = OH, alkoxy, aryloxy, etc.; R2 = (CH2)m-NR6-CQ-(NH)nR7; R6 = H, alkyl; R7 = alkyl, hetero/aryl, aralkyl, heterocyclyl; m, n = 0-1; Q = O, S; R3, R4 = independently H, halo, alkyl, etc.; A, B = independently (un)substituted Ph, pyridinyl, pyrimidinyl, thiazolyl, etc.; when one of A or B is aryl, then the other one is heteroaryl; and their optical and geometrical isomers] were prepared as PPAR activators for pharmaceutical or cosmetic uses. E.g., a multi-step synthesis starting from 2-amino-6-bromopyridine, was given for acid II. In a crossover-curve PPAR transactivation test, II displayed specific affinity for PPAR.gamma. (Kd = 250 nM) compared to PPAR.alpha. and PPAR.delta.. For example, a tablet formulation contains 3-[5-[3-[(Methyloctanoylamino)methyl]phenyl]thiophen-2-yl]acrylic acid 0.001, starch 0.114, dicalcium phosphate 0.020, silica 0.020, lactose 0.030, talc 0.010, and Mg stearate 0.005 g. I are useful in dermatol. and in the field of cardiovascular and immune diseases, and/or lipid metabolism-related diseases.

IT 887832-03-3P, 3-[5-[3-[(4-Butoxyphenyl)-1-ethylureido]phenyl]thiophen-2-yl]propanoic acid
 RI: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of substituted hetero/aryl propanoic acid derivs. as PPAR activators for pharmaceuticals and cosmetics)

RN 887832-03-3 CAPLUS

L18 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2-Thiophenepropanoic acid,
 5-[3-[[[(4-butoxyphenyl)amino]carbonyl]ethylami
 no]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:878382 CAPLUS
 DOCUMENT NUMBER: 141:350161
 TITLE: Preparation of azole compounds as PTP1B inhibitors
 INVENTOR(S): Ikemoto, Tomoyuki; Tanaka, Masahiro; Yuno, Takeo; Sakamoto, Johei; Nakanishi, Hiroyuki; Nakaqawa, Yuichi; Ohta, Takeshi; Sakata, Shohei; Morinaga, Hisayo
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
 SOURCE: PCT Int. Appl., 542 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089918	A1	20041021	WO 2004-085119	20040409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004228565 A1 20041021 AU 2004-228565 20040409

CA 2521830 20041021 CA 2004-2521830 20040409

EP 1553091 A1 20050713 EP 2004-726765 20040409

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, SK, SL, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

HR

BR 200400913 A 20060425 BR 2004-9136 20040409

CN 1780823 A 20060531 CN 2004-80009487 20040409

JP 3819405 B2 20060906 JP 2005-505323 20040409

JP 2005272476 A 20051006 JP 2005-133755 20050428

US 2006122181 A1 20060608 US 2005-176846 20050707

WO 2005005246 A 20051221 WO 2005-5246 20051108

WO 2005CN02927 A 20070608 IN 2005-CN2927 20051109

PRIORITY APPLN. INFO.: JP 2003-105267 A 20030409



JP 2003-157590 A 20030603

JP 2005-505323 A3 20040409

WO 2004-JP5119 W 20040409

OTHER SOURCE(S): MARPAT 141:350161
 GI


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I [V = N, CH; W = S, O; m = 0-2; R1, R2 = H, alkyl; X = NR4, etc.; R4 = H, alkyl; n = 0-4; p = 0, 1; L = CR2OR21, etc.; R20 = H, alkyl, etc.; R21 = H, alkyl, etc.; R = CO2R19, etc.; R19 = H, alkyl; B = aryl, heteroaryl; R3 = H, halo, etc.; Y = O, etc.; s = 0, 1; A = (un)substituted alkylene with cycloalkyl; Z = cycloalkyl, etc.] were prepared For example, O-alkylation of 5-hydroxynicotinic acid Me ester with compound II [Q = Cl], e.g., prepared from 4-bromoacetylbenzoic acid in 5 steps, followed by saponification afforded compound II [3-carboxypyridin-5-yloxy] in 44.1% overall yield. In PTP1B (protein tyrosine phosphatase 1B) inhibition assays, the IC50 value of compound II [Q = 3-carboxypyridin-5-yloxy] was 0.28 μ M. Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations are given. IT 776310-98-6P 776310-99-7P 776311-39-8P 776311-40-1P 776311-81-0P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of azole compds. as PTP1B inhibitors for treatment of obesity

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 776310-98-6 CAPLUS
CN Glycine, N-[(1-methyl-1H-benzimidazol-2-yl)methyl]-N-[[5-[4-[(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776310-99-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)




RN 776311-39-8 CAPLUS
CN Glycine, N-[(1-methyl-1H-benzimidazol-2-yl)methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1
CRN 776310-98-6
CMF C36 H41 N3 O3 S

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2
CRN 104-15-4
CMF C7 H8 O3 S



RN 776311-40-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 776310-99-7
CMF C31 H33 N O4 S




L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2
CRN 7664-93-9
CMF H2 O4 S




RN 776311-81-0 CAPLUS
CN Glycine, N-[(1-methyl-1H-benzimidazol-2-yl)methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 776311-02-5P 776311-05-8P 776311-06-9P
776311-07-0P 776311-08-1P 776311-09-2P
776311-12-7P 776311-14-9P 776311-15-0P
776311-22-9P 776311-25-2P 776311-26-3P
776311-28-5P 776311-29-6P 776311-30-9P
776311-34-3P 776311-36-5P 776311-37-6P
776311-38-7P 776311-41-2P 776311-42-3P
776311-43-4P 776311-44-5P 776311-45-6P
776311-46-7P 776311-47-8P 776311-48-9P
776311-49-0P 776311-50-3P 776311-51-4P
776311-52-5P 776311-53-6P 776311-54-7P
776311-55-8P 776311-56-9P 776311-57-0P
776311-58-1P 776311-62-7P 776311-67-2P
776311-68-3P 776311-69-4P 776311-70-7P
776311-71-8P 776311-73-0P 776311-74-1P
776311-75-2P 776311-76-3P 776311-79-6P
776311-80-9P 776311-84-3P 776311-85-4P
776311-86-5P 776311-87-6P 776311-88-7P
776311-89-8P 776311-90-1P 776311-91-2P
776311-92-3P 776311-93-4P 776311-94-5P
776311-95-6P 776311-96-7P 776311-97-8P
776311-98-9P 776311-99-0P 776312-01-7P
776312-03-9P 776312-04-0P 776312-05-1P
776312-62-0P 776312-63-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of azole compds. as PTP1B inhibitors for treatment of obesity

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 776311-02-5 CAPLUS
 CN 3-Pyridinecarboxylic acid,
 5-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)



RN 776311-05-8 CAPLUS
 CN Glycine, N-(1H-benzimidazol-2-ylmethyl)-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-06-9 CAPLUS
 CN 2-Pyridinecarboxylic acid,
 6-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B

—CH(Pr-n)₂

RN 776311-09-2 CAPLUS
 CN Glycine, N-[2-oxo-2-(phenylamino)ethyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-12-7 CAPLUS
 CN Glycine, N-[[5-(1,1-dimethylethyl)-2-thiazolyl]methyl]-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-14-9 CAPLUS
 CN Glycine, N-[[4-(1,1-dimethylethyl)-2-thiazolyl]methyl]-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 776311-07-0 CAPLUS
 CN Glycine, N-(1H-benzimidazol-2-ylmethyl)-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-08-1 CAPLUS
 CN Glycine,
 N-[2-[[4-(1-methylethyl)phenyl]amino]-2-oxoethyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-15-0 CAPLUS
 CN Glycine, N-[2-oxo-2-(phenylamino)ethyl]-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-22-9 CAPLUS
 CN Glycine, N-[[4,5-dimethyl-2-thiazolyl]methyl]-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-25-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-[[5-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 776311-26-3 CAPLUS
 CN Glycine,
 N-[[4-(1-methylethyl)phenyl]amino]-2-oxoethyl]-N-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 776311-30-9 CAPLUS
 CN 2-Pyridinecarboxylic acid,
 6-[[5-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)




RN 776311-34-3 CAPLUS
 CN Glycine, N-[[4-(1,1-dimethylethyl)-2-thiazolyl]methyl]-N-[[5-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-36-5 CAPLUS
 CN Glycine, N-[[5-(1,1-dimethylethyl)-2-thiazolyl]methyl]-N-[[5-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-28-5 CAPLUS
 CN Glycine, N-[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]-N-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-29-6 CAPLUS
 CN Glycine, N-[[1-methyl-1H-benzimidazol-2-yl]methyl]-N-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-37-6 CAPLUS
 CN Glycine, N-[[5-[[4-[[4-(1-ethylpropyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-N-[[1-methyl-1H-benzimidazol-2-yl]methyl]-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 776311-38-7 CAPLUS
 CN Glycine, N-[[5-[[4-[[4-(1-ethylpropyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-N-[[1-methyl-1H-benzimidazol-2-yl]methyl]-, calcium salt (9CI) (CA INDEX NAME)




● 1/2 Ca

RN 776311-41-2 CAPLUS
 CN Glycine, N-[[4-(1-methylethyl)phenyl]methyl]-N-[[5-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 776311-42-3 CAPLUS
 CN Glycine, N-[[[4-(dimethylamino)phenyl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 776311-43-4 CAPLUS
 CN Glycine, N-[[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 776311-44-5 CAPLUS
 CN Glycine, N-[[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 776311-45-6 CAPLUS
 CN 3-Pyridinecarboxylic acid, 5-[[[4-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 776310-99-7
 CMP C31 H33 N O4 S

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 3-Pyridinecarboxylic acid, 5-[[[4-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]-, sodium salt (9CI) (CA INDEX NAME)




RN 776311-48-9 CAPLUS
 CN 3-Pyridinecarboxylic acid, 5-[[[4-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 776311-49-0 CAPLUS

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 75-75-2
 CMP C H4 O3 S




RN 776311-46-7 CAPLUS
 CN Glycine, N-(methanesulfonyl)-N-[[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-47-8 CAPLUS

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN Benzoic acid, 4-[[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]carbonyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 776311-50-3 CAPLUS
 CN Benzoic acid, 4-[[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]carbonyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 776311-51-4 CAPLUS
 CN Glycine, N-[(1-methyl-1H-benzimidazol-2-yl)methyl]-N-[[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 776311-52-5 CAPLUS
 CN Glycine, N-[(1-methyl-1H-benzimidazol-2-yl)methyl]-N-[[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 776311-29-6

CMP C36 H41 N3 O3 S



CM 2

CRN 7664-93-9


CMP H2 O4 S



RN 776311-53-6 CAPLUS


CN Benzoic acid, 4-[[[(dimethylamino)acetyl]amino]-3-[[4-[4-[(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 776311-54-7 CAPLUS


CN Benzoic acid, 4-[(2-methyl-1-oxopropyl)amino]-3-[[4-[4-[(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 776311-55-8 CAPLUS

CN Benzoic acid, 4-[[4-[4-[(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)




RN 776311-56-9 CAPLUS

CN Benzoic acid, 4-[methyl(methylsulfonyl)amino]-3-[[4-[4-[(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 776311-57-0 CAPLUS

CN Benzoic acid, 4-[[4-[4-[(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methylthio]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-58-1 CAPLUS
 CN Benzoic acid,
 4-amino-3-[[4-[[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-
 thienyl]methoxy]- (9CI) (CA INDEX NAME)




RN 776311-62-7 CAPLUS
 CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[[[4-(1-

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-67-2 CAPLUS
 CN Glycine, N-[[4-([4-([4-(1-methylethyl)phenoxy]acetyl)-N-[[4-[[[4-(1-
 propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX
 NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-68-3 CAPLUS
 CN Glycine, N-[(1-methylethyl)benzoyl]-N-[[4-[[[4-(1-
 propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX
 NAME)




RN 776311-69-4 CAPLUS
 CN Glycine,
 N-(3-methylbutyl)-N-[[4-[[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-70-7 CAPLUS
 CN Glycine, N-[(methylphenylamino)carbonyl]-N-[[4-[[[4-(1-
 propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX
 NAME)




RN 776311-71-8 CAPLUS
 CN 7-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-[[4-[[[4-(1-
 propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX
 NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 776311-73-0 CAPLUS
 CN Glycine, N-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-74-1 CAPLUS
 CN Benzoic acid, 3-[[{(carboxymethyl)[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 776311-75-2 CAPLUS
 CN Glycine, N-[[4-methoxyphenyl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 776311-76-3 CAPLUS
 CN Glycine, N-[[4-(methylthio)phenyl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-79-6 CAPLUS
 CN Glycine, N-(diphenylmethyl)-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-80-9 CAPLUS
 CN Glycine, N-[2-oxo-2-[4-(1-pyrrolidinyl)phenyl]ethyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




● HCl

RN 776311-84-3 CAPLUS
 CN Glycine, N-[[1-methyl-1H-indol-3-yl]methyl]-N-[[4-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-85-4 CAPLUS
 CN Glycine, N-[[4-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]-N-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 776311-86-5 CAPLUS
 CN Glycine, N-(2-benzothiazolylmethyl)-N-[[4-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-87-6 CAPLUS
 CN Glycine, N-[[1-(phenylmethyl)-1H-imidazol-2-yl]methyl]-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 776311-88-7 CAPLUS
 CN Glycine, N-(1H-indol-5-ylmethyl)-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 776311-89-8 CAPLUS
 CN Glycine, N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A





RN 776311-90-1 CAPLUS
 CN Glycine, N-(2-benzoxazolylmethyl)-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-91-2 CAPLUS
 CN Glycine, N-((2,2'-bithiophen)-5-ylmethyl)-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 2-A




RN 776311-92-3 CAPLUS
 CN Glycine, N-((2-phenyl-1H-imidazol-4-yl)methyl)-N-[[4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-93-4 CAPLUS
 CN Glycine, N-[(3-phenyl-1H-pyrazol-4-yl)methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 776311-94-5 CAPLUS
 CN Glycine, N-(2-benzoxazolylmethyl)-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-95-6 CAPLUS
 CN Glycine, N-(benzo[b]thien-2-ylmethyl)-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-96-7 CAPLUS
 CN Glycine, N-[(4-phenyl-2-thienyl)methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776312-03-9 CAPLUS
 CN Glycine, N-[[4-[4-[(3,5-dichlorophenoxy)methyl]phenyl]-2-thienyl]methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 776312-04-0 CAPLUS
 CN Glycine, N-[[1-(2-propenyl)-1H-benzimidazol-2-yl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776311-97-8 CAPLUS
 CN Glycine, N-2-benzothiazolyl-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)



RN 776311-98-9 CAPLUS
 CN Glycine, N-[(5-chloro-2-thienyl)sulfonyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776311-99-0 CAPLUS
 CN Glycine, N-[[1-[2-(diethylamino)-2-oxoethyl]-1H-benzimidazol-2-yl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776312-01-7 CAPLUS
 CN Glycine, N-[[4-[4-[[4-(4-butoxyphenyl)sulfonyl]ethylamino]phenyl]-2-thienyl]methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 776312-05-1 CAPLUS
 CN Glycine, N-[[4-(4-chlorophenyl)-2-thiazolyl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 776312-62-0 CAPLUS
 CN Glycine, N-[(1-methyl-1H-benzimidazol-2-yl)methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 776312-63-1 CAPLUS
 CN Glycine, N-[[5-(1,1-dimethylethyl)-2-thiazolyl]methyl]-N-[[5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]carbonyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 776312-26-6P 776312-27-7P 776312-28-8P
 776312-29-9P 776312-33-5P 776312-34-6P
 776312-35-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of azole compds. as FTP1B inhibitors for treatment of
 obesity
 and diabetes)
 RN 776312-26-6 CAPLUS
 CN 2-Thiophenecarboxaldehyde,
 4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 776312-27-7 CAPLUS
 CN 2-Thiophenemethanol, 4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-
 (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 776312-28-8 CAPLUS
 CN Thiophene,
 2-(chloromethyl)-4-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 776312-29-9 CAPLUS
 CN 3-Pyridinecarboxylic acid,
 2-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-
 5-[[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-2-thienyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



RN 776312-33-5 CAPLUS
 CN 2-Thiophenecarboxaldehyde,
 5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 776312-34-6 CAPLUS
 CN 2-Thiophenemethanol, 5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-
 (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 776312-35-7 CAPLUS
 CN Thiophene,
 2-(chloromethyl)-5-[4-[[4-(1-propylbutyl)phenoxy]methyl]phenyl]-
 (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

PAGE 2-A



L18 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:606460 CAPLUS
 DOCUMENT NUMBER: 141:157025
 TITLE: Preparation of thiophenes as PPAR modulators for treatment of diabetes mellitus, cardiovascular diseases, inflammatory diseases, and related disorders
 INVENTOR(S): Mantlo, Nathan Bryan; Wang, Xiaodong; Zhu, Guoxin
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063184	A1	20040729	WO 2003-US39118	20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296402	A1	20040810	AU 2003-296402	20031231
EP 1583754	A1	20051012	EP 2003-815194	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006094768	A1	20060504	US 2005-540330	20050621
PRIORITY APPLN. INFO.:			US 2003-438587P	P 20030106
			WO 2003-US39118	W 20031231

OTHER SOURCE(S): MARPAT 141:157025
 GI

INSTANT APPLICATION

L18 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I [wherein R1 = H, (un)substituted alkyl, alkenyl, (hetero)aryl(alkyl), arylheteroalkyl, cycloalkylaryl(alkyl); R8 = H, alkyl, alkenyl, halo; R9 = H, (un)substituted alkyl, alkenyl, halo, arylalkyl, heteroaryl, allyl, alkoxy, etc.; R10, R11 = independently H, OH, CN, NO2, halo, oxo, (un)substituted (halo)alkyl, alkoxy, cycloalkyl, (hetero)aryl(alkyl), cycloalkylaryl(alkyl), aryloxy, acyl, carboxy, amino, sulfamoyl, etc.; E = (un)substituted carboxy(methyl), tetrazolyl(methyl), nitriloalkyl, carboxamido(methyl), sulfonamido(methyl); U = (un)substituted aliphatic linker wherein one C of the linker is optionally replaced with O, NH, or S; X = bond, O, S, SO2, NH; Y = bond, CH2, NH; or stereoisomers, pharmaceutically acceptable salts, solvates, and hydrates thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, coupling of 2-chloromethyl-5-(4-trifluoromethylphenyl)thiophene with 3-(4-hydroxy-2-methylphenyl)propionic acid Me ester in the presence of Cs2CO3 in acetonitrile, followed by saponification with NaOH in THF and MeOH provided II. I and their pharmaceutical compns. are expected to be effective in treating and preventing diabetes mellitus, cardiovascular disorders, inflammatory conditions, and other disorders (no data).

IT 728038-76-4P, [2-Methyl-4-[[5-(4-trifluoromethylphenyl)thien-2-yl]methoxy]phenoxy]acetic acid 728038-87-7P, (R)-[2-Methyl-4-[[2-[[3-methyl-5-(4-trifluoromethylphenyl)thien-2-yl]propyl]sulfonyl]phenoxy]acetic acid 728038-88-8P, (S)-[2-Methyl-4-[[2-[[3-methyl-5-(4-trifluoromethylphenyl)thien-2-yl]propyl]sulfonyl]phenoxy]acetic acid 728038-96-8P, [2-Methyl-4-[[2-[[3-methyl-5-(4-trifluoromethylphenyl)thien-2-yl]propyl]sulfonyl]phenoxy]acetic acid


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L18 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (PPAR modulator; prepn. of thiophenes as PPAR modulators for treatment of diabetes mellitus, cardiovascular diseases, inflammatory diseases, and other disorders)
 RN 728038-76-4 CAPLUS
 CN Acetic acid, [2-methyl-4-[[5-(4-(trifluoromethyl)phenyl)-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 728038-87-7 CAPLUS
 CN Acetic acid, [2-methyl-4-[[2(R)-2-[[3-methyl-5-(4-(trifluoromethyl)phenyl)-2-thienyl]propyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 728038-88-8 CAPLUS
 CN Acetic acid, [2-methyl-4-[[2(S)-2-[[3-methyl-5-(4-(trifluoromethyl)phenyl)-2-thienyl]propyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728038-96-8 CAPLUS
 CN Acetic acid, [2-methyl-4-[[2-[[3-methyl-5-(4-(trifluoromethyl)phenyl)-2-thienyl]propyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:220310 CAPLUS
 DOCUMENT NUMBER: 140:270625
 TITLE: Preparation of
 [[bis(biphenyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR. δ . agonists for treatment of diabetes and related conditions
 INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022533	A1	20040318	WO 2003-DK578	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499380	A1	20040318	CA 2003-2499380	20030904
AU 2003260282	A1	20040329	AU 2003-260282	20030904
US 2004143006	A1	20040722	US 2003-654699	20030904
US 7091245	B2	20060815		
EP 1537076	A1	20050608	EP 2003-793608	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014335	A	20050726	BR 2003-14335	20030904
CN 1688540	A	20051026	CN 2003-824179	20030904
JP 2005153153	T	20051215	JP 2004-533217	20030904
MX 2005PA02411	A	20050527	MX 2005-PA2411	20050302
PRIORITY APPLN. INFO.:			DK 2002-1301	A 20020905
			DK 2003-784	A 20030523
			US 2002-409814P	P 20020911
			WO 2003-DK578	W 20030904


OTHER SOURCE(S): MARPAT 140:270625
 GI

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently (un)substituted (hetero)alkyl; (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor δ (PPAR. δ . agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADMP-catalyzed condensation with (4-mercapto-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd(dba)₃, and Pd[P(t-Bu)₃]₂ in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR. δ .-mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).
 IT 673479-30-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673479-31-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-32-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-33-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-71-5P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673479-72-6P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-73-7P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]-2-methylphenoxy]acetic acid 673479-74-8P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-09-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-10-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-11-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-12-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-54-1P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-55-2P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-56-3P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673480-57-4P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673482-89-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673482-91-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673483-89-1P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673483-91-5P, [4-[[3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-62-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-63-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-64-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-65-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-66-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-67-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-68-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-69-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-70-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-71-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-72-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-73-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-74-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-75-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-76-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-77-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-78-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-79-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-80-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-81-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-82-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-83-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-84-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-85-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-86-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-87-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-88-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-89-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-90-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-91-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-92-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-93-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-94-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-95-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-96-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-97-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-98-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673484-99-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-00-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-01-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-02-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-03-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-04-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-05-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-06-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-07-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-08-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-09-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-10-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-11-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-12-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-13-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-14-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-15-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-16-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-17-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-18-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-19-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-20-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-21-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-22-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-23-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-24-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-25-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-26-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-27-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-28-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-29-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-30-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-31-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-32-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-33-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-34-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-35-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-36-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-37-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-38-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-39-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-40-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-41-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-42-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-43-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-44-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-45-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-46-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-47-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-48-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-49-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-50-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-51-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-52-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-53-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-54-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-55-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-56-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-57-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-58-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-59-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-60-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-61-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-62-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-63-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-64-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-65-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-66-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-67-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-68-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-69-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-70-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-71-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-72-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-73-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-74-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-75-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-76-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-77-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-78-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-79-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-80-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-81-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-82-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-83-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-84-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-85-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-86-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-87-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-88-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-89-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-90-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-91-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-92-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-93-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-94-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-95-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-96-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-97-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-98-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673485-99-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-00-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-01-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-02-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-03-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-04-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-05-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-06-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-07-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-08-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-09-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-10-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-11-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-12-3P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-13-4P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-14-5P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-15-6P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-16-7P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-17-8P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-18-9P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-19-0P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-20-1P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-21-2P, [4-[[3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)allyl]oxy]phenoxy]acetic acid 673486-22-3P, [4-[[3,3-Bis(4-(5-acetylthiophen

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673479-33-9 CAPLUS
CN Acetic acid,
[4-[[2-[[bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butyl]thio]-
2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-71-5 CAPLUS
CN Acetic acid,
[4-[[3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl]thio]-2-
methylphenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673479-72-6 CAPLUS
CN Acetic acid,
[4-[[3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]-2-
methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-73-7 CAPLUS
CN Acetic acid, [4-[[2-[[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butoxy]-2-
methylphenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673479-74-8 CAPLUS
CN Acetic acid,
[4-[[2-[[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butyl]thio]-
2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-09-6 CAPLUS
CN Acetic acid, [4-[[3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-
propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673480-10-9 CAPLUS
CN Acetic acid, [4-[[3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-
propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-11-0 CAPLUS
CN Acetic acid,
[4-[[2-[[bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butoxy]phen-
oxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673480-12-1 CAPLUS
 CN Acetic acid,
 [4-([2-[bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butyl]thio
]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-54-1 CAPLUS
 CN Acetic acid, [4-([3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-
 propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673480-55-2 CAPLUS
 CN Acetic acid, [4-([3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-
 propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-56-3 CAPLUS
 CN Acetic acid,
 [4-([2-[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butoxy]phen
 oxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673480-57-4 CAPLUS
 CN Acetic acid,
 [4-([2-[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butyl]thio
]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-89-8 CAPLUS
 CN Acetic acid, [4-([3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-ethoxy-2-
 propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673482-91-2 CAPLUS
 CN Acetic acid, [4-([3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-ethoxy-2-
 propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-89-1 CAPLUS
 CN Acetic acid, [4-([3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-ethoxy-2-
 propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673483-91-5 CAPLUS
 CN Acetic acid, [4-[[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-62-3 CAPLUS
 CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 673484-63-4 CAPLUS
 CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-64-5 CAPLUS
 CN Acetic acid, [4-[[[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butoxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 673484-65-6 CAPLUS
 CN Acetic acid, [4-[[[2-bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)





REFERENCE COUNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L18 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:946252 CAPLUS
 DOCUMENT NUMBER: 138:39276
 TITLE: Preparation of heterocyclecarboxylic acid, benzoic acid, and phenylalkanoic acid derivatives as agonists of peroxisome proliferator-activated receptors (PPAR)
 INVENTOR(S): Matsuura, Fumiyoshi; Emori, Eita; Shinoda, Masanobu; Clark, Richard; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Inoue, Takashi; Miyashita, Sadakazu;
 Hihara, Taro
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 293 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098840	A1	20021212	WO 2002-JP5511	20020604
W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002306235	A1	20021216	AU 2002-306235	20020604
EP 1394147	A1	20040303	EP 2002-733294	20020604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004214888	A1	20041028	US 2003-479427	20031203
PRIORITY APPLN. INFO.:			JP 2001-168356	A 20010604
			WO 2002-JP5511	W 20020604

OTHER SOURCE(S): MARPAT 138:39276
 GI



L18 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
AB Novel carboxylic acid derivs. represented by the following general formula

(I) [wherein L, M = a single bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; T = a single bond, each (un)substituted C1-3 alkylene, C2-3 alkenylene, or C2-3 alkynylene; W = CO₂H; each solid line accompanied by a dotted line represents a single or double bond; X = a single bond, O, each N-(un)substituted NHCO-O, NHC(S)-O, O-CO-NH, O-C(S)NH, CONHO, C(S)NHO, ONHCO, ONHC(S), NHCO, NHC(S), CONH, C(S)NH, NHCONH, NHC(S)NH, NHCO₂, or SO₂NH, OSO₂, SO₂O, etc.; Y = 5 to 14-membered aromatic group or C3-7 alicyclic hydrocarbon group each optionally having ≥1 substituents or ≥1 heteroatoms; the ring Z or U = 5 to 14-membered aromatic group optionally having 1-4 substituents or ≥1 heteroatoms wherein a part of the ring is optionally saturated], salts or esters thereof, or hydrates thereof are prepared

These compds. are dual agonists of PPAR α and γ or triple agonists of PPAR α, β(δ), and γ and useful as insulin resistance ameliorants, preventives and/or remedies for diabetes, fragile X syndrome, diabetes complications, hyperlipidemia, obesity, digestive tract diseases, and cancer. The digestive tract (gastrointestinal) diseases include (1) gastrointestinal inflammations such as ulcerative colitis, Crohn's disease, pancreatitis, and gastritis, (2) gastrointestinal proliferative diseases such as gastrointestinal benign tumor, polyp, hereditary polyposis, colon cancer, rectal cancer, and stomach cancer, and (3) gastrointestinal ulcer. They are also preventives and/or remedies for angina pectoris and myocardial infarction and sequelae thereof, senile dementia, and cerebral vascular dementia based on the improvement effects on energy metabolism. These compds. are also

useful as hypolipidemics, anti-osteoporosis agents, antiinflammatory agents, and immunomodulators. For example, 3-[4-methoxy-3-[[[4-methyl-2-(4-chlorophenyl)-1,3-thiazol-5-yl]carbonyl]amino]methyl]phenyl]benzoic acid (II) showed EC₅₀ of <0.0001, 0.176, and 0.711 for the transcription activity of human PPAR in host CV-1 cells transfected with GAL4-PPAR LBD chimera expression vector.

IT 478371-42-5P 478371-43-6P 478372-60-OP
478372-61-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclecarboxylic acid, benzoic acid, and phenylalkanoic acid derivs. as agonists of peroxisome proliferator-activated receptors

(PPAR) for prevention and/or treatment of diseases)

RN 478371-42-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 4-[3-[[[2-chloro-4-propoxybenzoyl]amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478371-43-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 4-[3-[[[2-chloro-4-(1-methylethoxy)benzoyl]amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 478372-60-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 4-[3-[[[2-chloro-4-propoxybenzoyl]amino]methyl]-4-propoxyphenyl]- (9CI) (CA INDEX NAME)



RN 478372-61-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 4-[3-[[[2-chloro-4-(1-methylethoxy)benzoyl]amino]methyl]-4-propoxyphenyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:888731 CAPLUS

DOCUMENT NUMBER: 137:384743

TITLE: Preparation of furan and thiophene derivatives that activate peroxisome proliferator-activated receptors

INVENTOR(S): Beswick, Paul John; Hamlett, Christopher Charles Frederick; Patel, Vipulkumar; Sierra, Michael Lawrence; Ramsden, Nigel Grahame

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl. 141 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092590	A1	20021121	WO 2002-GB2152	20020509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446797	A1	20021121	CA 2002-2446797	20020509
AU 2002253385	A1	20021125	AU 2002-253385	20020509
EP 1392674	A1	20040303	EP 2002-722506	20020509
EP 1392674	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200304051	A2	20040428	HU 2003-4051	20020509
CN 1507442	A	20040623	CN 2002-809694	20020509
BR 2002009468	A	20040803	BR 2002-9468	20020509
JP 2004534035	T	20041111	JP 2002-589475	20020509
AT 301649	T	20050815	AT 2002-722506	20020509
ES 2247322	T3	20060301	ES 2002-2722506	20020509
IN 2003KN01287	A	20060317	IN 2003-KN1287	20031009
ZA 2003008352	A	20050127	ZA 2003-8352	20031027
NO 2003004986	A	20031110	NO 2003-4986	20031110
MX 2003PA10285	A	20040309	MX 2003-PA10285	20031111
US 2004157890	A1	20040812	US 2004-476194	20040323
US 7091237	B2	20060815		
PRIORITY APPLN. INFO.:				
				GB 2001-11523 A 20010511
				WO 2002-GB2152 W 20020509

OTHER SOURCE(S): MARPAT 137:384743

GI

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. [I; X1 = O, S, NH, NMe, alkyl; R1, R2 = H, alkyl; R3-R5 = H, Me, CMe, CF3, halo; n = 0-3; X2 = (CR1OR11)n, O, S, OCH2; n = 1-2; R6, R7, R10, R11 = H, F, alkyl, etc.; one of Y and Z = CH, the other = S, O with the proviso that Y cannot be substituted and Z can only be substituted when it is carbon; R8 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3) with the provision that when R3 = pyridyl, the N is unsubstituted; R9 = alkyl, CF3, CH2D (D = N-substituted piperazino, furyl, piperidino, etc.); R26, R27 = H, alkyl; or R26 and


R27, together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring] and their pharmaceutically acceptable salts, useful for the treatment of a hPPAR mediated disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa, were prepared Thus, coupling (5-[4-(trifluoromethyl)phenyl]-3-furyl)methanol with Et (4-mercapto-2-methylphenoxy)acetate followed by hydrolysis of the resulting ester afforded the acid II.

IT 476154-81-1F 476154-87-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of furan and thiophene derivs. that activate human peroxisome proliferator activated receptors)

RN 476154-81-1 CAPLUS
 CN Acetic acid, [4-[1,1-dimethyl-2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 thienyl]ethyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


RN 476154-87-7 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[3-methyl-5-[4-(trifluoromethoxy)phenyl]-2-thienyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




IT 476154-11-7P 476154-12-8P 476154-13-9P
 476154-14-0P 476154-22-0P 476154-25-3P
 476154-29-7P 476154-31-1P 476154-55-9P
 476154-56-0P 476154-57-1P 476154-58-2P
 476154-59-3P 476154-60-6P 476154-61-7P
 476154-62-8P 476154-67-3P 476154-71-9P
 476154-72-0P 476154-75-3P 476154-76-4P
 476154-80-0P 476154-82-2P 476154-88-8P
 476154-89-9P 476154-90-2P 476154-91-3P
 476154-92-4P 476154-93-5P 476154-94-6P
 476154-95-7P 476154-96-8P 476154-97-9P
 476154-98-0P 476154-99-1P 476155-00-7P
 476155-01-8P 476155-02-9P 476155-03-0P
 476155-04-1P 476155-05-2P 476155-09-6P
 476155-10-9P 476155-11-0P 476156-38-4P
 476156-52-2P 476156-54-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of furan and thiophene derivs. that activate human peroxisome proliferator activated receptors)

RN 476154-11-7 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 476154-12-8 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-13-9 CAPLUS
 CN Acetic acid, 2-[2-methyl-4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (CA INDEX NAME)




RN 476154-14-0 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 476154-22-0 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-25-3 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[2-methyl-5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-29-7 CAPLUS
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 476154-56-0 CAPLUS
CN Acetic acid, [2-methyl-4-[[[3-(phenoxyethyl)-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-57-1 CAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[[[phenylmethyl]thio]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-58-2 CAPLUS
CN Acetic acid, [2-methyl-4-[[[3-[[4-(trifluoromethyl)phenoxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]-(9CI) (CA INDEX NAME)


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 476154-61-7 CAPLUS
CN Acetic acid, [2-methyl-4-[[[3-(methylphenylamino)methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-62-8 CAPLUS
CN Acetic acid, [4-[[[3-ethyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 476154-67-3 CAPLUS


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Acetic acid, [2-methyl-4-[2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-71-9 CAPLUS
 CN Acetic acid, [2-(1,1-dimethylethyl)-6-methyl-4-[2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-72-0 CAPLUS
 CN Acetic acid, [2,6-dimethyl-4-[2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-75-3 CAPLUS
 CN Acetic acid, [2-methyl-4-[[3-methyl-5-[4-(trifluoromethoxy)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 476154-76-4 CAPLUS
 CN Acetic acid, [2-methyl-4-[2-[5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-80-0 CAPLUS
 CN Acetic acid, [4-[2-[5-(4-cyano-3-fluorophenyl)-3-methyl-2-thienyl]ethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 476154-82-2 CAPLUS
 CN Acetic acid, [4-[1,1-dimethyl-2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 476154-88-8 CAPLUS
 CN Acetic acid, [2-methyl-4-[[3-methyl-5-[4-(trifluoromethoxy)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 476154-89-9 CAPLUS
 CN Acetic acid, [4-[5-[2,5-difluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 476154-90-2 CAPLUS
 CN Acetic acid, [4-[5-[2,5-difluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 476154-91-3 CAPLUS
 CN Acetic acid, [4-[5-[2,3-difluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 476154-92-4 CAPLUS
 CN Acetic acid, [4-[5-[2,3-difluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 476154-93-5 CAPLUS
 CN Acetic acid, [4-[5-[2-fluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 476154-94-6 CAPLUS
 CN Acetic acid, [4-[5-[2-fluoro-4-(trifluoromethyl)phenyl]-3-methyl-2-thienyl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 476154-95-7 CAPLUS
 CN Acetic acid, [2-methyl-4-[1-[5-[4-(trifluoromethyl)phenyl]-3-thienyl]ethoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 476154-96-8 CAPLUS
 CN Acetic acid, [2-methyl-4-[1-[5-[4-(trifluoromethyl)phenyl]-3-thienyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-97-9 CAPLUS
 CN Acetic acid, [2-methyl-4-[phenyl[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 476154-98-0 CAPLUS
 CN Acetic acid, [2-methyl-4-[phenyl[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 476154-99-1 CAPLUS
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[phenyl[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




RN 476155-00-7 CAPLUS
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[phenyl[5-[4-(trifluoromethyl)phenyl]-3-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 476155-01-8 CAPLUS


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Acetic acid, [2-methyl-4-[1-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 476155-02-9 CAPLUS
 CN Acetic acid, [2-methyl-4-[1-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 476155-03-0 CAPLUS
 CN Acetic acid, [2-methyl-4-[[3-[[[1-methylethyl]thio]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 476155-04-1 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-3-[(2,3,6-trimethylphenoxy)methyl]-2-thienyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 476155-05-2 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[3-[[[6-methyl-2-(1-methylethyl)-4-pyrimidinyl]oxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 476155-09-6 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[3-[[[1-methylethyl]thio]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)




L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 476156-52-2 CAPLUS
 CN Acetic acid, [2-methyl-4-[1-[5-[4-(trifluoromethyl)phenyl]-2-thienyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 476156-54-4 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[3-methyl-5-[4-(1,1,2-trifluoroethoxy)phenyl]-2-thienyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)




IT 476156-01-1P 476156-03-3P 476156-05-5P
 476156-07-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of furan and thiophene derivs. that activate human peroxisome proliferator activated receptors)


RN 476156-01-1 CAPLUS
 CN Benzonitrile, 2-fluoro-4-[4-methyl-5-[2-[3-methyl-4-[(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)methoxy]phenyl]ethyl]-2-thienyl]- (9CI) (CA INDEX NAME)

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 476155-10-9 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-3-[(2,3,6-trimethylphenoxy)methyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 476155-11-0 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[3-[[[6-methyl-2-(1-methylethyl)-4-pyrimidinyl]oxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 476156-38-4 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[3-methyl-4-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 476156-03-3 CAPLUS
 CN Ethanone, 2-(4-methoxy-3-methylphenyl)-1-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 476156-05-5 CAPLUS

L18 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1-Propanone, 2-(4-methoxy-3-methylphenyl)-2-methyl-1-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 476156-07-7 CAPLUS
 CN Acetic acid,
 [4-[1,1-dimethyl-2-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-2-oxoethyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L18 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:793403 CAPLUS
 DOCUMENT NUMBER: 137:310931
 TITLE: Preparation of phenylalkanoic acid derivatives as preventive or remedial agents for digestive tract diseases
 INVENTOR(S): Horizoe, Tatsuo; Shinoda, Masanobu; Emori, Eita; Matsura, Fumiyoshi; Kaneko, Toshihiko; Ohi, Norihito;
 PATENT ASSIGNEE(S): Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Miyashita, Sadakazu; Hihara, Taro; Seiki, Takashi; Clark, Richard; Harada, Hitoshi
 SOURCE: Eisai Co., Ltd., Japan
 PCT Int. Appl., 344 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: JAPANESE
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080899	A1	20021017	WO 2002-JP3006	20020327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002242989	A1	20021021	AU 2002-242989	20020327
PRIORITY APPLN. INFO.: JP 2001-101465 A 20010330				
JP 2001-105131 A 20010403				
WO 2002-JP3006 W 20020327				

OTHER SOURCE(S): MARPAT 137:310931
 GI




AB Disclosed is a preventive/remedy for digestive tract or inflammatory diseases, which contains as the active ingredient a novel carboxylic acid derivative represented by the following formula [I]; R1 = H, OH, each (un)substituted C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 hydroxyalkyl, C1-6 hydroxyalkoxy, C1-6 hydroxyalkylthio, C1-6 aminoalkyl,

L18 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 C1-6 aminoalkoxy, C1-6 aminoalkylthio, C2-12 alkoxyalkyl, C3-7 cycloalkyl,
 C3-7 cycloalkyloxy, C3-7 cycloalkylthio, C2-6 alkenyl, C2-6 alkenyloxy,
 or
 C2-6 alkenylthio, etc.; L = a single or double bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkenylene; M = a single bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkenylene;
 T = a single bond, each (un)substituted C1-3 alkylene, C2-3 alkenylene, or C2-3 alkynylene; W = 2,4-dioxothiazolidin-5-yl, 2,4-dioxothiazolidin-5-ylidene, carboxy, (un)substituted CONH2; X = O, (un)substituted C2-6 alkenylene, hydroxymethylene, CO, CS, N-(un)substituted CQNH, NHCQ,
 SO2NH,
 NHSO2, or NHCQNH (Q = O, S); Y = (un)substituted C5-12 arom. hydrocarbyl or C3-7 aliph. hydrocarbyl optionally contg. ≥1 heteroatoms; ring Z = C5-6 arom. hydrocarbyl; Y = (un)substituted arom. hydrocarbon group optionally contg. ≥1 heteroatoms; some provisos given], a salt of the deriv., or a hydrate of either. The above digestive tract diseases include (1) inflammatory digestive tract diseases such as ulcerous colitis, Crohn's disease, pancreatitis, and gastritis, (2) digestive tract proliferative diseases such as digestive tract benign tumors, digestive tract polyp, hereditary (genetic) polyposis syndromes, colon cancer, rectum cancer, and stomach cancer, and (3) digestive tract ulcerous diseases such as duodenal ulcer, stomach ulcer, esophagus ulcer, regurgitant esophagitis, stress ulcer or erosion, erosion caused by drugs, and Zollinger-Ellison syndromes. The above inflammatory diseases include arthritic rheumatism, multiple sclerosis, immunodeficiency, cachexia, osteoarthritis, osteoporosis, asthma, and allergy. The comps. I are triple agonists for PPAR (peroxisome proliferator-activated receptor) α, β, and γ subtype. Thus,


2-isopropoxy-3-[4-methoxy-3-[[[4-(trifluoromethyl)benzyl]amino]carbonyl]phenyl]propanoic acid in vitro showed the transcription activity for PPAR.α, β, and γ with EC50 of 0.08, 2.513, and 0.382 μM, resp., in CV-1 cell. (2S)-3-[3-[[[2,4-dichlorobenzoyl]amino]methyl]-4-methoxyphenyl]-2-isopropoxypropanoic acid at 1 mg/kg/day p.o. for 3 days showed a disease activity index based on diarrhea, bloody excrement, and wt. loss (DAI) of 2.0±0.3 in mice suffering from colitis induced by dextran sulfate sodium salt vs. 2.8±0.2 for the control group and 2.1±0.3 for the mice treated with rosiglitazone at 30 mg/kg/day. Many comps. prepd. do not possess the thiazolidine skeleton and thereby may completely avoid toxicity such as liver disorder which was noted in the past as a problem for comps.

having
 PPAR.γ agonist activity.
 IT 334012-36-1P 334012-37-2P 334012-42-9P
 334012-43-0P 334012-54-3P 334012-60-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylalkanoic acid derivs. as peroxisome proliferator-activated receptor agonists and remedial or preventive agents for digestive tract or inflammatory diseases)
 RN 334012-36-1 CAPLUS
 CN Benzenepropanoic acid, 3-[[[2-chloro-4-propoxybenzoyl]amino]methyl]-α-(1-methylethoxy)-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


L18 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 334012-37-2 CAPLUS
 CN Benzenepropanoic acid,
 3-[[[2-chloro-4-(1-methylethoxy)benzoyl]amino]methyl]-1)-α-(1-methylethoxy)-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 334012-42-9 CAPLUS
 CN Benzenepropanoic acid, 3-[[[2-chloro-4-propoxybenzoyl]amino]methyl]-α-(1-methylethoxy)-4-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 334012-43-0 CAPLUS
 CN Benzenepropanoic acid,
 3-[[[2-chloro-4-(1-methylethoxy)benzoyl]amino]methyl]-1)-α-(1-methylethoxy)-4-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


L18 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 334012-54-3 CAPLUS
CN Benzenepropanoic acid,
3-[[[2-chloro-4-(cyclopentyloxy)benzoyl]amino]methyl]-
1-α-(1-methylethoxy)-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 334012-60-1 CAPLUS
CN Benzenepropanoic acid,
3-[[[2-chloro-4-(cyclopentyloxy)benzoyl]amino]methyl]-
1-α-(1-methylethoxy)-4-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L18 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:265369 CAPLUS
DOCUMENT NUMBER: 134:295620
TITLE: Preparation and effect of 4-methoxyphenylpropionic acid derivatives useful in insulin resistance improvement
INVENTOR(S): Shinoda, Masanobu; Emori, Eita; Matsuura, Fumiyoshi; Kaneko, Toshihiko; Ohi, Norihito; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Miyashita, Sadakazu; Hibara, Taro; Seiki, Hisashi; Clark, Richard; Harada, Hitoshi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 350 pp.
DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 1 Japanese
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025181	A1	20010412	WO 2000-JP6788	20000929
W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
TW 262185	B	20060921	TW 2000-89120087	20000928
CA 2385081	A1	20010412	CA 2000-2385081	20000929
AU 200074499	A	20010510	AU 2000-74499	20000929
AU 776267	B2	20040902		
EP 1216980	A1	20020626	EP 2000-962993	20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
NZ 517719	A	20041029	NZ 2000-517719	20000929
US 6884821	B1	20050426	US 2002-88916	20000929
PRIORITY APPLN. INFO.:			JP 1999-282079	A 19991001
			JP 1999-369442	A 19991227
			JP 2000-38795	A 20000926
			JP 2000-104260	A 20000406
			WO 2000-JP6788	W 20000929

OTHER SOURCE(S): MARPAT 134:295620
GI



L18 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 334012-54-3 CAPLUS
CN Benzenepropanoic acid,
3-[[[2-chloro-4-(cyclopentyloxy)benzoyl]amino]methyl]-
1-α-(1-methylethoxy)-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 334012-60-1 CAPLUS
CN Benzenepropanoic acid,
3-[[[2-chloro-4-(cyclopentyloxy)benzoyl]amino]methyl]-
1-α-(1-methylethoxy)-4-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L18 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title comps. [Y:L:X:TEM:CWR1; R1 is hydrogen, hydroxyl, alkyl; L is single bond, double bond, alkylene; M is single bond, alkylene; T is single bond, alkylene; W is carboxyl, amide; X is oxygen, alkenylene; Y is aromatic hydrocarbon; Z is aromatic hydrocarbon; colon represents single, or double bond], salts, esters, and hydrates are prepared and are useful in prevention or treatment of diabetes and X-syndrome. Thus, the title compound I was prepared and biol. tested.
IT 334012-36-1P 334012-37-2P 334012-42-9P
334012-43-0P 334012-54-3P 334012-60-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and effect of methoxyphenylpropionic acid derivs. useful in insulin resistance improvement as PPAR agonists)

RN 334012-36-1 CAPLUS
CN Benzenepropanoic acid, 3-[[[2-chloro-4-(propoxybenzoyl)amino]methyl]-α-(1-methylethoxy)-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 334012-37-2 CAPLUS
CN Benzenepropanoic acid,
3-[[[2-chloro-4-(1-methylethoxy)benzoyl]amino]methyl]-
1-α-(1-methylethoxy)-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 334012-42-9 CAPLUS
CN Benzenepropanoic acid, 3-[[[2-chloro-4-(propoxybenzoyl)amino]methyl]-α-(1-methylethoxy)-4-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


L18 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 334012-43-0 CAPLUS
 CN Benzenepropanoic acid,
 3-[[[2-chloro-4-(1-methylethoxy)benzoyl]amino]methyl-
 1]-α-(1-methylethoxy)-4-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 334012-54-3 CAPLUS
 CN Benzenepropanoic acid,
 3-[[[2-chloro-4-(cyclopentyloxy)benzoyl]amino]methyl-
 1]-α-(1-methylethoxy)-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 334012-60-1 CAPLUS
 CN Benzenepropanoic acid,
 3-[[[2-chloro-4-(cyclopentyloxy)benzoyl]amino]methyl-
 1]-α-(1-methylethoxy)-4-(4-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


L18 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:167982 CAPLUS
 DOCUMENT NUMBER: 134:207811
 TITLE: Preparation of biaryloxa(thia)zole derivatives as
 PPAR modulators
 INVENTOR(S): Brooks, Dawn A.; Rito, Christopher J.; Shuker,
 Anthony
 J.; Dominianni, Samuel J.; Warshawsky, Alan M.;
 Gossett, Lynn S.; Matthews, Donald P.; Hay, David A.;
 Ardecky, Robert J.; Michellys, Pierre-Yves; Tyhonas,
 John S.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Ligand Pharmaceuticals
 Incorporated
 SOURCE: PCT Int. Appl., 232 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016120	A1	20010308	WO 2000-US23358	20000823
WO 2001016120	A9	20020711		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2382966	A1	20010308	CA 2000-2382966	20000823
EP 1206457	A1	20020522	EP 2000-959401	20000823
EP 1206457	B1	20031015		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6417212	B1	20020709	US 2000-644457	20000823
JP 2003508389	T	20030304	JP 2001-519687	20000823
AT 252091	T	20031115	AT 2000-959401	20000823
PT 1206457	T	20040331	PT 2000-959401	20000823
ES 2204684	T3	20040501	ES 2000-959401	20000823
US 2003045558	A1	20030306	US 2002-121373	20020411
US 6610696	B2	20030826		
US 2004019090	A1	20040129	US 2003-434425	20030507
US 6825222	B2	20041130		
PRIORITY APPLN. INFO.:			US 1999-151162P	P 19990827
			US 2000-644457	A3 20000823
			WO 2000-US23358	W 20000823
			US 2002-121373	A3 20020411



OTHER SOURCE(S): MARPAT 134:207811
 GI

L18 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L18 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. (I) [wherein n = 2-4; V = O or S; W = O, S, or SO₂; R₁ = H, alkyl, Ph, or CF₃; R₂ = independently H, (cyclo)alkyl, cycloalkylalkyl, aryl(alkyl), or together with the Ph to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R₃ = independently H, (cyclo)alkyl, cycloalkylalkyl, or aryl(alkyl); R₄ = independently H, alkyl, aryl, or benzyl; R₅ = independently H or (un)substituted (hetero)aryl, provided that at least one R₅ = (un)substituted (hetero)aryl; and R₆ = H or (amino)alkyl] were prepared as are modulators of peroxisome proliferator activated receptors (PPARs) and are useful in the treatment of type II diabetes and cardiovascular diseases. For example, a mixture of the toluene-4-sulfonic acid 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethyl ester and 2-(3-hydroxyphenoxy)-2-methylpropanoic acid Et ester was heated at 55°C in DMF for 18 h and the intermediate deesterified using NaOH in EtOH and THF to afford the title compound II. II bound to human PPAR.alpha. and PPAR.gamma. with IC₅₀ values of 97 nM and 532 nM, resp., and activated human PPAR.alpha. and PPAR.gamma. with efficacies of 97% and 70%, resp. In assays evaluating triglyceride and cholesterol levels in mice transgenic for human apoA1, administration of II reduced triglyceride serum levels by 60.5% and increased HDLc serum levels by 204%. Glucose normalization of 95% was attained in male diabetic (db/db) mice dosed with II.


IT 328918-74-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of biaryl oxazoline PPAR modulators by coupling biaryloxazolylalkyl tosylates with alcs. or thiols)

RN 328918-74-7 CAPLUS
 CN Propanoic acid, 2-methyl-2-[4-[2-[5-methyl-2-[4-(5-methyl-2-thienyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

108 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 328920-02-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of biaryl oxazazole PPAR modulators by
 coupling biaryloxazolylalkyl tosylates with alcs. or thiols)
 RN 328920-02-1 CAPLUS
 CN Propanoic acid, 2-methyl-2-[4-[2-methyl-2-[4-(5-methyl-2-
 thienyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]-, ethyl ester (9CI) (CA INDEX
 NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:49:07 ON 05 SEP 2007)

FILE 'REGISTRY' ENTERED AT 11:49:20 ON 05 SEP 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3
L5 21110 S L3 FULL
L6 STRUCTURE UPLOADED
L7 STRUCTURE UPLOADED
L8 12969 S L7 FULL SUB=L5
L9 STRUCTURE UPLOADED
L10 12463 S L9 FULL SUB=L8
L11 STRUCTURE UPLOADED
L12 STRUCTURE UPLOADED
L13 937 S L11 FULL SUB=L10
L14 428 S L12 FULL SUB=L10

FILE 'CAPLUS' ENTERED AT 12:01:42 ON 05 SEP 2007

L15 246 S L13
L16 88 S L14
L17 262 S L15 OR L16
L18 12 S L17 AND PPAR

=> s 117 not 118
L19 250 L17 NOT L18

=> s 119 and AP<2004
'2004' NOT A VALID FIELD CODE
 0 AP<2004
L20 0 L19 AND AP<2004

=>
=> d ibib abs hitstr L19 1-250

L19 ANSWER 1 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:673443 CAPLUS
 DOCUMENT NUMBER: 147:95531
 TITLE: Preparation of thiophene derivatives as factor Xla inhibitors
 INVENTOR(S): Han, Wei
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 145pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070816	A2	20070821	WO 2006-US61970	20061213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HA, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BG, BR, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY/REFLN. INFO.: US 2005-750131P P 20051214

OTHER SOURCE(S): MARPAT 147:95531
 GI



L19 ANSWER 2 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:501976 CAPLUS
 DOCUMENT NUMBER: 147:143034
 TITLE: Recoverable PEG-Supported Copper Catalyst for Highly Stereocontrolled Nitroaldol Condensation
 AUTHOR(S): Bandini, Marco; Benaglia, Maurizio; Sinigaglia, Riccardo; Tommasi, Simona; Umami-Ronchi, Achille
 CORPORATE SOURCE: Dipartimento di Chimica G. Ciamician, Università di Bologna, Bologna, 40126, Italy
 SOURCE: Organic Letters (2007), 9(11), 2151-2153
 CODEN: ORLEF7; ISSN: 1523-7066
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:143034


AB A new Cu(OAc)₂ complex with poly(ethylene glycol)-modified unsym. 1,2-bis(thienylmethylamino)cyclohexane smoothly catalyzes a base-free nitroaldol condensation of aldehydes RCHO (R = Me₃C, cyclohexyl, Ph, 4-FC₆H₄, n-heptyl, etc.) with nitromethane in a highly enantioselective manner (ee up to 93%) in reagent-grade solvent and in the presence of air.

Effective recovery and recycling (up to five runs) of supported catalysts are documented.

IT 943348-25-2P
 RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (asym. synthesis of vicinal nitro alcs. via highly stereocontrolled nitroaldol condensation of aldehydes with nitromethane using recoverable poly(ethylene glycol)-supported copper catalyst)

RN 943348-25-2 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α-methyl-ω-hydroxy-, ether with (S)-4-(3-bis(acetato-κO)[4-[3-[4-[5-[[[(1R,2R)-2-[[[2,2'-bithiophen]-5-ylmethylamino-κN]cyclohexyl]amino-κN]methyl]-2-(thienyl)phenoxy]propyl]phenyl]copper (CA INDEX NAME)


PAGE 1-A



L19 ANSWER 1 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AB The title thiophene derivs. I [wherein A = (un)substituted cycloalkyl, cycloalkenyl, Ph, naphthyl, or heterocyclyl; L = a bond, CH₂, CH₂CH₂, OCH₂, etc.; the thiophene ring is optionally further substituted with 0-2 R₄; R₃ = (un)substituted Ph, naphthyl, or heterocyclyl(alkyl); R₄ = independently H, F, Cl, Br, I, NO₂, etc.; R₁₁ = (un)substituted (cyclo)alkyl, alkenyl, alkynyl, etc.], or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof were prepared as factor Xla inhibitors. For example, II•TFA was prepared in a multi-step synthesis. Inhibitory activity were tested (no data). The compds. are useful for treating thromboembolic and/or inflammatory disorders.


IT 942119-86-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of thiophene derivs. as factor Xla inhibitors)

RN 942119-86-0 CAPLUS
 CN Carbamic acid, N-[4-[5-[1-[(2,6-difluoro-4-methoxybenzoyl)amino]-2-phenylethyl]-3-thienyl]phenyl]-, methyl ester (CA INDEX NAME)



L19 ANSWER 2 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



IT 943241-69-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (asym. synthesis of vicinal nitro alcs. via highly stereocontrolled nitroaldol condensation of aldehydes with nitromethane using recoverable poly(ethylene glycol)-supported copper catalyst)

RN 943241-69-8 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α-[4-[3-[4-[5-[[[(1R,2R)-2-[[[2,2'-bithiophen]-5-ylmethylamino]cyclohexyl]amino]methyl]-2-(thienyl)phenoxy]propyl]phenyl]-ω-methoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS

L19 ANSWER 2 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 3 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:433997 CAPLUS
DOCUMENT NUMBER: 146:422525
TITLE: Production of sulfo group-containing polymer and
organic electroluminescent element therefrom
INVENTOR(S): Togashi, Kazuhiko; Naruse, Junko; Mita, Naruyoshi
PATENT ASSIGNEE(S): Mitsui Chemicals, Inc., Japan
SOURCE: PCT Int. Appl., 64pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007043607	A1	20070419	2006-JP320376	20061012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GR, GU, HK, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CA, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			JP 2005-298775	A 20051013

GI




AB The polymer has a structure formed by introducing sulfo groups into a polymer comprising repeating units represented by the general formula I, wherein Ar1, Ar2 = monovalent aromatic group; Y = divalent group comprising an aromatic group; and W = C4-30 divalent aromatic group. Thus, 5.31 g N,N'-diphenyl-1,4-phenylenediamine and 11.15 g 2,5-bis(4-bromophenyl)-3,4-diphenylthiophene were reacted in the presence of 4.86 g sodium tert-butoxide and 92 mg tris(dibenzylideneacetone)dipalladium in o-xylene for 20 h at 135° to give 11.56 g polymer, 3.0 g of which was reacted with 30 mL 98% sulfuric acid for 17 h at room temperature to give 3.67 g title polymer after the workup.

L19 ANSWER 3 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 934408-90-9DP, 2,5-Bis(4-bromophenyl)-3,4-diphenylthiophene-N,N'-di(4-methoxyphenyl)-1,4-phenylene diamine copolymer, sru, reaction product with sulfuric acid 934408-99-8DP, 2,5-Bis(4-bromophenyl)-3,4-diphenylthiophene-N,N'-di(3-methoxyphenyl)-1,4-phenylene diamine copolymer, sru, reaction product with sulfuric acid 934408-99-8P,
2,5-Bis(4-bromophenyl)-3,4-diphenylthiophene-N,N'-di(3-methoxyphenyl)-1,4-phenylene diamine copolymer, sru
RL: IMF (Industrial manufacture); PREP (Preparation)
(production of sulfo group-containing polymer and organic electroluminescent element therefrom)
RN 934408-90-9 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene[(4-methoxyphenyl)imino]-1,4-phenylene[(4-methoxyphenyl)imino]-1,4-phenylene]
(CA INDEX NAME)




RN 934408-99-8 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene[(3-methoxyphenyl)imino]-1,4-phenylene[(3-methoxyphenyl)imino]-1,4-phenylene]
(CA INDEX NAME)

L19 ANSWER 3 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 934408-99-8 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene[(3-methoxyphenyl)imino]-1,4-phenylene[(3-methoxyphenyl)imino]-1,4-phenylene]
(CA INDEX NAME)



IT 934408-90-9P, 2,5-Bis(4-bromophenyl)-3,4-diphenylthiophene-N,N'-di(4-methoxyphenyl)-1,4-phenylene diamine copolymer, sru
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation);
RACT (Reactant or reagent)
(production of sulfo group-containing polymer and organic electroluminescent element therefrom)
RN 934408-90-9 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene[(4-methoxyphenyl)imino]-1,4-phenylene[(4-methoxyphenyl)imino]-1,4-phenylene]
(CA INDEX NAME)

L19 ANSWER 3 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 4 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2007:433906 CAPLUS
 DOCUMENT NUMBER: 146:441670
 TITLE: Preparation of 2-phenylisonicotinic acid derivatives as xanthine oxidase inhibitors
 INVENTOR(S): Sato, Junji; Hattori, Kazuyuki; Kubota, Hiroyasu; Munakata, Ryosuke; Asano, Toru; Watanabe, Junko; Kawakami, Masakatsu; Kamikawa, Akio
 PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
 SOURCE: PCT Int. Appl., 56pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007043457	A1	20070419	WO 2006-JP320061	20061006

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-295740 A 20051007


OTHER SOURCE(S): MARPAT 146:441670
 GI




AB The title compds. 2-phenylisonicotinic acid derivs. I [wherein A = (un)substituted aryl or heteroaryl; B = (un)substituted heteroaryl] or salts thereof are prepared as xanthine oxidase inhibitors for the treatment of hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy, diabetic retinitis, etc. For example, the compound II was prepared in a multi-step synthesis. II showed inhibitory activity with IC50 of 0.5 nM

L19 ANSWER 4 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 934469-57-5P 934469-73-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of phenylisonicotinic acid derivs. as xanthine oxidase inhibitors)
 RN 934469-57-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(2-cyano-3',4'-dimethoxy[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)



RN 934469-73-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-(4'-amino-2-cyano-3'-methoxy[1,1'-biphenyl]-4-yl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 5 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2007:410784 CAPLUS
 DOCUMENT NUMBER: 146:421829
 TITLE: Preparation of phloroglucinol derivatives as ligands of selectins
 INVENTOR(S): Aydt, Ewald; Kranich, Remo
 PATENT ASSIGNEE(S): Revotar Biopharmaceuticals AG, Germany
 SOURCE: PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007039112	A1	20070412	WO 2006-EP9153	20060920

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: EP 2005-205095 A 20050920

OTHER SOURCE(S): MARPAT 146:421829




AB The title phloroglucinol derivs. I [wherein X = -(CH2)n-(NH)m-C(=O)-, -L-(NH)m-C(=O)-, or -L-(CH2)p-C(=T)-; Y = -(NH)m-(CH2)p-Z; L = (CH2)n or

L19 ANSWER 5 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (hetero)ring; m = 0 or 1; n = 1-3; p = 0-2; T = O, S, or 2H; Z = substituted (hetero)aryl], or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof were prepd. as ligands to modulate the binding processes mediated by E-, P-, or L-selectins. For example, II was prepd. in a multi-step synthesis. II showed inhibitory activity against the binding of E-, P-, and L-selectins with IC50 data of 7.8, 5.2, and 6.1 μ M, resp. The compds. are useful for treatment of chronic obstructive pulmonary disease, acute lung injury, chronic inflammatory diseases, autoimmune diseases, etc. (no data).
 IT 934247-59-3P 934247-60-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of phloroglucinol derivs. as ligands of selectins)
 RN 934247-59-3 CAPLUS
 CN 2-Thiopheneacetic acid, 5-[2-[[[(2',4',6'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934247-60-6 CAPLUS
 CN 2-Thiopheneacetic acid, 5-[2-[[[(2',4',6'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 6 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:397610 CAPLUS
 DOCUMENT NUMBER: 146:513723
 TITLE: Synthesis and SAR studies of a novel class of S1P1 receptor antagonists
 AUTHOR(S): Nakamura, Tsuyoshi; Yonesu, Kiyooki; Mizuno, Yumiko; Suzuki, Chie; Sakata, Yuki; Takuwa, Yoshihara; Futoshi; Satoh, Susumu
 CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Sankyo Co., Ltd, Shinagawa-ku, Tokyo 140-8710, Japan
 SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(10), 3548-3564
 CODEN: BMECHS; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I


AB A series of Sodium 4-[(4-butoxyphenyl)thio]-2'-substituted-1,1'-biphenyl-3-sulfonates were identified as functional sphingosine-1-phosphate (S1P) antagonists with selectivity for the S1P1 receptor subtype starting from chemical lead 2 (I), which was found while screening our inhouse compound library. We performed chemical modifications on each regional structure of compound 2, for example, on the three ring compartments, the benzyl substituents, and the long alkyl chain part. The introduction of a biphenyl skeletal structure and the installation of a hydroxyl group onto the terminal carbon in the side-chain region resulted in the potent derivative 35c, which showed >500-fold more potent S1P1 inhibitory activity than lead compound 2. We report herein the synthesis and structure-activity relationships of structurally novel S1P1 receptor antagonists.
 IT 936832-96-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (biphenylsulfonates as S1P1 receptor antagonists)
 RN 936832-96-1 CAPLUS
 CN Benzenesulfonic acid, 2-(4-ethoxyphenoxy)-5-[5-(1-hydroxy-2-tridecyn-1-yl)- (CA INDEX NAME)

L19 ANSWER 5 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 6 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 2-thienyl]-, sodium salt (1:1) (CA INDEX NAME)



IT 936833-13-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (biphenylsulfonates as S1P1 receptor antagonists)
 RN 936833-13-5 CAPLUS
 CN Benzenesulfonic acid, 2-(4-ethoxyphenoxy)-5-(5-formyl-2-thienyl)- (CA INDEX NAME)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 7 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:384923 CAPLUS
DOCUMENT NUMBER: 146:401830
TITLE: Preparation of N-acylheterocycles as histone deacetylase (HDAC) inhibitors.
INVENTOR(S): Dobler, Marcus Rolf; Grob, Jonathan E.; Patnaik, Anup;
PATENT ASSIGNEE(S): Radetich, Branko; Shultz, Michael; Zhu, Yanyi
SOURCE: Novartis A.-G., Switz.; Novartis Pharma G.m.b.H. PCT Int. Appl., 117pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007038459	A2	20070405	WO 2006-US37358	20060925
WO 2007038459	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MD, ME, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: US 2005-720900P P 20050927
US 2005-754960P P 20051228

OTHER SOURCE(S): MARPAT 146:401830
GI



AB Title compds. [I; R1 = H, NH2, NHR6, SR6, OR6, O, OR6; R2, R3 = H, (heterosubstituted) alkyl, alkenyl; X = atoms to form (heterosubstituted) cycloalkyl, cycloalkenyl, aryl, heterocycloalkyl, heteroaryl, polyheterocyclyl; n, p = 0-4; R4 = H, (heterosubstituted) alkyl,

L19 ANSWER 8 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:332888 CAPLUS
DOCUMENT NUMBER: 146:358712
TITLE: Preparation of heterocyclic compounds containing biaryl moiety as LTA4H inhibitors
INVENTOR(S): Sandanayaka, Vincent; Singh, Jasbir; Gurney, Mark; Mamat, Bjorn; Yu, Peng; Bedel, Louis; Zhao, Lei
PATENT ASSIGNEE(S): Decode Chemistry, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 97pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007066820	A1	20070322	US 2006-426287	20060623
US 2007078263	A1	20070405	US 2006-426284	20060623
WO 2007040681	A1	20070412	WO 2006-US24393	20060623

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MD, ME, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
WO 2007040682 A1 20070412 WO 2006-US24393 20060623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MD, ME, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: US 2005-719016P P 20050921

OTHER SOURCE(S): MARPAT 146:358712
GI


L19 ANSWER 7 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
alkylaryl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, etc.; R5 = H, O, halo, alkoxy, (heterosubstituted) alkyl; R6 = H, alkyl], were prepd. Thus, title compd. (R)-2-amino-1-(4-biphenyl-3-yl-3,6-dihydro-2H-pyridin-1-yl)-3-(4-chlorophenyl)propan-1-one was prepd. from 1-Boc-4-piperidone, 3-biphenylboronic acid, and Boc-4-chloro-D-phenylalanine in 5 steps. I inhibited HDAC with IC50 = 0.005-100 µM.
IT 932717-01-6P 932717-38-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-acylheterocycles as histone deacetylase inhibitors)
RN 932717-01-6 CAPLUS
CN 1-Propanone, 2-amino-1-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]-3-[5-(2,4-dichlorophenyl)-2-thienyl]- (CA INDEX NAME)




RN 932717-38-9 CAPLUS
CN 1-Propanone, 2-amino-3-[5-(2,4-dichlorophenyl)-2-thienyl]-1-[4-[(4-methoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



L19 ANSWER 8 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I [Ar = aryl (optionally substituted with halo, alkyl, acyl, etc.), heteroaryl with (optionally substituted halo, alkyl, acyl, etc.); X = direct bond, O, SO, etc.; HetAr = aryl or heteroaryl ring attached via a ring carbon to Q, further characterized in that Q and X cannot be on adjacent positions in said aryl or heteroaryl ring; Q = -O-, -NR1-, S(O)p; R1 = H, alkyl; p = 0-2; n = 1-5; HET = saturated nitrogenous heterocycle (optionally substituted with halo, hydroxyl, amino, etc.); taken together ZW is H; or Z = (CH2)1-10, in which one or two (CH2) may optionally be replaced by -O-, -NR1-, -SO-, etc.; W = acyl, hydroxyl, carboxyl, etc.; with the proviso that (a) when Q is -O-, HET is (S)-pyrrolidine, rac-pyrrolidine or piperidine, Ar is Ph or halo-substituted Ph, and HetAr is p-phenylene, then the Z-W combination is other than H. (b) when Q is -NR1-, HET is thiazolidine, Ar is Ph or substituted Ph and HetAr is m-phenylene, then the Z-W combination is other than H. (c) when Q is -O-, HET is azetidine, Ar is Ph, n is 1 and HetAr is a 2,5-substituted pyridine, then the Z-W combination is other than H.] were prepared For example, reaction of (S)-2-[4-(4-chlorophenoxy)-phenoxy]methyl-piperidine hydrochloride, e.g., prepared from (S)-piperidine-1,2-dicarboxylic acid 1-tert-Bu ester in 5 steps, with 3-(chloromethyl)-1,2,4-oxadiazole followed by treatment with HCl afforded compound II·HCl. In leukotriene A4 hydrolase (LAT4H) inhibition assays, compound II·HCl exhibited the IC50 value of <5 µM. Compds. I are claimed useful for the treatment of inflammation, asthma, etc.
IT 929916-56-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



L19 ANSWER 8 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (prepn. of heterocyclic compds. contg. biaryl moiety as LTA4H
 inhibitors for treatment of inflammation, asthma, etc.)
 RN 929916-56-3 CAPLUS
 CN Pyrrolidine,
 2-[[4-[[4-(5-methyl-2-thienyl)phenyl]methyl]phenoxy]methyl]-,
 hydrochloride (1:1), (2R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 929916-61-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of heterocyclic compds. containing biaryl moiety as LTA4H
 inhibitors for treatment of inflammation, asthma, etc.)
 RN 929916-61-0 CAPLUS
 CN 1-Pyrrolidinebutanoic acid, 2-[[4-[[4-(5-methyl-2-
 thienyl)phenyl]methyl]phenoxy]methyl]-, hydrochloride (1:1), (2R)- (CA
 INDEX NAME)

Absolute stereochemistry.



● HCl

IT 929918-23-0P 929918-28-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of heterocyclic compds. containing biaryl moiety as LTA4H
 inhibitors for treatment of inflammation, asthma, etc.)
 RN 929918-23-0 CAPLUS


L19 ANSWER 9 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:328279 CAPLUS
 DOCUMENT NUMBER: 146:337748
 TITLE: Preparation of novel 1,2-dihydroquinoline derivatives
 having glucocorticoid receptor binding activity
 INVENTOR(S): Matsuda, Mamoru; Mori, Toshiyuki; Kawashima, Kenji;
 Nagatsuka, Masato; Kobayashi, Sachiko; Yamamoto,
 Minoru; Kato, Masatomo; Takai, Miwa; Oda, Tetsuko
 PATENT ASSIGNEE(S): Santen Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 272pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007032556	A1	20070322	2006-JP318674	20060914

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HN, HR, HU, IL, IN, IS, KE, KG, KM, KN, KP, KR,
 KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW,
 MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CA, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KP, MD, RU, TJ, TM

PRIORITY APPL. INFO.: JP 2005-266622 A 20050914
 JP 2006-27128 A 20060203


OTHER SOURCE(S): MARPAT 146:337748
 GI



AB The title compds. [I; ring X = benzene or a pyridine ring; R1 = halo,
 hydroxy-lower alkyl, lower alkoxy, each (un)substituted lower alkyl, or
 lower alkenyloxy, HO, NH2, NO2, cyano; p = an integer of 0-5; R2 =
 halo,
 HO or its ester, each (un)substituted lower alkyl or lower alkoxy; q = an
 integer of 0-2; R3 = H, each (un)substituted lower alkyl group, lower


L19 ANSWER 8 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1-Pyrrolidinecarboxylic acid, 2-[[4-[[4-(5-methyl-2-
 thienyl)phenyl]methyl]phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)-
 (CA INDEX NAME)

Absolute stereochemistry.



RN 929918-28-5 CAPLUS
 CN 1-Pyrrolidinebutanoic acid, 2-[[4-[[4-(5-methyl-2-
 thienyl)phenyl]methyl]phenoxy]methyl]-, methyl ester, (2R)- (CA INDEX
 NAME)

Absolute stereochemistry.



L19 ANSWER 9 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 alkenyl, lower alkynyl, aryl, lower alkylcarbonyl, lower alkenylcarbonyl,
 lower alkynylcarbonyl, or arylcarbonyl; R4, R5, R6 = H, lower alkyl; or

R4

and R5 together form 3- to 8-membered lower cycloalkane ring; A = lower
 alkylene or CO; R7 = OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 = formyl, CO2H,
 CONH2, each (un)substituted lower alkyl, lower alkenyl, lower alkynyl,
 lower cycloalkyl, aryl, or heterocyclyl, etc.; R9 = H, formyl, CO2H,
 CONH2, each (un)substituted lower alkyl, lower alkenyl, lower alkynyl,
 lower cycloalkyl, aryl, or heterocyclyl, etc.] or salts thereof are
 prepd.

These compds. are glucocorticoid receptor modulators and effective for
 treating diseases assocd. with a glucocorticoid receptor including (1)
 metabolic disorders such as diabetes and obesity, (2) inflammatory
 diseases such as enteritis and chronic obstructive pulmonary diseases,

(3)

autoimmune diseases such as collagen disease, (4) allergic diseases such
 as asthma, atopic dermatitis, and allergic rhinitis, (5) central nervous
 system diseases such as mental disorders, Alzheimer's disease, and drug
 abuse, (6) cardiovascular diseases such as hypertension, hypercalcemia,
 hyperinsulinemia, and hyperlipidemia, (7) homeostasis-related diseases
 causing abnormality in immunity and internal secretion, and (8) glaucoma.
 Thus, 52 mg 5-chloromethyl-6-(2-methoxyphenyl)-2,2,4-trimethyl-1,2-
 dihydroquinoline, 42 μL phenol, and 88 mg K2CO3 were suspended in 2 mL
 DMF, stirred at 80° for 5 h to give, after workup and silica gel
 chromatog., 6-(2-methoxyphenyl)-5-phenoxyethyl-2,2,4-trimethyl-1,2-
 dihydroquinoline (II). II showed 100% binding to glucocorticoid receptor
 in a receptor competitive binding assay by polarized fluorometry.


IT

929528-07-4P 929528-09-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of novel 1,2-dihydroquinoline derivs. having
 glucocorticoid
 receptor binding activity)


RN 929528-07-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 4-phenyl-, [6-(4-fluoro-2-methoxyphenyl)-1,2-
 dihydro-2,2,4-trimethyl-5-quinolinyl]methyl ester (CA INDEX NAME)



RN 929528-09-6 CAPLUS

L19 ANSWER 9 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2-Thiophenecarboxylic acid, 5-phenyl-, [6-(4-fluoro-2-methoxyphenyl)-1,2-dihydro-2,2,4-trimethyl-5-quinolyl]methyl ester (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 10 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:322891 CAPLUS
 DOCUMENT NUMBER: 146:323557
 TITLE: Novel aromatic compounds comprising trimethoxyphenyl subunits and their use as selectin antagonists
 INVENTOR(S): Aydt, Ewald M.; Kranich, Remo; Busemann, Anke S.
 PATENT ASSIGNEE(S): Revotar Biopharmaceuticals AG, Germany
 SOURCE: Eur. Pat. Appl., 46pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNTRY: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1764093	A1	20030321	EP 2005-20510	20050920
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
WO 2007039113	A1	20070412	WO 2006-EP9154	20060920
W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			EP 2005-20510	A 20050920

OTHER SOURCE(S): MARPAT 146:323557
 AB Pharmaceutical compns. comprising at least one aromatic compound containing a trimethoxyphenyl subunit, the pharmaceutically acceptable salts, esters or amides and prodrugs thereof and a pharmaceutically acceptable carrier, useful in a medicine are described. The compds. are applied to modulate the in vitro and in vivo binding processes mediated by E-, P- or L-selectin for the treatment, diagnosis or prophylaxis of inflammatory disorders and other conditions where selectin-mediated processes play a role. Thus, compds. of the present invention were prepared and assayed for their ability to inhibit the binding of P-, L-, or E-selectin chimeric mols. to sLex and tyrosine sulfate residues linked to a polymeric matrix as a PSGL-1 substitute.
 IT 864518-32-1P 928846-99-5P 928847-12-5P
 928847-14-7P 928847-16-9P 928847-17-0P
 RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L19 ANSWER 10 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (arom. compds. comprising trimethoxyphenyl subunits as selectin antagonists for treatment, diagnosis or prophylaxis of inflammatory disorders)
 RN 864518-32-1 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]acetyl]amino]phenyl]- (CA INDEX NAME)



RN 928846-99-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 928847-12-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)





RN 928847-14-7 CAPLUS


L19 ANSWER 10 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 2-Thiophenecarboxylic acid, 5-[2-[[[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 928847-16-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[2-[[[(2',3',4'-trimethoxy-5-nitro[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 928847-17-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




IT 864518-31-0P 928847-11-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (aromatic compds. comprising trimethoxyphenyl subunits as selectin

L19 ANSWER 10 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
antagonists for treatment, diagnosis or prophylaxis of inflammatory disorders)
RN 864518-31-0 CAPLUS
CN 2-Thiopheneacetic acid,
5-[2-[[2-(2,3,4-trimethoxyphenyl)acetyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 928847-11-4 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(3',4',5'-trimethoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:172184 CAPLUS
DOCUMENT NUMBER: 146:421689
TITLE: Rational Design of Novel, Potent Small Molecule Pan-Selectin Antagonists
AUTHOR(S): Kranich, Remo; Busemann, Anke S.; Bock, Daniel; Schroeter-Maas, Sabine; Beyer, Diana; Heinemann, Bo; Meyer, Michael; Schierhorn, Katrin; Zahlten, Rainer; Wolff, Gerhard; Aydt, Ewald M.
CORPORATE SOURCE: Revotar Biopharmaceuticals AG, Hennigsdorf, 16761, Germany
SOURCE: Journal of Medicinal Chemistry (2007), 50(6), 1101-1112
CODEN: JMCMAA; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:421689
AB The first results of a rational hit-finding strategy to design novel small mol. antiinflammatory drugs targeting selectins, a family of three cellular adhesion mols., are described. Based on recent progress in understanding of mol. interaction between selectins and their natural ligands as well as progress in clin. development of synthetic antagonists, such as bimosiamose (TBC1269), this study was initiated to discover small mol. selectin antagonists with improved pharmacol. properties. Considering bimosiamose as template structure, a ligand-based approach followed by focused chemical synthesis has been applied to yield novel synthetic small mols. (MW < 500) with a trihydroxybenzene motif, bearing neither peptidic nor glycosidic components, with nanomolar in vitro activity. Biol. evaluation involves two kinds of in vitro assays, a static mol. binding assay, and a dynamic HL-60 cell attachment assay. As compared to controls, the novel compds. showed improved biol. in vitro activity both under static and dynamic conditions.
IT 864518-32-1P 928846-99-5P 928847-11-4P
928847-12-5P 928847-14-7P 928847-17-0P
934176-26-8P 934176-27-9P 934176-29-1P
934176-31-5P 934176-43-9P 934176-44-0P
934176-45-1P 934176-48-4P 934176-50-8P
934176-51-9P 934176-52-0P 934176-53-1P
934176-56-4P 934176-57-5P 934176-59-7P
934176-63-3P 934176-64-4P 934176-68-8P
934176-71-3P 934176-72-4P 934176-76-8P
934176-77-9P 934176-81-5P 934176-82-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of small mols. with a trihydroxybenzene motif as pan-selectin antagonists and potential antiinflammatory agents)
RN 864518-32-1 CAPLUS
CN 2-Thiopheneacetic acid,
5-[2-[[2-(2,3,4-trimethoxyphenyl)acetyl]amino]phenyl]- (CA INDEX NAME)


L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 928846-99-5 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 928847-11-4 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(3',4',5'-trimethoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 928847-12-5 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(3',4',5'-trimethoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)


L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 928847-14-7 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 928847-17-0 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 934176-26-8 CAPLUS
CN 2-Thiopheneacetic acid,
5-[2-[[2-(3,4,5-trimethoxyphenyl)acetyl]amino]phenyl]-, methyl ester (CA INDEX NAME)


L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 934176-27-9 CAPLUS
CN 2-Thiopheneacetic acid,
5-[2-[[2-(3,4,5-trimethoxyphenyl)acetyl]amino]phenyl]- (CA INDEX NAME)




RN 934176-29-1 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[1-oxo-3-(3,4,5-trimethoxyphenyl)propyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-31-5 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[1-oxo-3-(3,4,5-trimethoxyphenyl)propyl]amino]phenyl]- (CA INDEX NAME)


L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 934176-48-4 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[1-oxo-4-(2,3,4-trimethoxyphenyl)butyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-50-8 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[1-oxo-3-(2,3,4-trimethoxyphenyl)propyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-51-9 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[1-oxo-3-(2,3,4-trimethoxyphenyl)propyl]amino]phenyl]- (CA INDEX NAME)


L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 934176-43-9 CAPLUS
CN 2-Thiopheneacetic acid,
5-[2-[[2-(2,3,4-trimethoxyphenyl)acetyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-44-0 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[1-oxo-4-(3,4,5-trimethoxyphenyl)butyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-45-1 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[1-oxo-4-(3,4,5-trimethoxyphenyl)butyl]amino]phenyl]- (CA INDEX NAME)

L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 934176-52-0 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]amino]phenyl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 934176-53-1 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]amino]phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 934176-56-4 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[2E)-1-oxo-3-(2,3,4-trimethoxyphenyl)-2-propen-1-yl]amino]phenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.

L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 934176-57-5 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2E)-1-oxo-3-(2,3,4-trimethoxyphenyl)-2-propen-1-yl]amino]phenyl]- methyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 934176-59-7 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(3',4',5'-trimethoxy[1,1'-biphenyl]-3-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-63-3 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)


L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 934176-72-4 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-4-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)



RN 934176-76-8 CAPLUS
CN 2-Thiopheneacetic acid, 5-[3-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-77-9 CAPLUS
CN 2-Thiopheneacetic acid, 5-[3-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-81-5 CAPLUS


L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 934176-64-4 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-68-8 CAPLUS
CN 2-Thiopheneacetic acid, 5-[4-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-71-3 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-4-yl)carbonylamino]phenyl]-, methyl ester (CA INDEX NAME)

L19 ANSWER 11 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)acetyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 934176-82-6 CAPLUS
CN 2-Thiopheneacetic acid, 5-[2-[[[(2',3',4'-trimethoxy[1,1'-biphenyl]-3-yl)acetyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:151696 CAPLUS
 DOCUMENT NUMBER: 146:402580
 TITLE: Probing the periphery of dendrimers by heterogeneous electron transfer
 AUTHOR(S): Krishnamoorthy, K.; Dasari, Raghunath Reddy; Nantalaksakul, Arpornrat; Thayumanavan, S.
 CORPORATE SOURCE: Department of Chemistry, University of Massachusetts, Amherst, MA, 01003, USA
 SOURCE: Chemical Communications (Cambridge, United Kingdom) (2007), (7), 739-741
 CODEN: CHCOFS; ISSN: 1359-7345
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The accessibility of the electroactive periphery was studied and compared for dendrimers and linear analogs by heterogeneous electron transfer using microelectrodes. The authors have shown that the electroactive units substituted at the periphery can be encapsulated significantly enough at higher generations to exhibit differences in electron transfer rates and radical ion stabilities. The authors also show that attempts to discern this information using the more classical, fully decorated dendrimers such as G(1)F-G(3)F could be deceiving. This study is likely to have implications not only in areas such as electrochem. sensing using dendrimers, but also in interpreting the polyvalent effects in biomol. recognition using dendrimer scaffolds. The results here show that the ligands at the periphery are not likely to be equally available for binding of dendrimers at higher generations.
 IT 840531-18-2
 RL: PRP (Properties)
 (heterogeneous electron transfer in diarylaminopyrene peripheral units of polyether dendrimers)
 RN 840531-18-2 CAPLUS
 CN 1-Pyrenamine, N,N',N'',N'''-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenyleneoxymethylene-5,1,3-benzenetriylbis(oxymethylene-3,1-phenylene)]]tetrakis[N-phenyl- (CA INDEX NAME)]

L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-A




L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




PAGE 3-A




IT 903562-03-8P 903562-04-9P 903562-05-0P
 903562-06-1P 903562-07-2P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (heterogeneous electron transfer in diarylaminopyrene peripheral units of polyether dendrimers)
 RN 903562-03-8 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenyleneoxymethylene-5-(phenylmethoxy)-3,1-phenylene]oxymethylene-3,1-phenylene]]bis[N-phenyl- (CA INDEX NAME)]

L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 903562-04-9 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenyleneoxymethylene-5-[[3,5-bis(phenylmethoxy)phenyl]methoxy]-3,1-phenylene]oxymethylene-5-(phenylmethoxy)-3,1-phenylene]oxymethylene-3,1-phenylene]]bis[N-phenyl- (CA INDEX NAME)]

L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 3-A




RN 903562-05-0 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-3,1-phenyleneoxymethylene-3,1-phenylene)]bis[N-phenyl-] (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 903562-06-1 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-3,1-phenyleneoxymethylene-3,1-phenylene)]bis[N-phenyl-] (CA INDEX NAME)

L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




PAGE 2-B




L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B




PAGE 2-A




L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B




RN 903562-07-2 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-3,1-phenyleneoxymethylene-3,1-phenyleneoxymethylene-3,1-phenyleneoxymethylene-3,1-phenylene)]bis[N-phenyl- (CA INDEX NAME)]

PAGE 1-A




PAGE 1-B




L19 ANSWER 12 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 13 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I (wherein W = CO, CS or CH₂; X = N, NO, S, etc.; Y = N, NO, S, O, etc.; Z = C, N, NO, S, etc.; R1 and R2 = H, (un)substituted C1-C6alkyl, etc.; R3 = H, (un)substituted C1-C6alkyl, etc.; R4, R5, R6, R7 and R8 = H, halo, NO₂, CN, etc.). The present invention also provides methods for the use thereof to inhibit β -secretase (BACE) and treat β -amyloid deposits and neurofibrillary tangles. Preparation of I is exemplified. For example, II was prepared in 7 steps by reactions involving 4-iodopyrazole, 3-bromophenylacetylene, 1-methylguanidine, and 5-pyrimidine boronic acid. In an in vitro assay involving human BACE1, II had an IC₅₀ of 0.11-1.00 μ M.

INVENTOR(S): William
 FLOYD; SOLVIBILE, WILLIAM RONALD; GUNAWAN, IWAN
 SUWANDI; ERDEI, JAMES JOSEPH; YAN, YINFANG; ANDRAE,
 PATRICK MICHAEL; QUAGLIATO, DOMINICK ANTHONY
 WYETH, JOHN, and Brother Ltd., USA
 U.S. Pat. Appl. Publ., 91pp.
 PATENT: USXXCO
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007004786	AI	20070104	US 2006-478122	20060629
WO 2007005366	AI	20070111	WO 2006-US24793	20060626

W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-695353P P 20050630

OTHER SOURCE(S): MARPAT 146:121969
 GI



L19 ANSWER 13 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


AB The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I (wherein W = CO, CS or CH₂; X = N, NO, S, etc.; Y = N, NO, S, O, etc.; Z = C, N, NO, S, etc.; R1 and R2 = H, (un)substituted C1-C6alkyl, etc.; R3 = H, (un)substituted C1-C6alkyl, etc.; R4, R5, R6, R7 and R8 = H, halo, NO₂, CN, etc.). The present invention also provides methods for the use thereof to inhibit β -secretase (BACE) and treat β -amyloid deposits and neurofibrillary tangles. Preparation of I is exemplified. For example, II was prepared in 7 steps by reactions involving 4-iodopyrazole, 3-bromophenylacetylene, 1-methylguanidine, and 5-pyrimidine boronic acid. In an in vitro assay involving human BACE1, II had an IC₅₀ of 0.11-1.00 μ M.

INVENTOR(S): William
 FLOYD; SOLVIBILE, WILLIAM RONALD; GUNAWAN, IWAN
 SUWANDI; ERDEI, JAMES JOSEPH; YAN, YINFANG; ANDRAE,
 PATRICK MICHAEL; QUAGLIATO, DOMINICK ANTHONY
 WYETH, JOHN, and Brother Ltd., USA
 U.S. Pat. Appl. Publ., 91pp.
 PATENT: USXXCO
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

as (drug candidate; preparation of amino hetero-arylimidazolone compds.


β -secretase modulators for treating diseases involving β -amyloid deposits and neurofibrillary tangles)

RN 918484-11-4 CAPLUS
 CN 4H-Imidazol-4-one,
 2-amino-5-[5-(4-fluorophenyl)-2-thienyl]-3,5-dihydro-5-(4-methoxy-3-methylphenyl)-3-methyl- (CA INDEX NAME)




RN 918484-13-6 CAPLUS
 CN 4H-Imidazol-4-one,
 2-amino-5-[4-(4-fluorophenyl)-2-thienyl]-3,5-dihydro-5-(4-methoxy-3-methylphenyl)-3-methyl- (CA INDEX NAME)

L19 ANSWER 13 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 918487-44-2P, 1-[5-(4-Fluorophenyl)thien-2-yl]-2-(4-methoxy-3-methylphenyl)ethane-1,2-dione 918487-48-6P, 1-[4-(4-Fluorophenyl)thien-2-yl]-2-(4-methoxy-3-methylphenyl)ethane-1,2-dione
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of amino hetero-arylimidazolone compds. as β -secretase modulators for treating diseases involving β -amyloid deposits and neurofibrillary tangles)
 RN 918487-44-2 CAPLUS
 CN 1,2-Ethanedione, 1-[5-(4-fluorophenyl)-2-thienyl]-2-(4-methoxy-3-methylphenyl)- (CA INDEX NAME)




RN 918487-48-6 CAPLUS
 CN 1,2-Ethanedione, 1-[4-(4-fluorophenyl)-2-thienyl]-2-(4-methoxy-3-methylphenyl)- (CA INDEX NAME)

L19 ANSWER 13 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 14 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 their pharmaceutically acceptable salts, isomers, and prodrugs thereof, are claimed. Example compd. V was prepd. by acylation of 2-acetyl-5-bromothiophene with Et trifluoroacetate; the resulting 1-(5-bromothiophen-2-yl)-4,4,4-trifluorobutane-1,3-dione underwent cyclization with 2,5-dichlorophenylhydrazine hydrochloride to give 5-(5-bromothiophen-2-yl)-1-(2,5-dichlorophenyl)-3-trifluoromethyl-1H-pyrazole, which underwent Suzuki cross-coupling with 3-aminosulfonylphenylboronic acid to give compd. II. All the invention compds. were evaluated for their LXR modulatory activity. From the assay, it was detd. that several of the tested compds. exhibited IC50 values of < 1 μ M.
 IT 918315-43-2P 918315-45-4P 918315-51-2P
 918315-64-7P 918317-96-1P 918317-97-2P
 918319-99-0P 918321-56-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrazoles as LXR modulators and their use in the treatment of diseases)
 RN 918315-43-2 CAPLUS
 CN 1H-Pyrazole, 1-(5-chloro-2-methoxyphenyl)-5-[5-[3-(methylsulfonyl)phenyl]-2-thienyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 918315-45-4 CAPLUS
 CN 1H-Pyrazole, 1-(5-chloro-2-phenoxyphenyl)-5-[5-[3-(methylsulfonyl)phenyl]-2-thienyl]-3-(trifluoromethyl)- (CA INDEX NAME)


L19 ANSWER 14 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:14431 CAPLUS
 DOCUMENT NUMBER: 146:121962
 TITLE: Pyrazole based LXR modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Busch, Breet B.; Platt, Brenton T.; Gu, Xiao Hui; Martin, Richard; Mohan, Raju; Nyman, Michael Charles; Schweiger, Edwin; Stevens, William C., Jr.; Wang, Tie Lin; Xie, Yinong
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 533pp., which CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002559	A1	20070104	WO 2006-US24749	20060626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2005-694372P	P 20050627
			US 2005-736120P	P 20051110
OTHER SOURCE(S):		MARPAT 146:121962		
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. of the invention, such as compds. of formulas I, II, III, and IV and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors. Pharmaceutical compns. containing the compds. and methods of using the compds. are also disclosed. Compds. of formulas I - IV wherein R1 is (un)substituted (hetero)aryl, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted (thio)ethers, etc.; R2 and R21 are independently (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkyldiyl, H, halo, NO2, CN, (hetero)aryl, etc.; R3 is (un)substituted alkyl, (un)substituted alkyldiyl, (un)substituted alkenyl, (un)substituted acetyl, (un)substituted thioacetyl, etc.; G is (un)substituted (hetero)aryl, (un)substituted biaryl, (un)substituted alkenoyl, etc.; and


L19 ANSWER 14 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918315-51-2 CAPLUS
CN 1H-Pyrazole,
1-(2-chloro-5-methoxyphenyl)-5-[5-[3-(methylsulfonyl)phenyl]-
2-thienyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 918315-64-7 CAPLUS
CN Benzenesulfonamide,
3-[5-[1-(5-chloro-2-phenoxyphenyl)-3-(trifluoromethyl)-
1H-pyrazol-5-yl]-2-thienyl]- (CA INDEX NAME)



RN 918317-96-1 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-(5-chloro-2-phenoxyphenyl)-*a,a*-

L19 ANSWER 14 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dimethyl-5-[5-[3-(methylsulfonyl)phenyl]-2-thienyl]- (CA INDEX NAME)


RN 918317-97-2 CAPLUS
CN Ethanone,
1-[1-(5-chloro-2-phenoxyphenyl)-5-[5-[3-(methylsulfonyl)phenyl]-
2-thienyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 918319-99-0 CAPLUS
CN 1H-Pyrazole-3-methanamine, 1-(2-chlorophenyl)-N-[2-(3,4-
dimethoxyphenyl)ethyl]-N-methyl-5-[5-[3-(methylsulfonyl)phenyl]-2-thienyl]-
(CA INDEX NAME)

L19 ANSWER 14 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 918321-56-9 CAPLUS
CN 1H-Pyrazole, 1-[5-chloro-2-(4-fluorophenoxy)phenyl]-5-[5-[3-
(methylsulfonyl)phenyl]-2-thienyl]-3-(trifluoromethyl)- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1357306 CAPLUS
 DOCUMENT NUMBER: 146:100548
 TITLE: Preparation of thiophene derivatives as 5IP1/EDG1 receptor agonists
 INVENTOR(S): Bolli, Martin; Lehmann, David; Mathys, Boris; Mueller, Claus; Velker, Joerg
 PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd, Switz.
 SOURCE: PCT Int. Appl., 56pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006:137019	A1	20060628	WO 2006-1B51990	20060620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: WO 2005-EP6840 20050624

OTHER SOURCE(S): MARPAT 146:100548

GI

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Thiophene derivs., I, wherein R1 and R2 are H, alkyl, alkoxy or halo groups; R3 is H, alkyl, (un)substituted ester, (un)substituted acid, (un)substituted amides, etc.; R4 is H, alkyl or halogen; R5 is trifluoromethyl, Me, Et or propyl; R6 is (un)substituted Me, Et, halo, methoxy; R7 is H or Me are their preparation as 5IP1/EDG1 receptor agonists.


Thus, II was prepared and tested in a GTPyS binding assay (EC50 was 6.7 nM) and had an in vivo efficacy of ~48.5% 3 h after oral administration of 10 mg/kg of compound to normotensive male Wistar rats.

IT 917873-40-6P
 R1: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of thiophene derivs. as 5IP1/EDG1 receptor agonists)

RN 917873-40-6 CAPLUS

CN 1-Propanone, 3-(3-chloro-4-hydroxy-5-methoxyphenyl)-1-(5-ethyl-4-phenyl-2-thienyl)- (CA INDEX NAME)



IT 917873-21-3P 917873-22-4P 917873-24-6P
 917873-26-8P 917873-27-9P 917873-28-0P
 917873-31-5P 917873-36-0P 917873-37-1P
 917873-39-3P 917873-42-8P 917873-44-0P

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

917873-51-9P 917873-56-4P 917873-60-0P
 917873-63-3P 917873-65-5P 917873-66-6P
 917873-68-8P 917873-70-2P 917873-79-1P
 917873-81-5P 917873-83-7P 917873-85-9P
 917873-89-3P 917873-90-6P 917873-91-7P
 917873-93-9P 917873-94-0P 917873-95-1P
 917873-96-2P 917873-98-4P 917873-99-5P
 917874-00-1P 917874-01-2P 917874-04-5P
 917874-05-6P 917874-06-7P 917874-07-8P
 917874-09-0P 917874-10-3P 917874-11-4P
 917874-12-5P 917874-13-6P 917874-14-7P
 917874-16-9P 917874-17-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of thiophene derivs. as 5IP1/EDG1 receptor agonists)

RN 917873-21-3 CAPLUS


CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[4-phenyl-5-(trifluoromethyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 917873-22-4 CAPLUS

CN 1-Propanone, 3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1-[4-phenyl-5-(trifluoromethyl)-2-thienyl]- (CA INDEX NAME)




RN 917873-24-6 CAPLUS

CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-(5-methyl-4-phenyl-2-thienyl)- (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 917873-26-8 CAPLUS

CN 1-Propanone, 3-[4-(3-amino-2-hydroxypropoxy)-3,5-dimethylphenyl]-1-(5-methyl-4-phenyl-2-thienyl)- (CA INDEX NAME)




RN 917873-27-9 CAPLUS

CN 1-Propanone, 3-[4-[2-hydroxy-3-(methylamino)propoxy]-3,5-dimethylphenyl]-1-(5-methyl-4-phenyl-2-thienyl)- (CA INDEX NAME)




RN 917873-28-0 CAPLUS

CN 1-Propanone, 3-[4-[2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-3,5-dimethylphenyl]-1-(5-methyl-4-phenyl-2-thienyl)- (CA INDEX NAME)




L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 917873-31-5 CAPLUS
 CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-(5-ethyl-4-phenyl-2-thienyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 917873-36-0 CAPLUS
 CN 1-Propanone, 3-[4-(3-amino-2-hydroxypropoxy)-3,5-dimethylphenyl]-1-(5-ethyl-4-phenyl-2-thienyl)- (CA INDEX NAME)




RN 917873-37-1 CAPLUS
 CN 1-Propanone, 1-(5-ethyl-4-phenyl-2-thienyl)-3-[4-[2-hydroxy-3-(methylamino)propoxy]-3,5-dimethylphenyl]- (CA INDEX NAME)



RN 917873-39-3 CAPLUS
 CN 1-Propanone, 1-(5-ethyl-4-phenyl-2-thienyl)-3-[4-[2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-3,5-dimethylphenyl]- (CA INDEX NAME)

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH


RN 917873-51-9 CAPLUS
 CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-methylphenyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 917873-56-4 CAPLUS
 CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(4-methylphenyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 917873-60-0 CAPLUS


L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 917873-42-8 CAPLUS
 CN Formic acid, compd. with 3-[4-(3-amino-2-hydroxypropoxy)-3-chloro-5-methoxyphenyl]-1-(5-ethyl-4-phenyl-2-thienyl)-1-propanone (1:1) (CA INDEX NAME)

CM 1

CRN 917873-41-7
 CMF C25 H28 Cl N O4 S



CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH


RN 917873-44-0 CAPLUS
 CN Formic acid, compd. with 3-[3-chloro-4-[2-hydroxy-3-(methylamino)propoxy]-5-methoxyphenyl]-1-(5-ethyl-4-phenyl-2-thienyl)-1-propanone (1:1) (CA INDEX NAME)

CM 1

CRN 917873-43-9
 CMF C26 H30 Cl N O4 S

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-(4-phenyl-5-propyl-2-thienyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 917873-63-3 CAPLUS
 CN Formic acid, compd. with 3-[4-[2-hydroxy-3-(methylamino)propoxy]-3,5-dimethylphenyl]-1-(4-phenyl-5-propyl-2-thienyl)-1-propanone (1:1) (CA INDEX NAME)

CM 1

CRN 917873-62-2
 CMF C28 H35 N O3 S



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 917873-65-5 CAPLUS
 CN Formic acid, compd. with 3-[4-[2-hydroxy-3-[(2-hydroxyethyl)amino]propoxy]-3,5-dimethylphenyl]-1-(4-phenyl-5-propyl-2-thienyl)-1-propanone (1:1) (CA INDEX NAME)



CM 1

CRN 917873-64-4
 CMF C29 H37 N O4 S



L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





CM 2

CRN 64-18-6
CMF C H2 O2RN 917873-66-6 CAPLUS
CN 1-Propanone, 3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1-(4-phenyl-5-propyl-2-thienyl)- (CA INDEX NAME)RN 917873-68-8 CAPLUS
CN 1-Propanone, 3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]-1-(4-phenyl-5-propyl-2-thienyl)- (CA INDEX NAME)RN 917873-70-2 CAPLUS
CN 1-Propanone, 3-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-1-(4-



L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 917873-85-9 CAPLUS
CN 1-Propanone, 3-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-ethylphenyl)-2-thienyl]- (CA INDEX NAME)RN 917873-89-3 CAPLUS
CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-(trifluoromethyl)phenyl)-2-thienyl]- (CA INDEX NAME)



Absolute stereochemistry.

RN 917873-90-6 CAPLUS
CN 1-Propanone, 1-[5-ethyl-4-[2-(trifluoromethyl)phenyl]-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
phenyl-5-propyl-2-thienyl)- (CA INDEX NAME)RN 917873-79-1 CAPLUS
CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-ethylphenyl)-2-thienyl]- (CA INDEX NAME)


Absolute stereochemistry.

RN 917873-81-5 CAPLUS
CN 1-Propanone, 1-[5-ethyl-4-(2-ethylphenyl)-2-thienyl]-3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)RN 917873-83-7 CAPLUS
CN 1-Propanone, 1-[5-ethyl-4-(2-ethylphenyl)-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)


L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 917873-91-7 CAPLUS
CN 1-Propanone, 3-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-[2-(trifluoromethyl)phenyl]-2-thienyl]- (CA INDEX NAME)RN 917873-93-9 CAPLUS
CN 1-Propanone, 1-[4-(2-chlorophenyl)-5-ethyl-2-thienyl]-3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]- (CA INDEX NAME)


Absolute stereochemistry.

RN 917873-94-0 CAPLUS
CN 1-Propanone, 1-[4-(2-chlorophenyl)-5-ethyl-2-thienyl]-3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)


L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 917873-95-1 CAPLUS
 CN 1-Propanone, 1-[4-(2-chlorophenyl)-5-ethyl-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 917873-96-2 CAPLUS
 CN 1-Propanone, 1-[4-(2-chlorophenyl)-5-ethyl-2-thienyl]-3-[4-(2-(dimethylamino)ethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 917873-98-4 CAPLUS
 CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-fluorophenyl)-2-thienyl]- (CA INDEX NAME)

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.

RN 917873-99-5 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(2-fluorophenyl)-2-thienyl]-3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 917874-00-1 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(2-fluorophenyl)-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 917874-01-2 CAPLUS
 CN 1-Propanone,
 3-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-fluorophenyl)-2-thienyl]- (CA INDEX NAME)

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 917874-04-5 CAPLUS
 CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-methoxyphenyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 917874-05-6 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(2-methoxyphenyl)-2-thienyl]-3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 917874-06-7 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(2-methoxyphenyl)-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)

L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 917874-07-8 CAPLUS
 CN 1-Propanone,
 3-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-1-[5-ethyl-4-(2-methoxyphenyl)-2-thienyl]- (CA INDEX NAME)




RN 917874-09-0 CAPLUS
 CN 1-Propanone, 3-[4-[(2S)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[4-(2,3-dimethylphenyl)-5-ethyl-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 917874-10-3 CAPLUS
 CN 1-Propanone, 1-[4-(2,3-dimethylphenyl)-5-ethyl-2-thienyl]-3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)


L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 917874-11-4 CAPLUS
 CN 1-Propanone, 1-[4-(2,3-dimethylphenyl)-5-ethyl-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 917874-12-5 CAPLUS
 CN 1-Propanone, 3-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-1-[4-(2,3-dimethylphenyl)-5-ethyl-2-thienyl]- (CA INDEX NAME)



RN 917874-13-6 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(4-methylphenyl)-2-thienyl]-3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)


L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 917874-17-0 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(3-methylphenyl)-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




IT 917873-25-7P 917873-35-9P 917873-61-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiophene derivs. as S1P1/EDG1 receptor agonists)

RN 917873-25-7 CAPLUS
 CN 1-Propanone, 3-[3,5-dimethyl-4-(2-oxiranylmethoxy)phenyl]-1-(5-methyl-4-phenyl-2-thienyl)- (CA INDEX NAME)




RN 917873-35-9 CAPLUS
 CN 1-Propanone, 3-[3,5-dimethyl-4-(2-oxiranylmethoxy)phenyl]-1-(5-ethyl-4-phenyl-2-thienyl)- (CA INDEX NAME)




RN 917873-61-1 CAPLUS
 CN 1-Propanone, 3-[3,5-dimethyl-4-(2-oxiranylmethoxy)phenyl]-1-(4-phenyl-5-propyl-2-thienyl)- (CA INDEX NAME)


L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 917874-14-7 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(4-methylphenyl)-2-thienyl]-3-[4-(2-hydroxypropoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)




RN 917874-16-9 CAPLUS
 CN 1-Propanone, 1-[5-ethyl-4-(3-methylphenyl)-2-thienyl]-3-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]- (CA INDEX NAME)



L19 ANSWER 15 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



L19 ANSWER 16 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1312155 CAPLUS
 DOCUMENT NUMBER: 146:81671
 TITLE: Preparation of 3,3-bis(3-methylphenyl)pentane derivatives having vitamin D-like activity
 INVENTOR(S): Takahashi, Tadakatsu; Omo, Yoshiyuki; Kashiwagi, Hirokazu; Haneishi, Teyoshi; Shimizu, Kazuki
 PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 590pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006132442	A1	2006-01-14	WO 2006-JP312081	20060609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: JP 2005-169568 A 20050609 JP 2005-259634 A 20050903				


OTHER SOURCE(S): MARPAT 146:81671
 GI



AB The title benzylbenzene compds. [I; R1, R2 = each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkoxy; R3-R6 = H, halo, or each (un)substituted C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkoxy; R7-R9 = H, each (un)protected HO, NH2, or CO2H, (un)substituted C1-10 alkyl, C1-6 haloalkyl; or one of (R7 and R8),

L19 ANSWER 16 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (R7 and R9), and (R8 and R9) pairs form (un)substituted C3-10 cycloalkyl, CO, or (un)substituted 3- to 12-membered heterocyclic ring, or C3-7 lactone; X = a direct bond, CH2, CH2CH2, CH=CH, C.tplbond, C, O, S, NH, CO,
 (un)substituted C6-12 aryl, 3- to 12-membered heterocyclic ring; Y = each (un)substituted C6-12 aryl, 3- to 12-membered heterocyclic ring, or C1-6 alkoxy; provided that when Y is (un)substituted C1-6 alkoxy, then X is selected from each (un)substituted C6-12 aryl and 3- to 12-membered heterocyclic ring; a = an integer of 0-3] or pharmacol. acceptable salts thereof are prep. These compds. or pharmaceutically acceptable salts thereof are useful as pharmaceuticals for the treatment of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy, or the like. Thus,
 tert-butyl[1-[2-[4-[1-ethyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-methylphenyl]propyl]-2-methylphenyl]ethyl]-2,2-dimethylpropoxy]dimethylsilane was coupled with 2-chloropyridine-5-acetic acid Et ester in the presence of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-dichloromethane (1:1) complex in DMF at 76-84° for 7.5 h to give, after deprotection, chiral [6-[4-[1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]propyl]-2-methylphenyl]pyridin-3-yl]acetic acid (II). II in vitro induced the prodn. of osteocalcin with relative EC50 value of 3,264% compared to 100% for 1,25-dihydroxyvitamin D3 in human osteoblastic cell MG-63 and the prodn. of ECA2 mRNA with relative EC50 value 88% compared to 556% for 1,25-dihydroxyvitamin D3 in Caco-2 cells. It exhibited good sepn. of osteocalcin-inducing activity from the activity for prodn. of ECA2 mRNA (side effect) and thereby showed high osteocalcin-inducing activity and weak serum calcium-increasing activity.
 IT 917022-83-4P, (R)-5-[4-[1-ethyl-1-[4-[5-(1-ethyl-1-hydroxypropyl)-3-(methyl)thiophen-2-yl]-3-methylphenyl]propyl]-2-methylphenyl]oxy]-4-hydroxypentanoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3,3-bis(3-methylphenyl)pentane derivs. having vitamin D-like activity)
 RN 917022-83-4 CAPLUS
 CN Pentanoic acid,
 5-[4-[1-ethyl-1-[4-[5-(1-ethyl-1-hydroxypropyl)-3-methyl-2-thienyl]-3-methylphenyl]propyl]-2-methylphenoxy]-4-hydroxy-, (4R)- (CA INDEX NAME)
 Absolute stereochemistry.

L19 ANSWER 16 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 17 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1311129 CAPLUS
 DOCUMENT NUMBER: 146:62699
 TITLE: Preparation of polycyclic oxadiazoles or isoxazoles as S1P receptor ligands
 INVENTOR(S): Albert, Rainer; Weiler, Sven; Zecri, Frederic
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 53pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006131336	A1	2006-01-14	WO 2006-EP5422	20060607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: GB 2005-11684 A 20050608 GB 2005-25064 A 20051208 GB 2006-405 A 20060110				

OTHER SOURCE(S): MARPAT 146:62699
 GI



II


L19 ANSWER 17 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. represented by the formula I [wherein X = -N=, Y = O; X = -O-, Y = -N=; R1 = substituted biphenyl, 4-phenoxyphenyl or 4-(phenylalkoxy)phenyl; R2 = (un)substituted alkyl, amino, sulfamoyl, etc.; and physiol. hydrolyzable derivs., hydrates or solvates thereof] were prepared as sphingosine-1-phosphate (S1P) receptor ligands. For example, II was provided in a multi-step synthesis starting from 4-chloro-3-trifluoromethylbenzoic acid. I showed binding affinity to human S1P1 receptor with EC50 < 1 nM, are active in in vitro FLIPR calcium flux assay at a concentration of from 10-12-3.10-5 nM, and have EC50 of less than 10 mg/kg in in vivo screening assays for measurement of blood lymphocyte depletion. Thus, I and their pharmaceutical compns. are useful as S1P receptor ligands, particularly as immunosuppressants.

IT 916804-91-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of polycyclic oxadiazoles or isoxazoles as S1P receptor ligands)

RN 916804-91-6 CAPLUS

CN Benzoic acid, 4-[[[4-[5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-1,2,4-oxadiazol-3-yl]phenyl]methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 18 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1253322 CAPLUS

DOCUMENT NUMBER: 146:45734

TITLE: Preparation of N-terminally modified GLP-1 receptor modulators and their use in the treatment of diabetes and related conditions

INVENTOR(S): Ewing, William R.; Mapelli, Claudio; Rieksinger, Douglas James; Lee, Ving G.; Sulsky, Richard B.; Zhu, Yeheng

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 186pp.

CODEN: PIXXBD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006127948	A2	20061130	WO 2006-US20332	20060526
WO 2006127948	A3	20070419		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-604805P P 20050526

OTHER SOURCE(S): MARPAT 146:45734

AB The invention provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 [Xaa1-Xaa3, Xaa5-Xaa11 are (certain) naturally or non-naturally occurring amino acid residues; Xaa4 is glycine] that have biol. activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The compds. include chemical-modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes. Thus, claimed peptide H-H-Aib-EGT-L- α -MePhe(2-fluoro)-TSD-Bip(2'-Et-4'-OMe)-4-(2'-methylphenyl)-3-pyridylalanine-NH2 (H, E, G, T, S and D are one-letter amino acid symbols, Aib = α -aminoisobutyric acid residue, Bip = biphenylalanine residue) was prepared by the solid-phase method and shown to produce a time-dependent statistically significant

L19 ANSWER 18 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

decrease in postprandial plasma glucose following s.c. administration in ob/ob mice.


IT 916247-92-2P 916247-93-3P 916247-94-4P
 916247-95-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-terminally modified GLP-1 receptor modulators and their use in treatment of diabetes and related conditions)

RN 916247-92-2 CAPLUS

CN L-Alaninamide, L-histidyl-2-methylalanyl-L- α -glutamylglycyl-L-threonyl-2-fluoro- α -methyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-3-(2'-ethyl-4'-methoxy[1,1'-biphenyl]-4-yl)-L-alanyl-3-[5-(2-methylphenyl)-2-thienyl]- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L19 ANSWER 18 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 916247-93-3 CAPLUS

CN L-Alaninamide, L-histidyl-2-methylalanyl-L- α -glutamylglycyl-L-threonyl-2-fluoro- α -methyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-3-(2'-ethyl-4'-methoxy[1,1'-biphenyl]-4-yl)-L-alanyl-3-[5-(3-methoxyphenyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L19 ANSWER 18 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 18 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A

PAGE 1-B




RN 916247-94-4 CAPLUS
 CN L-Alaninamide, L-histidyl-2-methylalanyl-L- α -glutamylglycyl-L-threonyl-2-fluoro- α -methyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-3-(2'-ethyl-4'-methoxy[1,1'-biphenyl]-4-yl)-L-alanyl-3-[5-(3,5-dimethylphenyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



L19 ANSWER 18 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 18 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

RN 916247-95-5 CAPLUS
 CN L-Alaninamide, L-histidyl-2-methylalanyl-L- α -glutamylglycyl-L-threonyl-2-fluoro- α -methyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-3-(2'-ethyl-4'-methoxy[1,1'-biphenyl]-4-yl)-L-alanyl-3-[5-(3-chloro-5-fluorophenyl)-2-thienyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L19 ANSWER 19 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1253006 CAPLUS
 DOCUMENT NUMBER: 146:35942
 TITLE: Photochromic and electrochromic compounds and synthesis and use thereof
 INVENTOR(S): Branda, Neil R.; Wuestenberg, Bettina; Lemieux, Vincent; Adams, Michael; Gauthier, Simon
 PATENT ASSIGNER(S): Simon Fraser University, Can.
 SOURCE: PCT Int. Appl., 61pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125317	A1	20061102	WO 2006-CA862	20060525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:		US 2005-684715P P 20050525		

OTHER SOURCE(S): MARPAT 146:35942
 AB Novel photochromic and electrochromic hexadiene compds. are described. The compds. are reversibly convertible between ring-open and ring-closed isomeric forms. The conversion between the different isomeric forms may be induced by light or electricity. In one embodiment the compds. may include a charge transfer moiety including electron donor and acceptor groups. The electron donor and acceptor are linearly conjugated in the ring-open form to enable electron transfer but are elec. insulated in the ring-closed form. Methods for synthesizing the compds. from photochem. and/or elec. inert precursors are also described. For example, the photoresponsive compds. may be synthesized by reacting diene precursors with dienophiles in a condensation reaction. The compds. may be utilized in reactivity-gated photochromic or electrochromic applications. In one embodiment of the invention, compds. of the invention may be used in a method to selectively release a releasable agent, such as a small mol. According to this method, a photochem. inert precursor compound is reacted with the releasable agent to form a carrier compound comprising a switching moiety, the switching moiety being reversibly convertible between a thermally unstable form and a thermally stable form. The switching moiety

L19 ANSWER 19 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 869207-58-9 CAPLUS
 CN Propanedinitrile, 2-[[[3,3,4,4,5,5-hexafluoro-2-(2-methyl-5-phenyl-3-thienyl)-1-cyclopenten-1-yl](4-methoxyphenyl)methylene]- (CA INDEX NAME)




RN 915951-79-0 CAPLUS
 CN Propanedinitrile, 2-[[[3,3,4,4,5,5-hexafluoro-2-(2-methyl-5-phenyl-3-thienyl)-1-cyclopenten-1-yl](3,4,5-trimethoxyphenyl)methylene]- (CA INDEX NAME)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 19 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 may be selectively converted between the first and second forms to cause controlled release of the releasable agent from the carrier compd.
 IT 869207-54-5P 915951-76-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (photochromic and electrochromic compds. and synthesis and use thereof)
 RN 869207-54-5 CAPLUS
 CN Methanone, [3,3,4,4,5,5-hexafluoro-2-(2-methyl-5-phenyl-3-thienyl)-1-cyclopenten-1-yl](4-methoxyphenyl)- (CA INDEX NAME)



RN 915951-76-7 CAPLUS
 CN Methanone, [3,3,4,4,5,5-hexafluoro-2-(2-methyl-5-phenyl-3-thienyl)-1-cyclopenten-1-yl](3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




IT 869207-58-9P 915951-79-0P
 RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (photochromic and electrochromic compds. and synthesis and use thereof)

L19 ANSWER 20 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1206741 CAPLUS
 DOCUMENT NUMBER: 145:489228
 TITLE: Preparation of thiazole compounds for treating Hepatitis C virus infections
 INVENTOR(S): Zhang, Suoming; Phadke, Avinash; Liu, Cuixian; Wang, Xiangzhu; Quinn, Jesse; Chen, Dawei; Gadachanda, Venkat; Li, Shouming; Deshpande, Milind
 PATENT ASSIGNER(S): Achillion Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 254pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006122011	A2	20061116	WO 2006-US17692	20060509
WO 2006122011	A3	200610503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:		US 2007004711 A1 20070104 US 2006-431159 20060509 US 2005-679133P P 20050509		

OTHER SOURCE(S): MARPAT 145:489228
 GI




AB The title compds. I [Ar1 = fluorenyl, Ph, naphthyl, etc.; R2 = halo, CO2H,

L19 ANSWER 20 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CONH2, etc.; R3 = H, alkyl, C(O)R5 (wherein R5 = alkyl, Ph, 5-6 membered heteroaryl); R4 = H, halo, OH, etc.; or R2 and R4 are taken together with the carbon atoms of the thiazole ring to which they are attached to form 5-7 membered carbocyclic ring which is arom. or partially unsatd.; r = 0-2; q = 0-1; t = 0-1] that are potent and/or selective inhibitors of Hepatitis C virus replication, were prepd. Thus, bromination of 3-acetylpyridine with Br2 followed by reacting 2-bromo-1-(pyridin-3-yl)ethanone with N-(4-pentyloxy-3-trifluoromethylphenyl)thiourea afforded II which showed EC50 of < 1 μ M when tested in a replicon based assay of HCV replication inhibition. Certain compds. I inhibit assembly of the replication complex. The invention also provides pharmaceutical compns. contg. one or more compds. I, or a salt, solvate, or acylated prodrug of such compds., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amt. of a compd. I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compd. I as a single active agent or administering a compd. I in combination with one or more other therapeutic agent.
 IT 914659-52-2P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazole compds. for treating Hepatitis C virus infections)
 RN 914659-52-2 CAPLUS
 CN 2-Thiazolamine,
 N-[4-(pentyloxy)-3-(trifluoromethyl)phenyl]-4-(5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RI: PRP (Properties)
 (energy and charge transfer dynamics in fully decorated benzyl ether dendrimers with aminopyrene end groups)
 RN 840531-18-2 CAPLUS
 CN 1-Pyrenamine, N,N',N'',N'''-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenyleneoxymethylene-5,1,3-benzenetriylbis(oxyethylene-3,1-phenylene)]]tetrakis[N-phenyl- (CA INDEX NAME)


PAGE 1-A




L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1184850 CAPLUS
 DOCUMENT NUMBER: 146:122741
 TITLE: Energy and Charge Transfer Dynamics in Fully Decorated Benzyl Ether Dendrimers and Their Disubstituted Analogues
 AUTHOR(S): Ahn, Tai-Sang; Nantalaksakul, Arpornrat; Dasari, Raghunath R.; Al-Kaysi, Rabi O.; Mueller, Astrid M.; Thayumanaavan, S.; Bardeen, Christopher J.
 CORPORATE SOURCE: Department of Chemistry, University of California, Riverside, CA, 92521, USA
 SOURCE: Journal of Physical Chemistry B (2006), 110(48), 24331-24339
 CODEN: JPCBPK; ISSN: 1520-6106
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The photophysics were studied of a series of mols. consisting of a benzthiadiazole core surrounded by a network of benzyl ether arms terminated by aminopyrene chromophores, which function as both energy and electron donors. Three classes of mols. were studied: dendrimers whose peripheries are fully decorated with aminopyrene donors (F), disubstituted dendrimers whose peripheries contain only two donors (D), and linear analogs in which a pair of benzyl ether arms link two donors to the central core (L). The electronic energy transfer (EET) and charge transfer (CT) rates were determined by fluorescence lifetime measurements on the energy donors and electron acceptors, resp. In all three types of mols., the EET time scales as the square root of the generation number G, consistent with the flexible nature of the benzyl ether framework. Transient anisotropy measurements confirm that donor-donor energy hopping does not play a major role in determining the EET times. The CT dynamics occur on the nanosecond time scale and lead to stretched exponential decays, probably due to conformational disorder. Measurements at 100° confirm that conformational fluctuations play a role in the CT dynamics. The average CT time increases with G in the L and D mols. but decreases for the F dendrimers. This divergent behavior as G increases is attributed to the competing effects of larger donor-acceptor distances (which lengthen the CT time) vs. a larger number of donors (which shorten the average CT time). This work illustrates two important points about light-harvesting and charge-separation dendrimers. First, the use of a flexible dendrimer framework can lead to a more favorable scaling of the EET time (and thus the light-harvesting efficiency) with dendrimer size, relative to what would be expected for a fully extended dendrimer. Second, fully decorated dendrimers can compensate for the distance-dependent slowdown in CT rate as G increases by providing addnl. pathways for the CT reaction to occur.
 IT 840531-18-2 903562-03-8 903562-04-9 903562-05-0 903562-06-1 903562-07-2

L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




PAGE 3-A




RN 903562-03-8 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenyleneoxymethylene-5,1,3-benzenetriylbis(oxyethylene-3,1-phenylene)]]bis[N-phenyl- (CA INDEX NAME)

L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 903562-04-9 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenylene]oxymethylene-5-[[3,5-bis(phenylmethoxy)phenyl]methoxy]-3,1-phenylene]oxymethylene-5-(phenylmethoxy)-3,1-phenylene]bis[N-phenyl- (CA INDEX NAME)]

L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A



PAGE 2-B




PAGE 3-A




L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 903562-05-0 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-3,1-phenylene]oxymethylene-3,1-phenylene]oxymethylene-3,1-phenylene]bis[N-phenyl- (CA INDEX NAME)]

PAGE 1-A




PAGE 2-A




RN 903562-06-1 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-3,1-phenylene]oxymethylene-3,1-phenylene]oxymethylene-3,1-phenylene]bis[N-phenyl- (CA INDEX NAME)]

L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L19 ANSWER 21 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B




RN 903562-07-2 CAPLUS
CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-3,1-phenyleneoxymethylene-3,1-phenyleneoxymethylene-3,1-phenyleneoxymethylene-3,1-phenylene)]bis[N-phenyl- (CA INDEX NAME)]

PAGE 1-A




PAGE 1-B



L19 ANSWER 22 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1096947 CAPLUS
DOCUMENT NUMBER: 145:438628
TITLE: Preparation of triazole-4-carboxamide derivatives as thrombin receptor antagonists
INVENTOR(S): Kubo, Keiji; Tobisu, Mamoru; Honda, Eiji; Taniguchi, Takahiko; Fukase, Yoshiyuki; Kawamura, Masaki; Nakayama, Masaharu
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 598pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006109846	A1	2006-019	WO 2006-JP307797	20060406
W:	AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, NI, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			JP 2005-110391	20050406
OTHER SOURCE(S):			MARPAT 145:438628	
GI				



AB The invention relates to a thrombin receptor antagonist comprising a compound represented by the formula (I) [R1a, R1b, R2 = independently H or each (un)substituted hydrocarbon, heterocyclic, or alkoxy; R3 = a group represented by any of the formulas, -NHCOR4, -NHSO2R5, -NHCOR6a, -NHCOR6b, -NHCOR6c, -NHCOR6d, -NHCOR6e, -NHCOR6f, -NHCOR6g, -NHCOR6h, -NHCOR6i, -NHCOR6j, -NHCOR6k, -NHCOR6l, -NHCOR6m, -NHCOR6n, -NHCOR6o, -NHCOR6p, -NHCOR6q, -NHCOR6r, -NHCOR6s, -NHCOR6t, -NHCOR6u, -NHCOR6v, -NHCOR6w, -NHCOR6x, -NHCOR6y, -NHCOR6z, -NHCOR6aa, -NHCOR6ab, -NHCOR6ac, -NHCOR6ad, -NHCOR6ae, -NHCOR6af, -NHCOR6ag, -NHCOR6ah, -NHCOR6ai, -NHCOR6aj, -NHCOR6ak, -NHCOR6al, -NHCOR6am, -NHCOR6an, -NHCOR6ao, -NHCOR6ap, -NHCOR6aq, -NHCOR6ar, -NHCOR6as, -NHCOR6at, -NHCOR6au, -NHCOR6av, -NHCOR6aw, -NHCOR6ax, -NHCOR6ay, -NHCOR6az, -NHCOR6ba, -NHCOR6bb, -NHCOR6bc, -NHCOR6bd, -NHCOR6be, -NHCOR6bf, -NHCOR6bg, -NHCOR6bh, -NHCOR6bi, -NHCOR6bj, -NHCOR6bk, -NHCOR6bl, -NHCOR6bm, -NHCOR6bn, -NHCOR6bo, -NHCOR6bp, -NHCOR6bq, -NHCOR6br, -NHCOR6bs, -NHCOR6bt, -NHCOR6bu, -NHCOR6bv, -NHCOR6bw, -NHCOR6bx, -NHCOR6by, -NHCOR6bz, -NHCOR6ca, -NHCOR6cb, -NHCOR6cc, -NHCOR6cd, -NHCOR6ce, -NHCOR6cf, -NHCOR6cg, -NHCOR6ch, -NHCOR6ci, -NHCOR6cj, -NHCOR6ck, -NHCOR6cl, -NHCOR6cm, -NHCOR6cn, -NHCOR6co, -NHCOR6cp, -NHCOR6cq, -NHCOR6cr, -NHCOR6cs, -NHCOR6ct, -NHCOR6cu, -NHCOR6cv, -NHCOR6cw, -NHCOR6cx, -NHCOR6cy, -NHCOR6cz, -NHCOR6da, -NHCOR6db, -NHCOR6dc, -NHCOR6dd, -NHCOR6de, -NHCOR6df, -NHCOR6dg, -NHCOR6dh, -NHCOR6di, -NHCOR6dj, -NHCOR6dk, -NHCOR6dl, -NHCOR6dm, -NHCOR6dn, -NHCOR6do, -NHCOR6dp, -NHCOR6dq, -NHCOR6dr, -NHCOR6ds, -NHCOR6dt, -NHCOR6du, -NHCOR6dv, -NHCOR6dw, -NHCOR6dx, -NHCOR6dy, -NHCOR6dz, -NHCOR6ea, -NHCOR6eb, -NHCOR6ec, -NHCOR6ed, -NHCOR6ee, -NHCOR6ef, -NHCOR6eg, -NHCOR6eh, -NHCOR6ei, -NHCOR6ej, -NHCOR6ek, -NHCOR6el, -NHCOR6em, -NHCOR6en, -NHCOR6eo, -NHCOR6ep, -NHCOR6eq, -NHCOR6er, -NHCOR6es, -NHCOR6et, -NHCOR6eu, -NHCOR6ev, -NHCOR6ew, -NHCOR6ex, -NHCOR6ey, -NHCOR6ez, -NHCOR6fa, -NHCOR6fb, -NHCOR6fc, -NHCOR6fd, -NHCOR6fe, -NHCOR6ff, -NHCOR6fg, -NHCOR6fh, -NHCOR6fi, -NHCOR6fj, -NHCOR6fk, -NHCOR6fl, -NHCOR6fm, -NHCOR6fn, -NHCOR6fo, -NHCOR6fp, -NHCOR6fq, -NHCOR6fr, -NHCOR6fs, -NHCOR6ft, -NHCOR6fu, -NHCOR6fv, -NHCOR6fw, -NHCOR6fx, -NHCOR6fy, -NHCOR6fz, -NHCOR6ga, -NHCOR6gb, -NHCOR6gc, -NHCOR6gd, -NHCOR6ge, -NHCOR6gf, -NHCOR6gg, -NHCOR6gh, -NHCOR6gi, -NHCOR6gj, -NHCOR6gk, -NHCOR6gl, -NHCOR6gm, -NHCOR6gn, -NHCOR6go, -NHCOR6gp, -NHCOR6gq, -NHCOR6gr, -NHCOR6gs, -NHCOR6gt, -NHCOR6gu, -NHCOR6gv, -NHCOR6gw, -NHCOR6gx, -NHCOR6gy, -NHCOR6gz, -NHCOR6ha, -NHCOR6hb, -NHCOR6hc, -NHCOR6hd, -NHCOR6he, -NHCOR6hf, -NHCOR6hg, -NHCOR6hh, -NHCOR6hi, -NHCOR6hj, -NHCOR6hk, -NHCOR6hl, -NHCOR6hm, -NHCOR6hn, -NHCOR6ho, -NHCOR6hp, -NHCOR6hq, -NHCOR6hr, -NHCOR6hs, -NHCOR6ht, -NHCOR6hu, -NHCOR6hv, -NHCOR6hw, -NHCOR6hx, -NHCOR6hy, -NHCOR6hz, -NHCOR6ia, -NHCOR6ib, -NHCOR6ic, -NHCOR6id, -NHCOR6ie, -NHCOR6if, -NHCOR6ig, -NHCOR6ih, -NHCOR6ii, -NHCOR6ij, -NHCOR6ik, -NHCOR6il, -NHCOR6im, -NHCOR6in, -NHCOR6io, -NHCOR6ip, -NHCOR6iq, -NHCOR6ir, -NHCOR6is, -NHCOR6it, -NHCOR6iu, -NHCOR6iv, -NHCOR6iw, -NHCOR6ix, -NHCOR6iy, -NHCOR6iz, -NHCOR6ja, -NHCOR6jb, -NHCOR6jc, -NHCOR6jd, -NHCOR6je, -NHCOR6jf, -NHCOR6jg, -NHCOR6jh, -NHCOR6ji, -NHCOR6jj, -NHCOR6jk, -NHCOR6jl, -NHCOR6jm, -NHCOR6jn, -NHCOR6jo, -NHCOR6jp, -NHCOR6jq, -NHCOR6jr, -NHCOR6js, -NHCOR6jt, -NHCOR6ju, -NHCOR6jv, -NHCOR6jw, -NHCOR6jx, -NHCOR6jy, -NHCOR6jz, -NHCOR6ka, -NHCOR6kb, -NHCOR6kc, -NHCOR6kd, -NHCOR6ke, -NHCOR6kf, -NHCOR6kg, -NHCOR6kh, -NHCOR6ki, -NHCOR6kj, -NHCOR6kl, -NHCOR6km, -NHCOR6kn, -NHCOR6ko, -NHCOR6kp, -NHCOR6kq, -NHCOR6kr, -NHCOR6ks, -NHCOR6kt, -NHCOR6ku, -NHCOR6kv, -NHCOR6kw, -NHCOR6kx, -NHCOR6ky, -NHCOR6kz, -NHCOR6la, -NHCOR6lb, -NHCOR6lc, -NHCOR6ld, -NHCOR6le, -NHCOR6lf, -NHCOR6lg, -NHCOR6lh, -NHCOR6li, -NHCOR6lj, -NHCOR6lk, -NHCOR6ll, -NHCOR6lm, -NHCOR6ln, -NHCOR6lo, -NHCOR6lp, -NHCOR6lq, -NHCOR6lr, -NHCOR6ls, -NHCOR6lt, -NHCOR6lu, -NHCOR6lv, -NHCOR6lw, -NHCOR6lx, -NHCOR6ly, -NHCOR6lz, -NHCOR6ma, -NHCOR6mb, -NHCOR6mc, -NHCOR6md, -NHCOR6me, -NHCOR6mf, -NHCOR6mg, -NHCOR6mh, -NHCOR6mi, -NHCOR6mj, -NHCOR6mk, -NHCOR6ml, -NHCOR6mn, -NHCOR6mo, -NHCOR6mp, -NHCOR6mq, -NHCOR6mr, -NHCOR6ms, -NHCOR6mt, -NHCOR6mu, -NHCOR6mv, -NHCOR6mw, -NHCOR6mx, -NHCOR6my, -NHCOR6mz, -NHCOR6na, -NHCOR6nb, -NHCOR6nc, -NHCOR6nd, -NHCOR6ne, -NHCOR6nf, -NHCOR6ng, -NHCOR6nh, -NHCOR6ni, -NHCOR6nj, -NHCOR6nk, -NHCOR6nl, -NHCOR6nm, -NHCOR6nn, -NHCOR6no, -NHCOR6np, -NHCOR6nq, -NHCOR6nr, -NHCOR6ns, -NHCOR6nt, -NHCOR6nu, -NHCOR6nv, -NHCOR6nw, -NHCOR6nx, -NHCOR6ny, -NHCOR6nz, -NHCOR6oa, -NHCOR6ob, -NHCOR6oc, -NHCOR6od, -NHCOR6oe, -NHCOR6of, -NHCOR6og, -NHCOR6oh, -NHCOR6oi, -NHCOR6oj, -NHCOR6ok, -NHCOR6ol, -NHCOR6om, -NHCOR6on, -NHCOR6oo, -NHCOR6op, -NHCOR6oq, -NHCOR6or, -NHCOR6os, -NHCOR6ot, -NHCOR6ou, -NHCOR6ov, -NHCOR6ow, -NHCOR6ox, -NHCOR6oy, -NHCOR6oz, -NHCOR6pa, -NHCOR6pb, -NHCOR6pc, -NHCOR6pd, -NHCOR6pe, -NHCOR6pf, -NHCOR6pg, -NHCOR6ph, -NHCOR6pi, -NHCOR6pj, -NHCOR6pk, -NHCOR6pl, -NHCOR6pm, -NHCOR6pn, -NHCOR6po, -NHCOR6pp, -NHCOR6pq, -NHCOR6pr, -NHCOR6ps, -NHCOR6pt, -NHCOR6pu, -NHCOR6pv, -NHCOR6pw, -NHCOR6px, -NHCOR6py, -NHCOR6pz, -NHCOR6qa, -NHCOR6qb, -NHCOR6qc, -NHCOR6qd, -NHCOR6qe, -NHCOR6qf, -NHCOR6qg, -NHCOR6qh, -NHCOR6qi, -NHCOR6qj, -NHCOR6qk, -NHCOR6ql, -NHCOR6qm, -NHCOR6qn, -NHCOR6qo, -NHCOR6qp, -NHCOR6qq, -NHCOR6qr, -NHCOR6qs, -NHCOR6qt, -NHCOR6qu, -NHCOR6qv, -NHCOR6qw, -NHCOR6qx, -NHCOR6qy, -NHCOR6qz, -NHCOR6ra, -NHCOR6rb, -NHCOR6rc, -NHCOR6rd, -NHCOR6re, -NHCOR6rf, -NHCOR6rg, -NHCOR6rh, -NHCOR6ri, -NHCOR6rj, -NHCOR6rk, -NHCOR6rl, -NHCOR6rm, -NHCOR6rn, -NHCOR6ro, -NHCOR6rp, -NHCOR6rq, -NHCOR6rr, -NHCOR6rs, -NHCOR6rt, -NHCOR6ru, -NHCOR6rv, -NHCOR6rw, -NHCOR6rx, -NHCOR6ry, -NHCOR6rz, -NHCOR6sa, -NHCOR6sb, -NHCOR6sc, -NHCOR6sd, -NHCOR6se, -NHCOR6sf, -NHCOR6sg, -NHCOR6sh, -NHCOR6si, -NHCOR6sj, -NHCOR6sk, -NHCOR6sl, -NHCOR6sm, -NHCOR6sn, -NHCOR6so, -NHCOR6sp, -NHCOR6sq, -NHCOR6sr, -NHCOR6ss, -NHCOR6st, -NHCOR6su, -NHCOR6sv, -NHCOR6sw, -NHCOR6sx, -NHCOR6sy, -NHCOR6sz, -NHCOR6ta, -NHCOR6tb, -NHCOR6tc, -NHCOR6td, -NHCOR6te, -NHCOR6tf, -NHCOR6tg, -NHCOR6th, -NHCOR6ti, -NHCOR6tj, -NHCOR6tk, -NHCOR6tl, -NHCOR6tm, -NHCOR6tn, -NHCOR6to, -NHCOR6tp, -NHCOR6tq, -NHCOR6tr, -NHCOR6ts, -NHCOR6tt, -NHCOR6tu, -NHCOR6tv, -NHCOR6tw, -NHCOR6tx, -NHCOR6ty, -NHCOR6tz, -NHCOR6ua, -NHCOR6ub, -NHCOR6uc, -NHCOR6ud, -NHCOR6ue, -NHCOR6uf, -NHCOR6ug, -NHCOR6uh, -NHCOR6ui, -NHCOR6uj, -NHCOR6uk, -NHCOR6ul, -NHCOR6um, -NHCOR6un, -NHCOR6uo, -NHCOR6up, -NHCOR6uq, -NHCOR6ur, -NHCOR6us, -NHCOR6ut, -NHCOR6uu, -NHCOR6uv, -NHCOR6uw, -NHCOR6ux, -NHCOR6uy, -NHCOR6uz, -NHCOR6va, -NHCOR6vb, -NHCOR6vc, -NHCOR6vd, -NHCOR6ve, -NHCOR6vf, -NHCOR6vg, -NHCOR6vh, -NHCOR6vi, -NHCOR6vj, -NHCOR6vk, -NHCOR6vl, -NHCOR6vm, -NHCOR6vn, -NHCOR6vo, -NHCOR6vp, -NHCOR6vq, -NHCOR6vr, -NHCOR6vs, -NHCOR6vt, -NHCOR6vu, -NHCOR6vv, -NHCOR6vw, -NHCOR6vx, -NHCOR6vy, -NHCOR6vz, -NHCOR6wa, -NHCOR6wb, -NHCOR6wc, -NHCOR6wd, -NHCOR6we, -NHCOR6wf, -NHCOR6wg, -NHCOR6wh, -NHCOR6wi, -NHCOR6wj, -NHCOR6wk, -NHCOR6wl, -NHCOR6wm, -NHCOR6wn, -NHCOR6wo, -NHCOR6wp, -NHCOR6wq, -NHCOR6wr, -NHCOR6ws, -NHCOR6wt, -NHCOR6wu, -NHCOR6wv, -NHCOR6ww, -NHCOR6wx, -NHCOR6wy, -NHCOR6wz, -NHCOR6xa, -NHCOR6xb, -NHCOR6xc, -NHCOR6xd, -NHCOR6xe, -NHCOR6xf, -NHCOR6xg, -NHCOR6xh, -NHCOR6xi, -NHCOR6xj, -NHCOR6xk, -NHCOR6xl, -NHCOR6xm, -NHCOR6xn, -NHCOR6xo, -NHCOR6xp, -NHCOR6xq, -NHCOR6xr, -NHCOR6xs, -NHCOR6xt, -NHCOR6xu, -NHCOR6xv, -NHCOR6xw, -NHCOR6xx, -NHCOR6xy, -NHCOR6xz, -NHCOR6ya, -NHCOR6yb, -NHCOR6yc, -NHCOR6yd, -NHCOR6ye, -NHCOR6yf, -NHCOR6yg, -NHCOR6yh, -NHCOR6yi, -NHCOR6yj, -NHCOR6yk, -NHCOR6yl, -NHCOR6ym, -NHCOR6yn, -NHCOR6yo, -NHCOR6yp, -NHCOR6yq, -NHCOR6yr, -NHCOR6ys, -NHCOR6yt, -NHCOR6yu, -NHCOR6yv, -NHCOR6yw, -NHCOR6yx, -NHCOR6yy, -NHCOR6yz, -NHCOR6za, -NHCOR6zb, -NHCOR6zc, -NHCOR6zd, -NHCOR6ze, -NHCOR6zf, -NHCOR6zg, -NHCOR6zh, -NHCOR6zi, -NHCOR6zj, -NHCOR6zk, -NHCOR6zl, -NHCOR6zm, -NHCOR6zn, -NHCOR6zo, -NHCOR6zp, -NHCOR6zq, -NHCOR6zr, -NHCOR6zs, -NHCOR6zt, -NHCOR6zu, -NHCOR6zv, -NHCOR6zw, -NHCOR6zx, -NHCOR6zy, -NHCOR6zz]

L19 ANSWER 22 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
to each other to form an (un)substituted nitrogen-contg. nonarom.
heterocyclic ring], or a salt thereof or a prodrug thereof. The thrombin
receptor antagonist of the invention has a thrombin receptor

(particularly

PAR-1) antagonism and is useful for preventing or treating PAR-1 assocd.
pathol. conditions or diseases, e.g. vein or artery thrombus such as
cerebral infarction, myocardial infarction, and acute heart failure.
Thus, 1-(4-aminophenyl)-N-cyclopropyl-5-propyl-1H-1,2,3-triazole-4-
carboxamide was condensed with 3,3,3-trifluoropropanoic acid using
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HOBT, and
Et3N in MeCN overnight at room temp. to give 43%

N-Cyclopropyl-5-propyl-1-

[4-[(3,3,3-trifluoropropanoyl)amino]phenyl]-1H-1,2,3-triazole-4-
carboxamide (II). II inhibited the increase in cellular calcium concn.

in

CHO cells expressing human PAR-1 with IC50 of 0.094 μ M. Pharmaceutical
formulations, e.g. a capsule and tablet formulation contg.

N-cyclopropyl-1-[4-[(ethylamino)carbonyl]amino]phenyl]-5-propyl-1H-1,2,3-
triazole-4-carboxamide, were described.

IT 912834-29-8P, N-[[5-(4-Chlorophenyl)-2-thienyl]methyl]-1-[4-
[(ethylamino)carbonyl]-2-[2-(2-fluoroethoxy)ethoxy]phenyl]-1H-1,2,3-
triazole-4-carboxamide 912835-11-1P, N-[[5-(4-Chlorophenyl)-2-
thienyl]methyl]-1-[2-[2-(2-fluoroethoxy)ethoxy]-4-[[2,2,2-
trifluoroethyl)amino]carbonyl]phenyl]-1H-1,2,3-triazole-4-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of triazolecarboxamide derivs. as thrombin receptor
antagonists


for treatment or prevention of vein or artery thrombus)

RN 912834-29-8 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxamide,


N-[[5-(4-chlorophenyl)-2-thienyl]methyl]-

1-[4-[(ethylamino)carbonyl]-2-[2-(2-fluoroethoxy)ethoxy]phenyl]- (9CI)
(CA INDEX NAME)




L19 ANSWER 22 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 912835-11-1 CAPLUS
CN 1H-1,2,3-Triazole-4-carboxamide,
N-[[5-(4-chlorophenyl)-2-thienyl]methyl]-

1-[2-[2-(2-fluoroethoxy)ethoxy]-4-[[2,2,2-trifluoroethyl)amino]carbonyl]p
henyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 23 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:904044 CAPLUS
DOCUMENT NUMBER: 145:471433
TITLE: Introduction of ethynylene and thienylene spacers
into
2,5-diarylthiazole and 2,5-diarylthiophene
AUTHOR(S): Kobayashi, Kei; Mohamed Ahmed, Mohamed S.; Mori,
Atsumori
CORPORATE SOURCE: Chemical Resources Laboratory, Tokyo Institute of
Technology, Yokohama, 226-8503, Japan
SOURCE: Tetrahedron (2006), 62(41), 9548-9553
CODEN: TETRAH; ISSN: 0040-4020
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:471433
GI



AB Syntheses of 2,5-diarylthiazole and 2,5-diarylthiophene derivs. bearing
ethynylene and thienylene spacers (e.g. I) are performed. With methods
for coupling reactions of terminal alkynes and at the CH bond of
heteroarom. compds., five kinds of thiazole and thiophene derivs. are
prepared

IT 913627-45-9P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of 2,5-diarylthiazole and 2,5-diarylthiophene derivs.

bearing

ethynylene and thienylene spacers via Pd-catalyzed coupling reactions
of terminal alkynes and heteroarom. compds.)

RN 913627-45-9 CAPLUS

CN Benzoic acid, 4-[5-[(4-methoxyphenyl)ethynyl]-2-thienyl]-, ethyl ester
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR
THIS


L19 ANSWER 24 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:887897 CAPLUS
 DOCUMENT NUMBER: 145:293047
 TITLE: Preparation of heterocyclic compounds as activators for peroxisome proliferator activated receptor δ
 INVENTOR(S): Sakuma, Shogo; Mochiduki, Nobutaka; Takahashi, Rie; Hirai, Toshitake; Yamakawa, Tomio; Masui, Seichiro
 PATENT ASSIGNEE(S): Nippon Chemphar Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 115pp.
 CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090920	A1	20060830	WO 2006-JP304193	20060228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PK, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, KE, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: JP 2005-52762 A 20050228

OTHER SOURCE(S): MARPAT 145:293047
 GI




AB The title compds. I [R1, R4 = H, alkyl, alkenyl, etc.; R2 = H; R3 = alkyl; or CR2R3 is CO, or CR2R3 is C=CR7R8; R7, R8 = H, alkyl; R5, R6 = H, alkyl, haloalkyl; X, Y = CH, N; Z = O, S; A = (un)substituted pyrazole, thiophene, furan, or pyrrole ring; B = (un)substituted alkylene; n = 0 - 5] are prepared. Thus, 2-[4-[3-[3-isopropyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]propionyl]-2-methylphenoxy]-2-methylpropionic acid was prepared


L19 ANSWER 24 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 908251-01-4 CAPLUS
 CN Acetic acid, [2-methyl-4-[3-[3-(1-methylethyl)-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 908251-03-6 CAPLUS
 CN Propanoic acid, 2-[4-[3-[3-hexyl-5-(4-methylphenyl)-2-thienyl]-1-oxopropyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




IT 908250-75-9P 908250-79-3P 908250-95-3P
 908250-99-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclic compds. as activators for peroxisome proliferator-activated receptor δ)
 RN 908250-75-9 CAPLUS
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 24 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 in a multistep process from [3-isopropyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol. In an assay for the activation of peroxisome proliferator-activated receptor δ , compds. of this invention showed high activity.

IT 908250-77-1P 908250-81-7P 908250-97-5P
 908251-01-4P 908251-03-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. as activators for peroxisome proliferator-activated receptor δ)

RN 908250-77-1 CAPLUS
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 908250-81-7 CAPLUS
 CN Acetic acid, [2-methyl-4-[3-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 908250-97-5 CAPLUS
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]- (9CI) (CA INDEX NAME)


L19 ANSWER 24 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 908250-79-3 CAPLUS
 CN Acetic acid, [2-methyl-4-[3-[3-methyl-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 908250-95-3 CAPLUS
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 908250-99-7 CAPLUS
 CN Acetic acid, [2-methyl-4-[3-[3-(1-methylethyl)-5-[4-(trifluoromethyl)phenyl]-2-thienyl]-1-oxopropyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 24 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 25 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:848440 CAPLUS
 DOCUMENT NUMBER: 145:230948
 TITLE: Effective tuning of HOMO and LUMO energy levels by
 p-n
 diblock and triblock oligomer approaches. [Retraction
 of document cited in CA144:451030]
 AUTHOR(S): Wan, Jun-Rua; Feng, Jia-Chun; Wen, Gui-An; Wei, Wei;
 Fan, Qu-Li; Wang, Chuan-Ming; Wang, Hong-Yu; Zhu,
 Rui;
 Yuan, Xiang-Dong; Huang, Chun-Hui; Wei, Huang.
 CORPORATE SOURCE: Institute of Advanced Materials (IAM), Fudan
 University, Shanghai, 200433, Peop. Rep. China
 SOURCE: Journal of Organic Chemistry (2006), 71(18), 7124
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The manuscript was withdrawn from publication by the Journal of Organic
 Chemical
 (JOC) Editor-in-Chief. The basis for the withdrawal was a violation of
 the Ethical Guidelines to Publication of Chemical Research of the
 American
 Cancer Society. Essentially the same material was submitted to and
 published by another journal while the manuscript was under review by
 JOC.
 The corresponding author did not withdraw the JOC manuscript or otherwise
 inform the Editor-in-Chief of the dual submissions.
 IT 885481-72-1P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (OT2O oligomer; preparation of thiophene and oxadiazole monomers and
 coupling to obtain p-n oligomers with effective tuning of HOMO and
 LUMO
 energy levels (Retraction))
 RN 885481-72-1 CAPLUS
 CN 1,3,4-Oxadiazole,
 2,2'-[(4,4'-dioctyl[2,2'-bithiophene]-5,5'-diyl)]bis[2,5-
 bis(octyloxy)-4,1-phenylene]]bis[5-phenyl- (9CI) (CA INDEX NAME)



IT 885481-73-2P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (T2O2T2 oligomer; preparation of thiophene and oxadiazole monomers and
 coupling to obtain p-n oligomers with effective tuning of HOMO and
 LUMO


L19 ANSWER 25 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 energy levels (Retraction))
 RN 885481-73-2 CAPLUS
 CN 1,3,4-Oxadiazole, 2,2'-[(1,4-phenylene)]bis[5-[4-(4,4'-dioctyl[2,2'-
 bithiophen]-5-yl)-2,5-bis(octyloxy)phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 26 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:652642 CAPLUS
 DOCUMENT NUMBER: 145:124334
 TITLE: Benzene amide derivatives as melanin-concentrating
 hormone receptor antagonists, pharmaceutical
 compositions containing them
 INVENTOR(S): Masui, Moriyasu; Yukioka, Hideo; Iwakawa, Tsuneo;
 Hasegawa, Yasushi
 PATENT ASSIGNMENT(S): Shionogi and Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 88 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT:
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006176443	A	20060706	JP 2004-371516	20041222
PRIORITY APPLN. INFO.:			JP 2004-371516	20041222

OTHER SOURCE(S): MARPAT 145:124334
 GI



AB Benzene derivs. I [Ar1 = (un)substituted C3-8 cycloalkanedyl,
 (un)substituted (hetero)arylene, (un)substituted nonarom.
 heterocyclylene;
 Ar2 = (un)substituted C3-8 cycloalkyl, (un)substituted (hetero)aryl,
 (un)substituted nonarom. heterocyclyl; R1, R2 = C1-6 alkyl or NR1N2 =
 (un)substituted 5-6-membered nonarom. cyclyl optionally containing 1
 selected

L19 ANSWER 26 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
from O, S, N(C1-6 alkyl), N(aryl); R3 = halo, C1-6 (halo)alkyl, C1-6 (halo)alkoxy, (un)substituted Ph, NO2, cyano; X1 = C(:Z1)NR4, NR5C(:Z2), NR5C(:Z3)NR4, CO, C(:NY1) (R4, R5 = H, C1-6 alkyl; Y1 = OH, C1-6 alkoxy, cyano; Z1, Z2, Z3 = O, S); Ar1X1 may be condensed N-heterocyclic group

Q1, Q2, Q3, Q4, etc.; X2 = C1-6 alkylene; X3 = C1-6 alkylene, O-C2-6 alkylene;
X3 and R2 may be bonded together to form a pyrrolidine or piperidine ring;


M = O, S; m = 0, 1; n = 0, 1, 2, 3], their pharmaceutically acceptable salts, and their solvates inhibit appetite and are useful for prevention and treatment of obesity, diabetes, arteriosclerosis, gonarthrosis, etc. Thus, 3-(pyrrolidinomethyl)phenol 3-aminopropyl ether (prepn. given) was condensed with 4-PhOC6H4NCO in toluene under reflux for 16 h to give 70%

I [Ar2(O)mAr1X1X2M = 4-PhOC6H4NHCONH(CH2)3O-4, 3-X3NR1R2 = pyrrolidinomethyl] (II). II antagonized inhibitory effect of MHC on forskolin-induced cAMP prodn. mediated by human melanin-conog. hormone receptor on CHO cells.

IT 897405-96-8P 897405-97-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzene amide derivs. as oral melanin-concentrating hormone receptor antagonists for treatment of obesity, diabetes, etc.)

RN 897405-96-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-(4-fluorophenyl)-N-[3-(1-pyrrolidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 897405-97-9 CAPLUS
CN 2-Thiophenecarboxamide, 5-(4-fluorophenyl)-N-[3-(1-pyrrolidinylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 26 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:536733 CAPLUS
DOCUMENT NUMBER: 145:189264
TITLE: Dendrimer Analogues of Linear Molecules to Evaluate Energy and Charge-Transfer Properties
AUTHOR(S): Nantalaksakul, Arpornrat; Dasari, Raghunath Reddy; Ahn, Tai-Sang; Al-Kaysi, Rabih; Bardeen, Christopher J.; Thayumanavan, S.
CORPORATE SOURCE: Department of Chemistry, University of Massachusetts, Amherst, MA, 01003, USA
SOURCE: Organic Letters (2006), 8(14), 2981-2984
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:189264


AB We have designed and synthesized difunctionalized polyether dendrimers containing two diarylamino groups in the periphery and an acceptor at the core to serve as scaffolds for comparison with linear analogs to study the advantage of dendritic scaffolds for energy and charge transfer. Comparison of these dendrimers with the fully decorated dendrimers provides information on the advantage of chromophore d. in energy/charge transfer from periphery to the core.

IT 903562-03-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (G1 dendrimer; preparation of polyether dendrimers and linear analogs to evaluate energy and charge-transfer properties)


RN 903562-03-8 CAPLUS
CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenylene]oxymethylene]-3,1-phenylene]oxymethylene-3,1-phenylene]]bis[N-phenyl]- (CA INDEX NAME)

L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




IT 903562-04-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (G2 dendrimer; preparation of polyether dendrimers and linear analogs to evaluate energy and charge-transfer properties)


RN 903562-04-9 CAPLUS
CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenylene]oxymethylene]-3,1-phenylene]oxymethylene-3,1-phenylene]]bis[N-phenyl]- (CA INDEX NAME)

L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 3-A




IT 903562-05-0P 903562-06-1P 903562-07-2P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (linear analog; preparation of polyether dendrimers and linear
 analogs to
 evaluate energy and charge-transfer properties)
 RN 903562-05-0 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-
 3,1-phenyleneoxymethylene-3,1-phenylene)]bis[N-phenyl- (CA INDEX NAME)]

PAGE 1-A




PAGE 2-A




L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




PAGE 2-B




L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 903562-06-1 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-
 3,1-phenyleneoxymethylene-3,1-phenylene)]bis[N-phenyl- (CA INDEX NAME)]


PAGE 1-A



PAGE 1-B




PAGE 2-A




L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B




RN 903562-07-2 CAPLUS
 CN 1-Pyrenamine, N,N'-[2,1,3-benzothiadiazole-4,7-diylbis(5,2-thiophenediyl-3,1-phenyleneoxymethylene-3,1-phenyleneoxymethylene-3,1-phenyleneoxymethylene-3,1-phenylene)]bis[N-phenyl- (CA INDEX NAME)]

PAGE 1-A




PAGE 1-B




L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




PAGE 2-B



IT 840531-18-2
 RL: PRP (Properties)
 (preparation of polyether dendrimers and linear analogs to evaluate energy and charge-transfer properties)
 RN 840531-18-2 CAPLUS
 CN 1-Pyrenamine, N,N',N'',N'''-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenyleneoxymethylene-5,1,3-benzenetriylbis(oxymethylene-3,1-phenylene)]]tetrakis[N-phenyl- (CA INDEX NAME)]

L19 ANSWER 27 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 3-A




REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 28 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:410178 CAPLUS
 DOCUMENT NUMBER: 144:450697
 TITLE: Preparation of novel sulfonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
 INVENTOR(S): Bladh, Haakan; Henriksson, Krister; Hulikal, Vijaykumar; Lepistö, Matti
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006046914	A1	20060504	WO 2005-SE1608	20051026
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005300148	A1	20060504	AU 2005-300148	20051026
CA 2584409	A1	20060504	CA 2005-2584409	20051026
EP 1807405	A1	20070718	EP 2005-797057	20051026
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRIORITY APPLN. INFO.:		SE 2004-2635	A 20041029	
		WO 2005-SE1608	W 20051026	

OTHER SOURCE(S): CASREACT 144:450697; MARPAT 144:450697
 GI




AB The title compds. R3LS(02)N(R1)L1WL2R2 [I; R3 = (un)substituted Ph,

L19 ANSWER 28 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 thienyl, furyl or pyrazolyl; L3 = a bond or CH2; R1 = H, alkyl; W = (un)substituted Ph, isoxazolyl or pyrazolyl, cyclohexyl, or acenaphthene ring; L1 = a bond, CH2; L2 = a bond, O, NH, (CH2)n or CH2NH; n = 1-2; R2 = (un)substituted cyclohexyl, Ph, methylenedioxyphenyl, etc.], useful in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal), were prepd. Thus, reacting 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride with [(5-methyl-3-phenylisoxazol-4-yl)methyl]amine afforded 20% II which showed IC50 of 14 nM against human glucocorticoid receptor binding. Pharmaceutical compn. comprising compd. I is disclosed.
 IT 886038-71-7P 886038-88-6P 886038-92-2P
 886038-93-3P 886038-94-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel sulfonamide derivs. as glucocorticoid receptor modulators for the treatment of inflammatory diseases)
 RN 886038-71-7 CAPLUS
 CN Benzenesulfonamide, N-[[5-(4-chlorophenyl)-2-thienyl]methyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 886038-88-6 CAPLUS
 CN Benzenesulfonamide, N-[[5-(4-chlorophenyl)-2-thienyl]methyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 886038-92-2 CAPLUS
 CN Benzenesulfonamide, N-[[5-(4-chlorophenyl)-2-thienyl]methyl]-3-methoxy- (9CI) (CA INDEX NAME)


L19 ANSWER 28 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 886038-93-3 CAPLUS
 CN Benzenesulfonamide, N-[[5-(4-chlorophenyl)-2-thienyl]methyl]-4-methoxy-2,3,6-trimethyl- (9CI) (CA INDEX NAME)



RN 886038-94-4 CAPLUS
 CN Benzenesulfonamide, N-[[5-(4-chlorophenyl)-2-thienyl]methyl]-3-(4-methylphenoxy)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 29 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:383818 CAPLUS
 DOCUMENT NUMBER: 144:432808
 TITLE: Preparation of spiroperidone compounds as β -secretase inhibitors for the treatment of Alzheimer's disease
 INVENTOR(S): Barrow, James C.; Coburn, Craig A.; Egbertson, Melissa
 S.; McGaughey, Georgia B.; McWherter, Melody A.; Neilson, Lou Anne; Selnick, Harold G.; Stauffer, Shaun
 R.; Yang, Zhi-Qiang; Yang, Wenjin; Lu, Wanli; Fahr, Bruce; Rittle, Kenneth E.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Sunesis Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 182 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044497	A2	20060427	WO 2005-US36752	20051012
WO 2006044497	A3	20060908		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005295814	A1	20060427	AU 2005-295814	20051012
CA 2583342	A1	20060427	CA 2005-2583342	20051012
EP 1804794	A2	20070711	EP 2005-812233	20051012
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRIORITY APPLN. INFO.:		A1 20070823	US 2007-663388	20070321
			US 2004-618420P	P 20041013
			WO 2005-US36752	W 20051012

OTHER SOURCE(S): MARPAT 144:432808
 GI

L19 ANSWER 29 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title compds. I or its tautomer II [X = CR5, N; X1 = CR5H or NH; Z = O

or S; R1 = H, alkyl, alkylaryl, etc.; R2 = H, alkyl, alkyl-carbocycl, etc.; R3 = H, alkylaryl, alkylheteroaryl, etc.] which are inhibitors of the β -secretase enzyme and that are useful in the treatment of diseases in which the β -secretase enzyme is involved, such as Alzheimer's disease, were prepared. Thus, reacting N-benzylpiperidinone

with benzyl isocyanide in MeOH followed by addition of KOH in H₂O and aniline.HCl

afforded I [X = N; Z = O; R1, R3 = CH₂Ph; R2 = Ph]. The exemplified compds. I had activity in inhibiting the β -secretase, generally with an IC₅₀ from about 1 nM to 500 μ M, preferably 1 nM to 100 μ M. The invention is also directed to pharmaceutical compns. comprising the compds. I and the use of these compds. and compns. in the treatment of such diseases in which the β -secretase enzyme is involved.

IT 885115-07-1P 885115-33-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spiropiperidine compds. as β -secretase inhibitors for treating Alzheimer's disease)

RN 885115-07-1 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[2-[4-(cyclohexylamino)-8-[[3-(1-methylethoxy)phenyl]methyl]-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-1-yl]phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 29 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 885115-33-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[3-[4-(cyclohexylamino)-8-[[3-(1-methylethoxy)phenyl]methyl]-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-1-yl]-5-fluorophenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 30 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:283605 CAPLUS

DOCUMENT NUMBER: 144:489035

TITLE: Synthesis of Homopolymer Containing Diphenyl End-Capped Oligothiophene Co-oligomer Unit in the

Side Chain
AUTHOR(S): Chain
Zhao, Chunchang; Zhang, Yong; Wang, Chengwei;
Rothberg, Lewis; Ng, Man-Kit
CORPORATE SOURCE: Department of Chemistry and Department of Chemical Engineering, University of Rochester, Rochester, NY, 14627, USA

SOURCE: Organic Letters (2006), 8(8), 1585-1588

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:489035

AB A new polymer with the di-Ph end-capped oligothiophene co-oligomer unit in

the side chain was obtained by the ROMP method. The polymer showed good photophys. characteristics, thermal stability, and film-forming properties. A photovoltaic cell fabricated from this polymer showed relatively large open-circuit voltage (VOC = 0.7 V), moderate short-circuit current (ISC = 0.7 mA/cm²), and excellent device stability under ambient conditions.

IT 887256-75-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate in monomer preparation; synthesis of homopolymer

containing di-Ph

end-capped oligothiophene co-oligomer unit in side chain)

RN 887256-75-9 CAPLUS

CN 2,2',5',2'',5'''-Quaterthiophene, 3'''-(2,5-dimethoxyphenyl)-5,5'''-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L19 ANSWER 31 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:274271 CAPLUS

DOCUMENT NUMBER: 144:489197

TITLE: New p-n diblock and triblock oligomers: effective tuning of HOMO/LUMO energy levels

AUTHOR(S): Wan, Jun-Rua; Feng, Jia-Chun; Wen, Gui-An; Wang, Hong-Yu; Fan, Qu-Li; Wei, Wei; Huang, Chun-Hui;

Huang,

CORPORATE SOURCE: Institute of Advanced Materials (IAM), Fudan University, Shanghai, 200433, Peop. Rep. China

SOURCE: Tetrahedron Letters (2006), 47(16), 2829-2833

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:489197

AB A series of oligomers consisting of thiophene as p-type unit and oxadiazole as n-type unit were synthesized, and their photophys. and electrochem. properties were evaluated. Cyclic voltammetry studies demonstrated that the electronic properties of the p-n diblock oligomers could be modulated by changing the number of thiophene and oxadiazole rings.


The mol. regiochem. effect to the electrochem. and optical properties was also studied.

IT 885481-72-1P

RL: PNU (Preparation, unclassified); PRP (Properties); PREP (Preparation) (T202T2; p-n diblock and triblock thiophene-oxadiazole oligomers with effective tuning of HOMO/LUMO energy levels)

RN 885481-72-1 CAPLUS

CN 1,3,4-Oxadiazole, 2,2'-(1,4-phenylene)bis[5-[4-(4,4'-diethoxy)bis[2,5-bis(octyloxy)-4,1-phenylene]]bis[5-phenyl]- (9CI) (CA INDEX NAME)




IT 885481-73-2P

RL: PNU (Preparation, unclassified); PRP (Properties); PREP (Preparation) (T202T2; p-n diblock and triblock thiophene-oxadiazole oligomers with effective tuning of HOMO/LUMO energy levels)

RN 885481-73-2 CAPLUS

CN 1,3,4-Oxadiazole, 2,2'-(1,4-phenylene)bis[5-[4-(4,4'-diethoxy)bis[2,5-bis(octyloxy)-4,1-phenylene]]bis[5-phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 31 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L19 ANSWER 32 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2006:207132 CAPLUS
DOCUMENT NUMBER: 144:451030
TITLE: Effective Tuning of HOMO and LUMO Energy Levels by p-n
AUTHOR(S): Diblock and Triblock Oligomer Approaches
Wan, Jun-Hua; Feng, Jia-Chun; Wen, Gui-An; Wei, Wei; Fan, Qu-Li; Wang, Chuan-Ming; Wang, Hong-Yu; Zhu, Rui;
CORPORATE SOURCE: Yuan, Xiang-Dong; Huang, Chun-Hui; Huang, Wei
Institute of Advanced Materials (IAM), Fudan University, Shanghai, 200433, Peop. Rep. China
SOURCE: Journal of Organic Chemistry (2006), 71(7), 2565-2571
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:451030
AB A series of oligomers consisting of thiophene as p-type unit and oxadiazole as n-type unit were synthesized. On the basis of the characterization of photophys. and electrochem. properties, the structure-property relationships of the oligomers were studied. Cyclic voltammogram studies showed that changing the number of thiophene and oxadiazole units could effectively modulate the electronic properties of the p-n diblock and triblock oligomers. The effect of mol. regiochem. on electronic properties is also studied. The observed electronic properties were consistent with theor. calns. These systems demonstrated the band gap control principle in p-n heterostructure oligomers.
IT 885481-72-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (OT2O oligomer; preparation of thiophene and oxadiazole monomers and coupling to obtain p-n oligomers with effective tuning of HOMO and LUMO energy levels)
RN 885481-72-1 CAPLUS
CN 1,3,4-Oxadiazole, 2,2'-bis[(4,4'-dioctyl[2,2'-bithiophene]-5,5'-diyl)]bis[2,5-bis(octyloxy)-4,1-phenylene]]bis[5-phenyl- (9CI) (CA INDEX NAME)



IT 885481-73-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (T2O2T2 oligomer; preparation of thiophene and oxadiazole monomers and

L19 ANSWER 32 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
coupling to obtain p-n oligomers with effective tuning of HOMO and LUMO

energy levels)
RN 885481-73-2 CAPLUS
CN 1,3,4-Oxadiazole, 2,2'-(1,4-phenylene)bis[5-[4-(4,4'-dioctyl[2,2'-bithiophen]-5-yl)-2,5-bis(octyloxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:101303 CAPLUS
DOCUMENT NUMBER: 144:192279
TITLE: Piperazine derivatives and their preparation, pharmaceutical compositions, and agonistic activity of growth hormone secretagogue (GHS) receptors for the treatment of gastrointestinal disorders
INVENTOR(S): Gaiba, Alessandra; King, Nigel Paul; Takle, Andrew Kenneth; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010629	A1	20060202	WO 2005-EP8263	20050726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PA, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005266448	A1	20060202	AU 2005-266448	20050726
CA 2575359	A1	20060202	CA 2005-2575359	20050726
EP 1778679	A1	20070502	EP 2005-263645	20050726
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
IN 2007DN00370	A	20070803	IN 2007-DN370	20070115
NO 2007001138	A	20070228	NO 2007-1138	20070228
PRIORITY APPLN. INFO.:			GB 2004-16844	A 20040728
			GB 2005-14029	A 20050708
			WO 2005-EP8263	W 20050726

OTHER SOURCE(S): CASREACT 144:192279; MARPAT 144:192279
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides compds. of formulas I and II or pharmaceutically acceptable salts thereof as defined in the specification. Compds. for formulas I and II wherein Y is a single bond, CH2, CH2CH2, or CH=CH; R1 is

L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(hetero)aryl, R2 is H, or Cl-6alkyl; R3 is H or Me; R4 is Cl-6 alkyl; R5 is H, Cl-6alkyl, C3-6cycloalkyl, COC1-6alkyl, Cl-6alkoxy, halo, OH, CF3, OCF3, or CN; R6 is H, Cl-6alkyl, C3-6cycloalkyl, COC1-6alkyl, Cl-6alkoxy, Cl-6alkoxy-Cl-6alkyl, halo, OH, CF3, OCF3, or CN; or pharmaceutically acceptable salts thereof are claimed in this invention. The compds. are partial or full agonists at the growth hormone secretagogue (GHS) receptors, which may be useful for the treatment of gastrointestinal disorders. Pharmaceutical compds. comprising the compds., methods of prep., the compds., uses of the compds. and methods involving the compds. are also provided. Example compd. III was prepd. by amination of 2-bromo-4-nitroanisole with cis-2,6-dimethylpiperazine and the resulting [(methoxy)nitrophenyl]dimethylpiperazine underwent hydrogenation to give intermediate IV, which was sulfonated with 5-(2-pyridinyl)-2-thiophenesulfonyl chloride to give example compd. III. Addnl. 316

example compds. were prepd. in this invention. All the example compds. were evaluated for their selective agonistic activity at the GHS receptors. All 317 example compds. have an activity of <1 μ M in the GHS-R GTPyS functional assays. In the GHS-R agonist BACMAN FLIPR assay, all the example compds. have an EC50 value of <1 μ M.


IT 874956-95-3P 874956-96-4P 874956-98-6P
874957-01-4P 874957-03-6P 874957-46-7P
874957-47-8P 874957-49-0P 874957-50-3P
874957-64-9P 874957-65-0P 874957-69-4P
874958-94-8P 874958-97-1P 874958-98-2P
874959-03-2P 874959-04-3P 874959-05-4P
874959-07-6P 874959-16-7P 874959-17-8P
874959-18-9P 874959-19-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of piperazines and their agonistic activity of growth hormone secretagogue (GHS) receptors for the treatment of gastrointestinal disorders)

RN 874956-95-3 CAPLUS
CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 874957-03-6 CAPLUS
CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-3-fluoro-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874957-46-7 CAPLUS
CN Benzenesulfonamide, N-[3-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-methoxyphenyl]-2-methyl-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 874957-47-8 CAPLUS
CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-4-(5-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 874956-96-4 CAPLUS
CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-2-methyl-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874956-98-6 CAPLUS
CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-2-fluoro-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 874957-01-4 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Relative stereochemistry.




RN 874957-49-0 CAPLUS
CN Benzenesulfonamide, 2-chloro-N-[3-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-methoxyphenyl]-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874957-50-3 CAPLUS
CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-4-(4-methyl-3-thienyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 874957-64-9 CAPLUS
CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-3-methyl-4-(4-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



Relative stereochemistry.




Relative stereochemistry.




L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-2-fluoro-4-(5-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



Relative stereochemistry.




Relative stereochemistry.




L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methoxyphenyl]-4-(5-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



Relative stereochemistry.




Relative stereochemistry.




L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 874959-07-6 CAPLUS
 CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-3-fluoro-4-(5-methyl-2-thienyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



Relative stereochemistry.




Relative stereochemistry.



L19 ANSWER 33 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 874959-18-9 CAPLUS
 CN Benzenesulfonamide, N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-4-(5-methyl-3-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874959-19-0 CAPLUS
 CN Benzenesulfonamide, 2-chloro-N-[5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2-methoxyphenyl]-4-(5-methyl-3-thienyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



L19 ANSWER 34 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1346218 CAPLUS
 DOCUMENT NUMBER: 144:88321
 TITLE: Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase
 INVENTOR(S): Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana; Raeppe, Stephane; Frechette, Sylvie; Bouchain, Giliane
 PATENT ASSIGNEE(S): Methylgene, Inc., Can.
 SOURCE: U.S. Pat. Appl. Publ., 324 pp., Cont.-in-part of U.S. Ser. No. 358,556.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288282	A1	20051229	US 2005-91025	20050325
US 2004106599	A1	20040603	US 2002-242304	20020912
US 2004142953	A1	20040722	US 2003-358556	20030204
US 6897220	B2	20050524		
JP 2005255683	A	20050922	JP 2005-80310	20050318
AU 2006252047	A1	20070111	AU 2006-252047	20061214
AU 2006252047			US 2001-322402P	P 20010914
			US 2002-391728P	P 20020626
			US 2002-242304	A2 20020912
			US 2003-358556	A2 20030204
			AU 2002-327627	A3 20020912
			JP 2003-528544	A3 20020912

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 144:88321
 GI

L19 ANSWER 34 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. Such compds. include carboxamides I [Cy2 = (un)substituted cycloalkyl, aryl, heteroaryl, heterocyclyl (each of which is optionally fused to one or two aryl or heteroaryl rings, or to one or two (un)saturated cycloalkyl or heterocyclic rings); X1 = a bond, M1L2M1, L2M2L2 (wherein L2 = a bond, alkylene, alkenylene, alkynylene; M1 = O, S, SO, NHCO, etc.; M2 = M1, heteroarylene, heterocyclylene); Ar2 = (un)substituted (hetero)arylene; R5, R6 = H, alkyl, aryl, aralkyl; q = 0-1; Ay2 = (un)substituted 5-6 membered cycloalkyl, heterocyclyl or heteroaryl substituted with an amino or hydroxy moiety; with provisos] which were prepared and claimed. E.g., a multi-step synthesis of II, starting from Me 4-(aminomethyl)benzoate.HCl, was given. The invention also provides compns. and methods for treating cell proliferative diseases

and conditions. Antineoplastic effects of some I are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. Although the methods of preparation are not claimed, hundreds of example preps. are included.

IT 503042-76-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503042-76-0 CAPLUS


CN Benzamide,

N-(2-aminophenyl)-4-[5-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2-thienyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 34 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 35 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1338260 CAPLUS
 DOCUMENT NUMBER: 144:201123
 TITLE: Study of [thienylene-dialkoxy phenylene] conjugated materials
 AUTHOR(S): Silva, R. A.; Cury, L. A.; Mazzoni, M. S.; Soares, E.;
 Guimaraes, P. S. S.; Serein-Spirau, F.; Lois, S.; Moreau, J.; Lere-Porte, J.-P.
 CORPORATE SOURCE: Faculdade de Fisica, Universidade Federal de Uberlandia, Bloco 1X, Minas Gerais, Brazil
 SOURCE: Macromolecular Symposia (2005), 229(Advanced Materials), 194-196
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB In this work we report on the electrochromic and optical studies of thin films of thienylene-dialkoxyphenylene. The films for the optical measurements were prepared by spin casting on glass and silicon substrates.
 Photoluminescence and absorption spectra were recorded in the temperature range from 300 K. The differences between the spectra of the polymer and the oligomer can be attributed to a higher mean conjugation length in the polymer than in the oligomer. We present also a first principles theoretical calculation, which shows that the conjugated oligomer has an HOMO-LUMO energy around 2.0 eV, which is consistent with the exptl. data.
 IT 875105-39-8
 RL: PRP (Properties)
 (thienylene-dialkoxy phenylene conjugated materials)
 RN 875105-39-8 CAPLUS
 CN Thienylene, 2,2'-(2,5-dimethoxy-1,4-phenylene)bis[5-(2,5-dimethoxyphenyl)]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L19 ANSWER 36 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1324614 CAPLUS
 DOCUMENT NUMBER: 144:224963
 TITLE: Palladium catalyzed synthesis of Ca²⁺ indicators with aryl bithiophene and terthiophene fluorophores
 AUTHOR(S): Boens, Noel; Avciyasi, Nesibe; Samanta, Subhendu S.; Kilonza, Amuri; Hoornaert, Georges J.; Van der Eycken, Erik
 CORPORATE SOURCE: Department of Chemistry, Katholieke Universiteit Leuven, Heverlee, 3001, Belg.
 SOURCE: Tetrahedron (2006), 62(4), 684-690
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:224963
 AB Five new fluorescent indicators for Ca²⁺ were synthesized using the Stille reaction. They all consist of the tricarboxylate chelator AFTRA (o-aminophenol-N,N,O-triacetic acid) linked to a (substituted) bithiophene or terthiophene fluorophore. The dissociation consts. K_d measured via fluorometric titrns. at 21° in 100 mM KCl buffered solution, pH 7.05, for the Ca²⁺ complexes with the new probes are at 10-40 μM.
 IT 875582-22-2P 875582-24-4P 875582-25-5P 875582-26-6P
 RL: AKG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
 (calcium determination by fluorometry with fluorescent indicators based on aryl bithiophene and terthiophene fluorophores and palladium catalyzed synthesis)
 RN 875582-22-2 CAPLUS
 CN Glycine, N-[2-(carboxymethoxy)-4-(5'-phenyl[2,2'-bithiophen]-5-yl)phenyl]-N-(carboxymethyl)-, tricesium salt (9CI) (CA INDEX NAME)



● 3 Cs


RN 875582-24-4 CAPLUS
 CN Glycine, N-[2-(carboxymethoxy)-4-(5'-(4-fluorophenyl)[2,2'-bithiophen]-5-yl)phenyl]-N-(carboxymethyl)-, tricesium salt (9CI) (CA INDEX NAME)

L19 ANSWER 36 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 3 Cs

RN 875582-25-5 CAPLUS
 CN Glycine, N-[2-(carboxymethoxy)-4-(5'-(4-methoxyphenyl)[2,2'-bithiophen]-5-yl)phenyl]-N-(carboxymethyl)-, tricesium salt (9CI) (CA INDEX NAME)



● 3 Cs

RN 875582-26-6 CAPLUS
 CN Glycine, N-[2-(carboxymethoxy)-4-(5'-(4-nitrophenyl)[2,2'-bithiophen]-5-yl)phenyl]-N-(carboxymethyl)-, tricesium salt (9CI) (CA INDEX NAME)




● 3 Cs


IT 875582-28-8P 875582-29-9P 875582-30-2P 875582-31-3P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (calcium determination by fluorometry with fluorescent indicators based on aryl

L19 ANSWER 36 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 bithiophene and terthiophene fluorophores and palladium catalyzed synthesis)


RN 875582-28-8 CAPLUS
 CN Glycine, N-[2-(2-methoxy-2-oxoethoxy)-4-(5'-phenyl[2,2'-bithiophen]-5-yl)phenyl]-N-(2-methoxy-2-oxoethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 875582-29-9 CAPLUS
 CN Glycine, N-[4-(5'-(4-fluorophenyl)[2,2'-bithiophen]-5-yl)-2-(2-methoxy-2-oxoethoxy)phenyl]-N-(2-methoxy-2-oxoethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 875582-30-2 CAPLUS
 CN Glycine, N-[2-(2-methoxy-2-oxoethoxy)-4-(5'-(4-methoxyphenyl)[2,2'-bithiophen]-5-yl)phenyl]-N-(2-methoxy-2-oxoethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 875582-31-3 CAPLUS
 CN Glycine, N-[2-(2-methoxy-2-oxoethoxy)-4-(5'-(4-nitrophenyl)[2,2'-bithiophen]-5-yl)phenyl]-N-(2-methoxy-2-oxoethyl)-, methyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 36 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE


L19 ANSWER 37 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1307935 CAPLUS
 DOCUMENT NUMBER: 144:62626
 TITLE: Device with small molecular thiophene compound having divalent linkage
 INVENTOR(S): Ong, Beng S.; Liu, Ping; Wu, Yiliang
 PATENT ASSIGNMENT(S): Xerox Corporation, USA
 SOURCE: Eur. Pat. Appl., 44 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1605533	A2	20051214	EP 2005-105046	20050609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, SK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 2005277760	A1	20051215	US 2004-865620	20040610
JP 2006036755	A	20060209	JP 2005-163735	20050603
PRIORITY APPLN. INFO.:			US 2004-865620	A 20040610

OTHER SOURCE(S): MARPAT 144:62626
 AB An electronic device composed of a semiconductor layer in contact with a number of electrodes, wherein the semiconductor layer includes a small mol. thiophene compound consisting of: at least one divalent linkage; and a plurality of thiophene units, each thiophene unit being represented by structure (A) wherein each thiophene unit is bonded at either or both of the 2nd ring position and the 5th ring position, wherein there is at least one thiophene unit where R1 is present at the 3rd ring position or the 4th ring position, or at both the 3rd ring position and the 4th ring position, wherein for any two adjacent thiophene units there is excluded the simultaneous presence of the same or different R1 at the 3-position of one thiophene unit and at the 3'-position of the other thiophene unit, and wherein the number of the thiophene units is at least 6.
 IT 871334-40-6P
 RL: PNU (Preparation, unclassified); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (electronic device with small mol. thiophene semiconductor compound having divalent linkage)
 RN 871334-40-6 CAPLUS
 CN 2,2':5',2''':5'',2'''-Quaterthiophene, 5,5'''-bis[2,5-bis(octyloxy)-4-(3'-octyl[2,2'-bithiophen]-5-yl)phenyl]-3',4'''-dioctyl- (9CI) (CA INDEX NAME)

L19 ANSWER 37 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-A



PAGE 1-B

L19 ANSWER 38 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1284489 CAPLUS
 DOCUMENT NUMBER: 145:18139
 TITLE: Synthesis and mesomorphic behaviour of novel light-emitting liquid crystals
 AUTHOR(S): Aldred, Matthew P.; Eastwood, Amanda J.; Kitney, Stuart P.; Richards, Gary J.; Vlachos, Panos; Kelly, Stephen M.; O'Neill, Mary
 CORPORATE SOURCE: Department of Chemistry, University of Hull, Hull, HU6 7RX, UK
 SOURCE: Liquid Crystals (2005), 32(10), 1251-1264
 CODEN: LICR66; ISSN: 0267-8292
 PUBLISHER: Taylor & Francis Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The results of a systematic study of the structure-mesomorphic behavior relations of a diverse range of light-emitting liquid crystals, but especially nematic 2,7-disubstituted-9,9-dialkylfluorenes, are reported. The dependence of the mesomorphic behavior and transition temps. on the nature and length of the terminal chains, the nature, position and number of lateral substituents and the number and nature of aromatic rings with and without heteroatoms in the central core was studied. The results of these studies were used to design polymerizable, light-emitting crystals (reactive mesogens) with a nematic phase having a high clearing point and a m.p. below room temperature for facile OLED fabrication.
 IT 888036-08-6P 888036-10-OP 888036-12-2P
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process) (preparation and liquid crystal properties of)
 RN 888036-08-6 CAPLUS
 CN Thiophene, 2,2'-(9,9-dipropyl-9H-fluorene-2,7-diyl)bis[5-[3-methyl-4-(octyloxy)phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— (CH₂)₇—Me

RN 888036-10-0 CAPLUS

L19 ANSWER 38 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Thiophene, 2,2'-(9,9-dipropyl-9H-fluorene-2,7-diyl)bis[5-[3,5-dimethyl-4-(octyloxy)phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— (CH₂)₇—Me

RN 888036-12-2 CAPLUS

CN Thiophene, 2,2'-(9,9-dipropyl-9H-fluorene-2,7-diyl)bis[5-[2-methyl-4-(octyloxy)phenyl]- (9CI) (CA INDEX NAME)



PAGE 1-B

— (CH₂)₇—Me

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS


FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L19 ANSWER 39 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2005:1132895 CAPLUS
 DOCUMENT NUMBER: 143:387313
 TITLE: Preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependent transporter
 INVENTOR(S): Nomura, Sumihiro; Kawanishi, Eiichi; Ueta, Kiichiro
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: U.S. Pat. Appl. Publ., 123 pp., Cont.-in-part of Appl.
 No. PCT/JP04/011312.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005233988	A1	20051020	US 2005-4446	20050131
WO 2005012326	A1	20050210	WO 2004-JP11312	20040730
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BC, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GB, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2006080577	A1	20060803	WO 2006-JP301921	20060131
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006217323	A1	20060928	US 2006-446014	20060602
US 2006229260	A1	20061012	US 2006-453728	20060615
US 2006234954	A1	20061019	US 2006-453727	20060615
US 2006293255	A1	20061228	US 2006-453726	20060615
PRIORITY APPLN. INFO.:			US 2003-491534P	P 20030801
			WO 2004-JP11312	A2 20040730
			US 2003-491523P	P 20030801


L19 ANSWER 39 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 2003-519155P P 20031112
 US 2003-519209P P 20031112
 US 2003-519210P P 20031112
 US 2003-519381P P 20031112
 US 2004-579722P P 20040615
 US 2004-579730P P 20040615
 US 2004-579758P P 20040615
 US 2004-579792P P 20040615
 US 2004-903034 A3 20040730
 US 2004-903136 A3 20040730
 US 2004-903233 A3 20040730
 US 2004-903234 A3 20040730
 JP 2005-23728 A 20050131
 US 2005-45446 A 20050131
 US 2005-726653P P 20051017

OTHER SOURCE(S): CASREACT 143:387313; MARPAT 143:387313
 GI



AB Glycosides I, wherein A and B are: (1) A is unsatd. monocyclic heterocyclic, and B is unsatd. monocyclic heterocyclic, fused hetero-bicyclic, or benzene, (2) A is benzene, and B is unsatd. monocyclic heterocyclic or unsatd. fused hetero-bicyclic, or (3) A is unsatd. fused hetero-bicyclic, and B are independently unsatd. monocyclic heterocyclic, unsatd. fused hetero-bicyclic, or benzene; X is a carbon atom or a nitrogen atom; Y is -(CH₂)_n- (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof. A method is claimed for treating or delaying the progression or onset of diabetes mellitus, diabetic

L19 ANSWER 39 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyper-insulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension. The pharmaceutical compns. may be orally administered to mammalian species including human beings, apes, dogs, etc., for example, in the dosage form of tablet, capsule, granule or powder, or administered in the form of injection prepn., or intra-nasally, or in the form of transdermal patch. Thus, 1-(β-D-glucopyranosyl)-4-chloro-3-(6-ethyl-benzo[b]thiophen-2-yl-methyl)benzene was prepd. as antidiabetic agent and having inhibitory activity against sodium-dependent transporter.
 IT 842135-51-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter)
 RN 842135-51-7 CAPLUS
 CN Thiophene, 2-[(5-bromo-2-methoxyphenyl)methyl]-5-phenyl- (9CI) (CA INDEX NAME)





L19 ANSWER 40 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1103743 CAPLUS
 DOCUMENT NUMBER: 143:387061
 TITLE: Preparation of alkoxyphenylpropanoic acid derivatives as GPR40 receptor function regulators
 INVENTOR(S): Yasuma, Tsuneo; Kitamura, Shuji; Sakai, Nozomu
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095338	A1	20051013	WO 2005-JP6522	20050328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BG, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1731505	A1	20041213	EP 2005-727536	20050328
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: JP 2004-101149 A 20040330				
WO 2005-JP6522 W 20050328				

OTHER SOURCE(S): MARPAT 143:387061
 GI

L19 ANSWER 40 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I [Het = (un)substituted heterocycle; n = 0, 1; R1, R2 = H, alkyl, halo; R3 = (un)substituted hydroxy, (un)substituted amino; R4 = H, (un)substituted hydrocarbon, (un)substituted hydroxy, etc.; R5, R6 = H, alkyl, halo; R7, R8 = H, alkyl, halo, etc.] were prepared. For example, 1,1'-(azodicarbonyl)dipiperidine mediated alkylation of 3-(4-hydroxyphenyl)propanoic acid Me ester with [3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol, e.g., prepared from 4-bromo-1,3,5-trimethyl-1H-pyrazole in 2 steps, followed by hydrolysis using NaOH afforded compound II

II [R = 1,3,5-trimethyl-1H-pyrazol-4-yl]. Compound II [R = 2,4,5-trimethyl-3-thienyl] has function regulating effect on GPR40 (G protein-coupled receptor 40) receptor with the EC50 value of <10 nM. Compds. I are claimed useful for the treatment of diabetes. Formulations are given.

IT 866586-16-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of alkoxyphenylpropanoic acid derivs. as GPR40 receptor function regulators for treatment of diabetes)


RN 866586-16-5 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-(2,4,5-trimethyl-3-thienyl)phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 40 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 866586-17-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of alkoxyphenylpropanoic acid derivs. as GPR40 receptor function regulators for treatment of diabetes)

RN 866586-17-6 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-(2,4,5-trimethyl-3-thienyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 41 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1053070 CAPLUS
 DOCUMENT NUMBER: 143:459818
 TITLE: 2-Methoxy-4-nitrobenzenediazonium salt as a practical diazonium-transfer agent for primary arylamines via tautomerism of 1,3-diaryltriazenes: Deaminative iodination and arylation of arylamines without direct diazotization

AUTHOR(S): Sueki, Tomoyuki; Son, Eun-Cheol; Tamao, Kohei
 CORPORATE SOURCE: International Research Center for Elements Science, Institute for Chemical Research, Kyoto University, Uji, Japan

SOURCE: Bulletin of the Chemical Society of Japan (2005), 78(9), 1654-1658
 CODEN: BCSJAS; ISSN: 0009-2673
 PUBLISHER: Chemical Society of Japan


DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:459818

AB 1,3-Diaryltriazenes, prepared from a 2-methoxy-4-nitrobenzenediazonium salt and primary arylamines, exist as azo-transfer tautomers in which the 2-methoxy-4-nitrophenyl group is present on the saturated nitrogen atom and forms a hydrogen bond between the 2-methoxy group and the N-H moiety.

The synthetic utility of the diazonium salt as a practical diazonium-transfer agent for primary arylamines via tautomerism of the 1,3-diaryltriazenes has been demonstrated by the deaminative iodination and arylation of the arylamines without direct diazotization. The starting 2-methoxy-4-nitrophenylamine can be easily recovered after the reactions.

IT 869373-83-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (2-methoxy-4-nitrobenzenediazonium salt as a practical diazonium-transfer agent for primary arylamines in deaminative iodination and arylation)

RN 869373-83-1 CAPLUS
 CN 1-Triazene, 1-(2-methoxy-4-nitrophenyl)-3-[(4-(5-methyl-2-thienyl)phenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 42 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1039645 CAPLUS
 DOCUMENT NUMBER: 144:7175
 TITLE: Monodisperse Aromatic Oligomers of Defined Structure and Large Size through Selective and Sequential

Suzuki

Palladium-Catalyzed Cross-Coupling Reactions
 Lightowler, Stephen; Hird, Michael
 CORPORATE SOURCE: Department of Chemistry, University of Hull, Hull,
 HU6

7RX, UK
 SOURCE: Chemistry of Materials (2005), 17(22), 5538-5549
 CODEN: CMATEX; ISSN: 0897-4756

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several monodisperse aromatic oligomers of defined structure have been prepared

through selective and sequential palladium-catalyzed cross-coupling reactions. The scope of the synthesis was evaluated in terms of (i) mol. size with materials ranging from relatively small sizes (5 and 6 aromatic rings) through to intermediate sizes (9 and 10 aromatic rings), right up

to a monodisperse oligomer with 21 aromatic rings, and (ii) variety of mol. structure, with materials including benzene and thiophene core units, and peripheral substituents, including octyloxy, fluoro, and cyano to aid solubility and enhance polarity. The synthetic strategy involved the preparation of

Grignard reagents and organolithium derivs. to generate arylboronic acids,

which were then involved in selective Suzuki palladium-catalyzed cross-couplings to generate intermediate bromides. These intermediates were either converted into boronic acids and then used in further couplings or used directly in further couplings. The scope and limitations of the synthetic methodol. are reported in terms of the size and variety of structure.

IT 869885-08-5P 869885-09-6P 869885-10-9P


869885-11-0P 869885-13-2P 869885-14-3P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of monodisperse aromatic oligomers of defined structure)

RN 869885-08-5 CAPLUS


CN Thiophene, 2,5-bis[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 42 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B




RN 869885-13-2 CAPLUS

CN Thiophene, 2,2'-[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4,4''-diyl]bis[5-[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 869885-14-3 CAPLUS

CN [2,2':5',2''-Terthiophene]-5-carbonitrile, 5',5'''-[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4,4''-diyl]bis- (9CI) (CA INDEX NAME)

L19 ANSWER 42 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 869885-09-6 CAPLUS

CN 2,2'-Bithiophene, 5,5'-bis[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4-yl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— (CH2)7—Me

RN 869885-10-9 CAPLUS

CN 2,2':5',2''-Terthiophene, 5,5'''-bis[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4-yl]- (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 1-B

— O— (CH2)7—Me

RN 869885-11-0 CAPLUS


CN 2,2':5',2''':5'',2''''-Quaterthiophene, 5,5''''-bis[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4-yl]- (9CI) (CA INDEX NAME)

L19 ANSWER 42 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-A

PAGE 1-B



REFERENCE COUNT: 40


THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L19 ANSWER 43 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1028945 CAPLUS
DOCUMENT NUMBER: 145:134075
TITLE: Photonic applications of glassy liquid crystals
AUTHOR(S): Chen, Huang-Ming P.; Kumar, K. G. Pani; Lin, Chi-Wen;
Kim, Chun K.; Chen, Shaw H.
CORPORATE SOURCE: Department of Photonics and Display Institute,
National Chiao Tung Univ., Taichung, Peop. Rep. China
SOURCE: Proceedings of SPIE-The International Society for
Optical Engineering (2005), 5872 (Advancements in
Polymer Optics Design, Fabrication, and Materials),
587201-1-587204/8
CODEN: PSISDG; ISSN: 0277-786X
PUBLISHER: SPIE-The International Society for Optical
Engineering
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Glassy liquid crystals (GLCs) possessing multi-functionalities, excellent
morphol. stability, and elevated phase transition temperature have been
designed
and synthesized for photonic device applications. Recent development has
been reported on deterministic synthesis approach for scalable process in
preparing GLC materials. The advanced processing eases the material
preparation
and tailors the material properties accordingly to suit device
applications. These applications can be found into (1) chiral nematic
GLCs
for circularly polarizers and notch filters, (2) photochromic nematic
GLC,
which can be photomodulated reflective indexes in the solid states, for
potential applications in nondestructive rewritable optical data storages
and photonic switching, and (3) ferroelec. GLCs for potential fast
switching light valves.
IT 611206-46-3
RL: TEM (Technical or engineered material use); USES (Uses)
(photonic applications of glassy liquid crystals)
RN 611206-46-3 CAPLUS
CN 1,3,5-Benzenetricarboxylic acid, (3,3,4,4,5,5-hexafluoro-1-cyclopentene-
1,2-diyl)bis[(3,5-dimethyl-4,2-thiophenediyl)-4,1-phenylene]
tetrakis[3-[4-[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]carbonyl]phenoxy]propyl]
ester (9CI) (CA INDEX NAME)

L19 ANSWER 43 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B




PAGE 2-A




L19 ANSWER 43 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B




PAGE 2-C



L19 ANSWER 43 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 3-B




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

RN 869207-58-9 CAPLUS
 CN Propanedinitrile, 2-[[3,3,4,4,5,5-hexafluoro-2-(2-methyl-5-phenyl-3-thienyl)-1-cyclopenten-1-yl](4-methoxyphenyl)methylene]- (CA INDEX NAME)

Cc1ccc(cc1)/C=C/C#N/C#N/C2=CC(=C(C=C2)S)C(C)=C(F)(F)F(F)(F)F

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


OTHER SOURCE(S): MARPAT 143:326392
GI

$$\begin{array}{c} \text{R}^3 - \text{Y} - \text{N} - \text{C}(\text{R}^1)_p - \text{C}(\text{Ar}^1)_n - \text{C}(\text{Ar}^2)_m - \text{R}^6 \\ | \\ \text{p}2 \end{array}$$


IT respiratory tract disorders.
865312-57-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

RN	865312-57-8	CAPLUS
CN	Benzamide, 3-ethoxy-N-[[3-[5-[(3S)-3-methyl-1-piperazinyl)methyl]-2-thienyl]phenyl]methyl]- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

L19 ANSWER 45 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 46 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1020451 CAPLUS
DOCUMENT NUMBER: 143:305710
TITLE: Non-glycosylated/-glycosidic/-peptidic small molecule
selectin inhibitors for the treatment of inflammatory
disorders
INVENTOR(S): Kranich, Remo; Aydt, Ewald Mirko
PATENT ASSIGNEE(S): Revotar Biopharmaceuticals A.-G., Germany
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1577289	A1	20050921	EP 2004-6461	20040318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
WO 2005090284	A1	20050929	WO 2005-EP2920	20050318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CO, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1732882	A1	20061220	EP 2005-716209	20050318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			EP 2004-6461	A 20040318
			WO 2005-EP2920	W 20050318
OTHER SOURCE(S):			MARPAT 143:305710	
GI				

L19 ANSWER 46 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The invention relates to compds. I [R2 = OH, R3 = H, R1 = H, CN, NO2, CF3, F, Cl, Br, I, Me (groups Q1); R3 = OH, R2 = H, R1 = groups Q1 or Et, Pr, iPr, Bu, t-Bu, Ph, thienyl, furyl, thiazolyl (groups Q2); R3 = OH, R1 = H, R2 = groups Q2; X = -E0-1CONH(CH2)1-2CO-, where E = NH or (CH2)1-3NH, -E0-1SO2NH(CH2)1-2(NH)0-1-, -(CH2)1-8(NH)0-1CO-, substituted phenylene- or 1,4-piperazinediyl-(NH)0-1CO-, etc.; Y = substituted Ph, anilino, piperidino, pyrrolidinyl, etc.] or their pharmaceutically-acceptable salts, esters, amides or prodrugs which can be used to modulate the in-vitro and in-vivo binding processes mediated by E-, P-, or L-selectin binding. Thus, compound II was prepared from 2-thiopheneacetic acid, 2-aminobenzeneboronic acid, and 2,3,4-trimethoxyphenylacetic acid and assayed for its ability to inhibit the binding of E-, P-, and L-selectin chimeric mols. to sLe and tyrosinesulfate residues linked to a polymeric matrix as a PSGL-1 substitute (46.5, 92.4, and 81.9 % inhibition, resp.).
IT 864518-31-OP 864518-32-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of non-glycosylated/-glycosidic/-peptidic small mol. selectin inhibitors for treatment of inflammatory disorders)
RN 864518-31-0 CAPLUS
CN 2-Thiopheneacetic acid,
5-[2-[(2-(2,3,4-trimethoxyphenyl)acetyl)amino]phenyl]-, ethyl ester (CA INDEX NAME)

L19 ANSWER 46 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 864518-32-1 CAPLUS
CN 2-Thiopheneacetic acid,
5-[2-[(2-(2,3,4-trimethoxyphenyl)acetyl)amino]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 47 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:696900 CAPLUS
 DOCUMENT NUMBER: 143:193903
 TITLE: Preparation of thiophene and furan compounds for potentiating glutamate receptor function
 INVENTOR(S): Castano Mansanet, Ana Maria; Dominguez-Manzanares, Esteban; Escribano, Ana Maria; Fernandez, Maria Carmen; Hornback, William Joseph; Jimenez-Aguado, Alma
 PATENT ASSIGNEE(S): Maria; Tromiczak, Eric George; Wu, Zhipei; Zarimayeh, Hamideh; Zimmerman, Dennis Michael
 SOURCE: Eli Lilly and Company, USA
 PCT Int. Appl., 249 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070916	A1	20050904	WO 2005-US4	20050105
W:	AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SE, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1706395	A1	20061004	EP 2005-704862	20050105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
US 2007105852	A1	20070510	US 2006-596419	20060613
PRIORITY APPLN. INFO.:			EP 2004-380005	20040109
			US 2004-552080P	P 20040310
			WO 2005-US4	W 20050105


OTHER SOURCE(S): MARPAT 143:193903
 GI

L19 ANSWER 47 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. I [C = S, O; R1 = H, F, Cl, Br, I, CHO, etc.; R2 = CN, CO2H, C(O)NHOH, etc.; A = OH, Br, I, CF3, etc.; and their pharmaceutically acceptable salts], useful in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression (no biol. data given), were prepared. Thus, the hydrolysis of the corresponding Et ester afforded the thiophene-2-carboxylic acid I [X = S; R1 = CF3; R2 = CO2H; A = 2-(MeS)C6H4]. The pharmaceutical composition comprising the compound

I is disclosed.
 IT 861963-07-7P 861963-39-5P 861963-41-9P
 861963-76-0P 861963-86-2P 861963-88-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiophene and furan compds. for potentiating glutamate receptor function)
 RN 861963-07-7 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-5-ethyl-3-(3'-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)




RN 861963-39-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-3-[4'-(cyanomethyl)-2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

L19 ANSWER 47 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 biphenyl]-4-yl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 861963-41-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-3-[4'-(cyanomethyl)-2'-ethoxy[1,1'-biphenyl]-4-yl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 861963-76-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-5-ethyl-3-[4-[(2-methoxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 47 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 861963-86-2 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-5-ethyl-3-[4-[(3-methoxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)




RN 861963-88-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-5-ethyl-3-[4-[(4-methoxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 47 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 861967-57-9P 861967-59-1P 861967-60-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of thiophene and furan compds. for potentiating glutamate
 receptor function)
 RN 861967-57-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-5-ethyl-3-[(2-methoxyphenyl)thio]phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 861967-59-1 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-5-ethyl-3-[(3-methoxyphenyl)thio]phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 47 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861967-60-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-cyano-5-ethyl-3-[(4-methoxyphenyl)thio]phenyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 48 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:453567 CAPLUS
 DOCUMENT NUMBER: 142:491882
 TITLE: Organic species that facilitate charge transfer to or
 from nanostructures
 INVENTOR(S): Whiteford, Jeffery A.; Buretea, Mihai A.; Nguyen,
 Linh; Scher, Erik
 PATENT ASSIGNEE(S): Nanosys, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S.
 Ser. No. 656,910.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: *****
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005109989	A1	20050526	US 2004-928625	20040826
US 2004178390	A1	20040916	US 2003-656910	20030904
US 6949206	B2	20050927		
US 2005205849	A1	20050922	US 2005-130296	20050516
US 2005205850	A1	20050922	US 2005-130303	20050516
US 2007122101	A1	20070531	US 2006-342087	20060126
US 7228050	B2	20070605		

PRIORITY APPLN. INFO.: **US 2002-408722P P 20020909**

US 2003-452232P	P	20030304
US 2003-656910	A2	20030904
US 2003-656916	A1	20030904


AB The present invention provides polymeric compns. that can be used to
 modify charge transport across a nanocrystal surface or within a
 nanocrystal-containing matrix, as well as methods for making and using
 the novel compns.

IT 671190-72-0 852056-71-4 852056-74-7
 RL: PRP (Properties)


(conductive composition; organic species that facilitate charge
 transfer to or from nanostructures)

RN 671190-72-0 CAPLUS
 CN Phosphonic acid, [[2-[5'-(1-decynyl)[2,2'-bithiophen]-5-yl]-5-[5'-[4-[5-(diethoxyphosphinyl)-2-thienyl]-2,5-bis(hexyloxy)phenyl][2,2'-bithiophen]-5-yl]-1,4-phenylene]bis(methylene)]bis-, tetraethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 48 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 852056-71-4 CAPLUS
 CN Phosphonic acid, [[2-[5'-(1-decynyl)-2-thienyl]-2,5-bis(hexyloxy)phenyl][2,2'-bithiophen]-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 852056-74-7 CAPLUS
 CN Phosphonic acid, [[2-[5'-(1-decynyl)[2,2'-bithiophen]-5-yl]-4-(diethoxyphosphinyl)-5-[5'-[4-[5-(diethoxyphosphinyl)-2-thienyl]-2,5-bis(hexyloxy)phenyl][2,2'-bithiophen]-5-yl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 48 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

— (CH₂)₇—Me

L19 ANSWER 49 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:325358 CAPLUS
DOCUMENT NUMBER: 142:392276
TITLE: Preparation of thiophene-2-carboxamide derivatives as antagonists of CB1 cannabinoid receptors and their therapeutic application
INVENTOR(S): Barth, Francis; Rinaldi, Carmona Murielle
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
SOURCE: Fr. Demande, 23 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2860792	A1	20050405	FR 2003-11861	20031010
FR 2860792	B1	20060224		
WO 2005035488	A2	20050405	WO 2004-FR2546	20041008
WO 2005035488	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1678159	A2	20060712	EP 2004-791498	20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007508279	T	20070405	JP 2006-530423	20041008
US 2006264470	A1	20061123	US 2006-400702	20060407
PRIORITY APPLN. INFO.:				FR 2003-11861 A 20031010
				WO 2004-FR2546 W 20041008
OTHER SOURCE(S): MARPAT 142:392276				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein R1 = H, alkyl; R2 = alkyl, (un)substituted nonarom. carbocyclyl, 1,2,3,4-tetrahydronaphthalen-1- or 2-yl, mononitrogen heterocyclyl substituted at N, etc.; or R1NR2 = (un)substituted piperazin-1-yl, 1,4-diazepin-1-yl, pyrrolidin-1-yl; R3-R8 = independently H, halo, alkyl, alkoxy, CF₃, S(O)n-alkyl; n = 0-2; their

L19 ANSWER 49 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
free bases or acid addn. salts, and their hydrates or solvates] were prepd. as antagonists of CB1 cannabinoid receptors and for treatment of the diseases it implies. For instance, II (m.p. = 232°) was prepd. by treating 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)ethanone with POCl₃, and 1,2-dichloroethane in DMF at 50° for 16 h, followed by TEA-cyclization with mercaptoacetic acid, and TEA-amination with 1-aminopiperidine. I exhibited an excellent affinity in vitro (IC₅₀ ≤ 10⁻⁷ M) for the CB1 cannabinoid receptors. Thus, I are useful for treating psychosis, appetite and gastrointestinal disorders, smoking and alc. cessation, etc.

IT 849812-85-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CB1 cannabinoid; preparation of thiophenecarboxamides derivs. as antagonists of CB1 cannabinoid receptors)

RN 849812-85-7 CAPLUS
CN 2-Thiophenecarboxamide, 4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE



FORMAT

L19 ANSWER 50 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300395 CAPLUS
DOCUMENT NUMBER: 142:355054
TITLE: Preparation of amide derivatives as inhibitors of histone deacetylase
INVENTOR(S): Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie; Vaisburg, Arkadi; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.
PATENT ASSIGNEE(S): Methylgene, Inc., Can.
SOURCE: PCT Int. Appl., 559 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030705	A1	20050407	WO 2004-US31591	20040924
WO 2005030705	A9	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276337	A1	20050407	AU 2004-276337	20040924
CA 2539117	A1	20050407	CA 2004-2539117	20040924
EP 1663953	A1	20060607	EP 2004-789074	20040924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1882529	A	20061220	CN 2004-80034571	20040924
JP 2007506785	T	20070322	JP 2006-528279	20040924
PRIORITY APPLN. INFO.:				US 2003-505884P P 20030329
				US 2003-532973P P 20031229
				US 2004-561082P P 20040409
				WO 2004-US31591 W 20040924
OTHER SOURCE(S): MARPAT 142:355054				
GI				


L19 ANSWER 50 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title comps. I [Ar1 = (un)saturated-, (un)substituted-mono or fused poly-cyclic hydrocarbonyl optionally containing 1-4 heteroatoms per ring;
R1 = (un)substituted-mono-, -bi-, -tri-cyclic-aryl or -heteroaryl; R2, R3, and R4 independently = H, halo, amino, etc.; R5 and R6 independently = H, alkyl, aryl, etc.; x = 0-1; Y = any pharmaceutically acceptable chemical moiety consisting of 1 to 50 atoms with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylase. Thus, e.g., II was prepared by Suzuki coupling of 2-bromo-2-nitro-phenylamine (preparation given) with 2-thiopheneboronic acid followed by carbonylation with 4-[3,4-dimethoxy-(phenylamino)-methyl]benzoic acid (preparation given) and subsequent reduction. The inhibitory capability of I towards antiproliferative activity of histone deacetylase enzyme was evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and it revealed that certain comps. of the invention had MTT IC 50 values in the range of below 1 up to 20 μ M. I as histone deacetylase inhibitors should prove useful in the treatment of diseases such as, but not limited to, cell proliferative disease, protozoal disease, and fungal disease.

IT 849233-46-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic


L19 ANSWER 50 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 849233-84-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-[4-amino-3-[(4-methoxybenzoyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 849233-85-8 CAPLUS
CN Benzamide, N-[2-amino-5-[5-(1-hydroxyethyl)-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 849234-99-7 CAPLUS
CN Benzamide, N-[2-amino-5-(5-methyl-2-thienyl)phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 50 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of amide derivs. as inhibitors of histone deacetylase)
RN 849233-46-1 CAPLUS
CN Benzamide, N-[2-amino-5-[5-(hydroxymethyl)-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



IT 849233-65-4P 849233-80-3P 849233-82-5P
849233-84-7P 849233-85-8P 849234-99-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amide derivs. as inhibitors of histone deacetylase)
RN 849233-65-4 CAPLUS
CN Benzamide, N-[5-(5-acetyl-2-thienyl)-2-aminophenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 849233-80-3 CAPLUS
CN Benzamide, N-[2-amino-5-[5-[2-(aminosulfonyl)-1,1-dimethylethyl]-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 849233-82-5 CAPLUS
CN Benzamide, N-[2-amino-5-[5-(3-isoxazolyl)-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



L19 ANSWER 51 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:300394 CAPLUS
DOCUMENT NUMBER: 142:373563
TITLE: Preparation of amide derivatives as inhibitors of histone deacetylase
INVENTOR(S): Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie; Vaisburg, Arkadii; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.
PATENT ASSIGNEE(S): Methylgene, Inc., Can.
SOURCE: PCT Int. Appl., 389 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030704	A1	20050407	WO 2004-US31590	20040924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, ZY			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, NO, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2003-50884P	P 20030924
			US 2003-532973P	P 20031229
			US 2004-561082P	P 20040409

OTHER SOURCE(S): MARPAT 142:373563
GI


L19 ANSWER 51 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I [Ar1 = (un)saturated-, (un)substituted-mono or fused poly-cyclic hydrocarbonyl optionally containing 1-4 heteroatoms per ring; R1 = (un)substituted-mono-, -bi-, -tri-cyclic-aryl or -heteroaryl; R2, R3, and R4 independently = H, halo, amino, etc.; R5 and R6 independently = H, alkyl, aryl, etc.; x = 0-1; Y = any pharmaceutically acceptable chemical moiety consisting of 1 to 50 atoms with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylase. Thus, e.g., II was prepared by Suzuki coupling of 2-bromo-2-nitro-phenylamine (preparation given) with 2-thiopheneboronic acid followed by carbonylation with 4-[3,4-dimethoxy-(phenylamino)-methyl]benzoic acid (preparation given) and subsequent reduction. The inhibitory capability of I towards antiproliferative activity of histone deacetylase enzyme was evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and it revealed that certain compds. of the invention had MTT IC 50 values in the range of below 1 up to 20 μ M. I as histone deacetylase inhibitors should prove useful in the treatment of diseases such as, but not limited to, cell proliferative disease, protozoal disease, and fungal disease.

IT 849233-46-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic


L19 ANSWER 51 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 849233-84-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-[4-amino-3-[(4-methoxybenzoyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 849233-85-8 CAPLUS
CN Benzamide, N-[2-amino-5-[5-(1-hydroxyethyl)-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 849234-99-7 CAPLUS
CN Benzamide, N-[2-amino-5-(5-methyl-2-thienyl)phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L19 ANSWER 51 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of amide derivs. as inhibitors of histone deacetylase)

RN 849233-46-1 CAPLUS
CN Benzamide, N-[2-amino-5-[5-(hydroxymethyl)-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




IT 849233-65-4P 849233-80-3P 849233-82-5P 849233-84-7P 849233-85-8P 849234-99-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amide derivs. as inhibitors of histone deacetylase)

RN 849233-65-4 CAPLUS
CN Benzamide, N-[5-(5-acetyl-2-thienyl)-2-aminophenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 849233-80-3 CAPLUS
CN Benzamide, N-[2-amino-5-[5-[2-(aminosulfonyl)-1,1-dimethylethyl]-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 849233-82-5 CAPLUS
CN Benzamide, N-[2-amino-5-[5-(3-isoxazolyl)-2-thienyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)


L19 ANSWER 52 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:183226 CAPLUS
DOCUMENT NUMBER: 143:97720
TITLE: Synthesis and luminescent properties of aromatic-thiophene copolymers
AUTHOR(S): Wu, Sheng-Han; Tsai, Raymond Chien-Chao
CORPORATE SOURCE: Department of Chemical Engineering, National Chung Cheng University, Chiayi, 21, Taiwan
SOURCE: PMSE Preprints (2005), 3, 3-4
CODEN: PPMRA9; ISSN: 1550-6703
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal; (computer optical disk)
LANGUAGE: English
AB A series of thiophene-based photoactive copolymers Poly 2-[4-(2-phenylethylene)phenyl]-5-[4-(4-(4-1,8-octanedioxyphenyl)ethylene)phenyl]thiophene and Poly 2-[4-(2-ethoxyphenyl)ethylene]phenyl-5-[4-(2-(3-ethoxy, 4-1,8-octanedioxyphenyl)ethylene)phenyl]thiophene consisting of alternating conjugated and nonconjugated segments were synthesized. 1H-NMR spectrum corroborated the well-defined structures, and both of copolymers were soluble in common organic solvents. The relative PL quantum efficiency were measured as 0.46 and 0.59 for these two copolymers, resp. As the results, the PL quantum efficiency increased with an increase in the electron-donating power of the substituent. Both copolymers emitted bluish-green to green light above the threshold bias of 5.0 V under the ambient condition.

IT 770720-62-2P 770720-8-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis and luminescent properties of aromatic-thiophene copolymers)


RN 770720-62-2 CAPLUS
CN Poly(2,5-thiophenediyl-1,4-phenylene-1,2-ethenediyl-1,4-phenyleneoxy-1,8-octanedioxy-1,4-phenylene-1,2-ethenediyl-1,4-phenylene) (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 52 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 770720-68-8 CAPLUS
 CN Poly[2,5-thiophenediyl-1,4-phenylene-1,2-ethenediyl(3-ethoxy-1,4-phenylene)oxy-1,8-octanedioxy(2-ethoxy-1,4-phenylene)-1,2-ethenediyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 53 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 53 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:167237 CAPLUS
 DOCUMENT NUMBER: 142:393038
 TITLE: A novel photoresponsive π -conjugated polymer based on diarylethene and its photoswitching effect in electrical conductivity
 AUTHOR(S): Kawai, Tsuyoshi; Nakashima, Yukiko; Irie, Masahiro
 CORPORATE SOURCE: Department of Chemistry and Biochemistry Graduate School of Engineering, Kyushu University, Fukuoka, 812-8581, Japan
 SOURCE: Advanced Materials (Weinheim, Germany) (2005), 17(3), 309-314
 CODEN: ADVMEW; ISSN: 0950-9648
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Photochromic conductivity modulation of conjugated polymers containing a diarylethene unit with high photochromic conversion ratios is described. The elec. conductivity can be switched quasi-reversibly from the bleached low-conductivity state (Figure, left) and the blue high-conductivity state (right) by alternate irradiation with visible and UV light, and may lead to applications in photon-mode mol. memory devices.
 IT 850080-63-6P
 RL: PRE (Properties); SPN (Synthetic preparation); PREP (Preparation)
 CN Poly[(3,5-dimethyl-2,4-thiophenediyl)(3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-diyl)(3,5-dimethyl-4,2-thiophenediyl)(2',2'',5',5''-tetramethoxy[1,1':4',1''-terphenyl]-4,4''-diyl)(9,9-dioctyl-9H-fluorene-2,7-diyl)(2,2',5,5'-tetramethoxy[1,1':4',1''-terphenyl]-4,4''-diyl)] (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 54 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:122800 CAPLUS
 DOCUMENT NUMBER: 142:191201
 TITLE: Antimicrobial biaryl compounds
 INVENTOR(S): Jefferson, Elizabeth Anne; Swayze, Eric E.; Seth, Punit P.; Robinson, Dale E.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 630,122.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: ~~2~~
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005032805	A1	20050210	US 2004-914256	20040809
US 6849660	B1	20050201	US 2000-630122	20000801

PRIORITY APPLN. INFO.: US 2000-630122 A2 20000801

OTHER SOURCE(S): MARPAT 142:191201
 AB Provided are antibacterial biaryl compds. having micromolar MIC activity against Gram-neg. and Gram-pos. pathogens, including a methicillin-resistant *S. aureus* strain. Other embodiments of invention are methods of treating bacterial infection in a mammal by administering to the mammal an effective amount of a compound described herein. The inhibitory effect of some of the compds. on bacterial translation was determined
 IT 838820-34-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 CN 2-Thiophenecarboxamide, N-[3-([(1,1'-biphenyl]-4-ylcarbonyl)amino]phenyl]-N-[1-[4-[3-(dimethylamino)propoxy]phenyl]-2-oxo-2-(1-piperazinyl)ethyl]]- (9CI) (CA INDEX NAME)




L19 ANSWER 55 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:120950 CAPLUS
 DOCUMENT NUMBER: 142:219491
 TITLE: Preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter
 INVENTOR(S): Nomura, Sumihiro; Kawanishi, Ei-ji; Ueta, Kiichiro
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 221 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012326	A1	20050210	WO 2004-JP11312	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260761	A1	20050210	AU 2004-260761	20040730
CA 2534024	A1	20050210	CA 2004-2534024	20040730
EP 1651658	A1	20060503	EP 2004-771314	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1829729	A	20060906	CN 2004-80022007	20040730
BR 2004013232	A	20061003	BR 2004-13232	20040730
JP 2007518693	T	20070712	JP 2006-519251	20040730
US 2005233988	A1	20051020	US 2005-45446	20050131
NO 2006000220	A	20060502	NO 2006-220	20060116
MX 2006PA01274	A	20060411	MX 2006-PA1274	20060131
IN 2006CN00734	A	20070608	IN 2006-CN734	20060228
US 2006217323	A1	20060928	US 2006-446014	20060602
US 2006229260	A1	20061012	US 2006-453728	20060615
US 2006234954	A1	20061019	US 2006-453727	20060615
US 2006293251	A1	20061228	US 2006-453726	20060615
PRIORITY APPLN. INFO.:			US 2003-491534P	P 20030800
			US 2003-491523P	P 20030801
			US 2003-519155P	P 20031112
			US 2003-519209P	P 20031112
			US 2003-519210P	P 20031112


L19 ANSWER 55 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 2003-519381P P 20031112
 US 2004-579722P P 20040615
 US 2004-579730P P 20040615
 US 2004-579758P P 20040615
 US 2004-579792P P 20040615
 US 2004-903034 A3 20040730
 US 2004-903136 A3 20040730
 US 2004-903234 A3 20040730
 US 2004-903233 A3 20040730
 WO 2004-JP11312 W 20040730

OTHER SOURCE(S): MARPAT 142:219491
 GI



AB Glycosides I, wherein A and B are: (1) A is unsatd. monocyclic heterocyclic, and B is unsatd. monocyclic heterocyclic, unsatd. fused hetero-bicyclic, or benzene, (2) A is benzene, and B is unsatd. monocyclic heterocyclic or unsatd. fused hetero-bicyclic, or (3) A is unsatd. fused hetero-bicyclic, and B are independently unsatd. monocyclic heterocyclic, unsatd. fused hetero-bicyclic, or benzene; X is a carbon atom or a nitrogen atom; Y is -(CH₂)_n- (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof. A method is claimed for treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyper-insulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension. The pharmaceutical compns. may be orally administered to mammalian species including human beings, apes, dogs, etc., for example, in the dosage form of tablet, capsule, granule or powder, or parenterally administered in the form of


L19 ANSWER 55 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 injection prepn., or intra-nasally, or in the form of transdermal patch. Thus, 1-(β-D-glucopyranosyl)-4-chloro-3-(6-ethylbenzo[b]thiophen-2-yl-methyl)benzene was prepd. as antidiabetic agent and having inhibitory activity against sodium-dependent transporter.
 IT 842135-51-7P
 R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of glycosides as antidiabetic agents and having inhibitory activity against sodium-dependant transporter)
 RN 842135-51-7 CAPLUS
 CN Thiophene, 2-[(5-bromo-2-methoxyphenyl)methyl]-5-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L19 ANSWER 56 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:96443 CAPLUS
 DOCUMENT NUMBER: 142:176557
 TITLE: Preparation of benzoic and phenylacetic acid derivatives as HNF-4α modulators
 INVENTOR(S): Mapes, Christopher; Karanewsky, Donald; Thompson, Anthony; Michellys, Pierre; Ruppard, Daniel; Chen, Jyun-hung
 PATENT ASSIGNEE(S): Ligand Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 150 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009104	A2	20050203	WO 2004-US23788	20040716
WO 2005009104	A3	20051229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-487915P	P 20030716
OTHER SOURCE(S):			CASREACT 142:176557; MARPAT 142:176557	
GI				



AB Title compds. I [R1 = H, halo, alkyl, etc.; R2, R4 = H, halo, alkyl, alkenyl, etc.; R3 = H, halo, acyl, Me, etc.; R5 = H, halo, alkyl, etc.; R6 = H, halo, Me, methoxy; R7 = CH₂OH, CHO, carboxy, etc.; X, Y = (un)substituted methylene, alkyl, etc.] are prepared For instance, 4-(2-phenylbenzyloxy)phenylacetic acid (II) is prepared from 2-phenylbenzyl bromide and Me 4-hydroxyphenylacetate (DMF, Cs₂CO₃) and the resulting product converted to the acid (MeOH, THF, H₂O, LiOH). II has K_i = 500 nM for the HNF-4α receptor. I are useful for the treatment of, e.g.,

L19 ANSWER 56 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
diabetes, cancer and obesity.
IT 833484-74-5P, 4-[2-(5-Acetyl-2-thienyl)benzyloxy]phenylacetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of benzoic and phenylacetic acid derivs. as HNF-4a
modulators)
RN 833484-74-5 CAPLUS
CN Benzeneacetic acid, 4-[[2-(5-acetyl-2-thienyl)phenyl]methoxy]- (9CI) (CA
INDEX NAME)




L19 ANSWER 57 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1124566 CAPLUS
DOCUMENT NUMBER: 142:49264
TITLE: aryl compounds and uses in modulating amyloid β
INVENTOR(S): Cheng, Soan; Comer, Daniel D.; Mao, Long; Balow,
Guity
P.; Pleynet, David
PATENT ASSIGNEE(S): Neurogenetics, Inc., USA
SOURCE: PCT Int. Appl., 178 pp.
CODEN: FIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110350	A2	20041223	WO 2004-US15239	20040514
WO 2004110350	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004247013	A1	20041223	AU 2004-247013	20040514
CA 2525547	A1	20041223	CA 2004-2525547	20040514
US 2005070538	A1	20050331	US 2004-846941	20040514
US 7244739	B2	20070717		
EP 1628666	A2	20060301	EP 2004-752297	20040514
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004010348	A	20060530	BR 2004-10348	20040514
CN 1787822	A	20060614	CN 2004-80012784	20040514
JP 2007504282	T	20070301	JP 2006-533094	20040514
ZA 2005009153	A	20060830	ZA 2005-9153	20051114
MX 2005PA12281	A	20060519	MX 2005-PA12281	20051114
PRIORITY APPLN. INFO.:			US 2003-470884P	P 20030514
			US 2003-532260P	P 20031222
			WO 2004-US15239	W 20040514

OTHER SOURCE(S): MARPAT 142:49264
AB Aryl compds., compns., and kits are provided. Methods of modulating $A\beta$ levels, and methods of treating a disease associated with aberrant $A\beta$ levels, are also provided. Preparation of compds., e.g. (I), (A)La(B)Lb(C)Lc(D)) is included.
IT 810663-19-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


L19 ANSWER 57 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Biological study); USES (Uses)
(aryl compds. and uses in modulating amyloid β)
RN 810663-19-5 CAPLUS
CN 2-Thiazolamine, 4-(5-phenyl-2-thienyl)-N-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)



L19 ANSWER 58 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1086454 CAPLUS
DOCUMENT NUMBER: 142:219658
TITLE: Energy and Electron Transfer in Bifunctional Non-Conjugated Dendrimers
AUTHOR(S): Thomas, K. R. Justin; Thompson, Alexis L.; Sivakumar, Athimaniandand V.; Bardeen, Christopher J.; Thayumanavan, S.
CORPORATE SOURCE: Department of Chemistry, University of Massachusetts, Amherst, MA, 01003, USA
SOURCE: Journal of the American Chemical Society (2005), 127(1), 373-383
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:219658
AB Nonconjugated dendrimers, which are capable of funneling energy from the periphery to the core followed by a charge-transfer process from the core to the periphery, were synthesized. The energy and electron donors involve a diarylamino pyrene unit and are incorporated at the periphery of these dendrimers. The energy and electron acceptor is at the core of the dendrimer, which involves a chromophore based on a benzthiadiazole moiety.
The backbone of the dendrimers is benzyl ether based. A direct electron-transfer quenching of the excited state of the periphery or a sequential energy transfer-electron-transfer pathway are the two limiting mechanisms of the observed photophysical properties. The latter mechanism is prevalent in these dendrimers. The energy transfer occurs on a picosecond time scale, while the charge-transfer process occurs on a nanosecond time scale. The lifetime of the charge separated species was in the range of microseconds. Energy transfer efficiency of 80-90% was determined using both steady-state and time-resolved measurements, while charge-transfer efficiency of 70-80% was deduced from fluorescence quenching of the core chromophore. The dependence of the energy and charge-transfer processes on dendrimer generation is analyzed in terms of the backfolding of the flexible benzyl ether backbone, which leads to a weaker dependence of the energy and charge-transfer efficiency on dendrimer size than would be expected for a rigid system.
IT 840531-18-2P
RL: PREP (Properties); SPN (Synthetic preparation); PREP (Preparation) (G1 dendrimer; energy and electron transfer in prepared benzyl ether non-conjugated dendrimers with benzthiadiazole core and diarylamino pyrene units)
RN 840531-18-2 CAPLUS
CN 1-Pyrenamine, N,N',N'',N'''-[2,1,3-benzothiadiazole-4,7-diylbis[5,2-thiophenediyl-3,1-phenyleneoxymethylene-5,1,3-benzenetriylbis(oxymethylene-3,1-phenylene)]]tetrakis[N-phenyl- (CA INDEX NAME)


L19 ANSWER 58 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




L19 ANSWER 58 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



PAGE 3-A



REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 59 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1048937 CAPLUS

DOCUMENT NUMBER: 142:147835

TITLE: A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists

AUTHOR(S): Hale, Jeffrey J.; Lynch, Christopher L.; Neway, William; Mills, Sander G.; Hajdu, Richard; Keohane, Carol Ann; Rosenbach, Mark J.; Milligan, James A.; Shel, Gan-Ju; Parent, Stephen A.; Chrebet, Gary; Bergstrom, James; Card, Deborah; Ferrer, Marc;

Hodder, Peter; Strulovici, Berta; Rosen, Hugh; Mandala, Suzanne

CORPORATE SOURCE: Departments of Medicinal Chemistry and Immunology and Rheumatology Research, Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6662-6665

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:147835


GI

L19 ANSWER 59 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

2-thienyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



I

AB Moderately potent, selective S1P1 receptor agonists identified from high-throughput screening have been adapted into lipophilic tails for a class of orally bioavailable amino acid-based S1P1 agonists represented by

I. Many of the new compds. are potent S1P1 agonists that select against the S1P2, S1P3, and S1P4 (although not S1P5) receptor subtypes. Two of the analogs are highly orally bioavailable and possess excellent pharmacokinetic profiles in the rat, dog, and rhesus monkey.

IT 570423-78-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (1-benzyl-3-carboxyazetidine derivs. as EDG-1 receptor agonists and immunosuppressants: high-throughput screening for oral bioavailability and preparation)


RN 570423-78-8 CAPLUS

CN 3-Azetidinecarboxylic acid,
 1-[[[3-methoxy-4-[[[4-phenyl-5-(trifluoromethyl)-

Searched by Jason M. Nolan, Ph.D.


Page 106

L19 ANSWER 60 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:907986 CAPLUS
 DOCUMENT NUMBER: 142:56144
 TITLE: Improved studies of cross-coupling reactions of
 (tri-n-butylstannyl)- and 5,5'-bis(tri-n-
 butylstannyl)-2,2'-bithiophene with aryl halides
 Hamad, Elgazvy, Abdel-Sattar S.
 AUTHOR(S): Department of Chemistry, Faculty of Science,
 CORPORATE SOURCE: University of Ain Shams, Cairo, 11566, Egypt
 SOURCE: Journal of Heterocyclic Chemistry (2004), 41(5),
 755-759
 CODEN: JHTCAD; ISSN: 0022-152X
 PUBLISHER: HeteroCorporation
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:56144
 AB Stille coupling under standard conditions proceeds in low yield when
 using hindered organostannanes (1) or (2) and aryl bromide partners. The
 inclusion of aryl iodide instead of aryl bromide with the same
 organostannanes, significantly improves the efficiency of the coupling,
 providing a variety of desired products in good to excellent yield. The
 yields of Stille coupling are compared to the different reactivity of
 aryl halides. This study of Stille coupling with different aryl halides are
 documented and rationalized.
 IT 808148-70-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Pd-catalyzed Stille cross-coupling reactions
 (tributylstannyl)bithiophene with aryl halides to give mono- and
 diarylbithiophenes)
 RN 808148-70-1 CAPLUS
 CN 2,2'-Bithiophene, 5,5'-bis(2,4-dimethoxy-6-methylphenyl)- (9CI) (CA
 INDEX NAME)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 61 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:907017 CAPLUS
 DOCUMENT NUMBER: 142:279996
 TITLE: Molecular recognition: Studies on the synthesis of
 methylene pivotal bithiophene carboxamide
 derivatives
 as ditopic receptors for suberic acid
 Brahma, Sulagna; Pan, Dipanjan; Ray, Jayanta K.
 AUTHOR(S): Department of Chemistry, Indian Institute of
 CORPORATE SOURCE: Technology, Kharagpur, 721302, India
 SOURCE: Supramolecular Chemistry (2004), 16(6), 447-452
 CODEN: SCHEER; ISSN: 1061-0278
 PUBLISHER: Taylor & Francis Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:279996
 GI



AB New mol. receptors I (X = N, MeOC) with diphenylmethane as a spacer and
 functional groups complementary to suberic acid have been developed. The
 high affinity of I (X = N) for suberic acid has been found.
 IT 847228-15-3P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and geometry calcs. of diphenylmethane-linked
 bis(thiophenecarboxamide)s as ditopic receptors for mol. recognition
 of suberic acid)
 RN 847228-15-3 CAPLUS
 CN 2-Thiophenecarboxamide, 5,5'-(methylene-4,1-phenylene)bis[N-(2-
 methoxyphenyl)- (9CI) (CA INDEX NAME)




L19 ANSWER 61 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 62 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:902333 CAPLUS
 DOCUMENT NUMBER: 141:379916
 TITLE: Novel hydroxamates as histone deacetylase inhibitors,
 process for their preparations, pharmaceutical
 compositions and uses in the treatment of cancer and
 hepatitis C
 Verner, Eric J.; Sendzik, Martin; Baskaran, Chitra;
 INVENTOR(S): Buggy, Joseph J.; Robinson, James
 PATENT ASSIGNEE(S): Axyx Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092115	A2	20041028	WO 2004-US10549	20040406
WO 2004092115	A3	20050017		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2004230889	A1	20041028	AU 2004-230889	20040406
CA 2521647	A1	20041028	CA 2004-2521647	20040406
US 2005187261	A1	20050825	US 2004-818755	20040406
EP 1611088	A2	20060104	EP 2004-749791	20040406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009227	A	20060328	BR 2004-9227	20040406
CN 1768031	A	20060503	CN 2004-80009225	20040406
JP 2006522157	T	20060928	JP 2006-509735	20040406
IN 2005KN01918	A	20061110	IN 2005-KN1918	20050926
LV 13394	B	20060620	LV 2005-141	20051103
NO 2005005216	A	20051208	NO 2005-5216	20051104
PRIORITY APPLN. INFO.:				
			US 2003-461286P	P 20030407
			US 2003-464448P	P 20030421
			WO 2004-US10549	W 20040406
OTHER SOURCE(S): MARPAT 141:379916				
GI				

L19 ANSWER 62 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



AB Title compds. I [wherein X = O, NR₂ or S(O)_n; n = 0-2; R₁, R₂ = H or alkyl; Y = alkyl(thio/sulfinyl/sulfonyl), OR, (un)substituted alkylene, Ph, phenylalkyl(thio/sulfonyl) or phenoxy; A = (un)substituted phenylene or heteroarylene; R₃ = H, (hydroxy)alkyl or (un)substituted phenyl; B = (hetero)aryl(aralkyl), (hetero)aralkenyl, (hetero)cycloalkyl(alkyl); or pharmaceutically acceptable salts thereof] were prepared. Pharmaceutical compns. comprising I and processes for the preps. of I and their intermediates are disclosed. Compds. I are inhibitors of histone deacetylase (HDAC) and therefore are useful in the treatment of diseases associated with HDAC activity, such as cancer. They are also useful in


the treatment of hepatitis C. In the biol. tests, I were found to inhibit the growth of HCT116 tumor cells, and most of them had KI values of <40 nM against HDAC. Thus, hydroxamate II was synthesized in six steps starting from 3-methyl-benzofuran-2-carboxylic acid, via esterification with methanol, NBS bromination, substitution of the bromide with dimethylamine, ester hydrolysis, coupling with Me 4-(2-aminoethoxy)benzoate and condensation with hydroxylamine.

IT 783353-29-7P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of novel hydroxamates as histone deacetylase inhibitors for the treatment of cancer and hepatitis C)

RN 783353-29-7 CAPLUS
 CN 2-Thiophenecarboxamide, N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-5-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 62 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



L19 ANSWER 63 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN


ACCESSION NUMBER: 2004:861108 CAPLUS
 DOCUMENT NUMBER: 142:56937
 TITLE: Synthesis, Self-Assembly, and Characterization of Supramolecular Polymers from Electroactive Dendron Rodcoil Molecules
 AUTHOR(S): Messmore, Benjamin W.; Hulvat, James F.; Sone, Eli D.;
 CORPORATE SOURCE: Stupp, Samuel I.
 Department of Chemistry, the Department of Materials Science & Engineering, and the Feinberg School of Medicine, Northwestern University, Evanston, IL, 60208, USA
 SOURCE: Journal of the American Chemical Society (2004), 126(44), 14452-14458
 CIPAN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:56937

AB We report here the synthesis and self-assembly of a series of three mols. with dendron rodcoil architecture that contain conjugated segments of oligo(thiophene), oligo(phenylene-vinylene), and oligo(phenylene). Despite their structural differences, all three mols. yield similar self-assembled structures. Electron and atomic force microscopy reveals the self-assembly of the mols. into high aspect ratio ribbon-like nanostructures which at low concns. induce gelation in nonpolar solvent. Self-assembly results in a blue-shifted absorption spectrum and a red-shifted, quenched fluorescence spectrum, indicating aggregation of the conjugated segments within the ribbon-like structures. The assembly of these mols. into one-dimensional nanostructures is a route to π - π stacked supramol. polymers for organic electronic functions. In the oligo(thiophene) derivative, self-assembly leads to a 3 orders of magnitude increase in the conductivity of iodine-doped films due to self-assembly. We also found that elec. field alignment of these supramol. assemblies can be used to create arrays of self-assembled nanowires on a device substrate.


IT 808142-50-9P 808142-65-6P
 RI: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis, self-assembly, and characterization of supramol. polymers from electroactive dendron rodcoil mols.)
 RN 808142-50-9 CAPLUS
 CN [2,2':5',2'':5'',2'''-Quaterthiophene]-5-carboxylic acid, 5'''-[4-[[[4'-[3,5-bis[(3,5-dihydroxybenzoyl)oxy]benzoyl]oxy][1,1'-biphenyl]-4-yl]carbonyl]oxy]phenyl]-, 2-octyldodecyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 63 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

PAGE 1-A




PAGE 1-B




RN 808142-65-6 CAPLUS
 CN [2,2':5',2'':5'',2'''-Quaterthiophene]-5-carboxylic acid, 5'''-[4-[[[4'-[3,5-bis[(3,5-dihydroxybenzoyl)oxy]benzoyl]oxy]phenyl]-, 2-octyldodecyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 63 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

PAGE 1-A




PAGE 1-B




IT 808142-49-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis, self-assembly, and characterization of supramol. polymers
 from electroactive dendron rodcoil mols.)
 RN 808142-49-6 CAPLUS
 CN [2,2':5',2'':5'',2''':5'''-Quaterthiophene]-5-carboxylic acid,
 5'''-[4-[[4'-[[[3,5-bis[[3,5-bis(1,1-dimethylethoxy)benzoyl]oxy]benzoyl]ox
 y][1,1'-biphenyl]-4-yl]carbonyl]oxy]phenyl]-, 2-octyldodecyl ester (9CI)
 (CA INDEX NAME)

L19 ANSWER 63 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 64 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:817666 CAPLUS
 DOCUMENT NUMBER: 141:309638
 TITLE: Inhibitors of cathepsin S for use in disease
 treatment
 INVENTOR(S): Liu, Hong; Tully, David; Epple, Robert; Bursulaya,
 Badry; Williams, Jennifer; Chatterjee, Arnab; Harris,
 Jennifer Leslie; Li, Jun
 PATENT ASSIGNEE(S): IRM LLC, Bermuda
 SOURCE: PCT Int. Appl., 146 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004084842	A2	20041007	WO 2004-US9218	20040324
WO 2004084842	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LV, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004198780	A1	20041007	US 2004-807612	20040323
US 7109243	B2	20060919	US 2003-457595	P 20030324
PRIORITY APPLN. INFO.:			US 2004-807612	A 20040323

OTHER SOURCE(S): MARPAT 141:309638
 AB The present invention provides WC(:O)NHCH2CH2NHAr [W = R1X(C:O)NHCH2R2; R1
 = (substituted)phenyl, pyridyl, or pyridinium N-oxide; X = furan, NHCH2,
 OCH2, phenylene, etc.; R2 = (substituted)phenyl, etc.; Ar = (substituted
 phenyl)] compds. and methods for the selective inhibition of cathepsin S.
 In a preferred aspect, cathepsin S is selectively inhibited in the
 presence of at least one other cathepsin isoenzyme (e.g., cathepsin K).
 The present invention also provides methods for treating a disease state
 in a subject by selectively inhibiting cathepsin S.


IT 768363-84-4P 768363-90-2P 768363-91-3P
 768363-96-8P 768364-01-8P 768364-04-1P
 768364-16-5P 768365-43-1P 768365-45-3P
 768365-54-4P 768365-58-8P 768365-60-2P
 768365-62-4P

THU RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (inhibitors of cathepsin S for use in disease treatment)

RN 768363-84-4 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-
 (trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-(4-fluorophenyl)-
 (9CI) (CA INDEX NAME)


L19 ANSWER 64 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

Absolute stereochemistry.




RN 768363-90-2 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-
 (trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-[2-
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 768363-91-3 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-
 (trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 768363-96-8 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-
 (trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)


L19 ANSWER 64 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 768364-01-8 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 768364-04-1 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 768364-16-5 CAPLUS

L19 ANSWER 64 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 768365-54-4 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 768365-58-8 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 768365-60-2 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 64 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 768365-43-1 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-methoxyphenyl]amino]ethyl]amino]ethyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 768365-45-3 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-methoxyphenyl]amino]ethyl]amino]ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 64 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

CF₃

RN 768365-62-4 CAPLUS
 CN 2-Thiophenecarboxamide, N-[(1S)-1-(cyclohexylmethyl)-2-oxo-2-[[2-[[4-(trifluoromethoxy)phenyl]amino]ethyl]amino]ethyl]-5-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

CF₃

L19 ANSWER 64 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 65 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:780696 CAPLUS
 DOCUMENT NUMBER: 141:295849
 TITLE: Preparation of carboxamidopyrrolidines as melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
 INVENTOR(S): Goodfellow, Val; Rowbottom, Martin; Dyck, Brian P.; Tamiya, Junko; Zhang, Mingzhu; Grey, Jonathan; Vickers, Troy D.
 PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081005	A1	20040923	WO 2004-US7259	20040308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006178403	A1	20060810	US 2004-797927	20040308
PRIORITY APPLN. INFO.:			US 2003-452776P	P 20030307
			US 2003-518265P	P 20031107


OTHER SOURCE(S): MARPAT 141:295849
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [m = 0 or 1; n = 1 or 2; X = -CH₂-, or -N(R₆)-; R₁ = H, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R₂ and R₅ independently = H, (un)substituted alkyl; R₃ = H, (un)substituted-alkyl, -arylalkyl, -heteroarylalkyl; R₄ = (un)substituted-alkyl, -aryl, -heterocycle; R₆ = H or (un)substituted alkyl] and their pharmaceutically acceptable salt, are disclosed as melanin-concentrating hormone (MCH) receptor antagonists having utility for the treatment of MCH receptor-based disorders such as obesity. Thus, e.g., II was prepared via amidation of of III (preparation given) with


L19 ANSWER 65 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 benzoyl chloride. Methods for evaluation of compds. are described (no data). Also disclosed are compns. contg. a compd. of this invention, as well as methods relating to the use thereof.
 IT 762283-65-8P 762300-82-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of carboxamidopyrrolidine derivs. as melanin-concentrating hormone receptor antagonists)
 RN 762283-65-8 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-fluorophenoxy)ethyl]-3-pyrrolidinyl]-3-[[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]methylamino]-N-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762300-82-3 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[(3R)-1-[2-(4-chlorophenoxy)ethyl]-3-pyrrolidinyl]-N-methyl-3-[methyl[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]carbonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 66 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:780502 CAPLUS
 DOCUMENT NUMBER: 141:295848
 TITLE: Preparation of bis(3-aminopyrrolidin-1-yl)methanones as melanin-concentrating hormone receptor antagonists for treatment of obesity and other disorders
 INVENTOR(S): Goodfellow, Val; Rowbottom, Martin; Dyck, Brian P.; Tamiya, Junko; Zhang, Mingzhu; Grey, Jonathan; Vickers, Troy; Kiankarimi, Mehrak; Wade, Warren; Hudson, Sarah Clough
 PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080411	A2	20040923	WO 2004-US7260	20040308
WO 2004080411	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004259931	A1	20041223	US 2004-797487	20040308
US 7067509	B2	20060627		
PRIORITY APPLN. INFO.:			US 2003-452709P	P 20030307

OTHER SOURCE(S): MARPAT 141:295848
 GI



L19 ANSWER 66 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title pyrrolidinamines I [wherein n = 0, 1; R1 = H, (un)substituted (aryl)alkyl, heterocyclyl(alkyl); R2 = H, (un)substituted alkyl, COR7, SO2R8; or NR1R2 = (un)substituted heterocyclyl; R3, R5, R6, R8 = independently H, (un)substituted alkyl; R4 = (un)substituted alkyl, (hetero)aryl, heterocyclyl; R7 = independently H, OH, alkoxy, (un)substituted alkyl, aryl, heterocyclyl; R9 = OH, alkoxy, (un)substituted alkyl, aryl; and stereoisomers, prodrugs, or pharmaceutically acceptable salts thereof] were prepared as melanin-concentrating hormone (MCH) receptor antagonists. For example, a 6-step synthesis starting from (R)-3-amino-1-benzylpyrrolidine, 4-nitrophenyl (S)-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine-1-carboxylate, 4-trifluoromethyl-5-phenylthiophene-2-carboxylic acid, and cycloheptanone gave II. Over half of the exemplified invention compds., including II, exhibited the ability to bind to the human [125I]-MCH receptor with Ki values <1 μM. Thus, I and their pharmaceutical compns. are useful for the treatment of MCH receptor-based disorders, such as obesity, anxiety, depression, digestive disorders, fertility, sexual function disorders,

and urinary disorders (no data).


IT 764720-84-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MCH receptor antagonist; preparation of pyrrolidinamines as MCH receptor antagonists for treatment of obesity and other disorders)



RN 764720-84-5 CAPLUS

CN 2-Thiophenecarboxamide, N-[(3S)-1-[[[(3R)-3-[[[(1S)-1-(4-methoxyphenyl)ethyl]amino]-1-pyrrolidinyl]carbonyl]-3-pyrrolidinyl]-N-methyl-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 67 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention relates to a preparation of benzene derivs. of formula I [wherein: R1 is OH, CN, CO2H, C(O)NH2, or tetrazolyl, etc.; R2 is halogen, haloalkyl, (cyclo)alkoxy, or NH2, etc.; R3 is (cyclo)alkyl, alkenyl, hydroxyalkyl, or carboxyalkyl, etc.; X is O, OCH2, OC(O), C(O), or N:CH, etc.], useful as modulators of KCNQ channel. For instance, benzene derivative


II was found to be an activator of the KCNQ channel (electrophysiol. determination: Ik = 115%).

IT 761455-98-5P 761456-10-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzene derivs., useful as KCNQ channel modulators)

RN 761455-98-5 CAPLUS

CN Benzoic acid, 4-[[[3-(5-acetyl-2-thienyl)phenyl]methoxy]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 761456-10-4 CAPLUS

CN Benzoic acid, 4-[[[3-(5-acetyl-2-thienyl)phenyl]methoxy]-2-hydroxy- (9CI) (CA INDEX NAME)

L19 ANSWER 67 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:775886 CAPLUS

DOCUMENT NUMBER: 141:295736

TITLE: A preparation of benzene derivatives, useful as KCNQ channel modulators

INVENTOR(S): Brown, William Dalby; Teuber, Lene; Dahl, Bjarne H.

PATENT ASSIGNEE(S): Neurosearch A/S, Den.

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

Patent

DOCUMENT TYPE: English

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080377	A2	20040923	WO 2004-EP50290	20040311
WO 2004080377	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1603858	A2	20051214	EP 2004-719459	20040311
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
JP 2006523196	T	20061012	JP 2006-505460	20040311
US 2006173058	A1	20060803	US 2005-546533	20050830
PRIORITY APPLN. INFO.:			DK 2003-370	A 20030811
			WO 2004-EP50290	W 20040311


OTHER SOURCE(S): MARPAT 141:295736

GI

L19 ANSWER 67 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 68 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:742173 CAPLUS
 DOCUMENT NUMBER: 141:395919
 TITLE: Palladium-Catalyzed Cross-Coupling Reactions in the Synthesis of Novel Aromatic Polymers
 AUTHOR(S): Lightowler, Stephen; Hird, Michael
 CORPORATE SOURCE: Department of Chemistry, University of Hull, Hull, HU6
 SOURCE: J. Polym. Sci. Part A: Polym. Chem. (2004), 42(20), 3963-3971
 CODEN: JPACED ISSN: 0887-624X
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Several aromatic polymers were prepared through palladium-catalyzed cross-coupling reactions involving two single Ph ring units, one containing two bromo substituents and the other containing either two boronic ester moieties or two tributyltin moieties. These sets of reactions were carried out under different conditions (catalyst, solvent, and base) to optimize the yield, the d.p., and the polydispersity. Following optimization of the reaction conditions, a series of substituted polymers were prepared to show the scope of the method. The synthesis of the polymerizable aromatic intermediates proved interesting and challenging, particularly those with many substituents.
 IT 787554-84-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (palladium-catalyzed cross-coupling reactions and polyens. to obtain octyloxy- and variously substituted phenyl-chain polymers)
 RN 787554-84-1 CAPLUS
 CN Poly[2,5-thiophenediyl[2',5'-bis(octyloxy)[1,1':4',1''-terphenyl]-4,4''-diyl]] (9CI) (CA INDEX NAME)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L19 ANSWER 69 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:663448 CAPLUS
 DOCUMENT NUMBER: 141:332565
 TITLE: Synthesis and characterization of new light-emitting copolymers in polymeric-light-emitting-diode device fabrications
 AUTHOR(S): Wu, Sheng-Han; Shen, Chi-Hsien; Chen, Jar-Hung; Hsu, Chia-Chen; Tsiang, Raymond Chien-Chao
 CORPORATE SOURCE: Department of Chemical Engineering, National Chung Cheng University, Chiayi, 621, Taiwan
 SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (2004), 42(16), 3954-3966
 CODEN: JPACED ISSN: 0887-624X
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of thiophene-containing photoactive copolymers consisting of alternating conjugated and nonconjugated segments were synthesized. The 1H NMR spectra corroborated the well-defined structures, and the copolymers not only were soluble in common organic solvents but also had high glass-transition temps. (ca. 130°) and good thermal stability up to 390°. Introducing aliphatic functional groups, such as alkyl or alkoxy, into chromophores of the copolymers red shifted the photoluminescence spectra and lowered the optical bandgaps. The electrochem. bandgaps calculated from cyclic voltammetry agreed with the optical bandgaps and thus indicated that electroluminescence and photoluminescence originated from the same excited state. The energy levels (HOMO and LUMO) of all the copolymers were lower than those of poly[2-methoxy-5-(2'-ethylhexyloxy)-1,4-phenylene] (MEH-PPV), indicating balanced hole and electron injection, which led to improved performance in both single-layer and double-layer polymeric light-emitting-diode devices fabricated with these copolymers. All the copolymers emitted bluish-green or green light above the threshold bias of 5.0 V under ambient conditions. At the maximum bias of 10 V, the electroluminescence of a device made of poly[2-[4-[2-(3-ethoxyphenyl)ethylenyl]phenyl]-5-[4-[2-(3-ethoxy-4-1,8-octanedioxyphenyl)ethylenyl]phenyl]thiophene] was 5836 cd/m2. The external electroluminescence efficiency decreased with the lifetime as the polymer degraded.
 IT 770720-68-8P
 RL: DEV (Device component use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (preparation and characterization of thiophene-containing photoactive copolymers in polymeric light-emitting-diode device fabrications)
 RN 770720-68-8 CAPLUS
 CN Poly[2,5-thiophenediyl-1,4-phenylene-1,2-ethenediyl(3-ethoxy-1,4-phenylene)oxy-1,8-octanedioxy(2-ethoxy-1,4-phenylene)-1,2-ethenediyl-1,4-phenylene] (9CI) (CA INDEX NAME)

L19 ANSWER 69 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




IT 770720-62-2P 770720-64-4P 770720-66-6P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and characterization of thiophene-containing photoactive copolymers in polymeric light-emitting-diode device fabrications)
 RN 770720-62-2 CAPLUS
 CN Poly[2,5-thiophenediyl-1,4-phenylene-1,2-ethenediyl-1,4-phenyleneoxy-1,8-octanedioxy-1,4-phenylene-1,2-ethenediyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 69 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 770720-64-4 CAPLUS
 CN Poly[2,5-thiophenediyl-1,4-phenylene-1,2-ethenediyl(3,5-dimethyl-1,4-phenylene)oxy-1,8-octanedioxy(2,6-dimethyl-1,4-phenylene)-1,2-ethenediyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 770720-66-6 CAPLUS
 CN Poly[2,5-thiophenediyl-1,4-phenylene-1,2-ethenediyl(3,5-dimethoxy-1,4-phenylene)oxy-1,8-octanedioxy(2,6-dimethoxy-1,4-phenylene)-1,2-ethenediyl-1,4-phenylene] (9CI) (CA INDEX NAME)


L19 ANSWER 71 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478372-60-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-[3-[(2-chloro-4-propoxybenzoyl)amino]methyl]-4-propoxyphenyl]- (9CI) (CA INDEX NAME)



RN 478372-61-1 CAPLUS
 CN 2-Thiophenecarboxylic acid, 4-[3-[(2-chloro-4-(1-methylethoxy)benzoyl)amino]methyl]-4-propoxyphenyl]- (9CI) (CA INDEX NAME)




L19 ANSWER 72 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:453192 CAPLUS
 DOCUMENT NUMBER: 141:6919
 TITLE: Preparation of substituted aralkyl derivatives as antidiabetic, hypolipidemic and hypocholesterolemic agents
 INVENTOR(S): Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Jain, Mukul R.; Basu, Sujay; Pingali, Harikishore; Raval, Saurin K.; Raval, Preeti S.
 PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046119	A1	20040603	WO 2003-IN358	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CB, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
IN 2002MU00992	A	20060901	IN 2002-MU992	20021115
IN 2003MU00792	A	20050401	IN 2003-MU792	20030812
CA 2506112	A1	20040603	CA 2003-2506112	20031114
AU 2003302111	A1	20040615	AU 2003-302111	20031114
EP 1569916	A1	20050907	EP 2003-808341	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, EE, HU, SK				
BR 2003015713	A	20050913	BR 2003-15713	20031114
CN 1738807	A	20060222	CN 2003-80108836	20031114
JP 2006514976	T	20060518	JP 2004-570329	20031114
MX 2005PA05063	A	20050816	MX 2005-PA5063	20050511
NO 2005002413	A	20050726	NO 2005-2413	20050513
US 2006142277	A1	20060629	US 2005-534726	20051118
PRIORITY APPLN. INFO.:				
			IN 2002-MU992	A 20021115
			IN 2003-MU792	A 20030812
			WO 2003-IN358	W 20031114

OTHER SOURCE(S): MARPAT 141:6919
 GI

L19 ANSWER 72 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The present invention relates to novel substituted aralkyl derivs. of formula A(CH₂)_nX-Ar-CH₂CH(R)CH(R)₂ [A = (substituted) aryl, heteroaryl, heterocyclyl; n = 1-3; X = O, S; Ar = aromatic, heteroarom. or heterocyclic

group; R, R₁ = (substituted) amino, (substituted) OH, N₃, CN, COOH, tetrazolyl, etc.; R₂ = H, alkyl, cycloalkyl], their derivs., their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compns.

containing them, use of these compds. in medicine and the intermediates involved in their preparation The compds. are useful as antidiabetic, hypolipidemic and


hypocholesterolemic agents. Thus, I was prepared, and lowered serum triglyceride in Swiss albino mice by 78%.

IT 696661-77-5P 696661-81-1P 696662-07-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aralkyl derivs. as antidiabetic, hypolipidemic and hypocholesterolemic agents)

RN 696661-77-5 CAPLUS
 CN Benzenepropanoic acid, α-ethoxy-4-[2-[5-methyl-2-(5-phenyl-2-thienyl)-4-oxazolyl]methoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696661-81-1 CAPLUS
 CN Benzenepropanoic acid, α-ethoxy-4-[2-[5-methyl-2-(5-phenyl-2-thienyl)-4-oxazolyl]ethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 72 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 696662-07-4 CAPLUS
 CN Benzenepropanoic acid, α-ethoxy-4-[2-[5-methyl-2-(5-phenyl-2-thienyl)-4-oxazolyl]ethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L19 ANSWER 73 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:390227 CAPLUS
 DOCUMENT NUMBER: 140:406742
 TITLE: Preparation of ethynylpyridines and related compounds as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.
 INVENTOR(S): Mueller, Stephan-Georg; Stenkamp, Dirk; Arndt, Kirsten; Roth, Gerald Juergen; Lotz, Ralf Richard Hermann; Lehmann-Lintz, Thorsten; Lenter, Martin; Lustenberger, Philipp; Rudolf, Klaus
 PATENT ASSIGNEE(S): Boehringer Ingelheim, Germany
 SOURCE: PCT Int. Appl., 361 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: ~~1~~
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039780	A1	20040513	WO 2003-EP11887	20031025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
FW: GB, GM, KE, LS, MW, MG, MN, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AE, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10250708	A1	20040513	DE 2002-10250708	20021031
CA 2504160	A1	20040513	CA 2003-2504160	20031025
AU 2003300507	A1	20040525	AU 2003-300507	20031025
EP 1558578	A1	20050803	EP 2003-809734	20031025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014839	A	20050830	BR 2003-14839	20031025
CN 1732154	A	20060208	CN 2003-80102635	20031025
JP 2006511492	T	20060306	JP 2004-547566	20031025
US 2004209865	A1	20061021	US 2003-697443	20031030
NO 2005000749	A	20060523	NO 2005-749	20050211
MX 2005PA03629	A	20060930	MX 2005-PA3629	20050405
PRIORITY APPLN. INFO.:			DE 2002-10250708	A 20021031
			US 2003-456543P	P 20030321
			WO 2003-EP11887	W 20031025

OTHER SOURCE(S): MARPAT 140:406742
 GI


L19 ANSWER 73 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [R¹, R² = H, (un)substituted alkyl, cycloalkyl, etc.; X = alkyl, alkenyl, alkynyl, etc.; W, Z = alkylene with provisos; Y = Cy with provisos; A = Cy; B = Cy, alkyl, alkenyl, etc.; Cy = (un)substituted carbocycle, heterocycle] and their pharmaceutically acceptable salts and formulations were prepared. For example, palladium mediated coupling of bromopyridine II, e.g., prepared from 4-iodophenol in 2-steps, and 4-bromophenylboronic acid afforded claimed ethynylpyridine III in 11% yield. In melanin concentrating hormone receptor (MCH-1R) binding assays, 2-examples of compds. I exhibited IC₅₀ values ranging from 8-74 nM, e.g., the IC₅₀ of ethynylpyridine III was 8 nM. Compds. I are claimed useful for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.

IT 690266-85-4P
 R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of ethynylpyridines and related compds. as melanin-concentrating hormone receptor (MCH-1) antagonist for the treatment of metabolic disorders.)
 RN 690266-85-4 CAPLUS
 CN Pyrrolidine,
 1-[2-[4-[[4-(4-chlorophenyl)-2-thienyl]ethynyl]phenoxy]ethyl]-
 (9CI) (CA INDEX NAME)


L19 ANSWER 73 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 74 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:333577 CAPLUS
 DOCUMENT NUMBER: 140:357386
 TITLE: Preparation of piperazine and homopiperazine derivatives for treatment of cancers
 INVENTOR(S): Mataka, Chikage; Kodama, Tatsuhiro; Doi, Takeshi; Tamura, Masahiro; Oda, Toshiaki; Ohkuchi, Masao
 PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: ~~1~~
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032931	A1	20040422	WO 2003-JP13047	20031010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
FW: GB, GM, KE, LS, MW, MG, MN, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003272973	A1	20040804	AU 2003-272973	20031010
PRIORITY APPLN. INFO.:			US 2002-417643P	P 20021011
			WO 2003-JP13047	W 20031010

OTHER SOURCE(S): MARPAT 140:357386
 GI



L19 ANSWER 74 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


AB The title compds. I [wherein A = a single bond, C.tplbond.C, CONH, or NHCO; ring B = heterocycle, etc.; m = 1 or 2; n = 1-5] or salts, or hydrates thereof are prepared for the treatment of cancers. For example, the compound II was prepared in a multi-step synthesis comprising reaction of 4-(chloromethyl)-2-(3,4,5-trimethoxyphenyl)pyridine (preparation given) and piperazine (91%). II showed strong anticancer effect against various cancers, such as human breast cancer, colorectal cancer, lung cancer, gastric cancer, and prostate cancer. Formulations containing I as an active ingredient were also described.

IT 473844-14-3P 681277-34-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of piperazine and homopiperazine derivs. for treatment of cancers)

RN 473844-14-3 CAPLUS
 CN Piperazine, 1,4-bis[[5-(3,4,5-trimethoxyphenyl)-2-thienyl]methyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 473844-13-2
 CMP C32 H38 N2 O6 S2



CM 2

CRN 110-16-7
 CMP C4 H4 O4

Double bond geometry as shown.




L19 ANSWER 75 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:331949 CAPLUS
 DOCUMENT NUMBER: 140:339318
 TITLE: Preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors
 INVENTOR(S): Brown, Matthew Lee; Cheung, Mui; Dickerson, Scott Howard; Gauthier, Cassandra; Harris, Philip Anthony; Hunter, Robert Neil, III; Pacofsky, Gregory; Peel, Michael Robert; Stafford, Jeffrey Alan
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 213 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1 *****
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032882	A2	20040422	WO 2003-US33317	20031010
WO 2004032882	A3	20040708		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003287178	A1	20040504	AU 2003-287178	20031010
EP 1551813	A2	20050713	EP 2003-781357	20031010
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006503081	T	20060126	JP 2004-543799	20031010
US 2005288515	A1	20051229	US 2005-530810	20050408
US 7189712	B2	20070313		
US 2007142437	A1	20070621	US 2007-670498	20070202
PRIORITY APPLN. INFO.:			US 2002-417548P	P 20021010
			WO 2003-US33317	W 20031010
			US 2005-530810	A3 20050408

OTHER SOURCE(S): MARPAT 140:339318
 GI




L19 ANSWER 74 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 681277-34-9 CAPLUS
 CN 1H-1,4-Diazepine, hexahydro-1,4-bis[[5-(3,4,5-trimethoxyphenyl)-2-thienyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 473844-15-4
 CMP C33 H40 N2 O6 S2



CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 75 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title compds. [I; D1 = (un)substituted aryl, heteroaryl, heterocyclyl; D2 = H, alkyl; D3 = (un)substituted aryl, heteroaryl] which are useful as VEGFR2, CDK2, and CDK4 inhibitors in the treatment of hyperproliferative diseases, were prepared E.g., a 5-step synthesis of I [D1 = 3-MeOC6H4; D2 = H; D3 = Ph], starting from 2-bromo-1-(3-methoxyphenyl)ethanone, was given.

IT 681004-04-6P, N-[5-(Ethylsulfonyl)-2-methoxyphenyl]-5-(3-(5-methylthien-2-yl)phenyl)-1,3-oxazol-2-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors for treating cancer)

RN 681004-04-6 CAPLUS
 CN 2-Oxazolinamine, N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(5-methyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 76 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:279581 CAPLUS
 DOCUMENT NUMBER: 141:24042
 TITLE: Synthesis and optical properties of poly(p-phenylenevinylene)s bearing tetraphenylthiophene or dibenzothiophene moieties along the main chain
 AUTHOR(S): Mikroyannidis, John A.; Spiliopoulos, Ioakim K.; Kulkarni, Abhishek P.; Jenekhe, Samson A.
 CORPORATE SOURCE: Chemical Technology Laboratory, Department of Chemistry, University of Patras, Patras, GR-26500, Greece
 SOURCE: Synthetic Metals (2004), 142(1-3), 113-120
 CODEN: SYMDEP ISSN: 0379-6779
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB 2,5-Bis(4-iodophenyl)-3,4-diphenylthiophene was synthesized by a four-step reaction starting from benzylchloride and sulfur. This reacted with 1,4-didodecyloxy-2,5-divinylbenzene to afford polymer P1. In addition, dibenzothiophene was brominated to give 2,8-dibromodibenzothiophene, that yielded by Heck coupling polymer P2. Both polymers are poly(p-phenylenevinylene) derivs. containing tetraphenylthiophene or dibenzothiophene moieties along the backbone. They dissolved readily in THF and chloroform with glass-transition temps. lower than 80°. The solns. of polymers emitted greenish light with photoluminescence (PL) maximum at 460-480 nm. The PL quantum yields in solution were 0.24 for P1 and 0.52 for P2. Thin films of polymers emitted bluish-green light with PL maximum near 510 nm and optical energy gap about 2.50 eV. P1 displayed lower tendency to form aggregates than P2. The cyclic voltammograms of polymers showed an irreversible oxidation and no reduction peaks, suggesting that electron transport through the polymers was very poor. Both single and bilayer LEDs of P2 exhibited low current densities with turn-on voltage at 6-7 V, while the electroluminescence (EL) was not measurable.
 IT 700843-18-1P
 RL: DEV (Device component use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (synthesis and optical properties of poly(phenylenevinylene)s bearing tetraphenylthiophene or dibenzothiophene moieties along the main chain)
 RN 700843-18-1 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene-1,2-ethenediyl][2,5-bis(dodecyloxy)-1,4-phenylene]-1,2-ethenediyl-1,4-phenylene] (9CI) (CA INDEX NAME)


L19 ANSWER 77 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:220435 CAPLUS
 DOCUMENT NUMBER: 140:262427
 TITLE: Organic species that facilitate charge transfer to or from nanostructures
 INVENTOR(S): Whiteford, Jeffery A.; Buretea, Mihai A.; Scher, Erik C.
 PATENT ASSIGNEE(S): Nanosys, Inc., USA
 SOURCE: PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022714	A2	20040318	WO 2003-US27847	20030904
WO 2004022714	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497451	A1	20040318	CA 2003-2497451	20030904
AU 2003272275	A1	20040329	AU 2003-272275	20030904
EP 1537187	A2	20050608	EP 2003-754451	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688670	A	20051026	CN 2003-824336	20030904
JP 2006511634	T	20060406	JP 2004-534640	20030904
US 2007122101	A1	20070531	US 2006-342087	20060126
US 7228050	B2	20070605		

PRIORITY APPLN. INFO.:
 US 2002-408722P P 20020905
 US 2003-452232P P 20030304
 US 2003-656916 A1 20030904
 WO 2003-US27847 W 20030904


AB The present invention provides compns. (small mols., oligomers and polymers) that can be used to modify charge transport across a surface or a nanostructure (e.g., nanocrystal) surface, or within a nanostructure (e.g., nanocrystal) containing matrix, as well as methods for making and using the novel compns. The compns. contain a conjugated organic species and at least one binding group capable of interacting with a nanostructure (e.g., nanocrystal) surface; during use, the compns. are coupled via the binding group to the nanostructure (e.g., nanocrystal) surface, such that the compns. are substantially conductive to electrons and/or holes being transported by/through the nanostructure (e.g., nanocrystal) (e.g., during

L19 ANSWER 76 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 77 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 the process of extg. or injecting the electrons or holes). The compns. of the present invention can optionally be derivatized with addnl. chem. groups, e.g., to enhance the electronic conjugation of the core org. species, to couple adjacent nanostructures (e.g., nanocrystals), or to facilitate dispersion, mixing and/or blending of nanostructures (e.g., nanocrystals) in various matrixes. In one aspect, the present invention provides conductive compns. for modification of charge transport across a nanostructure (e.g., nanocrystal) contg. matrix. The conductive compn. typically include (1) a conjugated org. moiety as the body structure, or core of the conductive mol.; (2) a nanostructure (e.g., nanocrystal) binding head group coupled to the body structure at a 1st position on the conjugated org. moiety; and (3) a tail group coupled to the body structure at a 2nd position on the conjugated org. moiety. After formation of an exciton in the nanostructure (e.g., nanocrystal) contg. matrix, the conductive compn. facilitates the injection and/or extn. of charge (electron and/or hole) with respect to the attached nanostructure, thereby modifying charge transport across a nanostructure-contg. matrix.
 IT 671190-41-3P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (organic species that facilitate charge transfer to or from nanostructures)
 RN 671190-41-3 CAPLUS
 CN Phosphonic acid, [4-[5'-[4-[5-(1-decynyl)-2-thienyl]-2,5-bis(hexyloxy)phenyl][2,2'-bithiophen]-5-yl]phenyl]- (9CI) (CA INDEX NAME)



IT 671190-72-0P
 RL: PRP (Properties); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (organic species that facilitate charge transfer to or from nanostructures)
 RN 671190-72-0 CAPLUS
 CN Phosphonic acid, [[2-[5'-(1-decynyl)[2,2'-bithiophen]-5-yl]-5-[5'-[4-[5-(diethoxyphosphinyl)-2-thienyl]-2,5-bis(hexyloxy)phenyl][2,2'-bithiophen]-5-yl]-1,4-phenylene]bis(methylene)]bis-, tetraethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 77 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 78 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:220333 CAPLUS
 DOCUMENT NUMBER: 140:270854
 TITLE: Preparation of 1,3,8-triazaspiro[4.5]decan-4-ones for the treatment of ORL-1 receptor mediated disorders
 INVENTOR(S): Battista, Kathleen; Bignan, Gilles; Connolly, Peter J.; Reitz, Allen B.; Morgan Ross, Tina; Scott, Malcolm; Middleton, Steve A.; Orsini, Michael
 PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
 SOURCE: PCT Int. Appl., 249 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022558	A2	20040318	WO 2003-US27956	20030905
WO 2004022558	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498275	A1	20040318	CA 2003-2498275	20030905
AU 2003268512	A1	20040329	AU 2003-268512	20030905
US 2004142955	A1	20040722	US 2003-656934	20030905
US 7081463	B2	20060725		
BR 2003006309	A	20041019	BR 2003-6309	20030905
CN 1694883	A	20051109	CN 2003-824990	20030905
EP 1601674	A2	20051207	EP 2003-749479	20030905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500393	T	20060105	JP 2004-534697	20030905
MX 2005PA02622	A	20050908	MX 2005-PA2622	20050309
IN 2005KN00578	A	20060421	IN 2005-KN578	20050406
ZA 2005002836	A	20060628	ZA 2005-2836	20050407
NO 2005001743	A	20050518	NO 2005-1743	20050408
US 2006030577	A1	20060209	US 2005-242654	20051004
IN 2007KN02550	A	20070824	IN 2007-KN2550	20070709
PRIORITY APPLN. INFO.:			US 2002-409134P	P 20020909
			US 2003-656934	A3 20030905
			WO 2003-US27956	W 20030905
			IN 2005-KN578	A3 20050406

OTHER SOURCE(S): MARPAT 140:270854

L19 ANSWER 78 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R0 = CRaRbCOHRA-(CRcRd)1-3X, (CRcRd)1-3COHRAcRaRbX; Ra, Rb = H, alkyl; Rc, Rd = H, OH, carboxy, etc.; X = NR1R2, CONR1R2, NR1, etc.; R1, R2 = H, alkyl, alkoxy, etc.; R3 = aryl, arylalkyl, heteroaryl, etc.; A = (R4)n; R4 = OH, alkyl, alkyl-OH; n = 0-2; B = (L1)m; L1 = alkyl, alkenyl with provisos; m = 0-1; C = (R5)p and (R6)q substituted cycloalkyl, partially unsatd. carbocyclyl (sic), aryl, etc.; R5 = OH, carboxy, halo, etc.; p = 0-5; R6 = (L2)0-1R7; q = 0-1; L2 = alkyl, alkenyl, alkynyl, etc.; R7 = aryl, partially unsatd. carbocyclyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts were prepared

For example, amination of epoxide II, e.g., prepared from cyclooctanecarboxaldehyde in 2-steps, with 4-aminopyridine afforded amino alc. III. In human ORL-1 receptor binding affinity assays, approx. 470-examples of compds. I exhibited IC50 values ranging from 0.10 - >10,000 nM, e.g., the IC50 value of triazaspiro[4.5]decan-4-one III was 8.73 nM. Compds. I are claimed useful for the treatment of anxiety, depression, migraine, etc..

IT 674466-48-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazaspiro[4.5]decan-4-ones for the treatment of ORL-1 receptor mediated disorders)


RN 674466-48-9 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-[(2S)-3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-hydroxypropyl]-1-(4-fluorophenyl)-8-[(5-phenyl-2-thienyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L19 ANSWER 79 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:189168 CAPLUS
 DOCUMENT NUMBER: 140:399338
 TITLE: Discovery of novel heteroaryl-substituted chalcones
 as
 inhibitors of TNF- α -induced VCAM-1 expression
 AUTHOR(S): Meng, Charles Q.; Zheng, X. Sharon; Ni, Liming; Ye, Zhihong; Simpson, Jacob E.; Worsncroft, Kimberly J.; Hotema, Martha R.; Weingarten, M. David; Skudlarek, Jason W.; Gilmore, Joshua M.; Soong, Lee K.; Hill, Russell R.; Marino, Elaine M.; Suen, Ki-Ling; Kunsch, Charles; Wasserman, Martin A.; Sikorski, James A.
 CORPORATE SOURCE: AtheroGenics, Inc., Alpharetta, GA, 30004, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(6), 1513-1517
 CODEN: BMCLE8; ISSN: 0950-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:399338
 AB Novel chalcone derivs. have been discovered as potent inhibitors of TNF- α -induced VCAM-1 expression. Thienyl or benzothienyl substitution at the meta-position of ring B helps boost potency while large substitution at the para-position on ring B is detrimental. Various substitutions are tolerated on ring A. A lipophilicity-potency relationship has been observed in several sub-series of compds.
 IT 690665-66-8 690665-67-9 690665-68-0
 690665-69-1 690665-70-4
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (discovery and structure-activity relationship of novel heteroaryl-substituted chalcones as inhibitors of TNF- α -induced VCAM-1 expression)
 RN 690665-66-8 CAPLUS
 CN 2-Propen-1-one, 1-(3,4-dimethoxyphenyl)-3-[2-methoxy-5-(5-methyl-2-thienyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.




RN 690665-67-9 CAPLUS
 CN 2-Propen-1-one, 1-(3,4-dimethoxyphenyl)-3-[2-methoxy-5-(4-methyl-2-thienyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

L19 ANSWER 79 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L19 ANSWER 79 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Double bond geometry as shown.



RN 690665-68-0 CAPLUS
 CN 2-Propen-1-one, 3-[2-methoxy-5-(5-methyl-2-thienyl)phenyl]-1-(3,4,5-trimethoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.



RN 690665-69-1 CAPLUS
 CN 2-Propen-1-one, 3-[2-methoxy-5-(4-methyl-2-thienyl)phenyl]-1-(3,4,5-trimethoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.





RN 690665-70-4 CAPLUS
 CN 2-Propen-1-one, 3-[3-(5-acetyl-2-thienyl)-4,5-dimethoxyphenyl]-1-(3,4,5-trimethoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)
 Double bond geometry as shown.

L19 ANSWER 80 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:181798 CAPLUS
 DOCUMENT NUMBER: 140:217508
 TITLE: Preparation of thiophenes as selective metalloproteinase MMP-12 inhibitors, as well as their pharmaceutical compositions for treating respiratory diseases
 INVENTOR(S): Dublanchet, Anne-Claude; Compere, Delphine; Cluzeau, Philippe; Blais, Stephane
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: Eur. Pat. Appl., 111 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1394159	A1	20040308	EP 2002-292037	20020813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2497632	A1	20040308	CA 2003-2497632	20030807
WO 2004018448	A1	20040308	WO 2003-EP8750	20030807
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003251695	A1	20030311	AU 2003-251695	20030807
EP 1534700	A1	20030601	EP 2003-792270	20030807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013734	A	20030712	BR 2003-13734	20030807
JP 2006504674	T	20060209	JP 2004-530099	20030807
US 2004072871	A1	20040415	US 2003-638016	20030808
MX 2005PA01782	A	20050425	MX 2005-PA1782	20050211
PRIORITY APPLN. INFO.:			EP 2002-292037	A 20020813
			WO 2003-EP8750	W 20030807
OTHER SOURCE(S):		MARPAT 140:217508		
GI				

L19 ANSWER 80 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [wherein X = O or S; Y = O, NH and derivs.; Ra = H, halo, alkyl, hydroxy, alkoxy; Rb = H, halo, alkyl; A = Ph, cycloalkyl, cycloalkenyl; R1, R2 = independently H, halo, CN, NO2, haloalkyl, haloalkoxy, alk(en/yn)yl, OH and derivs., NH2 and derivs., S(O)NH and derivs., CO2H and derivs., CONH2 and derivs., NHSO2H and derivs., etc.; n = 0-2; R3 = H, alkyl, (un)substituted cycloalkyl aryl, heterocyclyl, etc.; and their isomers, pharmaceutically acceptable salts of addition with an acid or base] were prepared as metalloproteinase MMP-12 inhibitors for treating respiratory diseases. For example, II was prepared, in 3 steps, by oxidation of 4-bromothiophene-2-carboxaldehyde, acylation of 2-morpholin-4-ylethanamine with thiophene carboxylic acid, followed by Pd-cross coupling of the bromothiophene intermediate with (4-isopropylphenyl)boronic acid. I selectively inhibited MMP-12 in vitro with an IC50 value < 5 μ M. Thus, I and their formulations are useful for treating obstructive pulmonary diseases, emphysema, asthma, chronic bronchitis, etc.

IT 666722-16-3P, 4-[4-(3,4,5-Trimethoxyphenyl)phenyl]-N-[2-(morpholin-4-yl)ethyl]thiophene-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L19 ANSWER 81 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:100823 CAPLUS
 DOCUMENT NUMBER: 140:163704
 TITLE: Preparation of arylsulfonylpyranhydroxamates as metalloprotease and/or aggrecanase inhibitors
 INVENTOR(S): Freskos, John N.; Fobian, Yvette M.; Awasthi, Alok K.; Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; Chandrakumar, Nizal S.; Decrescenzo, Gary A.; Desai, Bipin N.; Heron, Marcia I.; Hockerman, Susan L.; Jull, Sara M.; Kassab, Darren J.; Kolodziej, Steve A.; McDonald, Joseph; Mischke, Deborah A.; Mullins, Patrick B.; Norton, Monica B.; Rico, Joseph G.; Talley, John J.; Trivedi, Mahima; Villamil, Clara I.; Wang, Lijuan
 Jane
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 365 pp., Cont.-in-part of U.S. Ser. No. 142,737.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004024024	A1	20040205	US 2002-291983	20021112
US 2004010019	A1	20040115	US 2002-142737	20020510
US 6689794	B2	20040210		
US 2004110805	A1	20040610	US 2003-657034	20030905
US 6890928	B2	20050510		
CA 2504737	A1	20040527	CA 2003-2504737	20031103
WO 2004043943	A1	20040527	WO 2003-US34961	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TAU 2003290583	A1	20040603	AU 2003-290583	20031103
EP 1562928	A1	20050817	EP 2003-783118	20031103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016133	A	20050927	BR 2003-16133	20031103
JP 2006508964	T	20060316	JP 2004-551679	20031103
US 2005101641	A1	20050512	US 2004-992483	20041117
MX 2005PA05047	A	20050701	MX 2005-PA5047	20050511
PRIORITY APPLN. INFO.:			US 2001-290375P	P 20010511

L19 ANSWER 80 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


(MMP-12 inhibitor; prepn. of thiophenes as selective MMP-12 inhibitors, for treating pulmonary diseases)
 RN 666722-16-3 CAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(4-morpholinyl)ethyl]-4-(3',4',5'-trimethoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 81 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


US 2002-291983 A 20021112
 US 2003-657034 A3 20030905
 WO 2003-US34961 W 20031103
 OTHER SOURCE(S): MARPAT 140:163704
 GI




AB Title compds. [I; A1 = H, (substituted) alkylcarbonyl, alkoxy, carbonyl, carbocyclylcarbonyl, heterocyclylcarbonyl, aminoalkylthiocarbonyl, etc.; A2A3C = (substituted) heterocyclyl; E1 = O, S, SO, SO2, NR1, CONR1, CR1R2; E2 = (substituted) alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkylalkyl; E3 = CO, O2C, CNR3, NR4, NR4SO2, S, SO, etc.; E4 = bond, (substituted) alkyl, alkenyl; E5 = H, OH, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, carbocyclyl, heterocyclyl; R1, R2 = H, (substituted) alkyl; R4 = H, alkyl, cycloalkyl, etc.; with provisos], were prepared Thus, tetrahydro-4-[[4-[[5-(4-methoxyphenyl)-5-oxopentyl]oxy]phenyl]sulfonyl]-2H-pyran-4-carboxylic acid 1,1-dimethylethyl ester (preparation given) in CH2Cl2 was treated with Me3SiCN and ZnI2 to give 81% cyanohydrin. The product in DMF was treated with 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-methylmorpholine, and tetrahydropyranhydroxylamine to give 70% THP-protected hydroxamate. The latter was stirred with aqueous HCl in dioxane/MeOH to give 59% 4-[[4-[[4-(2-cyano-5-(4-methoxyphenyl)-4-pentenyl]oxy]phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide. This inhibited MMP-13 with IC50 = 0.2 nM.

IT 476183-89-8P 476186-47-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of arylsulfonylpyranhydroxamates as matrix metalloprotease and/or aggrecanase inhibitors)
 RN 476183-89-8 CAPLUS
 CN 2H-Pyran-4-carboxamide, 4-[[4-[[2-[[5-(4-chlorophenyl)-2-thienyl]acetyl]amino]ethoxy]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

L19 ANSWER 81 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





RN 476186-47-7 CAPLUS
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-(5-methyl-2-thienyl)phenyl]propoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 82 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:3668 CAPLUS
 DOCUMENT NUMBER: 140:89899
 TITLE: Thiazolidinone phospholipase D inhibitors and their use as antitumor and antiinflammatory agents
 INVENTOR(S): Klein, J. Peter; Kumar, Anil M.; McKenmon, Marc J.
 PATENT ASSIGNEE(S): Cell Therapeutics, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 32 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004002526	A1	20040101	US 2003-405059	20030401
PRIORITY APPLN. INFO.:			US 2002-369719P	P 20020403
OTHER SOURCE(S):			MARPAT 140:89899	
GI				



AB The invention is directed to thiazolidinones (I; R1 = H, alkyl, alkenyl, aryl, heteroaryl; R2 = H, alkyl, cycloalkyl, heteroalicyclic, aryl, arylalkyl, arylalkenyl; X = O, S; II; R1 = alkenyl, aryl, heteroaryl; R3, R4 = H, alkyl, aryl; R5-8 = H, alkyl, acyl, aryl; or R5 and R7 combined = aryl, heteroaryl, cycloalkyl, heteroalicyclic; n = 0-2) and their use to

inhibit phospholipase D (PLD) activity. The invention further relates to methods of treating cancer and inflammatory diseases using thiazolidinones. Thus, many I and II compds. were synthesized. These were tested for phospholipase D inhibition in vitro and in intact cells. One such phospholipase D inhibitor at 10 μ M inhibited proliferation of H-ras transformed Rat1 cells and at 25 μ M significantly inhibited formation of colonies by human pancreatic tumor cells MiaPaCa and Panc1.

L19 ANSWER 82 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Addnl., administration of this compd. i.p. to nude mice injected with Ki-ras expressing NIH/3T3 cells delayed tumor growth.

IT 639816-30-1P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(thiazolidinone phospholipase D inhibitors and their use as antitumor and antiinflammatory agents)


RN 639816-30-1 CAPLUS

CN Benzoic acid, 4-[5-[[4-oxo-2-thioxo-3-[(3,4,5-trimethoxyphenyl)methyl]-5-thiazolidinylidene]methyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L19 ANSWER 83 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:950770 CAPLUS
 DOCUMENT NUMBER: 140:4842
 TITLE: Bis-aromatic alkanols
 INVENTOR(S): Fan, Ying; Gao, Wenqi; Gray, Nathanael S.;
 Hinterting, Klaus; Lefebvre, Sophie; Mi, Yuan; Nussbaumer, Peter; Pan, Shifeng; Wang, Wei; Zecri, Frederic; Perez, Lawrence Blas; La Montagne, Kenneth Richard;
 Ettmayer, Peter
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; IRM LLC
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200309192	A2	20031204	WO 2003-EP5510	20030526
WO 200309192	A3	20040318		
WO 200309192	A8	20050217		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW			
RW:	AM, AZ, BY, BG, BR, CA, CH, CN, CO, CR, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR			
CA 2486853	A1	20031204	CA 2003-2486853	20030526
AU 2003240714	A1	20031212	AU 2003-240714	20030526
BR 2003011347	A	20050222	BR 2003-11347	20030526
EP 1511473	A2	20050309	EP 2003-730117	20030526
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1655774	A	20050817	CN 2003-812108	20030526
JP 2005527612	T	20050915	JP 2004-506719	20030526
NZ 536558	A	20060728	NZ 2003-536558	20030526
US 2004048857	A1	20040311	US 2003-445967	20030527
US 7169817	B2	20070130		
PRIORITY APPLN. INFO.:			GB 2002-12210	A 20020527
			GB 2002-26624	A 20021114
			US 2002-432704P	P 20021210
			WO 2003-EP5510	W 20030526

AB A compound of R1XYC(RN3R4)R2CR5 useful for pharmaceutical compns. is prepared wherein Y is -CH2CH2-, -CH2CH(OH)-, -CH(OH)CH2-, -C(O)CH2-, -CH2C(O)-, -CH=CH-, or 1,2-cyclopropylene; X is arylene or C5-6 heteroarylene, R1 is aryl, aryl-C2-4 alkenyl, heteroaryl, or heteroaryl-C2-4 alkenyl; R2 is hydrogen, halogen, C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, or aryl; each of R3 and R4 is H or C1-4 alkyl; and R5 is H, -OH, -Oacyl,

L19 ANSWER 83 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 -NHacyl etc. Thus, 6.9 g (2R,5R)-2-[2-(4-benzyloxyphenyl)ethyl]-3,6-diethoxy-5-isopropyl-2-methyl-2,5-dihydropyrazine was treated with 5.17 g tert-butoxycarbonyl anhydride to give Et
 (R)-4-(4-benzyloxyphenyl)-2-tert-butoxycarbonylamino-2-methylbutyrate, which (2.78 g) was treated with 1,3 mL trifluoromethanesulfonic anhydride to give Et (R)-2-tert-butoxycarbonylamino-2-methyl-4-(4-trifluoromethanesulfonyloxyphenyl)butyrate, which (100 mg) was treated with 75 mg butylboronic acid to give Et
 (R)-2-tert-butoxycarbonylamino-4-(4'-butylbiphenyl-4-yl)-2-methylbutyrate, which (22 mg) was treated with 20 mg lithium borohydride to give (R)-2-amino-4-(4'-butylbiphenyl-4-yl)-2-methylbutan-1-ol.
 IT 628735-17-1P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 RN 628735-17-1 CAPLUS
 CN 1,3-Propanediol, 2-amino-2-[2-[4-[5-[2-(4-butoxyphenyl)ethyl]-2-thienyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)





L19 ANSWER 84 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:931161 CAPLUS
 DOCUMENT NUMBER: 140:4955
 TITLE: Preparation of N-acylaminoacetonitriles for controlling parasites
 INVENTOR(S): Ducray, Pierre; Goebel, Thomas; Bouvier, Jacques; Durano, Corinne
 PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097036	A1	20031127	WO 2003-EP5334	20030521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2483286	A1	20031127	CA 2003-2483286	20030521
AU 2003242555	A1	20031202	AU 2003-242555	20030521
BR 2003011214	A	20050301	BR 2003-11214	20030521
EP 1509221	A1	20050302	EP 2003-752774	20030521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1649579	A	20050803	CN 2003-809965	20030521
US 2005182127	A1	20050818	US 2003-513806	20030521
JP 2005536466	T	20051202	JP 2004-505035	20030521
NZ 536184	A	20061027	NZ 2003-536184	20030521
ZA 2004007974	A	20060726	ZA 2004-7974	20041004
MX 2004PA11531	A	20050214	MX 2004-PA11531	20041119
PRIORITY APPLN. INFO.:			CH 2002-855	A 20020522
			WO 2003-EP5334	W 20030521

OTHER SOURCE(S): MARPAT 140:4955
 GI

L19 ANSWER 84 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title compds. [I; A1, A2 = (un)substituted aryl, heteroaryl, etc.; A3 = (un)substituted pyrimidyl, s-triazinyl, 1,2,4-triazinyl, etc.; R1 = H, alkyl, haloalkyl, allyl, alkoxyethyl; R2-R6 = H, halo, alkyl, etc.; or
 R2 and R3 are jointly alkylene; W = O, S, SO2, NR7; X = O, S, NR7; R7 = H, alkyl; a = 1-4; b = 0-4; c = 0-1] which have advantageous pesticidal properties, and are particularly suitable for controlling parasites in warm-blooded animals, were prepared and formulated. E.g., a multi-step synthesis of the benzamide II, starting from chloroacetone and 2-bromo-4,5-difluorophenol, was given.
 IT 627881-36-1P
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 RN 627881-36-1 CAPLUS
 CN Benzamide, N-[1-cyano-2-[4,5-difluoro-2-(4-methyl-2-thienyl)phenoxy]-1-methylethyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 84 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


119 ANSWER 85 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2003:844737 CAPLUS
DOCUMENT NUMBER: 140:61046
TITLE:
Controlling solubility and modulating peripheral
function in dendrimer encapsulated dyes
AUTHOR(S): Furuta, Paul; Frechet, Jean M. J.
CORPORATE SOURCE: Department of Chemistry, University of California,
Berkeley, CA, 94720-1460, USA
SOURCE: Journal of the American Chemical Society (2003),
125(43), 13173-13181
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CTRREACT 140:61046
AB The synthesis of large dendrons and dendrimers with site-isolated dyes at their core has been explored. The dyes selected for this work were coumarin 343 and pentaphenophene, as energy transfer processes prevail when the two dyes are intimately mixed but each should behave independently of the other if site-isolation is achieved. Because the two dyes have very different functional characteristics, a protocol involving orthogonal protecting groups and allowing the use of a single family of electroactive dendrons for their encapsulation had to be developed. The synthetic protocol must balance the need to incorporate electroactive groups at the periphery of the dendrons with the requirement for high solubility and a size sufficient to fully encapsulate the central dye. Because of their poor solubility and tendency to crystallize, dendrons with uniform triarylamine substitution proved unsatisfactory leading to the development of new unsym. dendrons with alternating branched alkyl groups and triarylamine moieties at their periphery. These dendrons, which show excellent solubility and no tendency to crystallize, were assembled into large dendrimers using a modular protocol with the light emitting dye at their core. It is expected that the large size of the dendritic shell will provide effective site-isolation for the encapsulated central dyes enabling them to exhibit their intrinsic emission properties with minimal energy transfer between neighboring core fluorophores when processed in bulk thin films.

IT 636984-43-5P 636984-44-GDP, reaction products with
benzyl-terminated dihydroxybenzylbromide dendrimers 636984-44-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(controlling solubility and modulating peripheral function in
dendrimer encapsulated light emitting dyes)


RN 636984-43-5 CAPLUS
CN [2,2',15',2''-(1,5'-bis[2,2'-(1,5'-bis[2,2'-(1,5'-bis[2,2'-(phenyl)-
yl)oxy]methylphenoxy)methyl]phenyl)-4''-octyl-, phenylmethyl ester (9CI)
CA INDEX NAME]

L19 ANSWER 85 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L19 ANSWER 85 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-B



RN	636984-44-6	CAPLUS
CN	[2,2':5',2'':5'',2''':5''',2''''-Quinquethiophene]-5-carboxylic acid, 5''''-[3,5-bis[[3,5-bis[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]phenoxy]methyl]phenyl]-4'''-octyl- (9CI) (CA INDEX NAME)	

L19 ANSWER 85 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




PAGE 2-A




```

RN      636984-44-6   CAPLUS
CN      [2,2':5',2'':5'',2''':5''',2''''-Quinquethiophene]-5-carboxylic acid,
        5''''-[3,5-bis[[[3,5-bis[[[tetrahydro-2H-pyran-2-
        yl]oxy]methyl]phenoxy]methyl]phenyl]-4'''-octyl- (9CI)  (CA INDEX NAME)

```



L19 ANSWER 85 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 85 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A

IT 637357-29-0DE, reaction products with naphthylphenylamine-terminated dihydroxybenzyl bromide dendrimers

RL: SPN (Synthetic preparation); PREP (Preparation) (controlling solubility and modulating peripheral function in encapsulated light emitting dyes)

RN 637357-29-0 CAPLUS

CN [2,2':5',2'':5'',2''':5''',2''':5''''-Quinquethiophene]-5-carboxylic acid, 5''''-bis[3,5-bis[3,5-bis(hydroxymethyl)phenoxy)methyl]phenyl]-4''-octyl-(9CI) (CA INDEX NAME)



L19 ANSWER 85 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

CH₂-OH

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L19 ANSWER 86 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:796665 CAPLUS

DOCUMENT NUMBER: 139:307607

TITLE: Preparation of substituted biaryl amides as C5a receptor modulators

INVENTOR(S): Gao, Yang; Hutchison, Alan; Peterson, John; Pringle, Wallace; Thurkauf, Andrew; Yoon, Taeyoung; Zhao, He

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082826	A1	20031009	WO 2003-US9045	20030325
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2479928	A1	20031009	CA 2003-2479928	20030325
AU 2003225971	A1	20031013	AU 2003-225971	20030325
EP 1487796	A1	20041222	EP 2003-745585	20030325
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006502095	T	20060113	JP 2003-580294	20030325
US 2004048913	A1	20040311	US 2003-401270	20030327
US 6858637	B2	20050222		
US 2005096358	A1	20050505	US 2004-994224	20041119
US 7148225	B2	20061212		
US 2006178414	A1	20060810	US 2006-324729	20060103
PRIORITY APPLN. INFO.:			US 2002-368462P	P 20020328
			US 2002-372150P	P 20021204
			WO 2003-US9045	W 20030325
			US 2003-401270	A1 20030327
			US 2004-994224	A1 20041119
OTHER SOURCE(S):		MARPAT 139:307607		
GI				

L19 ANSWER 86 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. Ar1CONR1R2 [Ar1 = (un)substituted Ph, 9H-fluorenyl, naphthyl, heteroaryl; R1 = (un)substituted cycloalkyl, (cycloalkyl)alkyl, (heteroaryl)alkyl, etc.; R2 = alkyl, cycloalkyl, aryl, etc.] which are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathol. C5a receptor activation in humans, domesticated companion animals and livestock animals, were prepared and formulated. Thus, treating 2-iodobenzoic acid with 1,1'-carbonyldiimidazole followed by addition of N-(3,4-methylenedioxybenzyl)-N-benzylamine, and coupling of the resulting intermediate with 4-trifluoromethylphenylboronic acid in the presence of Pd(PPh₃)₄ afforded I. Preferred compds. exhibit IC₅₀ values of less than 1 μM in the assay for C5a receptor mediated chemotaxis. Pharmaceutical compns. and methods for using them to treat such mentioned above disorders are provided, as are methods for using such ligands for receptor localization studies.


IT 610794-89-3P 610795-34-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of biaryl amides as C5a receptor modulators)

RN 610794-89-3 CAPLUS
 CN Benzamide, N-[(2,3-dihydro-1H-inden-2-yl)-5-methoxy-N-[(3-methoxyphenyl)methyl]-2-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 86 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 610795-34-1 CAPLUS
 CN Benzamide, N-[[4-(difluoromethoxy)phenyl]methyl]-2-(5-methyl-2-thienyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 87 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:750705 CAPLUS
 DOCUMENT NUMBER: 139:267732
 TITLE: Organic electroluminescent devices showing stable and bright emission and arylaminophenylthiophene derivatives therefor
 INVENTOR(S): Shimamura, Takehiko; Tanabe, Yoshimitsu; Ishida, Tsutomu; Totani, Yoshiyuki; Nakatsuka, Masakatsu
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003267973	A	20030925	JP 2002-74286	20020318
PRIORITY APPLN. INFO.:			JP 2002-74286	20020318

OTHER SOURCE(S): MARPAT 139:267732
 GI




AB Arylaminophenylthiophene derivs. I [Ar1-Ar4 = aryl where ≥1 of them is anthryl] and organic electroluminescent devices having I in hole-injecting or emission layers and exhibiting the mentioned advantages are both claimed.

IT 603132-56-5P 603132-57-6P
 RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
 (novel arylaminophenylthiophene derivs. for organic electroluminescent devices showing stable and bright emission)


RN 603132-56-5 CAPLUS
 CN 9-Anthracenamine, N-[4-[5-[(4-methoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 87 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 603132-57-6 CAPLUS
 CN 9-Anthracenamine, N,N'-[(3,4-diphenyl-2,5-thiophenediyl)di-4,1-phenylene]bis[N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




L19 ANSWER 88 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:675790 CAPLUS
 DOCUMENT NUMBER: 139:221357
 TITLE: Organic electroluminescent component with thiophene derivative
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003243176	A	20030829	JP 2002-38422	20020215
JP 3788603	B2	20060621		

PRIORITY APPLN. INFO.: JP 2002-38422 20020215

OTHER SOURCE(S): MARPAT 139:221357
 GI




AB The invention refers to an organic electroluminescent component comprising a thiophene derivative I [Ar1-4 = (un)substituted aryl; and Ar1 and Ar2, Ar3 and Ar4 may join to form N-containing rings, and at least one of Ar1-4 must be a(n) (un)substituted fluorenyl].

IT 586964-18-3 586964-19-4
 RL: DEV (Device component use); USES (Uses)
 (organic electroluminescent component with thiophene derivative)


RN 586964-18-3 CAPLUS
 CN 9H-Fluoren-2-amine, N,N'-[(3,4-diphenyl-2,5-thiophenediyl)di-4,1-phenylene]bis[N-(3-methoxyphenyl)-9,9-dimethyl- (9CI) (CA INDEX NAME)]

L19 ANSWER 88 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 586964-19-4 CAPLUS
 CN 9H-Fluoren-2-amine, N,N'-[(3,4-diphenyl-2,5-thiophenediyl)di-4,1-phenylene]bis[7-ethoxy-9,9-dimethyl-N-[4-(octyloxy)phenyl]- (9CI) (CA INDEX NAME)]

PAGE 1-A



PAGE 1-B




L19 ANSWER 89 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:673858 CAPLUS
 DOCUMENT NUMBER: 139:214323
 TITLE: Preparation of 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene derivatives as positive hole injection transport materials for organic electroluminescent devices
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003238559	A	20030827	JP 2002-31611	20020208
			JP 2002-31611	20020208

PRIORITY APPLN. INFO.: JP 2002-31611 20020208

OTHER SOURCE(S): MARPAT 139:214323
 GI




AB The title compds. [I; Ar1, Ar2 = (un)substituted biphenyl; Ar3, Ar4 = (un)substituted Ph] are prepared. Thus, 2,5-bis(4-iodophenyl)-3,4-diphenylthiophene 64, N,N-bis(4-phenylphenyl)amine 32, copper powder 10, and anhydrous K2CO3 20 g were stirred in 200 g o-chlorobenzene at 190° for 8 h, cooled to 100°, filtered, and treated with 400 g methanol followed by filtration of the precipitated crystals, drying, and alumina chromatog. to give 32 g 2-[4-[N,N-bis(4-phenylphenyl)amino]phenyl]-5-(4-iodophenyl)-3,4-diphenylthiophene (II). II 8.3, N,N-diphenylamine 2.0, and anhydrous K2CO3 5.0 g were stirred in 50 g o-chlorobenzene at 190° for 8 h, processed similarly as described above to give, after purification by sublimation at 270° and 10-6 torr, 6.2 g 2-[4-[N,N-bis(4-phenylphenyl)amino]phenyl]-5-[4-(N,N-diphenylamino)phenyl]-3,4-diphenylthiophene (III) as light yellow solid (glass transition temperature 127°). An electroluminescent device with a hole injection layer of III vapor-deposited on a ITO electrode emitted green light at 50°, 6.5 V, 10 mA/cm2, and luminance of 460 cd/m2 with a half life of 740 h.

L19 ANSWER 89 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 404389-98-6P
 RL: DEV (Device component use); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation of bis(p-aminophenyl)diphenylthiophene derivs. as pos. hole injection transport materials for organic electroluminescent devices)

RN 404389-98-6 CAPLUS
 CN [1,1'-Biphenyl]-4-amine, N-[1,1'-biphenyl]-4-yl-N-[4-[5-[4-[(4-ethoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI) (CA INDEX NAME)




L19 ANSWER 90 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:671094 CAPLUS
 DOCUMENT NUMBER: 139:214329
 TITLE: Preparation of 2,5-bis(4-aminophenyl)-3,4-diphenylthiofuran derivatives as positive hole injection transport materials for organic electroluminescent devices
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003238560	A	20030827	JP 2002-36873	20020214
PRIORITY APPLN. INFO.: JP 2002-36873 20020214				
OTHER SOURCE(S): MARPAT 139:214329				
GI				




AB The title compds. [I; Ar1-Ar4 = (un)substituted aryl; or Ar1 and Ar2 or Ar3 and Ar4 together with the N atom to which they are bonded form a N-containing heterocyclic ring; provided that at least one of Ar1-Ar4 is (un)substituted phenanthryl] are prepared. Thus, 2,5-bis(4-iodophenyl)-3,4-diphenylthiofuran 64, N-(9-phenanthryl)-N-phenylamine 27, copper powder 10, and anhydrous K₂CO₃ 20 g were stirred in 200 g o-chlorobenzene at 190° for 8 h, cooled to 100°, filtered, and treated with 400 g methanol followed by filtration of the precipitated crystals, drying, and alumina chromatog. to give 32 g 2-[4-[N-(9-phenanthryl)-N-phenylamino]phenyl]-5-(4-iodophenyl)-3,4-diphenylthiofuran (II). II 7.8, N,N-diphenylamine 2.0, and anhydrous K₂CO₃ 5.0 g were stirred in 30 g o-chlorobenzene at 190° for 8 h, processed similarly as described above to give, after purification by sublimation at 300° and 10-6 torr, 5.8 g 2-[4-[N-(9-phenanthryl)-N-phenylamino]phenyl]-5-[4-(N,N-

L19 ANSWER 90 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 diphenylamino]phenyl]-3,4-diphenylthiofuran (III) as yellow solid (glass transition temp. 128°). An electroluminescent device with a hole injection layer of III vapor-deposited on a ITO electrode emitted green light at 50°, 6.5 V, 10 mA/cm², and luminance of 470 cd/m² with a half life of 760 h.
 IT 587848-11-1P
 RL: DEV (Device component use); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation of (p-phenanthrylaminophenyl)(aminophenyl)diphenylthiofuran derivs. as pos. hole injection transport materials for organic electroluminescent devices)
 RN 587848-11-1 CAPLUS
 CN 9-Phenanthrenamine, N,N'-[(3,4-diphenyl-2,5-thiophenediyl)di-4,1-phenylene]bis[N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)]



L19 ANSWER 91 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:671093 CAPLUS
 DOCUMENT NUMBER: 139:214320
 TITLE: Preparation of 2,5-bis(4-aminophenyl)-3,4-diphenylthiofuran derivatives as positive hole injection transport materials for organic electroluminescent devices
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003238557	A	20030827	JP 2002-31609	20020208
PRIORITY APPLN. INFO.: JP 2002-31609 20020208				
OTHER SOURCE(S): MARPAT 139:214320				
GI				




AB The title compds. [I; Ar1, Ar2 = (un)substituted naphthyl; Ar3, Ar4 = (un)substituted Ph] are prepared. Thus, 2,5-bis(4-iodophenyl)-3,4-diphenylthiofuran 64, N,N-bis(1-naphthyl)amine 27, copper powder 10, and anhydrous K₂CO₃ 20 g were stirred in 200 g o-chlorobenzene at 190° for 8 h, cooled to 100°, filtered, and treated with 400 g methanol followed by filtration of the precipitated crystals, drying, and alumina chromatog., 30 g 2-[4-[N,N-di(1-naphthyl)amino]phenyl]-5-(4-iodophenyl)-3,4-diphenylthiofuran (II). II 6.5, N,N-diphenylamine 2.0, and anhydrous K₂CO₃ 5 g were stirred in 30 g o-chlorobenzene at 190° for 8 h, processed similarly as described above to give, after purification by sublimation at 270° and 10-6 torr, 6.1 g 2-[4-[N,N-di(1-naphthyl)amino]phenyl]-5-[4-(bis(4-methylphenyl)amino)phenyl]-3,4-diphenylthiofuran (III) as light yellow solid (glass transition temperature 126°). An electroluminescent device with a hole injection layer of III vapor-deposited on a ITO electrode emitted green light at 50°, 6.5 V, 10 mA/cm², and luminance of 480 cd/m² with a half life of 760 h.
 IT 404353-96-4P
 RL: DEV (Device component use); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

L19 ANSWER 91 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (prepn. of bis(p-aminophenyl)diphenylthiofuran derivs. as pos. hole injection transport materials for org. electroluminescent devices)
 RN 404353-96-4 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-[bis(4-methoxyphenyl)amino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-2-naphthalenyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L19 ANSWER 92 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:596595 CAPLUS
 DOCUMENT NUMBER: 139:157140
 TITLE: Novel amine compounds for hole-injecting/transporting materials of organic electroluminescent devices
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003221393	A	20030805	JP 2002-18720	20020128
PRIORITY APPLN. INFO.:			JP 2002-18720	20020128

OTHER SOURCE(S): MARPAT 139:157140
 GI




AB The compds. are I (Ar1-Ar3 = biphenyl; Ar4 = Ph, naphthyl).
 Electroluminescent devices containing the compds. show improved stability and durability.
 IT 401479-81-0
 RL: DEV (Device component use); TEM (Technical or engineered material use); USES (Uses)
 (novel amine compds. for hole-injecting/transporting materials of organic LED)
 RN 401479-81-0 CAPLUS
 CN [1,1'-Biphenyl]-4-amine, N-[1,1'-biphenyl]-4-yl-N-[4-[5-[4-[1,1'-biphenyl]-4-yl-(4-ethoxyphenyl)amino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 93 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:591193 CAPLUS
 DOCUMENT NUMBER: 139:149520
 TITLE: Preparation of aralkylpyrrolidines and -azetidines as Edg receptor agonists
 INVENTOR(S): Bugianesi, Robert L.; Doherty, George A.; Gentry, Amy;
 Sander Hale, Jeffrey J.; Lynch, Christopher L.; Mills, G.; Neway, William E., III
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062252	A1	20030731	WO 2003-US1196	20030115
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2472715	A1	20030731	CA 2003-2472715	20030115
EP 1470137	A1	20041027	EP 2003-705779	20030115
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 200515259	T	20050526	JP 2003-562129	20030115
US 2005033055	A1	20050210	US 2004-500895	20040707
PRIORITY APPLN. INFO.:			US 2002-350000P	P 20020118
			WO 2003-US1196	W 20030115

OTHER SOURCE(S): MARPAT 139:149520
 GI




AB Title compds. I [Ar = (un)substituted Ph, naphthyl; A = CO2H, P(O)(OH)2, P(O)OH, SO3H, 1H-tetrazol-5-yl; R1, R2 = H, halogen, OH, CO2H, (un)substituted alkyl; R3 = H, (un)substituted alkyl; m, n = 0, 1] were


L19 ANSWER 92 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 93 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 prepd. for use as Edg receptor agonists, useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection (no data). Thus, 3-pyrrolidinol was converted to di-Et 3-hydroxypyrrolidin-3-ylphosphonate and treated with 4-nonylbenzaldehyde, followed by ester hydrolysis to give 1-(4-nonylbenzyl)-3-hydroxypyrrolidine-3-phosphonic acid.
 IT 570424-11-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aralkylpyrrolidines and -azetidines as Edg receptor agonists)
 RN 570424-11-2 CAPLUS
 CN Benzaldehyde, 3-methoxy-4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)



IT 570423-77-7P 570423-78-8P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aralkylpyrrolidines and -azetidines as Edg receptor agonists)
 RN 570423-77-7 CAPLUS
 CN 3-Pyrrolidinecarboxylic acid, 1-[[3-methoxy-4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 570423-78-8 CAPLUS
 CN 3-Azetidinecarboxylic acid, 1-[[3-methoxy-4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

L19 ANSWER 93 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 94 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:590932 CAPLUS
DOCUMENT NUMBER: 139:149413
TITLE: Selective S1P1/Edg1 receptor agonists
INVENTOR(S): Doherty, George A.; Forrest, Michael J.; Hajdu,
Richard; Hale, Jeffrey J.; Li, Zhen; Mandala, Suzanne
M.; Mills, Sander G.; Rosen, Hugh; Scolnick, Edward
M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061567	A2	20030731	WO 2003-US1120	20030114
WO 2003061567	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004058894	A1	20040325	US 2003-339380	20030109
CA 2472680	A1	20030731	CA 2003-2472680	20030114
EP 1469863	A2	20041027	EP 2003-731917	20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2003216054	B2	20070104	AU 2003-216054	20030114
US 2005070506	A1	20050331	US 2004-501176	20040712
PRIORITY APPLN. INFO.:				
			US 2002-349991P	P 20020118
			US 2002-362566P	P 20020307
			US 2002-382933P	P 20020523
			WO 2003-US1120	W 20030114

AB The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount


L19 ANSWER 94 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
effective for treating said immunoregulatory abnormality. Thus, 4-HOC6H4CHO was treated with Me(CH2)7I to give 4-Me(CH2)7OC6H4CHO which was treated with H2N(CH2)3P(O)(OH)2 to give 4-Me(CH2)7OC6H4CH2NH(CH2)3P(O)(OH)2 which had an EC50 for S1P1 agonism of 1.5 nM and for S1P3 agonism of 6.0 nM.

IT 570423-77-7P 570423-78-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino functionalized organo phosphonates or organo carboxylates as S1P1/Edg1 receptor agonists)

RN 570423-77-7 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 1-[[3-methoxy-4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 570423-78-8 CAPLUS
CN 3-Azetidinecarboxylic acid, 1-[[3-methoxy-4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 570424-11-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino functionalized organo phosphonates or organo carboxylates as S1P1/Edg1 receptor agonists)


RN 570424-11-2 CAPLUS
CN Benzaldehyde, 3-methoxy-4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)




L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:566703 CAPLUS
DOCUMENT NUMBER: 139:314378
TITLE: Novel glassy nematic liquid crystals for
non-destructive rewritable optical memory and
photonic switching
AUTHOR(S): Chen, Shaw H.; Chen, H. M. Philip; Geng, Yanhou;
Jacobs, Stephen D.; Marshall, Kenneth L.; Blanton,
Thomas N.
CORPORATE SOURCE: Department of Chemical Engineering Center for
Optoelectronics and Imaging, University of Rochester,
Rochester, NY, 14623-1212, USA
SOURCE: Advanced Materials (Weinheim, Germany) (2003),
15(13),
1061-1065
CODEN: ADVMEW; ISSN: 0935-9648
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Dithienylethene-containing glassy nematic liquid crystals were
synthesized, in
which the dithienylethene core's electronic transition moment is
uniaxially aligned. Large changes in refractive index and optical
birefringence could be induced in the solid state by photochem. means.
Applications in non-destructive rewritable optical memory and high-speed
photonic switches are envisaged.
IT 611206-44-1P 611206-45-2P 611206-46-3P
RI: CPS (Chemical process); PEP (Physical, engineering or chemical
process); PRP (Properties); PYP (Physical process); SPN (Synthetic
preparation); PREP (Preparation); PROC (Process)
(design and properties of morphol. stable glassy nematic liquid
crystals
containing dithienylethene core for rewritable optical memory and
photonic switching)
RN 611206-44-1 CAPLUS
CN 1,4-Benzenedicarboxylic acid, (3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-
diyl)bis[(3,5-dimethyl-4,2-thiophenediyl)-4,1-phenylene]
bis[2-[4-[[[4'-methoxy[1,1'-biphenyl]-4-yl]oxy]carbonyl]phenoxy]ethyl]
ester (9CI) (CA INDEX NAME)

L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-B

L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1,4-Benzenedicarboxylic acid, (3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-
diyl)bis[(3,5-dimethyl-4,2-thiophenediyl)-4,1-phenylene]
bis[3-[4-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]carbonyl]phenoxy]propyl]
ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 3-A





PAGE 3-B




RN 611206-45-2 CAPLUS

L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




PAGE 2-B




L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



PAGE 2-A




PAGE 2-B



L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 3-A




RN 618206-46-3 CAPLUS

CN 1,3,5-Benzenetricarboxylic acid, (3,3,4,4,5,5-hexafluoro-1-cyclopentene-2,2-diyl) bis[(3,5-dimethyl-4,2-thiophenediyl)-4,1-phenylene]


tetrakis[3-[4-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]carbonyl]phenoxy]propyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 95 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-C



PAGE 3-B

REFERENCE COUNT:
THIS
FORMAT


38

THERE ARE 38 CITED REFERENCES AVAILABLE FOR
RECORD. ALL CITATIONS AVAILABLE IN THE RE

L19 ANSWER 96 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:488876 CAPLUS
 DOCUMENT NUMBER: 139:60191
 TITLE: Organic electroluminescence devices with high luminescence efficiency
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003178881	A	20030627	JP 2001-375493	20011210
PRIORITY APPLN. INFO.:			JP 2001-375493	20011210


OTHER SOURCE(S): MARPAT 139:60191
 GI




AB The device has ≥ 1 layers containing arylaminothiophenes I (Ar1-6 = aryl; m, n = 0, 1; m \neq n; Ar1 and Ar2, Ar3 and Ar4, Ar5 and Ar6 maybe forming a ring with N) between a pair of electrodes. The layer containing I may be a hole transport layer or a luminescence layer.

IT 547755-30-6 547755-31-7 547755-41-9
 547755-53-3 547755-54-4
 RL: DEV (Device component use); USES (Uses)
 (hole transport layer containing; arylaminothiophenes for organic electroluminescence devices with high luminescence efficiency)
 RN 547755-30-6 CAPLUS
 CN Benzenamine,
 4,4'-(4,5-diphenyl-2,3-thiophenediyl)bis[N-(4-methoxyphenyl)-

L19 ANSWER 96 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 N-phenyl- (9CI) (CA INDEX NAME)




RN 547755-31-7 CAPLUS
 CN Benzenamine, 4-[3-[4-[bis(3-fluorophenyl)amino]phenyl]-4,5-diphenyl-2-thienyl]-N,N-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 547755-41-9 CAPLUS

L19 ANSWER 96 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzenamine,
 N-(3-ethoxyphenyl)-4-[5-[4-[(3-methylphenyl)phenylamino]phenyl-1]-2,4-diphenyl-3-thienyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 547755-53-3 CAPLUS
 CN Benzenamine, 4,4'-(4,5-diphenyl-2,3-thiophenediyl)bis[N-(4-(hexyloxy)phenyl)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 547755-54-4 CAPLUS
 CN Benzenamine,
 4,4'-(3,5-diphenyl-2,4-thiophenediyl)bis[N-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 96 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 97 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:412165 CAPLUS
 DOCUMENT NUMBER: 138:409114
 TITLE: Organic field-type electroluminescent device and thiophene compounds for it
 INVENTOR(S): Ishida, Tsutomu; Shimamura, Takehiko; Tanabe, Yoshimitsu; Totani, Yoshiyuki; Nakatsuka, Masakatsu
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003157977	A	20030530	JP 2001-353764	20011119
JP 3818894	B2	20060906		


PRIORITY APPLN. INFO.: JP 2001-353764 20011119

OTHER SOURCE(S): MARPAT 138:409114
 GI




AB The electroluminescent (EL) device contains ≥ 1 thiophene compound represented by I (R1-3 = H, linear, branched, or cyclic alkyl, (substituted) aryl, (substituted) aralkyl; Ar1-2 = (substituted) aryl; Ar1 and Ar2 may form N-containing heterocyclic ring; Z1-2 = H, halo, linear, branched, or cyclic alkyl or alkoxy, (substituted) aryl, (substituted) aralkyl, (substituted) amino) as a hole-transporting material, a luminescent material, and/or an electron-injecting/transporting material. The thiophene compound is also claimed. The EL device has high luminescent efficiency and emits light with high brightness.
 IT 531509-21-4P 531509-22-5P
 RL: DEV (Device component use); IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (organic field-type electroluminescent device containing thiophene compound for


L19 ANSWER 97 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 97 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 high luminescent efficiency and brightness)
 RN 531509-21-4 CAPLUS
 CN Benzenamine,
 4-[5-[4-(1,2-diphenylethenyl)phenyl]-3,4-diphenyl-2-thienyl]-
 N,N-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 531509-22-5 CAPLUS
 CN Benzenamine,
 4-[5-[4-[2-(4-methoxyphenyl)-1-phenyl-1-propenyl]phenyl]-3,4-diphenyl-2-thienyl]-N,N-diphenyl- (9CI) (CA INDEX NAME)




IT 531509-47-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (organic field-type electroluminescent device containing thiophene compound for high luminescent efficiency and brightness)
 RN 531509-47-4 CAPLUS
 CN Thiophene, 2-(4-bromophenyl)-5-[4-[2-(4-methoxyphenyl)-1-phenyl-1-propenyl]phenyl]-3,4-diphenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 98 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:398371 CAPLUS
 DOCUMENT NUMBER: 139:14695
 TITLE: Organic electroluminescent device with aryl amine-substituted thiophene
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003151778	A	20030523	JP 2001-343640	20011108

PRIORITY APPLN. INFO.: JP 2001-343640 20011108


OTHER SOURCE(S): MARPAT 139:14695
 GI




AB The invention refers to an organic electroluminescent device comprising I [Ar1-6 = (un)substituted aryl, where adjacent groups may joining together and form heterocyclic rings including the shared N atom].

IT 530129-05-6 530129-06-7 530129-07-8
 530129-26-1
 RL: DEV (Device component use); USES (Uses)
 (organic electroluminescent device with aryl amine-substituted thiophene)
 RN 530129-05-6 CAPLUS
 CN Benzenamine, 4,4',4''-(5-phenyl-2,3,4-thiophenetriyl)tris[N-(3-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 98 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 530129-06-7 CAPLUS
 CN Benzenamine, 4,4'-[4-[4-[bis(4-methoxyphenyl)amino]phenyl]-5-phenyl-2,3-thiophenediyl]bis[N,N-bis(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 530129-07-8 CAPLUS
 CN Benzenamine, N-[4-[3,4-bis[4-(diphenylamino)phenyl]-5-phenyl-2-thienyl]phenyl]-3-ethyl-5-methoxy-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 98 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A





PAGE 2-A




L19 ANSWER 98 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 530129-26-1 CAPLUS
 CN Benzenamine, 4,4',4''-(5-phenyl-2,3,4-thiophenetriyl)tris[N-(4-(hexyloxy)phenyl)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)


L19 ANSWER 99 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:356419 CAPLUS
 DOCUMENT NUMBER: 138:368770
 TITLE: Preparation of pyridinylethylamines and amides as anticancer drugs.
 INVENTOR(S): Menon, Sanjay R.; Lu, Yingchun; Sakamuri, Sukumar; Chen, Quin-Zene; Khazak, Vladimir; Agarwal, Seema
 PATENT ASSIGNEE(S): Morphochem Aktiengesellschaft fuer Kombinatorische Chemie, Germany
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: ***

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037865	A1	20030508	WO 2002-EP12222	20021031
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2468761	A1	20030508	CA 2002-2468761	20021031
EP 1442018	A1	20040804	EP 2002-787539	20021031
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
US 2005228017	A1	20051013	US 2005-497449	20050330
PRIORITY APPLN. INFO.:			US 2001-335300P	P 20011031
			WO 2002-EP12222	W 20021031


OTHER SOURCE(S): MARPAT 138:368770
 AB (R3Y) (R1X)NUR2 [n = 0-5; X, Y = CH2, CO, SO2, CONH; R1 = (substituted) aryl, aralkyl, heteroaryl, heteroarylalkyl; R2 = (substituted) heteroalkyl, aryl, aralkyl, heteroaryl, heteroalkyl, cycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, heteroarylalkyl, aralkyl], were prepared. Thus, N-(4-benzyloxy-3-methoxybenzyl)-N-(2-pyridin-2-ylethyl)amine (preparation given) in ClCH2CH2Cl was treated with polymer-supported morpholine and 2-chlorobenzoyl chloride followed by stirring for 24 h. Polymer-supported isocyanate, polymer-supported tris(2-aminoethyl)amine, and ClCH2CH2Cl were added followed by stirring for 24 h to give 84% N-(4-benzyloxy-3-methoxybenzyl)-N-(2-pyridin-2-ylethyl)-2-chlorobenzamide. Title compds. showed IC50's of 5-60 μM in secondary luciferase assays in NIH3T3, CHO, or HEK293 cells.
 IT 521312-57-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L19 ANSWER 99 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Biological study); USES (Uses)
 (prepn. of pyridinylethylamines and amides as anticancer drugs)
 RN 521312-57-2 CAPLUS
 CN 2-Thiophenecarboxamide, N-[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]-5-phenyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 100 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:311129 CAPLUS
 DOCUMENT NUMBER: 139:345301
 TITLE: Synthesis of the aroyl thiourea derivatives as novel small molecule inhibitors of cysteine protease of Trypanosoma cruzi
 AUTHOR(S): Guo, Chun; Fang, Lin; Du, Xiaohui; McKerrow, James H.; Cohen, Fred E.
 CORPORATE SOURCE: School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, 110016, Peop. Rep. China
 SOURCE: Zhongguo Yaowu Huaxue Zazhi (2002), 12(4), 200-204
 CODEN: ZYHZEJ; ISSN: 1005-0108
 PUBLISHER: Zhongguo Yaowu Huaxue Zazhi Bianjibu
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:345301
 GI




AB New aroyl thiourea derivs. were designed and synthesized to find novel small mol. inhibitors of cysteine protease of Trypanosoma cruzi. A series of aroyl thiourea derivs. was prepared from corresponding aroyl isothiocyanates and substituted anilines. The chemical structures were characterized by HRMS(EI) and 1H-NMR spectroscopy. A total of 20 aroyl thiourea derivs. were synthesized. The results of the bioassay in vitro against cruzain showed that all the synthetic compds. exhibited certain activity, among which two compds. [I (R1 = 3-acetamido, R2 = o-fluoro, X = S, Y = 2-O) and I (R1 = 4-chloro, R2 = o-fluoro, X = O, Y = 2-O)] were more active than the control inhibitor tf-175. The class of inhibitors might be potential drugs for antitrypanosomal chemotherapy.
 IT 618889-86-P 618889-89-7P 618889-90-0P
 618889-91-1P 618889-92-2P 618889-93-3P
 618889-94-4P 618889-95-5P 618889-96-6P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of aroyl thiourea derivs. as novel small mol. inhibitors of cysteine protease of Trypanosoma cruzi)


L19 ANSWER 100 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 618889-88-6 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[2-(phenylmethoxy)phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)




RN 618889-89-7 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[4-(phenylmethoxy)phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)



RN 618889-90-0 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[3-(phenylmethoxy)phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)




RN 618889-91-1 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[2-[(2-fluorophenyl)methoxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)




RN 618889-92-2 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[4-[(2-fluorophenyl)methoxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 100 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 618889-93-3 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[3-[(2-fluorophenyl)methoxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)



RN 618889-94-4 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[2-[(2-methylphenyl)methoxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)




RN 618889-95-5 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[4-[(2-methylphenyl)methoxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)



RN 618889-96-6 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[[[3-[(2-methylphenyl)methoxy]phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 100 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT:
FORMAT

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE


L19 ANSWER 101 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:242160 CAPLUS
DOCUMENT NUMBER: 138:271705
TITLE: Preparation of triazinyl and other carboxamides as
inhibitors of histone deacetylase
INVENTOR(S): Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii;
Moradel, Oscar; Leit, Silvana; Raeppe, Stephane;
Frechette, Sylvie; Bouchain, Giliane
PATENT ASSIGNEE(S): Methygene, Inc., Can.
SOURCE: PCT Int. Appl., 347 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024448	A2	20030327	WO 2002-US29017	20020912
WO 2003024448	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465978	A1	20030327	CA 2002-2465978	20020912
AU 2002327627	A1	20030401	AU 2002-327627	20020912
EP 1429765	A2	20040623	EP 2002-763627	20020912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012510	A	20040824	BR 2002-12510	20020912
CN 1578663	A	20050209	CN 2002-822690	20020912
JP 2005508905	T	20050407	JP 2003-528544	20020912
JP 3795044	B2	20060712		
IN 2004KN00257	A	20061110	IN 2004-KN257	20040225
MX 2004PA02397	A	20041202	MX 2004-PA2397	20040312
JP 2005255683	A	20050922	JP 2005-80310	20050318
AU 2006252047	A1	20070111	AU 2006-252047	20061214
PRIORITY APPLN. INFO.:				
			US 2002-391728P	P 20020626
			AU 2002-327627	A3 20020912
			JP 2003-528544	A3 20020912
			WO 2002-US29017	W 20020912

OTHER SOURCE(S): MARPAT 138:271705
GI

L19 ANSWER 101 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention relates to triazines (shown as I; variables defined below; e.g.

4-[[4-amino-6-(2-indanylamino)-[1,3,5]triazin-2-ylamino]methyl]-N-(2-aminophenyl)benzamide and Cy3-X1-Ar2-(C(R5):C(R6))qC(O)NH-Ay2 (II; variables defined below; e.g.), many of which are N-(o-aminophenyl)carboxamides, as inhibitors of histone deacetylase (data included for many I and II). The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I and II are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. For I: R3 and R4 = H, L1, Cy1 and -L1-Cy1 (L1 = C1-C6 alkyl, C2-C6 heteroalkyl, or C3-C6 alkenyl; Cy1 = cycloalkyl, aryl, heteroaryl, or heterocyclyl) or R3 and R4 are taken together with the adjacent N atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms = C, O, S, and N, and wherein the ring is optionally substituted, and optionally forms part of a bicyclic ring system, or is optionally fused to one or two aryl or heteroaryl rings, or to one or two saturated

or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings and ring systems is optionally substituted. Y1 = -N(R1)(R2), -CH2-C(O)-N(R1)(R2), halogen, and H (R1 and R2 = H, L1, Cy1, and -L1-Cy1).

Y2 = chemical bond or N(R0) (R0 = H, alkyl, aryl, aralkyl, and acyl);

Ak1 = C1-C6 alkylene, C1-C6-heteroalkylene (preferably, in which one -CH2- is replaced with -NH-, and more preferably -NH-CH2-), C2-C6 alkenylene or C2-C6 alkynylene; Ar1 = arylene or heteroarylene, either of which is optionally substituted; and Z1 = C(O)NH-Ay1 and CH:CHC(O)NH-Ay1 (Ay1 = aryl or heteroaryl, each of which is optionally substituted). For II:

Cy2 = cycloalkyl, aryl, heteroaryl, or heterocyclyl; X1 = covalent bond, M1-L2-M1, and L2-M2-L2 (L2 = chemical bond, C1-C4 alkylene, C2-C4 alkenylene,

and C2-C4 alkynylene, provided that L2 is not a chemical bond when X1 is M1-L2-M1; M1 = -O-, -N(R7)-, -S-, -S(O)-, S(O)2-, -S(O)2N(R7)-, -N(R7)S(O)2-, -C(O)-, -C(O)NH-, -NHC(O)-, and -OC(O)NH- (R7 = H, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl); and M2 =

M1, heteroarylene, and heterocyclylene, either of which rings is optionally substituted). Ar2 = arylene or heteroarylene, each of which is optionally

substituted; R5 and R6 = H, alkyl, aryl, and aralkyl; q is 0 or 1; and

Ay2 is a 5-6 membered cycloalkyl, heterocyclyl, or heteroaryl substituted

with

L19 ANSWER 101 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
an amino or hydroxy moiety (preferably these groups are ortho to the amide


N to which Ay2 is attached) and further optionally substituted; provided that when Cy2 is naphthyl, X1 is -CH2-, Ar2 is Ph, R5 and R6 are H, and q is 0 or 1, Ay2 is not Ph or o-hydroxyphenyl. Although the methods of prepn. are not claimed, hundreds of example prepn. are included.

IT 503042-76-0P, N-(2-Aminophenyl)-4-(5-(((3,4,5-trimethoxyphenyl)amino)methyl)thien-2-yl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503042-76-0 CAPLUS

CN Benzamide,
N-(2-aminophenyl)-4-[5-(((3,4,5-trimethoxyphenyl)amino)methyl)-2-thienyl]- (9CI) (CA INDEX NAME)




L19 ANSWER 102 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:240287 CAPLUS
 DOCUMENT NUMBER: 138:278160
 TITLE: Organic electroluminescent device showing high emission efficiency and long service life
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003092187	A	20030328	JP 2001-283808	20010918


PRIORITY APPLN. INFO.: JP 2001-283808 20010918

OTHER SOURCE(S): MARPAT 138:278160
 GI




AB The device contains a arylamino-substituted tetraphenylthiophene derivative I
 [Ar1-4 = (substituted) aryl; Ar1 and Ar2 may be connected to form a heterocycle; Ar3 and Ar4 may be connected to form a heterocycle; m = 0, 1]
 as a hole-transport material.
 IT 503279-41-2 503279-43-4 503279-71-8
 503279-73-0 503279-75-2
 RI: DEV (Device component use); USES (Uses)
 (hole-transport material; organic electroluminescent device containing arylamino-substituted tetraphenylthiophene as hole-transport material)
 RN 503279-41-2 CAPLUS
 CN Benzenamine, N-(4-methoxyphenyl)-N-phenyl-4-(2,4,5-triphenyl-3-thienyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 102 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 503279-43-4 CAPLUS
 CN Benzenamine, 3,4-dimethoxy-N-phenyl-N-[4-(2,4,5-triphenyl-3-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 503279-71-8 CAPLUS
 CN Benzenamine, 4,4'-(2,5-diphenyl-3,4-thiophenediyl)bis[N-(4-methoxyphenyl)-N-phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 102 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 503279-73-0 CAPLUS
 CN Benzenamine, 4,4'-(2,5-diphenyl-3,4-thiophenediyl)bis[N-(4-(hexyloxy)phenyl)-N-(3-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 503279-75-2 CAPLUS
 CN Benzenamine, 4,4'-(2,5-diphenyl-3,4-thiophenediyl)bis[N-(3-ethyl-5-methoxyphenyl)-N-phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 102 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



L19 ANSWER 103 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:221683 CAPLUS
 DOCUMENT NUMBER: 138:238014
 TITLE: Preparation of 2-(thiophenyl)thiopyran-1,1-dioxides
 as
 INVENTOR(S): MMP or TNF- α inhibitors
 Neya, Masahiro; Sawada, Akihiko; Ohne, Kazuhiko; Abe,
 Yoshito; Mizutani, Tsuyoshi; Ishibashi, Naoki; Inoue,
 Makoto
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022842	A1	20030320	WO 2002-JP8895	20020902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459882	A1	20030320	CA 2002-2459882	20020902
AU 2002326168	A1	20030324	AU 2002-326168	20020902
EP 1423386	A1	20040602	EP 2002-760801	20020902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005502706	T	20050127	JP 2003-526917	20020902
CN 1582287	A	20050216	CN 2002-822158	20020902
US 2004266826	A1	20041230	US 2004-487242	20040227
PRIORITY APPLN. INFO.:			AU 2001-7555	A 20010907
			WO 2002-JP8895	W 20020902

OTHER SOURCE(S): MARPAT 138:238014
 GI



II

L19 ANSWER 103 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 501946-13-0P, 4-Methoxybenzyl (S)-[2-[5-[4-(oxazol-5-yl)phenyl]phenyl]thiophen-2-yl]-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-15-2P, 4-Methoxybenzyl (S)-[2-[5-[4-(tert-butoxycarbonylamino)phenyl]phenyl]thiophen-2-yl]-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-21-0P, 4-Methoxybenzyl (S)-[2-[5-[4-(E)-2-(oxazol-5-yl)ethenyl]phenyl]thiophen-2-yl]-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-22-1F, 4-Methoxybenzyl (S)-[2-[5-[4-(oxazol-5-ylmethoxy)phenyl]thiophen-2-yl]-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-24-3P, 4-Methoxybenzyl (S)-[2-[5-[4-(E)-2-(methylcarbamoyl)ethenyl]phenyl]thiophen-2-yl]-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-26-5P, 4-Methoxybenzyl (S)-[2-[5-[4-[(oxazol-5-yl)carbonyl]amino]phenyl]thiophen-2-yl]-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-67-4P, 4-Methoxybenzyl (S)-[1,1-dioxo-2-[5-(4-pentyloxyphenyl)thiophen-2-yl]-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-69-6P, 4-Methoxybenzyl (S)-[1,1-dioxo-2-[5-(4-(1-methylethoxy)phenyl)thiophen-2-yl]-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MMP or TNF- α inhibitor; preparation of (thiophenyl)thiopyrandioxides as MMP or TNF- α inhibitors)

RN 501946-13-0 CAPLUS
 CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-[4'-(5-oxazolyl)(1,1'-biphenyl)-4-yl]-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 103 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. I [wherein R1 = (un)substituted Ph, naphthyl, bicyclic heterocycl, alkenyl, or alkynyl; R2 = CO2H or protected CO2H; or a salt thereof] were prepared as matrix metalloproteinase (MMP) or tumor necrosis factor α (TNF- α) inhibitors. For example, coupling of 2-(trimethylsilyl)ethyl (S)-[2-(5-bromothiophen-2-yl)-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate and 2-(4'-cyano-4-biphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane followed by deesterification gave II. Five compds. of the invention were tested for gelatinolytic activity against human MMP-9 and displayed inhibitory activity with IC50 values ranging from 1.37 nM to 16.0 nM. Thus, I are useful for treating and/or preventing diseases mediated by MMP or TNF- α (no data).


IT 501945-63-7P, 4-Methoxybenzyl (S)-[2-[5-(4-butoxyphenyl)thiophen-2-yl]-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate 501946-35-6P, 4-Methoxybenzyl (S)-[1,1-dioxo-2-[5-(4-hydroxyphenyl)thiophen-2-yl]-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(MMP or TNF- α inhibitor; preparation of (thiophenyl)thiopyrandioxides as MMP or TNF- α inhibitors)

RN 501945-63-7 CAPLUS
 CN 2H-Thiopyran-2-acetic acid, 2-[5-(4-butoxyphenyl)-2-thienyl]tetrahydro-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501946-35-6 CAPLUS
 CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-(4-hydroxyphenyl)-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L19 ANSWER 103 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 501946-15-2 CAPLUS
 CN 2H-Thiopyran-2-acetic acid, 2-[5-[4'-[(1,1-dimethylethoxy)carbonyl]amino][1,1'-biphenyl]-4-yl]-2-thienyl]tetrahydro-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Me


RN 501946-21-0 CAPLUS
 CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-[4-[(1E)-2-(5-oxazolyl)ethenyl]phenyl]-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

L19 ANSWER 103 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 501946-22-1 CAPLUS
CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-[4-((5-oxazolylmethoxy)amino)phenyl]-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501946-24-3 CAPLUS
CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-[4-((1E)-3-(methylamino)-3-oxo-1-propenyl)phenyl]-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L19 ANSWER 103 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 501946-26-5 CAPLUS
CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-[4-((5-oxazolylcarbonyl)amino)phenyl]-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501946-67-4 CAPLUS
CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-[4-(pentyloxy)phenyl]-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 103 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 501946-69-6 CAPLUS
CN 2H-Thiopyran-2-acetic acid, tetrahydro-2-[5-[4-(1-methylethoxy)phenyl]-2-thienyl]-, (4-methoxyphenyl)methyl ester, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:216943 CAPLUS
DOCUMENT NUMBER: 138:262449
TITLE: Thiophene derivatives and organic electroluminescent devices using them
INVENTOR(S): Ishida, Tsutomu; Shimamura, Takehiko; Tanabe, Yoshimitsu; Totani, Yoshiyuki; Nakatsuka, Masakatsu
PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 136 pp.
CODEN: JKXKAF
DOCUMENT TYPE: Patent
LANGUAGE: ~~Japanese~~
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003081969	A	2003/3/19	JP 2002-147629	2002/5/22
PRIORITY APPLN. INFO.:				
			JP 2001-162586	A 2001/5/30
			JP 2001-203918	A 2001/7/04

OTHER SOURCE(S): MARPAT 138:262449
GI




AB The invention relates to an organic electroluminescent device comprising
a pair of electrodes sandwiching ≥ 1 layer(s) containing ≥ 1 thiophene derivs. I [R1-3 = H, straight, branched or cyclic alkyl, (un)substituted aryl or aralkyl; Y = H or C(R4):C(R5)(R6); R4-6 = H, straight, branched or cyclic alkyl, (un)substituted aryl or aralkyl; Z1-2 = H, halo, straight, branched or cyclic alkoxy, (un)substituted amino, aryl or aralkyl].
IT 502639-57-8 502639-59-0 502639-65-8
502639-69-2 502639-71-6 502639-72-7
502639-79-4 502639-80-7 502639-82-9
502639-87-4 502639-92-1 502639-93-2
502639-98-7 502639-99-8 502640-04-2
502640-07-5 502640-08-6 502640-12-2
502640-16-6 502640-20-2 502640-21-3
502640-28-0 502640-33-7 502640-34-8
502640-35-9 502640-39-3 502640-40-6
RL: DEV (Device component use); USES (Uses)


L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(novel thiophene derivs. for org. electroluminescent devices)
RN 502639-57-8 CAPLUS
CN Thiophene, 2-[4-[1-methyl-2-(4-propoxyphenyl)ethenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)



RN 502639-59-0 CAPLUS
CN Thiophene, 2-[4-[2-(4-methoxyphenyl)-1-propenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




RN 502639-65-8 CAPLUS
CN Thiophene, 2-[4-[2-(4-methoxyphenyl)ethenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




RN 502639-69-2 CAPLUS
CN Thiophene, 2-[4-[1-ethyl-2-(4-methoxyphenyl)-1-propenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)


L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 502639-71-6 CAPLUS
CN Thiophene, 2-[4-[2-[4-(1,1-dimethylethoxy)phenyl]-1-methyl-1-propenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




RN 502639-72-7 CAPLUS
CN Thiophene, 2-[4-[2-[4-(hexyloxy)phenyl]-1-methyl-1-propenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




RN 502639-79-4 CAPLUS
CN Thiophene, 2-[4-[2,2-bis(4-methoxyphenyl)-1-methylethenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)


L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 502639-80-7 CAPLUS
CN Thiophene, 2-[4-[2-bis[4-(1-methyl-2,2-bis(4-propoxyphenyl)ethenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




RN 502639-82-9 CAPLUS
CN Thiophene, 2-[4-[2-bis[4-(decyloxy)phenyl]-1-methylethenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




RN 502639-87-4 CAPLUS
CN Thiophene, 2-[4-[2-(4-ethoxyphenyl)-1-phenylethenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)


L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 502639-92-1 CAPLUS
CN Thiophene, 2-[4-[2-(4-methoxyphenyl)-1-phenyl-1-propenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




RN 502639-93-2 CAPLUS
CN Thiophene, 2,3,4-triphenyl-5-[4-[1-phenyl-2-(4-propoxyphenyl)-1-propenyl]phenyl]- (9CI) (CA INDEX NAME)




RN 502639-98-7 CAPLUS
CN Thiophene, 2-[4-[2-bis(4-methoxyphenyl)-1-phenylethenyl]phenyl]-3,4,5-triphenyl- (9CI) (CA INDEX NAME)




L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 502639-99-8 CAPLUS
 CN Thiophene,
 2-[4-[2,2-bis[4-(hexyloxy)phenyl]-1-phenylethenyl]phenyl]-3,4-
 triphenyl- (9CI) (CA INDEX NAME)



RN 502640-04-2 CAPLUS
 CN Thiophene, 2,5-bis[4-[1-methyl-2-(4-propoxyphenyl)ethenyl]phenyl]-3,4-
 diphenyl- (9CI) (CA INDEX NAME)




RN 502640-07-5 CAPLUS
 CN Thiophene,
 2,5-bis[4-[2-(4-methoxyphenyl)-1-propenyl]phenyl]-3,4-diphenyl-
 (9CI) (CA INDEX NAME)




RN 502640-08-6 CAPLUS
 CN Thiophene,
 2,5-bis[4-[2-[4-(1-methylethoxy)phenyl]-1-propenyl]phenyl]-3,4-
 diphenyl- (9CI) (CA INDEX NAME)




L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Thiophene,
 2,5-bis[4-[2,2-bis(4-methoxyphenyl)-1-methylethenyl]phenyl]-3,4-
 diphenyl- (9CI) (CA INDEX NAME)



RN 502640-21-3 CAPLUS
 CN Thiophene,
 2,5-bis[4-[1-methyl-2,2-bis(4-propoxyphenyl)ethenyl]phenyl]-3,4-
 diphenyl- (9CI) (CA INDEX NAME)




RN 502640-28-0 CAPLUS
 CN Thiophene, 2,5-bis[4-[2-(4-ethoxyphenyl)-1-phenylethenyl]phenyl]-3,4-
 diphenyl- (9CI) (CA INDEX NAME)




RN 502640-33-7 CAPLUS
 CN Thiophene,
 2,5-bis[4-[2-(4-methoxyphenyl)-1-phenyl-1-propenyl]phenyl]-3,4-
 diphenyl- (9CI) (CA INDEX NAME)


L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 502640-12-2 CAPLUS
 CN Thiophene, 2,5-bis[4-[2-[4-(hexyloxy)phenyl]-1-methyl-1-propenyl]phenyl]-
 3,4-diphenyl- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 1-B

RN 502640-16-6 CAPLUS
 CN Thiophene,
 2,5-bis[4-[2,2-bis(4-methoxyphenyl)ethenyl]phenyl]-3,4-diphenyl-
 (9CI) (CA INDEX NAME)




RN 502640-20-2 CAPLUS


L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 502640-34-8 CAPLUS
 CN Thiophene, 3,4-diphenyl-2,5-bis[4-[1-phenyl-2-(4-propoxyphenyl)-1-
 propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 502640-35-9 CAPLUS
 CN Thiophene, 2,5-bis[4-[2-[4-(hexyloxy)phenyl]-1-phenyl-1-propenyl]phenyl]-
 3,4-diphenyl- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 1-B

RN 502640-39-3 CAPLUS
 CN Thiophene,
 2,5-bis[4-[2,2-bis(4-methoxyphenyl)-1-phenylethenyl]phenyl]-3,4-
 diphenyl- (9CI) (CA INDEX NAME)


L19 ANSWER 104 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 502640-40-6 CAPLUS
 CN Thiophene,
 2,5-bis[4-[2,2-bis[4-(hexyloxy)phenyl]-1-phenylethenyl]phenyl]-
 3,4-diphenyl- (9CI) (CA INDEX NAME)



PAGE 1-B



L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN



ACCESSION NUMBER: 2003:173435 CAPLUS
 DOCUMENT NUMBER: 138:221606
 TITLE: Preparation of substituted 2-(1,1-dioxoperhydro-1,4-thiazepin-7-yl)acetamides for treating inflammatory respiratory diseases
 INVENTOR(S): Oku, Takuma; Hirayama, Yoshitaka; Yamagami, Kaoru; Ohkubo, Yoshitaka; Matsuoaka, Hideaki
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 495 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018019	A2	20030306	WO 2002-JP8443	20020821
WO 2003018019	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002313591 A1 20030310 AU 2002-313591 20020821
 PRIORITY APPLN. INFO.: AU 2001-7262 A 20010824
 WO 2002-JP8443 W 20020821

OTHER SOURCE(S): MARPAT 138:221606
 GI

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title comps. [I and the like; R1 = halo, alkoxy, aryl, etc.; R2 = (un)protected CO2H, amidated CO2H; R3 = H, acyl; Ar = aryl, heterocycl; X = S, SO, SO2; Y, Z = alkylene; m, n = 0-2], useful for the treatment of inflammatory respiratory disease, were prepared Thus, mesylation of

N-(2-tetrahydropyranyloxy)-2-[7-(5-bromo-2-thienyl)-1,1-dioxoperhydro-1,4-thiazepin-7-yl]acetamide followed by coupling intermediate with 4-methoxyphenylboronic acid in the presence of Pd(PPh3)4 in 1,2-dimethoxyethane afforded II.

IT 355842-94-3P 355842-97-6P 355843-16-2P
 355843-49-1P 355844-41-6P 355844-47-2P
 355844-48-3P 355844-65-4P 355845-06-6P
 355845-27-1P 355845-42-0P 355845-43-1P
 355845-44-2P 355845-52-2P 355845-63-5P
 355845-64-6P 355845-69-1P 355845-70-4P
 355845-72-6P 355845-73-7P 355845-75-9P
 355846-00-3P 355846-01-4P 355846-02-5P
 355846-10-5P 355846-18-3P 355846-52-5P
 355846-53-6P 355846-75-2P 355846-76-3P
 355846-78-5P 355846-79-6P 355846-81-0P
 355846-91-2P 355846-95-6P 355847-76-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted 2-(1,1-dioxoperhydro-1,4-thiazepin-7-yl)acetamides for treating inflammatory respiratory diseases)


RN 355842-94-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 7-[5-(4-fluorophenyl)-2-thienyl]hexahydro-4-(2-methoxybenzoyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI)

(CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355842-97-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 7-[5-(4-cyanophenyl)-2-thienyl]hexahydro-4-(2-methoxybenzoyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI)
 (CA INDEX NAME)




RN 355843-16-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-4-[(4-methoxyphenyl)sulfonyl]-7-[5-[4-(5-oxazoly)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355843-49-1 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-chlorophenyl)-2-thienyl]-4-(2-ethoxybenzoyl)hexahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355844-41-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-(4-methoxybenzoyl)-7-[5-[3-[(methylamino)carbonyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 355844-65-4 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-[(2-methoxyphenyl)amino]carbonyl]-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-06-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-chlorophenyl)-2-thienyl]hexahydro-N-hydroxy-4-(2-methoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-27-1 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-ethylphenyl)-2-thienyl]hexahydro-N-

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355844-47-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2-phenoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355844-48-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-(2-hydroxy-3-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-42-0 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-4-(2-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-43-1 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-4-(3-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-44-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-4-(4-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-52-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2-propoxybenzoyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-63-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(2,3-dimethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-64-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(2,4-dimethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-69-1 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(2,5-dimethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-70-4 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-(2,3,4-trimethoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-72-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(2-ethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-73-7 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[2-(trifluoromethoxy)benzoyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-75-9 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(4-chloro-2-methoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolylphenyl)-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-00-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 hexahydro-N-hydroxy-4-(2-methoxybenzoyl)-7-[5-[4-(5-oxazolylphenyl)-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-10-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-7-[5-[4-(5-oxazolylphenyl)-2-thienyl]-4-(2-propoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-18-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-[4-(4-chlorophenyl)-2-thienyl]-4-(2-ethoxybenzoyl)hexahydro-N-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-01-4 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 hexahydro-N-hydroxy-4-(3-methoxybenzoyl)-7-[5-[4-(5-oxazolylphenyl)-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-02-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 hexahydro-N-hydroxy-4-(4-methoxybenzoyl)-7-[5-[4-(5-oxazolylphenyl)-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-52-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2,3-dimethoxybenzoyl)hexahydro-N-hydroxy-7-[5-[4-(5-oxazolylphenyl)-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-53-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2,4-dimethoxybenzoyl)hexahydro-N-hydroxy-7-[5-[4-(5-oxazolylphenyl)-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-75-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2,5-dimethoxybenzoyl)hexahydro-N-hydroxy-7-
 [5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-76-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2,3,4-trimethoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-78-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2-ethoxybenzoyl)hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-79-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-[2-(trifluoromethoxy)benzoyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-81-0 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(4-chloro-2-methoxybenzoyl)hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-91-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-fluorophenyl)-2-thienyl]hexahydro-N-hydroxy-4-(2-methoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-95-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-cyanophenyl)-2-thienyl]hexahydro-N-hydroxy-4-(2-methoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355847-76-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 105 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 106 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:94718 CAPLUS
 DOCUMENT NUMBER: 138:144850
 TITLE: Organic electroluminescent element
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Tanabe, Yoshimitsu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003036978	A	20030307	JP 2001-218944	20010719
PRIORITY APPLN. INFO.:			JP 2001-218944	20010719
OTHER SOURCE(S):			MARPAT 138:144850	
GI				



AB The invention refers to an electroluminescent device comprising the thiophene derivative I [Ar1-4 = (un)substituted aryl, wherein Ar1,2 and Ar3,4 may join together to form a heterocyclic ring, but at least one of Ar1-4 is an (un)substituted phenanthryl].
 IT 494759-82-9
 RL: DEV (Device component use); USES (Uses)
 (organic electroluminescent element using phenanthryl thiophene derivative)
 RN 494759-82-9 CAPLUS
 CN 9-Phenanthrenamine, N,N'-[(3,4-diphenyl-2,5-thiophenediyl)di-4,1-phenylene]bis[N-(4-methoxy-3-methylphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 106 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 107 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:964342 CAPLUS
 DOCUMENT NUMBER: 138:24951
 TITLE: Preparation of amino acid biaryl derivatives for the treatment or prevention of flavivirus infections
 INVENTOR(S): Chan, Chun Kong Laval; Bedard, Jean; Das, Sanjoy Kumar; Pereira, Oswy Z.; Shuttleworth, Steve; Siddiqui, M. Arshad; Wang, Wuyi
 PATENT ASSIGNEE(S): Shire Biochem Inc., Can.; Nguyen Ba, Nghe
 SOURCE: PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100846	A1	20021219	WO 2002-CA877	20020611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449999	A1	20021219	CA 2002-2449999	20020611
AU 2002344855	A1	20021223	AU 2002-344855	20020611
US 2003229053	A1	20031211	US 2002-166030	20020611
US 6887877	B2	20050503		
EP 1395571	A1	20040310	EP 2002-742564	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500287	T	20050106	JP 2003-503614	20020611
PRIORITY APPLN. INFO.:			US 2001-296732P	P 20010611
			WO 2002-CA877	W 20020611

OTHER SOURCE(S): MARPAT 138:24951
 AB Novel compds. R4-Z-Y-N(M-R3)C(R1)2-A1-A [M = SO2, CO, CS, CH2CO, COCH2O, CO2, CH2, or alkylmethylene; A1 = a bond, alkyl, alkenyl, or alkynyl; A = CO2R5, COCO2R5, PO3R52, SO3R5, tetrazolyl, CONR5CHR5CO2R5, CONR52, CONR5OH
 (R5 = H or alkyl); R1, R2 = H, alkyl, aryl, heterocyclyl, aralkyl, or heteroaralkyl; R3 = aryl, heterocyclyl, aralkyl, or heteroaralkyl; Y = CH2, CO, CH2CO, NH, or a bond; Z = alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; R4 = H, halo, CN, NO2, alkyl, aryl, heterocyclyl, aralkyl, heteroaralkyl, NR52, SO2Me, alkoxy, aryloxy, aralkyloxy, or COR7, where
 R7 = aryl or heterocyclyl, with the proviso that the compound is other than 3-[3-(2,6-dichloropyridin-4-yl)-1-(4-thiophen-2-ylbenzyl)ureido]-3-thiophen-2-ylpropionic acid] or their pharmaceutically-acceptable salts were prepared for treating Flaviviridae viral infection. Thus,
 2-[(2,4-dichlorobenzoyl)[3-(3,5-difluorophenyl)thiophen-2-ylmethyl]amino]-3-phenylpropionic acid was prepared from 2-amino-3-phenylpropionic acid tert-Bu ester by reductive acylation with 3-bromothiophene-2-

L19 ANSWER 107 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
carboxaldehyde, acylation with 2,4-dichlorobenzoyl chloride, arylation with 3,5-difluorophenylzinc chloride, and ester cleavage with TFA. The product showed IC50 < 5 µM in the hepatitis C virus RNA-dependent polymerase assay.

IT 478294-43-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino acid biaryl derivs. for treatment or prevention

of flavivirus infections)

RN 478294-43-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[4-[[[(1S)-1-carboxy-2-phenylethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]phenyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 478296-34-3P 478296-35-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid biaryl derivs. for treatment or prevention

of flavivirus infections)


RN 478296-34-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[4-[[[(1S)-2-methoxy-2-oxo-1-

(phenylmethyl)ethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L19 ANSWER 107 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 478296-34-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[4-[[[(1S)-1-carboxy-2-phenylethyl][(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]phenyl]-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:
THIS

38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L19 ANSWER 108 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:893949 CAPLUS

DOCUMENT NUMBER: 139:188188

TITLE: Fluorescence switching of photochromic diarylethenes
AUTHOR(S): Kawal, Tsuyoshi; Kim, Myeong-Suk; Sasaki, Takatoshi; Irie, Masahiro

CORPORATE SOURCE: Japan Science and Technology Corporation, Graduate School of Engineering, Department of Chemistry and Biochemistry, Kyushu University and CREST,

Higashi-ku,

SOURCE: Fukuoka, 812-8581, Japan
Optical Materials (Amsterdam, Netherlands) (2003), 21(1-3), 275-278

CODEN: CMATET; ISSN: 0925-3467

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Fluorescence switching performance of photochromic diarylethenes has been studied. A bisbenzothienylethene having m-terphenyl substituents underwent reversible photochromic reactions in the amorphous solid state and exhibited fluorescence intensity change and shift of the emission

band

with the photochromic reaction. A diarylethene connected with a fluorescent 9,10-bis(phenylethynyl)anthracene unit through an adamantyl unit shows reversible fluorescence intensity change with the photochromic reactions of the diarylethenes.

IT 579512-51-9P

RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(fluorescence switching of photochromic diarylethenes)


RN 579512-51-9 CAPLUS

CN Benzo[b]thiophene, 3-[2-[5-[4-[3-[4-[10-[(4-chloro-2,5-


dimethoxyphenyl)ethynyl]-9-anthracenyl]ethynyl]phenyl]tricyclo[3.3.1.1^{3,7}]dec-1-yl]phenyl]-2,4-dimethyl-3-thienyl]-3,3,4,4,5,5-hexafluoro-1-cyclopenten-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L19 ANSWER 108 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:
THIS

17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR

FORMAT


RECORD. ALL CITATIONS AVAILABLE IN THE RE

L19 ANSWER 109 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:888730 CAPLUS
 DOCUMENT NUMBER: 137:384747
 TITLE: Preparation of arylsulfonylpyranhydroxamates as
 matrix metalloprotease and/or aggrecanase inhibitors
 INVENTOR(S): Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis
 J.; Boehm, Terri L.; Fobian, Yvette M.; Freskos, John N.;
 Hockerman, Susan L.; Kassab, Darren J.; Kolodziej,
 Steve A.; McDonald, Joseph J.; Norton, Monica B.;
 Rico, Joseph G.; Talley, John J.; Villamil, Clara I.;
 Wang, Tijuana Jane
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 627 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092588	A2	20021121	WO 2002-US15257	20020510
WO 2002092588	A3	20030227		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2446586	A1	20021121	CA 2002-2446586	20020510
AU 2002259212	A1	20021125	AU 2002-259212	20020510
EP 1385836	A2	20040204	EP 2002-729204	20020510
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002009525	A	20040309	BR 2002-9525	20020510
HU 200304069	A2	20040428	HU 2003-4069	20020510
JP 2004530691	T	20041007	JP 2002-589473	20020510
CN 1764655	A	20060426	CN 2002-809672	20020510
ZA 2003008525	A	20050217	ZA 2003-8525	20030131
BG 108285	A	20040930	BG 2003-108285	20031023
IN 2003CN01720	A	20051118	IN 2003-CN1720	20031030
NO 2003004995	A	20031216	NO 2003-4995	20031110
MX 2003PA10326	A	20040730	MX 2003-PA10326	20031111
US 2005101641	A1	20050512	US 2004-992483	20041117
PRIORITY APPLN. INFO.:			US 2001-290375P	P 20010511
			US 2002-142737	A3 20020510
			WO 2002-US15257	W 20020510

L19 ANSWER 109 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 2003-657034 A3 20030905

OTHER SOURCE(S): MARPAT 137:384747
 GI



AB Title compds. [I; A1 = H, (substituted) alkylcarbonyl, alkoxy carbonyl, carbocyclylcarbonyl, heterocyclylcarbonyl, aminoalkylthiocarbonyl, etc.; A2A3C = (substituted) heterocyclyl; E1 = O, S, SO, SO2, NR1, CONR1, CR1R2;

E2 = (substituted) alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkylalkyl; E3 = CO, O2C, CNR3, NR4, NR4SO2, S, SO, etc.; E4 = bond, (substituted) alkyl, alkenyl; E5 = H, OH, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, carbocyclyl, heterocyclyl; R1, R2 = H, (substituted) alkyl; with provisos], were prepared Thus,

tetrahydro-4-[[4-[[5-(4-methoxyphenyl)-5-oxopentyl]oxy]phenyl]sulfonyl]-2H-pyran-4-carboxylic acid 1,1-dimethylethyl ester (preparation given) in CH2Cl2

was treated with Me3SiCN and ZnI2 to give 81% cyanohydrin. The product in DMF was treated with 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-methylmorpholine, and tetrahydroxyranhydroxylamine to give 70% THP-protected hydroxamate. The latter was stirred with aqueous HCl in dioxane/MeOH to give 59%


4-[[4-[[[(4Z)-5-cyano-5-(4-methoxyphenyl)-4-pentenyl]oxy]phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide. This inhibited MMP-13 with IC50 = 0.2 nM.

IT 476183-89-P 476186-47-7P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of arylsulfonylpyranhydroxamates as matrix metalloprotease and/or aggrecanase inhibitors)

RN 476183-89-8 CAPLUS
 CN 2H-Pyran-4-carboxamide, 4-[[[4-[[[5-(4-chlorophenyl)-2-thienyl]acetyl]amino]ethoxy]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)

L19 ANSWER 109 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 476186-47-7 CAPLUS
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[3-[3-(5-methyl-2-thienyl)phenyl]propoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 110 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:830253 CAPLUS
 DOCUMENT NUMBER: 137:325446

TITLE: Preparation of bis(trimethoxyphenylazolyalkyl) (homo) piperazines as cell adhesion inhibitors.

Kodama, Tatsuhiko; Tamura, Masahiro; Oda, Toshiaki; Yamazaki, Yukiyo; Nishikawa, Masahiro; Doi, Takeshi; Kyotani, Yoshinori


PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
 SOURCE: U.S., 23 pp.

CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6472386	B1	20021029	US 2001-893682	20010629
CA 2451238	A1	20030109	CA 2002-2451238	20020627
WO 2003002540	A1	20030109	WO 2002-JP6488	20020627
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002311277	A1	20030303	AU 2002-311277	20020627
EP 1400515	A1	20040324	EP 2002-736187	20020627
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1522250	A	20040818	CN 2002-813110	20020627
PRIORITY APPLN. INFO.:			US 2001-893682	A 20010629
			WO 2002-JP6488	W 20020627

OTHER SOURCE(S): MARPAT 137:325446
 GI




AB Title compds. [I; A = bond, C.tplbond, C, CONH NHCO; W = C, N; X = CH, N, O, S; Y = CH, CHR1, in which R1 = H, alkyl, hydroxyalkyl, alkoxyalkyl, aryl, aralkyl, heteroarylalkyl, N, O, S, NR2; R2 = H, alkyl, hydroxyalkyl, alkoxyalkyl, aryl, aralkyl, heteroarylalkyl; Z = N, O, S, CH, NR3; R3 = H.

L19 ANSWER 110 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
alkyl, hydroxyalkyl, alkoxyalkyl, aryl, aralkyl, heteroarylalkyl; m = 1, 2; n = 1-5, with the proviso that 1 or 2 of W, X, Y Z = heteroatoms],
were
prepd. Thus, 4-chloromethyl-2-(3,4,5-trimethoxyphenyl)thiazole (prepn. given), piperazine, K₂CO₃, and KI were stirred 5 h in DMF to give 33% N,N'-bis[[2-(3,4,5-trimethoxyphenyl)thiazol-4-yl]methyl]piperazine. I at 1 μ M inhibited TNF α -stimulated binding of U937 cells to HUVEC by 45-60%. Drug formulations contg. the latter are given. The compds. have inhibitory effects on cell adhesion and are useful for prevention or treatment of diseases such as allergy, asthma, rheumatism, arteriosclerosis and inflammation.
IT 473844-14-3P 473844-16-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bis(trimethoxyphenylazolyalkyl) (homo)piperazines as cell adhesion inhibitors)
RN 473844-14-3 CAPLUS
CN Piperazine, 1,4-bis[[5-(3,4,5-trimethoxyphenyl)-2-thienyl]methyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
CM 1
CRN 473844-13-2
CMF C32 H38 N2 O6 S2




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 473844-16-5 CAPLUS
CN 1H-1,4-Diazepine, hexahydro-1,4-bis[[5-(3,4,5-trimethoxyphenyl)-2-

L19 ANSWER 110 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
thienyl]methyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
CM 1
CRN 473844-15-4
CMF C33 H40 N2 O6 S2




CM 2
CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
FORMAT

L19 ANSWER 111 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:816702 CAPLUS
DOCUMENT NUMBER: 138:47633
TITLE: Effects of Desymmetrization on Thiophene-Based Bent-Rod Mesogens
AUTHOR(S): Paraskos, Alexander J.; Swager, Timothy M.
CORPORATE SOURCE: Department of Chemistry and Center for Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
SOURCE: Chemistry of Materials (2002), 14(11), 4543-4549
CODEN: CMATEX; ISSN: 0897-4756
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis and characterization of various thiophene-based bent-rod liquid crystals are reported, and the effects of varying lateral dipole and core desymmetrization upon mesophase behavior are described. Incorporation of desymmetrized core 7 into the mol. framework has very different consequences depending upon whether n-alkoxy or tetracatenar-type end groups were used. Tetracatenar-type mesogens 8-11 are significantly less mesogenic than the previously reported sym. series 3. When sym. straight-chain compds. 13-17 and unsym. straight-chain compds. 18-21 were studied, however, the desymmetrized core gave rise to mesophases with much broader temperature ranges. Variable temperature x-ray diffraction of these compds. suggests the formation of antiparallel dimers of mols. within the liquid crystal phase, and this may explain the relatively stable mesophases formed by these compds. and their incompatibility with chiral induction. The effects of altering the lateral substituents were also explored, and 3,4-difluorothiophene-based compds. 24-27 exhibit broad nematic mesophases.
IT 478678-57-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dealkylation of)
RN 478678-57-8 CAPLUS
CN 3,4-Thiophenedicarbonitrile, 2-[4-(phenylmethoxy)phenyl]-5-[[4-(phenylmethoxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



IT 478678-40-9P 478678-41-0P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation and phase transition temps. and phase transition enthalpies of)
RN 478678-40-9 CAPLUS
CN Benzoic acid, 3,4-bis(hexyloxy)-, 4-[[5-[4-[[3,4-

L19 ANSWER 111 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
bis(hexyloxy)benzoyl]oxy]phenyl]-3,4-dicyano-2-thienyl]ethynyl]phenyl ester (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 1-B

RN 478678-41-0 CAPLUS
CN Benzoic acid, 3,4-bis(octyloxy)-, 4-[[5-[4-[[3,4-bis(octyloxy)benzoyl]oxy]phenyl]-3,4-dicyano-2-thienyl]ethynyl]phenyl ester (9CI) (CA INDEX NAME)





PAGE 1-A




PAGE 1-B

IT 478678-42-1P 478678-43-2P 478678-47-6P
478678-48-7P 478678-49-8P 478678-50-1P


L19 ANSWER 111 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: PEP (Physical, engineering or chemical process); PRP (Properties);
 PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
 (prepn., liq. crystal properties and phase transition enthalpies of)
 RN 478678-42-1 CAPLUS
 CN Benzoic acid, 3,4-bis(decyloxy)-, 4-[[5-[4-[[3,4-bis(decyloxy)benzoyloxy]phenyl]-3,4-dicyano-2-thienyl]ethynyl]phenyl ester (9CI) (CA INDEX NAME)



RN 478678-43-2 CAPLUS
 CN Benzoic acid, 3,4-bis(dodecyloxy)-, 4-[[5-[4-[[3,4-bis(dodecyloxy)benzoyloxy]phenyl]-3,4-dicyano-2-thienyl]ethynyl]phenyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 111 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L19 ANSWER 111 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-B




RN 478678-47-6 CAPLUS
 CN 3,4-Thiophenedicarbonitrile, 2-[4-(hexyloxy)phenyl]-5-[[4-(hexyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 478678-48-7 CAPLUS
 CN 3,4-Thiophenedicarbonitrile, 2-[4-(octyloxy)phenyl]-5-[[4-(octyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 478678-49-8 CAPLUS
 CN 3,4-Thiophenedicarbonitrile, 2-[4-(decyloxy)phenyl]-5-[[4-(decyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 478678-50-1 CAPLUS
 CN 3,4-Thiophenedicarbonitrile, 2-[4-(dodecyloxy)phenyl]-5-[[4-(dodecyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 112 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:575057 CAPLUS
 DOCUMENT NUMBER: 137:140514
 TITLE: Preparation of thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
 INVENTOR(S): Banker, Pierrette; Cadilla, Rodolfo; Lambert, Millard Hurst, III; Rafferty, Stephen William; Sternbach, Daniel David; Sznajdman, Marcos Luis
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059098	A1	20020801	WO 2001-US51056	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002246903	A1	20020806	AU 2002-246903	20011219
EP 1349843	A1	20031008	EP 2001-994514	20011219
EP 1349843	B1	20050420		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520377	T	20040708	JP 2002-559400	20011219
AT 293611	T	20050515	AT 2001-994514	20011219
PT 1349843	T	20050930	PT 2001-994514	20011219
ES 2240558	T3	20051016	ES 2001-1994514	20011219
US 2004072838	A1	20040415	US 2003-451295	20031031
US 2007072871	A1	20070329	US 2006-550060	20061017
US 7229998	B2	20070612		
PRIORITY APPLN. INFO.:				
			GB 2000-31103	A 20001220
			WO 2001-US51056	W 20011219
			US 2003-451295	B1 20031031

OTHER SOURCE(S): MARPAT 137:140514
 GI

L19 ANSWER 112 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I




II

AB The title compds. [I; R1, R2 = H, alkyl; X2 = O, S, CH2; R3-R5 = H, alkyl, OMe, CF3, OCF3, CN, allyl, halo; Y = S, O; R25 = Me, OMe, CF3, halo; y = 0-5; R26 = substituted piperazino, piperidino, morpholino, etc.] which activate human peroxisome proliferator activated receptors (hPPARs) and are useful for the treatment of associated disorders such as cardiovascular disease and hypercholesterolemia, were prepared. Thus, reacting 4-(2-{4-([4-(4-methoxyphenyl)-1-piperazinyl]methyl)-2-(4-(trifluoromethylphenyl)-1,3-thiazol-5-yl)ethyl}-2-methylphenol (preparation given) with 2-trichloromethyl-2-propanol in the presence of NaOH pellets in acetone afforded 40% II. All exemplified compds. I were agonists of at least one hPPAR subtype (no data given).

IT 444613-76-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiazole and oxazole derivs. as activators of human peroxisome proliferator activated receptors)

RN 444613-76-7 CAPLUS
 CN Acetic acid,
 [4-[[[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 112 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 113 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2002:424635 CAPLUS
 DOCUMENT NUMBER: 137:140869
 TITLE: Functionalizable Polycyclic Aromatics through Oxidative Cyclization of Pendant Thiophenes
 AUTHOR(S): Tovar, John D.; Rose, Aimee; Swager, Timothy M.
 CORPORATE SOURCE: Department of Chemistry and the Center for Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
 SOURCE: Journal of the American Chemical Society (2002), 124(26), 7762-7769
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We present a general strategy for obtaining large sulfur-containing polycyclic aroms. from thienyl precursors through iron(III) chloride mediated oxidative cyclizations. By placing thienyl moieties in close proximity to adjacent arenes, we have directed the oxidized intermediates into controlled cyclization pathways, effectively suppressing polymer formation. Utilizing these cyclized compds. and their thienyl precursors, we have studied cyclization/polymerization pathways of polymers such as poly(2). The unsubstituted positions α to the sulfur atoms within these aromatic cores allowed for efficient halogenation and further functionalization. As a demonstration, we prepared a series of arylene-ethynylene polymers with varying degrees of chromophore aromatization and used them to probe the effects of synthetically imposed rigidity on polymer photophys. behavior. The symmetries and effective conjugation pathways within the monomers play a key role in determining photophys. properties. We observed that rigid, aromatized chromophores generally led to increased excited-state lifetimes by decreasing radiative rates of fluorescence decay.

IT 444922-05-8P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (functionalizable polycyclic aroms. through oxidative cyclization of pendant thiophenes)

RN 444922-05-8 CAPLUS
 CN Thiophene, 2,2'-[3,3'',4,4''-tetrakis[(2-ethylhexyloxy)[1,1':4',1''-terphenyl]-2'',5'-diyl]bis[5-[[4-(dodecyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 113 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

IT 444922-01-4P 444922-10-5P 444922-16-1P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (functionalizable polycyclic aroms. through oxidative cyclization of pendant thiophenes)


RN 444922-01-4 CAPLUS
 CN Thiophene, 2,2'-[3,3'',4,4''-tetrakis[(2-ethylhexyloxy)[1,1':3',1''-terphenyl]-4',6'-diyl]bis[5-[[4-(dodecyloxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 113 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 444922-10-5 CAPLUS
CN


Poly[2,5-thiophenediyl[3,3'',4,4''-tetrakis[(2-ethylhexyl)oxy][1,1':4',1''-terphenyl]-2',5'-diyl]-2,5-thiophenediyl-1,2-ethynediyl(5,7,12,14-tetrahydro-5,14[1',2']:7,12[1'',2'']-dibenzenopentacene-6,13-diyl)-1,2-ethynediyl] (9CI) (CA INDEX NAME)

L19 ANSWER 113 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 444922-16-1 CAPLUS
CN


Poly[2,5-thiophenediyl[3,3'',4,4''-tetrakis[(2-ethylhexyl)oxy][1,1':3',1''-terphenyl]-4',6'-diyl]-2,5-thiophenediyl-1,2-ethynediyl(5,7,12,14-tetrahydro-5,14[1',2']:7,12[1'',2'']-dibenzenopentacene-6,13-diyl)-1,2-ethynediyl] (9CI) (CA INDEX NAME)

L19 ANSWER 113 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 114 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:193377 CAPLUS
DOCUMENT NUMBER: 136:270226
TITLE: Organic electroluminescent devices containing naphthylbiphenylaminophenyldiphenylthiophene derivatives
INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Totani, Yoshiyuki
PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002075650	A	20020315	JP 2000-259042	20000829
PRIORITY APPLN. INFO.:			JP 2000-259042	20000829

OTHER SOURCE(S): MARPAT 136:270226
GI




AB The invention relates to an organic electroluminescent device comprising a pair of electrodes sandwiching ≥ 1 layer(s) containing ≥ 1 general compound I [Ar1, Ar3 = (un)substituted biphenyl; Ar2, Ar4 = (un)substituted naphthyl].
IT 404392-80-9
RL: DEV (Device component use); USES (Uses) (organic electroluminescent devices containing naphthylbiphenylaminophenyldiphenylthiophene derivs.)
RN 404392-80-9 CAPLUS
CN 1-Naphthalenamine, N-[4-[5-[4-([1,1'-biphenyl]-4-yl)-2-naphthalenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-(5-methoxy[1,1'-biphenyl]-2-yl)- (9CI) (CA INDEX NAME)

L19 ANSWER 114 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 115 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:193376 CAPLUS
 DOCUMENT NUMBER: 136:254352
 TITLE: Organic electroluminescent devices containing bisphenylaminophenyldiphenylthiophene derivatives
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 34 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002075649	A	20020315	JP 2000-259041	20000829
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 136:254352				
GI				




AB The invention relates to an organic electroluminescent device comprising a pair of electrodes sandwiching ≥ 1 layer(s) containing ≥ 1 general compound I [Ar1-2 = (un)substituted biphenyl; Ar3-4 = (un)substituted phenyl].
 IT 404389-98-6 404390-03-0 404390-10-9
 404390-16-5 404390-18-7 404390-19-8
 404390-22-3 404390-25-6
 RL: DEV (Device component use); USES (Uses)
 (organic electroluminescent devices containing bisphenylaminophenyldiphenylthiophene derivs.)
 RN 404389-98-6 CAPLUS
 CN [1,1'-Biphenyl]-4-amine, N-[1,1'-biphenyl]-4-yl-N-[4-[5-[4-[(4-ethoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)


L19 ANSWER 115 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 404390-03-0 CAPLUS
 CN [1,1'-Biphenyl]-3-amine, N-[1,1'-biphenyl]-4-yl-N-[4-[5-[4-[(4-methoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)




RN 404390-10-9 CAPLUS
 CN [1,1'-Biphenyl]-3-amine, N-[1,1'-biphenyl]-3-yl-N-[4-[5-[4-[(4-methoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)




RN 404390-16-5 CAPLUS
 CN [1,1'-Biphenyl]-2-amine, N-[1,1'-biphenyl]-2-yl-N-[4-[5-[4-[(4-ethoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)


L19 ANSWER 115 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 404390-18-7 CAPLUS
 CN [1,1'-Biphenyl]-4-amine, N-[1,1'-biphenyl]-4-yl-N-[4-[5-[4-[(4-methoxy-3-methylphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)




RN 404390-19-8 CAPLUS
 CN [1,1'-Biphenyl]-2-amine, N-[1,1'-biphenyl]-3-yl-N-[4-[5-[4-[(4-methoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)




RN 404390-22-3 CAPLUS
 CN [1,1'-Biphenyl]-3-amine, N-[1,1'-biphenyl]-3-yl-N-[4-[5-[4-[bis(4-ethoxyphenyl)amino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)

L19 ANSWER 115 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 404390-25-6 CAPLUS
 CN [1,1'-Biphenyl]-2-amine, N-[1,1'-biphenyl]-2-yl-N-[4-[5-[[4-(hexyloxy)phenyl]phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI)
 (CA INDEX NAME)




L19 ANSWER 116 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:193374 CAPLUS
 DOCUMENT NUMBER: 136:254350
 TITLE: Organic electroluminescent devices containing bisnaphthylaminophenylthiophene derivatives
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002075647	A	20020315	JP 2000-259039	20000829
PRIORITY APPLN. INFO.: JP 2000-259039 20000829				
OTHER SOURCE(S): MARPAT 136:254350				
GI				




AB The invention relates to an organic electroluminescent device comprising a pair of electrodes sandwiching ≥ 1 layer(s) containing ≥ 1 general compound I [Ar1-2 = (un)substituted naphthyl; Ar3-4 = (un)substituted phenyl].
 IT 404353-80-6 404353-83-9 404353-84-0
 404353-96-4 404353-98-6
 RL: DEV (Device component use); USES (Uses)
 (organic electroluminescent devices containing bisnaphthylaminophenylthiophene derivs.)
 RN 404353-80-6 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-[(3,4-dimethoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 116 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 404353-83-9 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-[(4-methoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 404353-84-0 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-[(3-ethoxyphenyl)phenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-2-naphthalenyl- (9CI)
 (CA INDEX NAME)

L19 ANSWER 116 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 404353-96-4 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-[bis(4-methoxyphenyl)amino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-2-naphthalenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 116 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 404353-98-6 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-[(4-hexylphenyl)[4-(octyloxy)phenyl]amino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-2-naphthalenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 116 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L19 ANSWER 117 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:183754 CAPLUS
 DOCUMENT NUMBER: 136:226804
 TITLE: Combination, for treating depression and anxiety, containing a 5HT1D receptor antagonist and a CNS penetrant NK-1 receptor antagonist
 INVENTOR(S): Schmidt, Christopher Joseph; Sobolov-Jaynes, Susan Beth
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 58 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1186318	A2	20020313	EP 2001-307220	20010824
EP 1186318	A3	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002049211	A1	20020425	US 2001-867357	20010529
JP 2002121153	A	20020423	JP 2001-264226	20010831
CA 2356797	A1	20020306	CA 2001-2356797	20010904
MX 2001PA08993	A	20041110	MX 2001-PA8993	20010905
BR 2001003913	A	20020521	BR 2001-3913	20010906
PRIORITY APPLN. INFO.:			US 2000-230257P	P 20000906

OTHER SOURCE(S): MARPAT 136:226804

AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a 5HT1D receptor antagonist. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable

carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT1D receptor antagonist.


IT 250383-78-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination, for treating depression and anxiety, containing a 5HT1D receptor antagonist and a CNS penetrant NK-1 receptor antagonist)

RN 250383-78-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[(4-methoxyphenyl)methyl]-5-[2-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 117 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 118 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:142657 CAPLUS
 DOCUMENT NUMBER: 136:183822
 TITLE: Preparation of 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
 INVENTOR(S): Hoshina, Yoichiro; Ikegami, Satoru; Matsuo, Atsushi; Harada, Tatsuhiko; Okuyama, Akihiko
 PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 162 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014262	A1	20020221	WO 2001-JP6934	20010810
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 200178709	A	20020225	AU 2001-78709	20010810
CA 2419008	A1	20030211	CA 2001-2419008	20010810
EP 1325903	A1	20030709	EP 2001-956840	20010810
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004072878	A1	20040415	US 2003-344105	20030819
PRIORITY APPLN. INFO.:			JP 2000-244226	A 20000811
			JP 2001-115840	A 20010413
			WO 2001-JP6934	W 20010810

OTHER SOURCE(S): MARPAT 136:183822
 GI

L19 ANSWER 118 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. [I; A, B, C = H, halo, NO₂, cyano, OH, CO₂H, alkyl, aryl, heteroaryl, alkoxy, aryloxy, heteroaryloxy, alkylloxycarbonyl, aryloxy-carbonyl, heteroaryloxy-carbonyl, alkanoyl, aroyl, heteroaryl, alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, alkylthio, arylthio, heteroarylthio, alkylthio, arylthio, heteroarylthio, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, NR1R2, NR1COR2, NR1SO2R2, NR1CONR2R3, CONR1R2 (wherein R1, R2, R3 = H, alkyl, alkenyl, alkoxy, aryl, aryloxy, heteroaryloxy, or heteroaryl, or R1 and R2 or R2 and R3 are linked to each other to form a (un)substituted ring optionally containing at least one ring atom selected from O, N, and S and optionally containing a double bond); or when two of A, B, and C are linked to adjacent carbon atoms, they form a benzene ring or methylenedioxy; X, XI = H, halo, NO₂, cyano, OH, CO₂H, alkyl, alkenyl or alkynyl, aryl, heteroaryl, alkoxy, aryloxy, heteroaryloxy, alkanoyl, aroyl, heteroaryl, alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, alkylthio, arylthio, heteroarylthio, heteroaryloxy-carbonyl, alkylthio, arylthio, heteroarylthio, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, NR4R5, NR4COR5, NR4SO2R5, NR4CONR5R6, O2CONR4R5, CONR4R5 (where R4 - R6 group listed in R1 - R3)] or their salts are prepared. Also claimed are cell adhesion inhibitors, integrin VLA-4 (α4β1) and/or LFA-1 (α4β7) antagonists, α4 integrin inhibitors, or therapeutics or preventives inflammatory diseases related to cell adhesion process containing I or the salts as the active ingredients. These compds. are superior in oral absorption and in vivo dynamic. Thus, acylation of 3-(4-aminophenyl)-2-[3-[(2,2-dimethylpropionyl)isobutylamino]-4-methoxyphenyl]propionic acid Et ester by 2,6-dichlorobenzoyl chloride in pyridine gave 71% 3-[4-(2,6-dichlorobenzoylamino)phenyl]-2-[3-[(2,2-


L19 ANSWER 118 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 dimethylpropionyl)isobutylamino]-4-methoxyphenyl]propionic acid Et ester which was saponified with a mixt. of aq. NaOH, THF, and MeOH followed by acidification with aq. HCl to give 91% 2,3-diphenylpropionic acid deriv. (II; B = MeO, Z = CH) (III). III and II (B = Et, Z = N) inhibited adhesion of myeloid leukemic cells HL-60 expressing VLA-4 to Chinese hamster (CHO) cells expressing human VCAM-1 with IC₅₀ of 2 and 0.1 nM, resp.
 IT 400646-55-1P 400646-63-1P 400646-71-1P
 400646-79-9P 400646-87-9P 400646-95-9P
 400647-03-2P 400647-11-2P 400647-19-0P
 400647-27-0P 400647-35-0P 400647-43-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2,3-diphenylpropionic acid derivs. or their salts as

cell adhesion inhibitors, integrin antagonists or inhibitors, and antiinflammatory agents)

RN 400646-55-1 CAPLUS
 CN Benzenepropanoic acid, α-[3-[(2,2-dimethyl-1-oxopropyl)(2-methylpropyl)amino]phenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 400646-63-1 CAPLUS
 CN Benzenepropanoic acid, α-[4-methoxy-3-[(2-methylpropyl)(1-oxopropyl)amino]phenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 400646-71-1 CAPLUS
 CN Benzenepropanoic acid, α-[4-methoxy-3-[(2-methyl-1-oxo-2-propenyl)(2-methylpropyl)amino]phenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


L19 ANSWER 118 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 400646-79-9 CAPLUS
 CN Benzenepropanoic acid, α-[3-[(2-ethyl-1-oxobutyl)(2-methylpropyl)amino]-4-methoxyphenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 400646-87-9 CAPLUS
 CN Benzenepropanoic acid, α-[3-[(cyclopentylcarbonyl)(2-methylpropyl)amino]-4-methoxyphenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 400646-95-9 CAPLUS
 CN Benzenepropanoic acid, α-[3-[(benzoyl)(2-methylpropyl)amino]-4-methoxyphenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


L19 ANSWER 118 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 400647-03-2 CAPLUS
 CN Benzenepropanoic acid, α -[3-[(2,2-dimethyl-1-oxopropyl)(2-methylbutyl)amino]-4-methoxyphenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 400647-11-2 CAPLUS
 CN Benzenepropanoic acid, α -[4-methoxy-3-[(2-methylbutyl)(1-oxo-2-butenyl)amino]phenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 400647-19-0 CAPLUS
 CN Benzenepropanoic acid, α -[4-methoxy-3-[(2-methylbutyl)(2-methyl-1-oxo-2-propenyl)amino]phenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


L19 ANSWER 118 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 400647-27-0 CAPLUS
 CN Benzenepropanoic acid, α -[3-[(2-ethyl-1-oxobutyl)(2-methylbutyl)amino]-4-methoxyphenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 400647-35-0 CAPLUS
 CN Benzenepropanoic acid, α -[3-[(cyclopentylcarbonyl)(2-methylbutyl)amino]-4-methoxyphenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 400647-43-0 CAPLUS
 CN Benzenepropanoic acid, α -[3-[benzoyl(2-methylbutyl)amino]-4-methoxyphenyl]-4-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 118 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L19 ANSWER 119 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:139114 CAPLUS
 DOCUMENT NUMBER: 136:207491
 TITLE: Organic electroluminescent component
 INVENTOR(S): Nakatsuka, Masakatsu; Ishida, Tsutomu; Shimamura, Takehiko; Totani, Yoshiyuki
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002056984	A	20020222	JP 2000-242477	20000810

PRIORITY APPLN. INFO.: JP 2000-242477 20000810

OTHER SOURCE(S): MARPAT 136:207491
 GI




AB The invention refers to an organic electroluminescent component comprising at least layer containing one compound of type I [Ar1-3 = biphenyl; Ar4 = unsubstituted Ph or naphthyl] between two electrodes.


IT 401479-81-0 401479-87-6 401479-88-7
 401480-02-2 401480-25-9 401480-29-3
 RL: DEV (Device component use); USES (Uses)
 (organic electroluminescent component)

RN 401479-81-0 CAPLUS
 CN [1,1'-Biphenyl]-4-amine, N-[1,1'-biphenyl]-4-yl-N-[4-[5-[4-[1,1'-biphenyl]-4-yl (4-ethoxyphenyl)amino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 119 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 401479-87-6 CAPLUS
 CN 2-Naphthalenamine,
 N-[4-[5-[4-[bis([1,1'-biphenyl]-4-yl)amino]phenyl]-3,4-
 diphenyl-2-thienyl]phenyl]-N-(5-methoxy[1,1'-biphenyl]-2-yl)- (9CI) (CA
 INDEX NAME)




RN 401479-88-7 CAPLUS
 CN [1,1'-Biphenyl]-3-amine, N-[1,1'-biphenyl]-4-yl-N-[4-[5-[4-[1,1'-
 biphenyl]-4-yl(4-methoxyphenyl)amino]phenyl]-3,4-diphenyl-2-
 thienyl]phenyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 119 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 401480-02-2 CAPLUS
 CN [1,1'-Biphenyl]-3-amine, N-[1,1'-biphenyl]-3-yl-N-[4-[5-[4-[1,1'-
 biphenyl]-3-yl(4-methoxyphenyl)amino]phenyl]-3,4-diphenyl-2-
 thienyl]phenyl]- (9CI) (CA INDEX NAME)




RN 401480-25-9 CAPLUS
 CN [1,1'-Biphenyl]-3-amine, N-[1,1'-biphenyl]-3-yl-N-[4-[5-[4-[1,1'-
 biphenyl]-4-yl(4-(pentyloxy)phenyl)amino]phenyl]-3,4-diphenyl-2-
 thienyl]phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 119 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 401480-29-3 CAPLUS
 CN [1,1'-Biphenyl]-3-amine,
 N-[4-[5-[4-([1,1'-biphenyl]-3-yl[1,1'-biphenyl]-4-
 ylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-[4-(dodecyloxy)phenyl]-
 (9CI) (CA INDEX NAME)





L19 ANSWER 120 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:107327 CAPLUS
 DOCUMENT NUMBER: 136:167394
 TITLE: Preparation of carboxamide compounds and their use as
 antagonists of a human 11CBY receptor
 Johnson, Christopher Norbert; Jones, Martin; O'Toole,
 Catherine Anne; Stemp, Geoffrey; Thewlis, Kevin
 Michael; Witty, David
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010146	A1	20020207	WO 2001-EP8637	20010726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GE, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417638	A1	20020207	CA 2001-2417638	20010726
EP 1305304	A1	20030502	EP 2001-956562	20010726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012856	A	20030701	BR 2001-12856	20010726
HU 200302966	A2	20031229	HU 2003-2966	20010726
JP 200405070	T	20040219	JP 2002-515877	20010726
IN 2002KN01581	A	20050311	IN 2002-KN1581	20021226
ZA 2003000262	A	20040413	ZA 2003-262	20030109
NO 2003000471	A	20030328	NO 2003-471	20030130
MX 2003PA00923	A	20030609	MX 2003-PA923	20030130
BG 107510	A	20030930	BG 2003-107510	20030130
US 2004063686	A1	20040401	US 2003-343424	20030930
PRIORITY APPLN. INFO.:				
GB 2000-18758 A 20000731				
GB 2001-12544 A 20010523				
WO 2001-EP8637 W 20010726				

OTHER SOURCE(S): MARPAT 136:167394
 GI

L19 ANSWER 120 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. [I; A = H, Cl-6alkyl optionally substituted by hydroxyl, Cl-6alkoxy, Cl-6alkenyl, Cl-6 acyl, halogeno, OH, CN, CF3; R3 = H, CH3, CH2CH2; R4 = aromatic carbocycle, heterocycle; Z = O, S, NH, CH2, single bond, at the 3 or 4 position of R4 relative to the carbonyl group; R5 = aromatic carbocycle, heterocycle; Q = XYNR1R2; X = O, S; Y = C2-4 alkylene,

C5-6 cycloalkylene; R1, R2 independently = Cl-6 alkyl, phenyl-Cl-6 alkyl; R1R2 = 5-, 6-, 7-membered ring optionally containing one or more heteroatom

selected from O, S, N; etc.], pharmaceutically acceptable salts, and solvate are prepared and as antagonists of a human 11CBY receptor. Title compds. and pharmaceutical composition are useful in the treatment and/or prophylaxis of one or more of the disorder, such as, major depression, manic depression, anxiety, etc. Thus, the title compound II was prepared from

2'-methyl-biphenyl-4-carboxylic acid and 4-(2-diisopropylamino-ethoxy)-3-methoxy-phenylamine in DMF in the presence of

1-(3-dimethylaminopropyl)-3-Et carbodiimide hydrochloride and 1-hydroxy-7-azabenzotriazole.

IT 395679-02-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxamide compds. as antagonists of human 11CBY receptor)

RN 395679-02-4 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-5-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 121 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:72091 CAPLUS

DOCUMENT NUMBER: 136:134566

TITLE: Synthesis and use of heteroaryl-substituted-aryloxyalkylaryl compounds as β 3-adrenergic agonists

INVENTOR(S): Evers, Britta; Jesudason, Cynthia Darshini; Karanjawala, Rushad Eruch; Remick, David Michael; Ruehter, Gerd; Sall, Daniel Jon; Schotten, Theo; Siegel, Miles Goodman; Stenzel, Wolfgang; Stucky, Russell Dean; Werner, John Arnold

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

Patent

English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006276	A1	20020124	WO 2001-US16519	20010709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2415331	A1	20020124	CA 2001-2415331	20010709
AU 200172917	A	20020130	AU 2001-72917	20010709
EP 1303509	A1	20030423	EP 2001-952125	20010709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012409	A	20030722	BR 2001-12409	20010709
HU 200301329	A2	20030828	HU 2003-1329	20010709
JP 2004504320	T	20040212	JP 2002-512179	20010709
IN 2002RN01338	A	20040501	IN 2002-RN1338	20021025
ZA 2002008741	A	20040216	ZA 2002-8741	20021029
US 2003191156	A1	20031009	US 2002-311112	20021213
US 6730792	B2	20040504		
NO 2003000098	A	20030109	NO 2003-98	20030109
MX 2003PA00308	A	20030606	MX 2003-PA308	20030110
HR 2003000018	A1	20030430	HR 2003-18	20030113
US 2004242633	A1	20041202	US 2004-838904	20040504
PRIORITY APPLN. INFO.:			US 2000-217965P	P 20000713
			US 2000-241614P	P 20001019
			US 2001-292988P	P 20010523
			WO 2001-US16519	W 20010709
			US 2002-311112	A1 20021213

OTHER SOURCE(S): MARPAT 136:134566

GI

L19 ANSWER 120 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 121 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A1-3 = C, N provided that only one of A1-3 can be nitrogen; Het = (un)substituted, optionally benzofused 5 or 6 membered heterocyclic ring; R1,1a,1b = H, halo, OH, alkyl, alkoxy, haloalkyl, SO2-alkyl; R2 = H, alkyl; R3 = H alkyl; R4 = H, alkyl; or R3 and R4 combine with the carbon to which both are attached to form a C3-C6 cyclic ring; or R4 and X1 combine with the carbon to which both are attached to form a C3-C8 cyclic ring; or R4 combines with X1, the carbon to which

both are attached, and the Ph group to which X1 is attached to form a benzofused cycloalkyl radical; X is OCH2, SCH2, bond; X1 = bond, divalent hydrocarbon moiety; X2 = O, S, NH, NHO2, SO2NH, CH2, bond; X3 = (un)substituted Ph, 5 or 6 membered heterocyclic ring] were prepared For instance, 2-(1-methylpyrazol-3-yl)phenol was reacted with (2S)-glycidyl 3-nitrobenzenesulfonate (THF, t-BuOK, reflux, 16 h) to give epoxide II. This was reacted with the amine derived from 4-(2-amino-2-methylpropyl)phenol and 2-chloro-3-cyanopyridine (alc. solvent, 80°C, 2-72 h) to give III. The intrinsic activity (Emax) of representative compds. of the invention was assessed relative to isoproterenol (a nonselective β 3-agonist); III had Emax = 55.0%. I are used in the treatment of diabetes, obesity, etc.

IT 391925-49-8P 391925-51-2P 391925-81-8P
391925-83-0P 391925-86-3P 391925-90-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug; synthesis and use of heteroaryl-substituted-aryloxyalkylaryl compds. as β 3-adrenergic agonists)

RN 391925-49-8 CAPLUS

CN Ethanone, 1-[5-[2-[(2S)-3-[[1,1-dimethyl-2-[4-[4-(methylsulfonyl)phenoxy]phenyl]ethyl]amino]-2-hydroxypropoxy]phenyl]-2-thienyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L19 ANSWER 121 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 391925-51-2 CAPLUS
 CN 2-Propanol,
 1-[[1,1-dimethyl-2-[4-[4-(methylsulfonyl)phenoxy]phenyl]ethyl]
 amino]-3-[2-(5-methyl-2-thienyl)phenoxy]-, hydrochloride, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 391925-81-8 CAPLUS
 CN Benamide, 4-[4-[2-[[[(2S)-2-hydroxy-3-[2-(5-methyl-2-
 thienyl)phenoxy]propyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride
 (9CI) (CA INDEX NAME)

L19 ANSWER 121 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


Absolute stereochemistry.



● HCl

RN 391925-83-0 CAPLUS
 CN Benamide, 4-[4-[2-[[[(2S)-3-[2-(5-acetyl-2-thienyl)phenoxy]-2-
 hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 391925-86-3 CAPLUS
 CN Benamide, 2-[4-[2-[[[(2S)-2-hydroxy-3-[2-(5-methyl-2-
 thienyl)phenoxy]propyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride
 (9CI) (CA INDEX NAME)

L19 ANSWER 121 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




● HCl

RN 391925-90-9 CAPLUS
 CN Benamide, 2-[4-[2-[[[(2S)-3-[2-(5-acetyl-2-thienyl)phenoxy]-2-
 hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, mono(trifluoroacetate)
 (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 391925-89-6
 CMF C32 H34 N2 O5 S

Absolute stereochemistry.



L19 ANSWER 121 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 76-05-1
 CMF C2 H F3 O2





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 122 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:935594 CAPLUS
 DOCUMENT NUMBER: 136:69730
 TITLE: Preparation of
 1,3-bis-(substituted-phenyl)-2-propen-1-ones as VCAM-1 inhibitors for treatment of inflammatory disorders
 INVENTOR(S): Meng, Charles Q.; Ni, Liming; Sikorski, James A.; Hoong, Lee K.
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA
 SOURCE: PCT Int. Appl., 220 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098291	A2	20011227	WO 2001-US19720	20010620
WO 2001098291	A3	20020516		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2413878	A1	20011227	CA 2001-2413878	20010620
BR 2001011889	A	20030624	BR 2001-11889	20010620
EP 1330448	A2	20030730	EP 2001-946583	20010620
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 6608101	B1	20030819	US 2001-886348	20010620
JP 2004501147	T	20040115	JP 2002-504247	20010620
NZ 523443	A	20041126	NZ 2001-523443	20010620
MX 2002PA12660	A	20040514	MX 2002-PA12660	20021218
IN 2003DN00008	A	20060609	IN 2003-DN8	20030101
ZA 2003000134	A	20051006	ZA 2003-134	20030106
US 2003236298	A1	20031225	US 2003-443470	20030521
US 7078431	B2	20060718		
US 2006258735	A1	20061116	US 2006-485940	20060713
PRIORITY APPLN. INFO.:			US 2000-212769P	P 20000620
			US 2000-255934P	P 20001215
			US 2001-886348	A1 20010620
			WO 2001-US19720	W 20010620
			US 2003-443470	A1 20030521

OTHER SOURCE(S): MARPAT 136:69730


L19 ANSWER 122 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 GI




AB Title compds. I [wherein R2a, R3a, R4a, R5a, R6a, R2b, R3b, R4b, R5b, and R6b = independently H, (cyclo)alkyl, (hetero)aryl, carbocyclyl, (halo)alkylthio, (un)substituted alkoxy or amino, (halo)acyl, amido, (halo)alkylsulfonyl, aminocarbonyl, alkenyl, alkynyl, halo, OH, SH, CN, NO2, SO3H, sulf(on)amido, PO3H2, alditol, carbohydrate, amino acid, etc.; R22 and R23 = independently H or alkyl; or R22 and R6a or R23 and R6a can join together to form a bridged carbocycle, (hetero)aryl, or heterocycle; R2a and R3a, R3a and R4a, R4a and R5a, R5a and R6a, R2b and R3b, R3b and R4b, R4b and R5b, or R5b and R6b and independently join to form a bridged (un)substituted carbocycle, cycloalkenyl, cycloalk(en)ylcarbonyl, (hetero)aryl, heterocycle, or alkylenedioxy; and the E or Z isomers thereof] were prepared to inhibit the expression of VCAM-1. For example, 3',5'-dimethoxy-4'-hydroxyacetophenone was treated with Et glycolate, PPh3, and di-Et azodicarboxylate in THF to give 4'-ethoxycarbonylmethoxy-3',5'-dimethoxyacetophenone (90%). Coupling the acetophenone and 5-(benzo[b]thien-2-yl)-2,4-dimethoxybenzaldehyde (preparation given) in the presence of NaOH in absolute EtOH afforded the 1,3-diphenyl-2-propen-1-one II (39%), which stimulated cultured human aortic smooth muscle cell activity with IC50 of 0.45 μ M. I are useful for the treatment of inflammatory disorders that are mediated by VCAM-1, including arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy,

L19 ANSWER 122 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.
 IT 383173-76-0P 383174-14-9P 383174-15-0P
 383174-17-2P 383174-18-3P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bis(substituted phenyl)propenones as VCAM-1 inhibitors for treatment of inflammatory disorders)


RN 383173-76-0 CAPLUS
 CN 2-Propen-1-one, 3-[3-(5-acetyl-2-thienyl)-4,5-dimethoxyphenyl]-1-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 383174-14-9 CAPLUS
 CN 2-Propen-1-one, 3-[2-methoxy-5-(5-methyl-2-thienyl)phenyl]-1-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 383174-15-0 CAPLUS
 CN 2-Propen-1-one, 1-(3,4-dimethoxyphenyl)-3-[2-methoxy-5-(5-methyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 122 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 383174-17-2 CAPLUS
 CN 2-Propen-1-one, 3-[2-methoxy-5-(4-methyl-2-thienyl)phenyl]-1-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 383174-18-3 CAPLUS
 CN 2-Propen-1-one, 1-(3,4-dimethoxyphenyl)-3-[2-methoxy-5-(4-methyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 123 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:903581 CAPLUS
 DOCUMENT NUMBER: 136:29077
 TITLE: Bisaminophenyldiphenylthiophene derivatives and organic electroluminescent devices using them
 INVENTOR(S): Nakatsuka, Masakatsu; Shimamura, Takehiko; Ishida, Tsutomu
 PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001345181	A	20011214	JP 2000-161965	20000531
PRIORITY APPLN. INFO.: JP 2000-161965 20000531				

OTHER SOURCE(S): MARPAT 136:29077
 GI



AB The invention relates to an electroluminescent device comprising a pair of electrodes sandwiching ≥ 1 layer(s) containing ≥ 1 bis (naphthyl/phenyl)aminophenyldiphenylthiophene I [Ar1-3 = (un)substituted naphthyl; Ar4 = (un)substituted Ph or naphthyl]. The long


luminous life is superior in durability.
 IT 378798-83-5P 378798-98-2P 378799-02-1P
 RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (organic electroluminescent devices containing)

RN 378798-83-5 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-(di-1-naphthalenylamino)phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 124 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:798196 CAPLUS
 DOCUMENT NUMBER: 135:344382
 TITLE: Preparation of arylbiphenylpropanoates and analogs for treatment of prostaglandin E-mediated disorders
 INVENTOR(S): Gallant, Michel; Lachance, Nicholas; Labelle, Marc; Zamboni, Robert; Juteau, Helene; Gareau, Yves; Lacombe, Patrick
 PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081312	A2	20011101	WO 2001-CA563	20010423
WO 2001081312	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2405170	A1	20011101	CA 2001-2405170	20010423
EP 1278734	A2	20030129	EP 2001-927526	20010423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531194	T	20031021	JP 2001-578407	20010423
US 2002082266	A1	20020627	US 2001-840942	20010424
US 6627656	B2	20030930		
PRIORITY APPLN. INFO.: US 2000-199299P P 20000424				
WO 2001-CA563 W 20010423				

OTHER SOURCE(S): MARPAT 135:344382
 GI




AB RZCHR1CR2R3R4 [R = (hetero)aryl; R1,R4 = H; R1R4 = bond; R2 = CO2H,


L19 ANSWER 123 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 378798-98-2 CAPLUS
 CN 1-Naphthalenamine, N-[4-[5-[4-(4-methoxyphenyl)-1-naphthalenylamino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]-N-2-naphthalenyl- (9CI) (CA INDEX NAME)




RN 378799-02-1 CAPLUS
 CN 1-Naphthalenamine, N-2-naphthalenyl-N-[4-[5-[4-[2-naphthalenyl[4-(octyloxy)phenyl]amino]phenyl]-3,4-diphenyl-2-thienyl]phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 124 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CONHSO2R5, etc.; R3 = e.g., H or Me; R5 = cycloalkyl, (hetero)aryl, etc.; Z = (un)substituted 1,2-phenylene were prepd. treatment of prostaglandin E-mediated disorders (no data). Thus, 2-(OHC)C6H4B(OH)2 was arylated by 3-BrC6H4Br and the product condensed with (EtO)2P(O)CH2CO2Et to give, in


2 addnl. steps, 3-BrC6H4C6H4(CH2CH2CO2H)-2 the Me ester of which was treated with diboron pinacol ester and the product arylated by 3-bromo-5-chloro-2-phenylmethoxypyridine (prepn. given) to give title compd. I.
 IT 371146-89-3P 371146-93-9P 371146-97-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylbiphenylpropanoates and analogs for treatment of prostaglandin E-mediated disorders)
 RN 371146-89-3 CAPLUS
 CN Benzenepropanamide, 2-[4-[2-[(4-methoxyphenyl)methoxy]phenyl]-2-thienyl]- α -methyl-N-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 371146-93-9 CAPLUS
 CN 2-Propenamide, 3-[2-[4-[2-[(2,3-dichlorophenyl)methoxy]phenyl]-2-thienyl]phenyl]-N-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 124 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 371146-97-3 CAPLUS
 CN Benzenepropanamide, N-[(2,5-dimethylphenyl)sulfonyl]-2-[4-[2-[(4-methoxyphenyl)methoxy]phenyl]-2-thienyl]-6,6-dimethyl- (9CI)
 (CA INDEX NAME)

L19 ANSWER 124 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:617988 CAPLUS
 DOCUMENT NUMBER: 135:195581
 TITLE: Preparation of thiazepinyl hydroxamic acid
 derivatives

INVENTOR(S): as matrix metalloproteinase inhibitors
 Neya, Masahiro; Yamazaki, Hitoshi; Ohne, Kazuhiko;
 Sawada, Yuki; Mizutani, Tsuyoshi; Imamura, Yoshimasa;
 Mukai, Noriko


PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 446 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060808	A1	20010823	WO 2001-JP1206	20010220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2400862	A1	20010823	CA 2001-2400862	20010220
AU 200134097	A	20010827	AU 2001-34097	20010220
EP 1259499	A1	20021127	EP 2001-906142	20010220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
HU 200204501	A2	20030428	HU 2002-4501	20010220
JP 2003523337	T	20030805	JP 2001-560193	20010220
BR 2001008791	A	20040427	BR 2001-8791	20010220
NO 2002003921	A	20021011	NO 2002-3921	20020819
US 2003134849	A1	20030717	US 2002-203627	20020819
US 6967197	B2	20051122		
MX 2002PA08175	A	20030523	MX 2002-PA8175	20020821
IN 2002CN01484	A	20050128	IN 2002-CN1484	20020918
PRIORITY APPLN. INFO.:			AU 2000-5751	A 20000221
			AU 2000-8603	A 20000706
			WO 2001-JP1206	W 20010220

OTHER SOURCE(S): MARPAT 135:195581
 GI

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title comps. [I; R1 = halo, alkoxy, (un)substituted aryl, etc.; R2 = amidated carboxy; R3 = H, acyl; Ar = aryl, heterocyclyl; X = S, SO, SO2; Y, Z = alkylene; m, n = 0-2], useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor α (TNF α), were prepared E.g., a multi-step synthesis of II which showed IC50 of 2.85 nM against human MMP-9, was given.


IT 355842-94-3P 355842-97-6P 355843-16-2P 355843-49-1P 355844-41-6P 355844-47-2P 355844-48-3P 355844-65-4P 355845-06-6P 355845-27-1P 355845-42-0P 355845-43-1P 355845-44-2P 355845-52-2P 355845-63-5P 355845-64-6P 355845-69-1P 355845-70-4P 355845-72-6P 355845-73-7P 355845-75-9P 355846-00-3P 355846-01-4P 355846-02-5P 355846-10-5P 355846-18-3P 355846-52-5P 355846-53-6P 355846-75-2P 355846-76-3P 355846-78-5P 355846-79-6P 355846-81-0P 355846-91-2P 355846-95-6P 355847-76-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of thiazepinyl hydroxamic acid derivs. as matrix metalloproteinase inhibitors)

RN 355842-94-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 7-[5-(4-fluorophenyl)-2-thienyl]hexahydro-4-(2-methoxybenzoyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI)
 (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355842-97-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 7-[5-(4-cyanophenyl)-2-thienyl]hexahydro-4-(2-
 methoxybenzoyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA
 INDEX NAME)




RN 355843-16-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-4-[(4-methoxyphenyl)sulfonyl]-7-[5-
 [4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355843-49-1 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-chlorophenyl)-2-thienyl]-4-(2-
 ethoxybenzoyl)hexahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355844-41-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 hexahydro-N-hydroxy-4-(4-methoxybenzoyl)-7-[5-
 [3-[(methylamino)carbonyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355844-47-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-[[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2-phenoxybenzoyl)-], 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355844-48-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-(2-hydroxy-3-
 methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 355844-65-4 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-[[2-(
 methoxyphenyl)amino]carbonyl]-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-06-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-chlorophenyl)-2-thienyl]hexahydro-N-
 hydroxy-4-(2-methoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-27-1 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-ethylphenyl)-2-thienyl]hexahydro-N-

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hydroxy-4-(2-methoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-42-0 CAPLUS
CN 1,4-Thiazepine-7-acetamide, hexahydro-4-(2-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-43-1 CAPLUS
CN 1,4-Thiazepine-7-acetamide, hexahydro-4-(3-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-44-2 CAPLUS
CN 1,4-Thiazepine-7-acetamide, hexahydro-4-(4-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-52-2 CAPLUS
CN 1,4-Thiazepine-7-acetamide, hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2-propoxybenzoyl)-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-63-5 CAPLUS
CN 1,4-Thiazepine-7-acetamide, 4-(2,3-dimethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-64-6 CAPLUS
CN 1,4-Thiazepine-7-acetamide, 4-(2,4-dimethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-69-1 CAPLUS
CN 1,4-Thiazepine-7-acetamide, 4-(2,5-dimethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-70-4 CAPLUS
CN 1,4-Thiazepine-7-acetamide, hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-(2,3,4-trimethoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-72-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(2-ethoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355845-73-7 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-4-[2-(trifluoromethoxy)benzoyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355845-75-9 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(4-chloro-2-methoxybenzoyl)hexahydro-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-00-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-(2-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-01-4 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-(3-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-02-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-(4-methoxybenzoyl)-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-10-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2-propoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-18-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2-ethoxybenzoyl)hexahydro-N-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-52-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2,3-dimethoxybenzoyl)hexahydro-N-hydroxy-7-
 [5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-53-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2,3-dimethoxybenzoyl)hexahydro-N-hydroxy-7-
 [5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-75-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2,5-dimethoxybenzoyl)hexahydro-N-hydroxy-7-
 [5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-76-3 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-(2,3,4-trimethoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-78-5 CAPLUS
 CN 1,4-Thiazepine-7-acetamide,
 4-(2-ethoxybenzoyl)hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-79-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-4-[2-(trifluoromethoxy)benzoyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 355846-81-0 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 4-(4-chloro-2-methoxybenzoyl)hexahydro-N-hydroxy-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355846-91-2 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-fluorophenyl)-2-thienyl]hexahydro-N-hydroxy-4-(2-methoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 355846-95-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, 7-[5-(4-cyanophenyl)-2-thienyl]hexahydro-N-hydroxy-4-(2-methoxybenzoyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 355847-76-6 CAPLUS
 CN 1,4-Thiazepine-7-acetamide, hexahydro-N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]-7-[5-[4-(5-oxazolyl)phenyl]-2-thienyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L19 ANSWER 126 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:597968 CAPLUS
 DOCUMENT NUMBER: 135:180769
 TITLE: Preparation of novel triazole derivatives as arginine vasopressin receptor antagonists
 INVENTOR(S): Suzuki, Takeshi; Tobe, Takahiko; Murakami, Takeshi; Tahara, Atsuo
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058880	A1	20010816	WO 2000-JP668	20000208
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			WO 2000-JP668	20000208

OTHER SOURCE(S): MARPAT 135:180769
 GI




I



II


L19 ANSWER 125 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 126 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


AB Title compds. [I; R = H, CH₃, CH₂CH₃, CH₂CH₂CH₃; R₁ = H, OCH₃, OCH₂CH₃, CH₃, C₆H₅, I, OH, CH(CH₃)₂, heterocyclylalkoxy, heterocyclylcarbonylphenylmethoxy; R₃ = H, CH₃; A = 4-C₆H₅C₆H₄, 4-(2-CH₃C₆H₄NHCONH)₂C₆H₄, 4-(2-CH₃C₆H₄NHCONH)₂C₆H₄] and pharmaceutically acceptable salts thereof are prepared as arginine vasopressin V_{1a} receptor antagonists. Title compds. I are tested for AVP (arginine vasopressin) inhibitory effect with pK_i = 6.0-9.1. Thus, the title compound II was prepared
 IT 354799-47-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of triazole derivs. as arginine vasopressin receptor antagonists)
 RN 354799-47-6 CAPLUS
 CN Piperazine, 1-methyl-4-[4-[[[3-methyl-2-[3-methyl-5-[4-(5-phenyl-2-thienyl)phenyl]-4H-1,2,4-triazol-4-yl]phenoxy]methyl]benzoyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 127 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:574518 CAPLUS
 DOCUMENT NUMBER: 135:357824
 TITLE: Molecular recognition: studies on the synthesis of some bis thiophene carboxamide derivatives as ditopic receptors for long chain dicarboxylic acids
 AUTHOR(S): Ray, J. K.; Gupta, S.; Pan, D.; Kar, G. K.
 CORPORATE SOURCE: Department of Chemistry, Indian Institute of Technology, Kharagpur, 721302, India
 SOURCE: Tetrahedron (2001), 57(33), 7213-7219
 CODEN: TETRA; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:357824
 GI

C₃₀H₃₂N₂O₃S₂
 Stereo: ns




AB New mol. receptors I (R = Bu, 2-Py, 2-MeO-Ph, and X = O, S) with di-Ph ether/di-Ph sulfide as spacer having functional groups complementary to long chain dicarboxylic acids were developed. Binding studies with different dicarboxylic acids showed high association consts. with receptors I
 (R = Bu and X = O, S).
 IT 372111-21-2P 372111-22-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of bithiophenecarboxamide ditopic receptors and lack of mol. recognition of dicarboxylic acids)
 RN 372111-21-2 CAPLUS
 CN 2-Thiophenecarboxamide,
 5,5'-(oxydi-4,1-phenylene)bis[N-(2-methoxyphenyl)-
 (9CI) (CA INDEX NAME)



RN 372111-22-3 CAPLUS
 CN 2-Thiophenecarboxamide,
 5,5'-(thiodi-4,1-phenylene)bis[N-(2-methoxyphenyl)-
 (9CI) (CA INDEX NAME)


L19 ANSWER 128 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:315858 CAPLUS
 DOCUMENT NUMBER: 135:92463
 TITLE: Synthesis and Photoisomerization of Dithienylethene-Bridged Diporphyrins
 AUTHOR(S): Oeuka, Atsuhiko; Fujikane, Daisuke; Shimori, Hideyuki; Kobatake, Seiya; Irie, Masahiro
 CORPORATE SOURCE: Department of Chemistry Graduate School of Science, Kyoto University and CREST Japan Science Technology Corporation (JST), Kyoto, 606-8502, Japan
 SOURCE: Journal of Organic Chemistry (2001), 66(11), 3913-3923
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:92463
 GI



I


AB Dithienylethene-bridged diporphyrins, e.g. I, were prepared as photochem. switching mol's. The close attachment of the porphyrin chromophore to the dithienylethene led to the loss of their photochromic reactivity, and therefore some examples did not undergo any photochem. isomerization, probably due to efficient quenching of the excited dithienylethene by the attached porphyrin moiety via intramol. energy transfer. The pertinent insertion of a spacer between the dithienylethene and porphyrin moieties allowed two examples to undergo open-to-closed and closed-to-open photoisomerizations in quantum yields of 4.3×10^{-2} and 1.8×10^{-3} , and 2.6×10^{-3} and 7.5×10^{-4} , resp., by irradiation with 313 and 625 nm light, which are considerably smaller than quantum yields of 0.52 and 3.8×10^{-3} for a reference dithienylethene. The fluorescence of one example was regulated in a reversible manner by the photoisomerization of the dithienylethene moiety. In addition, the absorption properties of the porphyrin in another example changed in response to the photochromic reaction of the dithienylethene bridge.
 IT 348638-95-9P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

L19 ANSWER 127 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 128 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (synthesis and photoisomerization of dithienylethene-bridged diporphyrins)
 RN 348638-95-9 CAPLUS
 CN 21H,23H-Porphine, 5,5'-[(3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-diyl)bis[(5-methyl-4,2-thienyldiyl)-4,1-phenylene-2,1-ethynyldiyl]]bis[10,20-bis[3,5-bis(octyloxy)phenyl]- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B




REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 128 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L19 ANSWER 129 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:872024 CAPLUS
DOCUMENT NUMBER: 134:147952
TITLE: Synthesis and characterization of aromatic-aliphatic polyamides
AUTHOR(S): Ubale, V. P.; Sagar, A. D.; Maldar, N. N.; Birajdar, M. V.
CORPORATE SOURCE: Chemistry Department, Shivaji University Centre for Post-Graduate Studies, Solapur, 413 003, India
SOURCE: Journal of Applied Polymer Science (2000), Volume 79(3), 566-571
Date: 2001, 79(3), 566-571
CODEN: JAPNAB; ISSN: 0021-8995
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new monomer, 2,5-bis(4-carboxy methylene phenyl)-3,4-diphenyl thiophene (V) has been synthesized and characterized by phys. and spectroscopic methods. A series of eight aromatic-aliphatic polyamides was prepared from the (V) and different aromatic diamines using Yamazaki's direct phosphorylation reaction. The polyamides were characterized by IR spectroscopy, viscosity measurements, and thermal anal. An excellent yield of these polyamides was obtained, with inherent viscosities in the range of 0.28 to 0.67 dL/g, and the polyamide were readily soluble in aprotic polar solvents such as N-methyl-2-pyrrolidone, N-N-di-Me acetamide, DMSO, and so forth. Polyamides could be cast into transparent and flexible films. They had glass transition temps. of 225-273°C. When evaluated by thermogravimetry, thermal anal. of the polyamides showed no weight loss below 311°C, and the char yield in air at 900°C was 55%-67%. The structure-property correlation among these polyamides is also discussed.
IT 324078-29-7P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis and characterization of aromatic-aliphatic polyamides)
RN 324078-29-7 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene(2-oxo-1,2-ethanediy)imino-1,4-phenyleneoxy-1,4-phenyleneimino(1-oxo-1,2-ethanediy)-1,4-phenylene] (9CI) (CA INDEX NAME)

L19 ANSWER 129 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:475658 CAPLUS
DOCUMENT NUMBER: 133:104964
TITLE: Preparation of tetrahydro-2H-thiopyran-1,1-dioxides as inhibitors of matrix metalloproteinases or tumor necrosis factor α
INVENTOR(S): Taniguchi, Kiyoshi; Neya, Masahiro; Terasawa, Takeshi;
Yamazaki, Hitoshi; Sato, Kentaro; Hosoi, Kumi; Tomishima, Yasuyo; Yoshida, Noriko; Imamura, Yoshimasa; Takasugi, Hisashi; Setoi, Hiroyuki
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040576	A2	20000713	WO 2000-JP18	20000106
WO 2000040576	A3	20010322		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2357874	A1	20000713	CA 2000-2357874	20000106
AU 200018905	A	20000724	AU 2000-18905	20000106
AU 759900	B2	20030501		
EP 1140895	A2	20011010	EP 2000-900122	20000106
EP 1140895	B1	20040324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101936	T2	20011221	TR 2001-1936	20000106
BR 200008589	A	20020129	BR 2000-8589	20000106
HU 200104859	A2	20021028	HU 2001-4859	20000106
RU 2221792	C2	20040120	RU 2001-121981	20000106
AT 262517	T	20040415	AT 2000-900122	20000106
ES 2213563	T3	20040901	ES 2000-900122	20000106
MX 2001PA06896	A	20020604	MX 2001-PA6896	20010705
PRIORITY APPLN. INFO.:				
			AU 1999-8068	A 19990107
			AU 1999-1702	A 19990719
			WO 2000-JP18	W 20000106
OTHER SOURCE(S): MARPAT 133:104964				
GI				

L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title comps. (I) [wherein R¹ = alkyl, halogen, (un)substituted heterocyclic or aryl; R² = (protected or amidated) carboxy; Ar = (un)substituted aryl heterocyclic; A = alkylene; X = O or a single bond; Y = S, S(O), or SO₂; Z = methylene, S, S(O), or SO₂; m and n = independently 0-6, and 1 ≤ m+n ≤ 6] and their salts were prepared by addition reactions of alkyl or aryl halides with tetrahydro-2H-thiopyrans and subsequent oxidation to form the 1,1-dioxides. For example, II was synthesized in a multi-step sequence involving (1) etherification of 3,4,5,6-tetrahydro-2-(4-hydroxyphenyl)-2H-thiopyran (preparation given) with

4-bromochlorobenzene, (2) addition of tert-Bu bromoacetate, (3) formation of the 1,1-dioxide using oxone, (4) deesterification with CF₃CO₂H, and (5) amidation of the acid with hydroxylammonium chloride. In an in vitro assay, II suppressed matrix metalloproteinase 13 (MMP-13) activity with IC₅₀ of 2.2 nM. I are useful for the treatment and/or prevention of diseases such as stroke, arthritis, cancer, tissue ulceration, decubitus ulcer, restenosis, periodontal disease, epidermolysis bullosa, scleritis, psoriasis, and other disease characterized by MMP activity, as well as AIDS, sepsis, septic shock, and other diseases caused by the production of TNF α (no data).

IT 282112-91-8P 282112-92-9P 282112-94-1P
282112-95-2P 282113-48-8P 282113-56-8P
282113-58-0P 282113-59-1P 282113-97-7P
282114-04-9P 282114-09-4P 282114-20-9P
282114-77-6P 282114-87-8P 282115-02-0P
282115-49-5P 282115-68-8P 282115-88-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(prepn. of tetrahydro-2H-thiopyran 1,1-dioxides as MMP or TNF α inhibitors by addn. reactions of alkyl or aryl halides with tetrahydro-2H-thiopyrans and subsequent oxidn. to form 1,1-dioxides)
RN 282112-91-8 CAPLUS
CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[3-[[[4-methoxyphenyl)acetyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282112-92-9 CAPLUS
CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[3-[[[3-methoxyphenyl)acetyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282112-94-1 CAPLUS
CN 2H-Thiopyran-2-acetamide, 2-[5-[3-[[[4-fluorophenyl)acetyl]amino]phenyl]-2-thienyl]tetrahydro-N-hydroxy-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 282112-95-2 CAPLUS
CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[3-[[[4-methoxyphenyl)acetyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282113-48-8 CAPLUS
CN 2H-Thiopyran-2-acetamide, tetrahydro-2-[5-[3-[[[4-methoxyphenyl)acetyl]amino]phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282113-56-8 CAPLUS
CN 2H-Thiopyran-2-acetamide, tetrahydro-2-[5-[3-[[[3-methoxyphenyl)acetyl]amino]phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 282113-58-0 CAPLUS
CN 2H-Thiopyran-2-acetamide, 2-[5-[3-[[[4-fluorophenyl)acetyl]amino]phenyl]-2-thienyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282113-59-1 CAPLUS
CN 2H-Thiopyran-2-acetamide, tetrahydro-2-[5-[3-[[[4-methoxyphenyl)acetyl]amino]phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282113-97-7 CAPLUS
CN 2H-Thiopyran-2-acetamide, 2-[5-[3-[[[4-chlorophenyl)acetyl]amino]phenyl]-2-thienyl]tetrahydro-N-hydroxy-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 282114-04-9 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[3-[[[(4-methoxyphenyl)amino]carbonyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282114-09-4 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[3-[[[(4-methylphenoxy)acetyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 282114-87-8 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-2-[5-[3-[[[(4-methylphenoxy)acetyl]amino]phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282115-02-0 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-2-[5-[4-[(1E)-3-[(4-methoxyphenyl)amino]-3-oxo-1-propenyl]phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 282114-20-9 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[4-[(1E)-3-[(4-methoxyphenyl)amino]-3-oxo-1-propenyl]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 282114-77-6 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-2-[5-[3-[[[(4-methoxyphenyl)amino]carbonyl]amino]phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 282115-49-5 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-2-[5-[3-[[[(4-methoxyphenyl)sulfonyl]amino]acetyl]amino]phenyl]-2-thienyl]-N-[(tetrahydro-2H-pyran-2-yl)oxy]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 282115-68-8 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[3-[[[(4-methoxyphenyl)sulfonyl]amino]acetyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L19 ANSWER 130 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 282115-88-2 CAPLUS
 CN 2H-Thiopyran-2-acetamide, tetrahydro-N-hydroxy-2-[5-[3-[[3-methylphenoxy]acetyl]amino]phenyl]-2-thienyl]-, 1,1-dioxide, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 131 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:457921 CAPLUS
 DOCUMENT NUMBER: 133:193729
 TITLE: Redox States of Well-Defined π -Conjugated Oligothiophenes Functionalized with Poly(benzyl ether)

AUTHOR(S): Dendrons
 Apperloo, Joke J.; Janssen, Rene A. J.; Malenfant, Patrick R. L.; Groenendaal, Lambertus; Frechet, Jean M. J.

CORPORATE SOURCE: Laboratory for Macromolecular and Organic Chemistry, Eindhoven University of Technology, Eindhoven, 5600 MB, Neth.

SOURCE: Journal of the American Chemical Society (2000), 122(29), 7042-7051
 CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal

LANGUAGE: English

AB The redox states of a series of well-defined hybrid dendrimers based on oligothiophene cores and poly(benzyl ether) dendrons have been studied using cyclic voltammetry and variable-temperature UV/visible/near-IR spectroscopy. The oxidation potentials and the electronic transitions of the neutral, singly oxidized, and doubly oxidized states of these novel hybrid materials have been determined as a function of oligothiophene length varying between 4 and 17 repeat units. The attachment of poly(benzyl ether) dendritic wedges at the termini of these lengthy oligothiophenes considerably enhances their solubility, thus enabling the first detailed investigation of the electronic structure of oligothiophenes having 11 and 17 repeat units with minimal β -substitution. In the case of the undecamer and heptadecamer, we find that the dicationic state consists of two individual polarons, rather than a single bipolaron. The effect of the dendritic poly(benzyl ether) solubilizers on the properties of the redox states varies with the oligothiophene length and dendron size. More specifically, we observe a kinetic limit to the electrochem. oxidation of the oligothiophene core when the dendron is large compared to


the electrophore. Finally, we have observed the first example of self-complexation of cation radicals via π -dimerization leading to the formation of dendritic supramol. assemblies.

IT 288860-98-0P
 RL: PREP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (redox states of π -conjugated oligothiophenes functionalized with poly(benzyl ether) dendrons)



RN 288860-98-0 CAPLUS
 CN [2,2':5',2'':5'',2''':5''',2''''-Quinquethiophene]-5-carboxylic acid, 4''-octyl-5''''-phenyl-, [3,5-bis[[3,5-bis[[3,5-bis(phenylmethoxy)phenyl]methoxy]phenyl]methoxy]phenyl]methyl ester (9CI)
 (CA INDEX NAME)

L19 ANSWER 131 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




L19 ANSWER 131 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B




REFERENCE COUNT: 63
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 132 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:136274 CAPLUS
 DOCUMENT NUMBER: 132:166239
 TITLE: Preparation of triazoles as arginine vasopressin V1 receptor antagonists, and pharmaceuticals containing them
 INVENTOR(S): Suzuki, Takeshi; Tobe, Takahiko; Murakami, Takeshi; Tahara, Atsuo
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000063363	A	20000229	JP 1998-228403	19980812
PRIORITY APPLN. INFO.:			JP 1998-228403	19980812

OTHER SOURCE(S): MARPAT 132:166239
 GI



AB Triazoles I (ring A = benzene or thiophene ring; ring B = aryl, heterocyclyl; R1 = H, halo, NO2, NH2, lower alkyl; R2 = alkyl, halo, OH, Ph, alkoxy, alkynyl, amino, etc.; R3 = H, lower alkyl; R4 = lower alkyl, alkoxy, alkylsulfonyl, halo, amino, cyano, trihalomethyl, nitro; X = bond, O, NHCO, etc.; m = 1-3) or their salts, useful for treatment of diabetic nephropathy, are prepared 2-(4'-Biphenyl)-1,3,4-oxadiazole was treated with o-anisidine at 150° for 12 h to give 12% 4-(2-methoxyphenyl)-3-(4'-biphenyl)-1,2,4-triazole.
 IT 258878-09-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of triazoles as arginine vasopressin V1 receptor antagonists)
 RN 258878-09-0 CAPLUS
 CN Piperazine, 1-methyl-4-[[4-[[3-methyl-2-[3-methyl-5-(5-phenyl-2-thienyl)-4H-


L19 ANSWER 132 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1,2,4-triazol-4-yl]phenoxy]methyl]benzoyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 133 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:98236 CAPLUS
 DOCUMENT NUMBER: 132:151811
 TITLE: Preparation of heterocyclecarboxamides and analogs as CCR5 receptor modulators
 INVENTOR(S): Neeb, Michael J.; Bondinell, William E.; Ku, Thomas
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006085	A2	20000210	WO 1999-US17118	19990728
WO 2000006085	A3	20000504		
W: CA, JP, US				
RW: AT, BE, CH, PT, SE				
CA 2338697	A1	20000210	CA 1999-2338697	19990728
EP 1102535	A2	20010530	EP 1999-937586	19990728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002521408	T	20020716	JP 2000-561942	19990728
US 6399656	B1	20020604	US 2001-744629	20010409
PRIORITY APPLN. INFO.:			US 1998-94414P	P 19980728
			US 1998-94424P	P 19980728
			WO 1999-US17118	W 19990728

OTHER SOURCE(S): MARPAT 132:151811
 GI



AB Title compds. were prepared Thus, 5-amino-1'-[1-methylethyl]spiro[benzofuran-3(2H),4'-piperidine] (preparation given) was amidated by 2-(2,3-dihydro-1,4-benzodioxin-2-yl)thiazole-4-carboxylic acid to give title compound I. Data for biol. activity of title compds. were given.
 IT 257875-42-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L19 ANSWER 133 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of heterocyclecarboxamides and analogs as CCR5 receptor modulators)
 RN 257875-42-6 CAPLUS
 CN 2-Thiophenecarboxamide, N-[3-[2-[[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-5-phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 134 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:808686 CAPLUS
DOCUMENT NUMBER: 132:36959
TITLE: Long-wavelength dyes for infrared tracing and their use
INVENTOR(S): Wu, Yexin; Klaubert, Dieter H.; Kang, Hee Chol; Zhang,
Yu-zhong
PATENT ASSIGNEE(S): Molecular Probes, Inc., USA
SOURCE: U.S., 20 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6005113	A	19991221	US 1997-856422	19970514
PRIORITY APPLN. INFO.:			US 1996-17716P	P 19960515

OTHER SOURCE(S): MARPAT 132:36959

AB The invention relates to fluorescent dyes that are substituted or unsubstituted derivs. of 1-(isoindolyl)methylene-isoindole that are bound through both isoindole nitrogens to a boron difluoride moiety, forming a fluorescent dibenzopyrrometheneboron difluoride compds. which are further substituted by bathochromic substituents that are aryl or heteroaryl moieties further substituted by an addnl. aryl or heteroaryl that is itself optionally further substituted by an addnl. aryl or heteroaryl. These aryl and heteroaryl groups are separated by a covalent bond, or by an ethenyl, butadienyl or hexatrienyl linkage. The dyes of the invention are particularly useful as labels for carriers, particularly polymeric microparticles. The resulting microparticles have a long-wavelength fluorescence emission, and possess utility for tracing flow in biol. systems, particularly in tracing blood flow. In an example, fluorescent difluoro-(5-methoxy-1-(5-methoxy-3-(2-(5-(4-methoxyphenyl))thienyl)-2H-

isoindol-1-yl)methylene)-3-(2-(5-(4-methoxyphenyl))thienyl)-1H-isoindolato-N1,N2)boron was prepared and incorporated into polystyrene microspheres.
IT 252666-61-8P 252666-69-6P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation);

RACT (Reactant or reagent)
(intermediate; production of fluorescent dyes for IR tracing)
RN 252666-61-8 CAPLUS
CN Ethanone,
1-(4-methoxy-2-[[5-(4-methoxyphenyl)-2-thienyl]carbonyl]phenyl]-
(9CI) (CA INDEX NAME)

L19 ANSWER 135 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:736280 CAPLUS
DOCUMENT NUMBER: 131:351348
TITLE: Preparation of heterocyclic carboxamides as 5-HT1 agonists or antagonists
INVENTOR(S): Howard, Harry Ralph
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 957099	A2	19991117	EP 1999-302288	19990325
EP 957099	A3	19991124		
EP 957099	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 228119	T	20021215	AT 1999-302288	19990325
ES 2188095	T3	20030616	ES 1999-302288	19990325
JP 11322711	A	19991124	JP 1999-103917	19990412
JP 3224372	B2	20011029		
CA 2268870	A1	19991015	CA 1999-2268870	19990413
CA 2268870	C	20050329		
BR 9901052	A	20000425	BR 1999-1052	19990414
US 6277852	B1	20010821	US 1999-291352	19990414
US 2001041705	A1	20011115	US 2001-862932	20010522
US 6602874	B2	20030805		
US 2002002168	A1	20020103	US 2001-862691	20010522
US 6537995	B2	20030325		
US 2003232841	A1	20031218	US 2003-601209	20030620
PRIORITY APPLN. INFO.:			US 1998-81790P	P 19980415
			US 1999-291352	A3 19990414
			US 2001-862932	A3 20010522

OTHER SOURCE(S): MARPAT 131:351348
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Z = O, S(O)m (wherein m = 0-2), NQ (Q = H, alkyl, Ph); X = H, halo, OH, etc.; Y = II-IV (M = O, S; X2 = H, F, Cl, etc.; R1 = V, VI, etc.; R6 = H, alkyl, etc.; R8 = H, alkyl; R10 = H, alkyl); R2 = H, alkyl, (un)substituted Ph, naphthyl; R3 = (CH2)tB (t = 0-3; B = H, (un)substituted Ph, naphthyl, etc.)], useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist, is indicated, were prepared. Thus, reaction of 5-bromofuran-2-carboxylic acid 4-chlorobenzylamide with 2-(4-methylpiperazin-1-yl)phenylboronic acid (preps. were given) in the presence of Na2CO3 and Pd(PPh3)4 in 1,2-dimethoxyethane and water afforded

L19 ANSWER 134 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 252666-69-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(4-methoxyphenyl)-, [1-(2-hydroxy-4-methoxyphenyl)ethylidene]hydrazide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 135 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
the title compd. VII.HC1. Compds. I which were tested exhibited IC50's of

< 0.60 µM for 5-HT1D and IC50's of < 1.0 µM for 5-HT1A affinity.


IT 250383-67-6P 250383-78-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic carboxamides as 5-HT1 agonists or antagonists)

RN 250383-67-6 CAPLUS
CN 2-Thiophenecarboxamide, N-[(4-methoxyphenyl)methyl]-5-[2-(4-methyl-1-piperazinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HC1

RN 250383-78-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[(4-methoxyphenyl)methyl]-5-[2-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




L19 ANSWER 136 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:625540 CAPLUS
 DOCUMENT NUMBER: 132:12244
 TITLE: Solid phase parallel synthesis of highly substituted thiophene derivatives and identification of novel phosphodiesterase-4 (PDE-4) inhibitors
 AUTHOR(S): Han, Yongxin; Giroux, Andre; Lepine, Carole; Laliberte, France; Huang, Zheng; Perrier, Helene; Bayly, Christopher I.; Young, Robert N.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Frosst Centre
 for Therapeutic Research, Merck Frosst Canada Inc., Pointe-Claire-Dorval, QC, H9R 4P8, Can.
 SOURCE: Tetrahedron (1999), 55(39), 11669-11685
 CODEN: TETRA; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:12244
 AB A versatile protocol for solid phase synthesis of highly substituted thiophene derivs. and their activity against the PDE-4 enzyme are discussed. This protocol employs 3-(hydroxymethyl)-2-thiopheneboronic acid as the scaffold and sequential palladium catalyzed cross-coupling reactions as the C-C bond forming step. This methodol. allows convenient modification of the thiophene core from three directions, giving rise to structurally diverse derivs. with overall high chemical purity and yield.
 A novel series of potent PDE-4 inhibitors was identified from these compds. Thus, polymer-bound 4-[3-(bromomethyl)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-thienyl]benzoic acid was prepared, treated with amines and the resulting product was cleaved from the support resin. Also prepared were 3-[5-(3,4-dimethoxyphenyl)-3-[[4,6-dimethyl-2-pyrimidinyl]thio]methyl]-2-thienyl]- α,α -dimethylbenzenemethanol and analogs thereof.
 IT 222840-29-1P 222840-43-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (solid-phase parallel synthesis of thiophene derivs. and their identification as phosphodiesterase-4 inhibitors)
 RN 222840-29-1 CAPLUS
 CN Benzoic acid, 4-[5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-[[3-methoxyphenyl]thio]methyl]-2-thienyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 136 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 222840-43-9 CAPLUS
 CN Benzoic acid, 4-[5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-[[2-methoxyphenyl]thio]methyl]-2-thienyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 137 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:495123 CAPLUS
 DOCUMENT NUMBER: 131:129760
 TITLE: Preparation of sulfonamidobenzenehydroxamates and analogs as matrix metalloproteinase and TACE inhibitors
 INVENTOR(S): Levin, Jeremy Ian; Du, Mila T.; Venkatesan, Aranam
 Mudumbai, Nelson, Frances Christy; Zask, Arie; Gu, Yansong
 PATENT ASSIGNEE(S): American Cyanamid Co., USA
 SOURCE: U.S., 68 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5929097	A	19990727	US 1997-944593	19971006
PRIORITY APPLN. INFO.:			US 1996-28504P	P 19961016

OTHER SOURCE(S): MARPAT 131:129760
 AB RSO2N(CH2R7)ZCONHOH [I; R = (un)substituted (hetero)aryl; R7 = H, alkyl, Ph, etc.; Z = (un)substituted phenylene or -naphthylene] were prepared Thus, 2-(H2N)C6H4CO2Me was amidated by 4-(MeO)C6H4SO2Cl and the N-benzylated product converted in 2 steps to I [R = C6H4(CMe)-4, R7 = Ph, Z = 1,2-phenylene]. Data for biol. activity of I were given.
 IT 206549-37-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of sulfonamidobenzenehydroxamates and analogs as matrix metalloproteinase and TACE inhibitors)
 RN 206549-37-3 CAPLUS
 CN Benzamide, 5-(5-acetyl-2-thienyl)-N-hydroxy-2-[[4-(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methyl- (3CI) (CA INDEX NAME)




IT 206549-35-1P 206549-36-2P

L19 ANSWER 137 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of sulfonamidobenzenehydroxamates and analogs as matrix metalloproteinase and TACE inhibitors)
 RN 206549-35-1 CAPLUS
 CN Benzoic acid, 5-(5-acetyl-2-thienyl)-2-[[4-(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 206549-35-2 CAPLUS
 CN Benzoic acid, 5-(5-acetyl-2-thienyl)-2-[[4-(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:394826 CAPLUS
 DOCUMENT NUMBER: 131:80577
 TITLE: Organic electric-field light-emitting device
 containing thiophene derivative
 Nakatsuka, Masakatsu; Kitamoto, Noriko
 INVENTOR(S): Mitsui Chemicals Inc., Japan
 PATENT ASSIGNEE(S): Jpn. Kokai Tokkyo Koho, 26 pp.
 SOURCE: CODEN: JKXXAF
 Patent
 DOCUMENT TYPE: Japanese
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11167990	A	19990622	JP 1997-332149	19971202
JP 3659781	B2	20050615		

PRIORITY APPLN. INFO.: JP 1997-332149 19971202

OTHER SOURCE(S): MARPAT 131:80577
 GI




AB The device has a pair of electrodes sandwiching a layer containing a thiophene derivative I (X1 = N-carbazoyl, N-phenoxy, N-phenothiazyl; X2-4 = N-carbazoyl, N-phenoxy, N-phenothiazyl, NAr1Ar2; Ar1, 2 = aryl; l, m, n = 0, 1). The device shows long life and excellent durability.

IT 228869-85-0 228869-86-1 228869-92-9
 228869-96-3 228870-00-6 228870-04-0
 228870-10-8 228870-12-0 228870-14-2
 RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
 (organic elec.-field light-emitting device containing thiophene derivative)

RN 228869-85-0 CAPLUS
 CN Benzenamine, N-[4-[5-[4-(9H-carbazol-9-yl)phenyl]-3,4-diphenyl-2-thienyl]phenyl]-2-methoxy-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 228869-86-1 CAPLUS
 CN Benzenamine, 4-[5-[4-(9H-carbazol-9-yl)phenyl]-3,4-diphenyl-2-thienyl]-N,N-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 228869-92-9 CAPLUS
 CN Benzenamine, 4-[5-[4-(4a,10a-dihydro-10H-phenoxazin-10-yl)phenyl]-3,4-diphenyl-2-thienyl]-N-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A


RN 228869-96-3 CAPLUS
 CN Benzenamine, N-[4-[5-[4-(4a,10a-dihydro-10H-phenothiazin-10-yl)phenyl]-3,4-diphenyl-2-thienyl]phenyl]-3-ethoxy-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 228870-00-6 CAPLUS
 CN Benzenamine, N-[4-[2,5-bis[4-(9H-carbazol-9-yl)phenyl]-4-phenyl-3-thienyl]phenyl]-4-methoxy-N-(4-methoxy-2-methylphenyl)-2-methyl- (9CI)
 (CA INDEX NAME)

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 228870-04-0 CAPLUS
 CN Benzenamine, 4-[2,5-bis[4-(4a,10a-dihydro-10H-phenoxazin-10-yl)phenyl]-4-phenyl-3-thienyl]-N,N-bis(4-ethoxyphenyl)- (9CI)
 (CA INDEX NAME)




RN 228870-10-8 CAPLUS

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Benzenamine, 4,4'-[2,5-bis[4-(9H-carbazol-9-yl)phenyl]-3,4-thiophenediyl]bis[N-(4-butoxyphenyl)-N-phenyl]- (9CI)
 (CA INDEX NAME)




RN 228870-12-0 CAPLUS
 CN Benzenamine, 4,4'-[2,5-bis[4-(10H-phenoxazin-10-yl)phenyl]-3,4-thiophenediyl]bis[N-(3-methoxyphenyl)-N-phenyl]- (9CI)
 (CA INDEX NAME)



RN 228870-14-2 CAPLUS
 CN Benzenamine, 4,4'-[2,5-bis[4-(10H-phenothiazin-10-yl)phenyl]-3,4-

L19 ANSWER 138 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 thiophenediyl]bis[N-(3-methoxyphenyl)-N-(4-methoxyphenyl)- (9CI)
 (CA INDEX NAME)



L19 ANSWER 139 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:244657 CAPLUS
 DOCUMENT NUMBER: 130:281985
 TITLE: Preparation of arylthiophenes as PDE IV inhibitors
 INVENTOR(S): Han, Yongxin; Macdonald, Dwight; Giroux, Andre;
 Young,
 Robert N.; Perrier, Helene; Lepine, Carole
 PATENT ASSIGNEE(S): Merck Frosst Canada Inc., Can.
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: FIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918099	A1	19990415	WO 1998-CA931	19981001
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6034089	A	20000307	US 1998-163033	19980928
CA 2305414	A1	19990415	CA 1998-2305414	19981001
AU 9893347	A	19990427	AU 1998-93347	19981001
AU 732406	B2	20010426		
EP 1019399	A1	20000719	EP 1998-946190	19981001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001519347	T	20011023	JP 2000-514910	19981001
JP 3409029	B2	20030519		
PRIORITY APPLN. INFO.:			US 1997-60914P	P 19971003
			GB 1998-8109	A 19980416
			WO 1998-CA931	W 19981001


OTHER SOURCE(S): MARPAT 130:281985
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Ar1 = (un)substituted Ph, quinolinyl, pyridinyl, etc.; R1 = H, alkyl (optionally substituted with OH), X1Y1Ar2 (wherein X1 = CH2, a bond; Y1 = O, S, NH, etc.; Ar2 = (un)substituted Ph, naphthyl, pyrimidinyl, etc.); R2 = H, alkyl; R3 = (un)substituted Ph, naphthyl, pyridinyl, etc.], useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV), were prepared


L19 ANSWER 139 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 E.g., reaction of bromide II with lithium
 2-(4-N-methylpiperazino)pyridine-
 5-trimethylboronate salt in the presence of Pd(PPh3)4 in DME/H2O afforded
 thiophene III. The instant compds. I showed IC50 of 1 nM - 5 μM
 against PDE IV in human whole blood assay and IC50 of 0.1 nM - 5 μM in
 human mononuclear cell assay.
 IT 222839-54-5P 222840-29-1P 222840-43-9P
 222840-45-1P 222840-52-0P 222840-57-5P
 RU: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylthiophenes as PDE IV inhibitors)

222839-54-5 CAPLUS
 CN Benzenecetic acid,
 4-[4-[(4,6-dimethyl-2-pyrimidinyl)thio]methyl]-5-
 (4-methoxyphenyl)-2-thienyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 222840-29-1 CAPLUS
 CN Benzoic acid, 4-[5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-[(3-methoxyphenyl)thio]methyl]-2-thienyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 139 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 222840-43-9 CAPLUS
 CN Benzoic acid, 4-[5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-[(2-methoxyphenyl)thio]methyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 222840-45-1 CAPLUS
 CN Benzoic acid,
 4-[5-(3,4-dimethoxyphenyl)-3-[(3-methoxyphenyl)thio]methyl]-
 2-thienyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 139 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 222840-52-0 CAPLUS
 CN Benzoic acid,
 4-[5-(3,4-dimethoxyphenyl)-3-[(2-methoxyphenyl)thio]methyl]-
 2-thienyl]- (9CI) (CA INDEX NAME)



RN 222840-57-5 CAPLUS
 CN Benzenemethanol, 4-[3-[(3-(cyclopentyloxy)-4-methoxyphenyl)methyl]-5-(3-pyridinyl)-2-thienyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)

L19 ANSWER 139 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L19 ANSWER 140 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:122253 CAPLUS
DOCUMENT NUMBER: 130:325056
TITLE: Friedel-Crafts type reaction of chlorothiophenes with aromatic compounds and its application to the syntheses of aryl- and oligothiophenes
AUTHOR(S): Sone, Tyo; Sato, Kazuaki
CORPORATE SOURCE: Fac. Eng., Yamagata Univ., Yonezawa, 992-8510, Japan
SOURCE: Yamagata Daigaku Kiyo, Kogaku (1999), 25(2), 69-85
CODEN: YDKKAR, ISSN: 0085-834X
PUBLISHER: Yamagata Daigaku
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:325056
AB Chlorothiophenes react with active aromatic compds. in the presence of AlCl₃

under mild conditions, yielding the corresponding arylthiophenes. Similarly, chlorinated bi- and terthiophenes are produced as the main products in the AlCl₃-catalyzed self-condensation of the chlorothiophenes.


The reactions are discussed in terms of an ionic mechanism involving the thiophenium ions produced by the protonation of the chlorothiophenes. Versatility of the products for the syntheses of arylthiophenes, mixed thiophene-arene oligomers, and oligothiophenes is also demonstrated.

IT 223675-01-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

RN 223675-01-2 CAPLUS (Friedel-Crafts type reactions of chlorothiophenes)

CN 2,2'-Bithiophene, 5,5'-bis(2,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




L19 ANSWER 141 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:651124 CAPLUS
DOCUMENT NUMBER: 129:308409
TITLE: Positive-hole injection material for organic electroluminescent device
INVENTOR(S): Enokida, Toshio; Onikubo, Shunichi; Tamano, Michiko;
PATENT ASSIGNEE(S): Toyo Ink Mfg. Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 43 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10265773	A	19981006	JP 1997-69911	19970324
PRIORITY APPLN. INFO.:			JP 1997-69911	19970324


OTHER SOURCE(S): MARPAT 129:308409
GI



AB The material has a formula I [R1-20 = H, halo, alkyl, alkoxy, thioalkoxy, amino, monocyclic group, polycyclic group, O; R21-25 = H, halo, alkyl, alkoxy, thioalkoxy, amino, monocyclic group, polycyclic group; R21-25 may form a cycloalkyl ring, aryl ring; X1 = direct bond, alkylene, (CR26R27)xO(CR28R29)y, (CR30R31)xS(CR32R33)y, O, S, CO, SO2, SiR34(R35), NR36, PR37, PO(R38); x, y = 0-8 integer; x = y ≠ 0; Z1 = Ar1, Ar2NR39Ar3, Ar4NR40Ar5NR41Ar6; Ar1-6 = arylene; R26-41 = alkyl, monocyclic group, polycyclic group]. The device shows high luminance, efficiency,



L19 ANSWER 141 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

long life, and storage stability.
IT 214338-45-1
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(organic electroluminescent device containing aromatic pos.-hole injection material)
RN 214338-45-1 CAPLUS
CN Benzenamine, 4,4'-(2,5-thiophenediyl)bis[N,N-bis[4-[(5,6,7,8-tetrahydro-1-naphthalenyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 142 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:531855 CAPLUS
 DOCUMENT NUMBER: 129:260997
 TITLE: Design, synthesis, and electrochemical polymerization of conjugated monomers with tetrahedral geometry: towards three-dimensional conductors
 AUTHOR(S): Marsella, Michael J.; Li, Hong; Reid, Rodney J.
 CORPORATE SOURCE: Department of Chemistry, University of California at Riverside, Riverside, CA, 92521, USA
 SOURCE: Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (1998), 39(2), 521-522
 PUBLISHER: American Chemical Society, Division of Polymer Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB He design, synthesis, and potential applications of conjugated mols. with two- and three-dimensional geometries is discussed. The synthesis of tetrahedral thiophene-based monomers with conjugation extending in three dimensions is described. The electrochem. polymerization of the monomers is also discussed with emphasis on the potential for obtaining high-mol.-weight polymers which retain the characteristics of small-mol. conductors.
 IT 213701-51-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (design, synthesis, and electrochem. polymerization of conjugated monomers with tetrahedral geometry as route towards three-dimensional conductors)
 RN 213701-51-0 CAPLUS
 CN Thiophene, 2,2',2'',2'''-[methanetetrayltetrakis(4,1-phenylene-2,1-ethynediyl)]tetrakis[5-[2,5-bis(hexyloxy)-4-(2-thienyl)phenyl]-, homopolymer (9CI) (CA INDEX NAME)
 CM 1
 CRN 213701-50-9
 CMP C137 H148 O8 S8


L19 ANSWER 142 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 143 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:480858 CAPLUS
 DOCUMENT NUMBER: 129:168019
 TITLE: Aggregation of dendrimers with a photochromic dithienylethene core group on the mica surface-atomic force microscopic imaging
 AUTHOR(S): Hellmann, Jorg; Hamano, Mitsuo; Karthaus, Olaf; Ijio, Kuniharu; Shimomura, Masatsugu; Irie, Masahiro
 CORPORATE SOURCE: Department of Chemistry and Biochemistry, Graduate School of Engineering, Kyushu University, Hakozaki, Higashi-ku. Fukutoka, 812, Japan
 SOURCE: Japanese Journal of Applied Physics, Part 2: Letters (1999), 37(7A), L816-L819
 CODEN: JAPLDB; ISSN: 0021-4922
 PUBLISHER: Japanese Journal of Applied Physics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Atomic force microscopic (AFM) imaging revealed that a polyether third generation dendrimer having a photochromic dithienylethene core group forms regularly aligned (hexagonal alignment) droplets of more or less equal size (100-120 nm) and height of the long axis of the dendrimer (5.0 ± 0.5 nm) on a mica surface when the surface is rinsed with a benzene solution of the dendrimer. The size suggests that one droplet contains around 104 dendrimers. The subtle balance among surface hydrophilicity, hydrophobicity of solvent and dendrimers, and structure or shape of the dendrimers is considered to control the regular alignment.
 IT 211242-81-8P 211242-83-0P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (aggregation of dendrimers with photochromic dithienylethene core group on mica surface-atomic force microscopic imaging)
 RN 211242-81-8 CAPLUS
 CN Thiophene, 3,3'-(3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-diyl)bis[5-[4-[[3,5-bis(phenylmethoxy)phenyl]methoxy]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L19 ANSWER 143 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 211242-83-0 CAPLUS
 CN Thiophene, 3,3'-(3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-diyl)bis[5-[4-[[3,5-bis(phenylmethoxy)phenyl]methoxy]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




L19 ANSWER 143 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




PAGE 2-A



L19 ANSWER 144 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:353085 CAPLUS
 DOCUMENT NUMBER: 129:24482
 TITLE: Preparation of thiophene-2-carboxylic acid derivatives
 INVENTOR(S): as agrochemical microbicides
 Fischer, Reiner; Lui, Norbert; Dutzmann, Stefan;
 Haenssler, Gerd
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 28 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19649093	A1	19980528	DE 1996-19649093	19961127
WO 9823605	A1	19980604	WO 1997-EP6368	19971114
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854824	A	19980622	AU 1998-54824	19971114
EP 944615	A1	19990929	EP 1997-951205	19971114
R: BE, CH, DE, FR, GB, IT, LI, NL, PT				
JP 2001504832	T	20010410	JP 1998-524220	19971114
US 6013664	A	20000111	US 1999-308903	19990526
PRIORITY APPLN. INFO.:			DE 1996-19649093	A 19961127
			WO 1997-EP6368	W 19971114


OTHER SOURCE(S): CASREACT 129:24482; MARPAT 129:24482
 GI



AB The title compds. I [R1 = halo, CN, NO2, (halo)alkyl, (halo)alkoxy, (halo)alkylthio, Ph or PhO; n = 0-5; R2 = OH, SH, (un)substituted NH2, etc.] are prepared as agrochem. bactericides and fungicides.
 IT 208108-48-9P 208108-66-1P 208108-71-8P
 RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological)


L19 ANSWER 143 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L19 ANSWER 144 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 study); PREP (Preparation); USES (Uses)
 (prepn. as agrochem. microbicide)
 RN 208108-48-9 CAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-4-phenyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 208108-66-1 CAPLUS
 CN 2-Thiophenecarboxamide, 4-(4-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 208108-71-8 CAPLUS
 CN 2-Thiophenecarboxamide, 4-(2,4-dichlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L19 ANSWER 144 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 145 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:314121 CAPLUS
 DOCUMENT NUMBER: 129:60393
 TITLE: Organic electroluminescent device
 INVENTOR(S): Nakatsuka, Masakatsu; Kitamoto, Noriko
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10125468	A	19980515	JP 1997-217720	19970812
JP 3870288	B2	20070117		
JP 2007049177	A	20070222	JP 2006-257035	20060922
PRIORITY APPLN. INFO.:			JP 1996-230118	A 19960830
			JP 1997-217720	A3 19970812


OTHER SOURCE(S): MARPAT 129:60393
 GI




AB The invention relates to an organic electroluminescent device that comprises the organic compound represented by I [Ar1-8 = (un)substituted aryl group; X = O or S; m, n, p = 0 or 1], sandwiched between a pair of electrodes.
 IT 123715-38-8 123715-39-9 208599-72-8
 208599-73-9 208599-75-1 208599-76-2
 208599-83-1 208599-84-2 208599-91-1
 208599-92-2
 RL: DEV (Device component use); USES (Uses)

L19 ANSWER 145 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 123715-38-8 CAPLUS
 CN Benzenamine, 4,4'-(3,4-diphenyl-2,5-thiophenediyl)bis[N-(4-methoxy-2-methylphenyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 123715-39-9 CAPLUS
 CN Benzenamine, 4,4',4'''-(4-phenyl-2,3,5-thiophenetriyl)tris[N-(4-methoxy-2-methylphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 208599-72-8 CAPLUS
 CN Benzenamine, N,N-bis(4-ethoxyphenyl)-4-(3,4,5-triphenyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 208599-73-9 CAPLUS
 CN Benzenamine, 4-methoxy-N-(4-methoxy-2-methylphenyl)-2-methyl-N-[4-(3,4,5-triphenyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 145 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 208599-75-1 CAPLUS
 CN Benzenamine, 4,4'-(3,4-diphenyl-2,5-thiophenediyl)bis[N-(3-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 208599-76-2 CAPLUS
 CN Benzenamine, 4,4'-(3,4-diphenyl-2,5-thiophenediyl)bis[N,N-bis(3-chloro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 208599-83-1 CAPLUS
 CN Benzenamine, 4,4',4'''-(4-phenyl-2,3,5-thiophenetriyl)tris[N-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 145 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 208599-84-2 CAPLUS
CN Benzenamine, 4,4'-[5-[4-[bis(4-methoxyphenyl)amino]phenyl]-4-phenyl-2,3-thiophenediyl]bis[N,N-bis(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 208599-91-1 CAPLUS
CN Benzenamine, 4,4',4'',4'''-(2,3,4,5-thiophenetetrayl)tetrakis[N-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 145 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




L19 ANSWER 145 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 208599-92-2 CAPLUS
CN Benzenamine, 4,4',4'',4'''-(2,3,4,5-thiophenetetrayl)tetrakis[N,N-bis(3-methoxy-5-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 146 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

1998:251153 CAPLUS
DOCUMENT NUMBER: 128:308308
TITLE: The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
INVENTOR(S): Levin, Jeremy Ian; Du Mila, T.; Venkatesan, Aranapakam
Mudumbai; Nelson, Frances Christy; Zask, Arie; Gu, Yansong
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9816503	A2	19980423	WO 1997-US18280	19971008
WO 9816503	A3	19980528		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, SZ, BE, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2268894	A1	19980423	CA 1997-2268894	19971008
AU 9851458	A	19980511	AU 1998-51458	19971008
AU 731737	B2	20010405		
EP 938471	A1	19990901	EP 1997-946246	19971008
EP 938471	B1	20011212		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
BR 9712525	A	19991019	BR 1997-12525	19971008
CN 1240429	A	20000105	CN 1997-180613	19971008
HU 200000641	A2	20001028	HU 2000-641	19971008
HU 200000641	A3	20010228		
JP 2001504809	T	20010410	JP 1998-518448	19971008
AT 210637	T	20011215	AT 1997-946246	19971008
ES 2166102	T3	20020401	ES 1997-946246	19971008
PT 938471	T	20020531	PT 1997-946246	19971008
ZA 9709233	A	19990415	ZA 1997-9233	19971015
TW 410220	B	20001101	TW 1997-86114187	19971015
KR 2000049196	A	20000725	KR 1999-703294	19990415
HK 1021178	A1	20020404	HK 2000-100090	20000106
PRIORITY APPLN. INFO.:			US 1996-732631	A 19961016
			WO 1997-US18280	W 19971008

OTHER SOURCE(S): MARPAT 128:308308
GI

L19 ANSWER 146 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



II

AB The invention relates to novel, low mol. weight, non-peptide inhibitors of

matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF- α converting enzyme (TACE, tumor necrosis factor- α converting enzyme). The comps. are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic

joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, and ocular angiogenesis/neovascularization. The invention comps. are represented by

the formula ZSO₂N(CH₂R⁷)ACONHOH [I; A = (un)substituted Ph or naphthyl; Z = (un)substituted aryl, heteroaryl, or benzo-fused heteroaryl; R⁷ = H, (un)substituted alk(en)ynyl, Ph, naphthyl, 5- or 6-membered heteroaryl, cycloalkyl, or cycloheteroalkyl; or R⁷CH₂NA forms a non-aromatic 1,2-benzo-fused 7- to 10-membered heterocyclic ring with an optional addition

benzo fusion; where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A], and include pharmaceutically acceptable salts, optical isomers, and diastereomers. Preps. of over

400 comps., including I and their intermediates, are given. For instance, 2-[(4-methoxybenzenesulfonyl)amino]-3-methylbenzoic acid Me ester (preparation

given) was N-alkylated by 3-picolyl chloride-HCl (83%), followed by hydrolysis of the ester with LiOH in aqueous THF (100%), activation with oxalyl chloride, and hydroxamidation with NH₂OH.HCl (51%), to give title compound II. At 50 mg/kg/day in rats with cartilage implants, II gave

44.6% inhibition of cartilage weight loss, and 51.2% inhibition of cartilage collagen loss.

L19 ANSWER 146 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 206549-35-1P 206549-36-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of ortho-sulfonamido aryl hydroxamic acids

as matrix metalloproteinase and TACE inhibitors)


RN 206549-35-1 CAPLUS

CN Benzoic acid, 5-(5-acetyl-2-thienyl)-2-[[4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 206549-36-2 CAPLUS

CN Benzoic acid, 5-(5-acetyl-2-thienyl)-2-[[4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methyl- (9CI) (CA INDEX NAME)



IT 206549-37-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)

(preparation of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors)

RN 206549-37-3 CAPLUS

CN Benzamide, 5-(5-acetyl-2-thienyl)-N-hydroxy-2-[[4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methyl- (9CI) (CA

L19 ANSWER 146 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 147 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:229645 CAPLUS

DOCUMENT NUMBER: 128:270353

TITLE: π -Dimers of Prototype High-Spin Polaronic Oligomers
AUTHOR(S): van Haare, John A. E. H.; van Bortel, Marc; Janssen, Rene A. J.

CORPORATE SOURCE: Laboratory of Organic Chemistry, Eindhoven University of Technology, Eindhoven, 5600 MB, Neth.
SOURCE: Chemistry of Materials (1998), 10(4), 1166-1175
CODEN: CMATEX; ISSN: 0897-4756

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 128:270353

AB Novel well-defined oligomers consisting of two dopable π -conjugated segments, 2,2'-bipyrrrole or 2,2'-bithiophene, linked via 1,3-phenylene

and end-capped with Ph groups have been synthesized using palladium-catalyzed cross-coupling reactions. The mols. are considered as prototypical examples for polaronic ferromagnetic chains based on pyrrole and

thiophene units, which have been proposed as candidates for organic magnetic materials.

The oligomers are designed to investigate whether high-spin (i.e. triplet-state) oligocations can be obtained after oxidative doping. We find that the oligomers can be oxidized to the corresponding di(cation radical)s, in which each heterocyclic segment is singly oxidized and carries an unpaired electron, as required for a high-spin state. While these di(cation radical)s are stable at ambient temperature,

UV/visible/near-IR and ESR spectroscopy reveals that the singly charged cation radical segments reversibly form π -dimers in solution, especially at low temps.

This π -dimerization involves the intermol. antiferromagnetic pairing of electron spins and is detrimental for the formation of high-spin oligomers


or polymers via the polaronic concept with oxidized oligopyrrole or oligothiophene segments as spin-carrying units.

IT 205510-28-7
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)

(π -dimers of prototype high-spin polaronic oligomers)

RN 205510-28-7 CAPLUS


CN 2,2'-Bithiophene, 5,5'-[2-(dodecyloxy)-5-methyl-1,3-phenylene]bis[5'-phenyl-, radical ion(2+)] (9CI) (CA INDEX NAME)




IT 205436-45-9

RL: FMU (Formation, unclassified); PRP (Properties); RCT (Reactant); FORM

L19 ANSWER 147 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Formation, nonpreparative); RACT (Reactant or reagent)
 RN 205436-45-9 CAPLUS
 CN 2,2'-Bithiophene, 5,5''-[2-(dodecyloxy)-5-methyl-1,3-phenylene]bis[5'-phenyl-, radical ion(1+) (9CI) (CA INDEX NAME)




IT 205436-40-4P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (π-dimers of prototype high-spin polaronic oligomers)
 RN 205436-40-4 CAPLUS
 CN 2,2'-Bithiophene, 5,5''-[2-(dodecyloxy)-5-methyl-1,3-phenylene]bis[5'-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L19 ANSWER 148 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:224220 CAPLUS
 DOCUMENT NUMBER: 128:230937
 TITLE: Synthesis and photophysics of silylene-tethered divinylarene copolymers
 AUTHOR(S): Chen, Ruey-Min; Deng, Z. B.; Sun, G.; Lee, Shuit-Tong;
 CORPORATE SOURCE: Luh, Tien-Yau
 Department of Chemistry National Taiwan University, Taipei, 106, Taiwan
 SOURCE: Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (1998), 39(1), 89
 CODEN: ACPPAY; ISSN: 0032-3934
 PUBLISHER: American Chemical Society, Division of Polymer Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Hydrosilylation of bis-arylynes with bis(vinylsilylhydrides) yields silylene-tethered divinylarene polymers containing aryl or aryl-thiophene groups in the main chain. Polymers with aryl groups in the main chain exhibit dual fluorescence spectra and the intensity in the blue light region increases with mol. weight Intramol. interaction between luminophores in the polymers, both at the ground and at the excited states might occur.
 The polymers exhibited an electroluminescence band at 460 nm.
 IT 204577-89-9P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (synthesis and fluorescence and electroluminescence of silylene-tethered divinylarene and arene-thiophene copolymers)
 RN 204577-89-9 CAPLUS
 CN Poly[2,5-thiophenediyl-1,4-phenylene-2,5-thiophenediyl-1,2-ethenediyl(dimethylsilylene)-1,2-ethenediyl[2,5-bis(octyloxy)-1,4-phenylene]-1,2-ethenediyl(dimethylsilylene)-1,2-ethenediyl] (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 148 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L19 ANSWER 149 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:129418 CAPLUS
 DOCUMENT NUMBER: 128:217243
 TITLE: Preparation and characterization of new substituted phenylthienylacetylenes: comparison of three possible pathways
 AUTHOR(S): Latassa, D.; Prim, D.; Kirsch, G.
 CORPORATE SOURCE: Groupe de Synthèse Organique et Hétérocyclique, Laboratoire de Chimie Organique, Université de Metz
 Ile du Saulcy, METZ, F-57 012, Fr.
 SOURCE: Heterocyclic Communications (1998), 4(1), 81-94
 CODEN: HOCMEJ; ISSN: 0793-0283
 PUBLISHER: Freund Publishing House Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The synthesis of new substituted phenyl(thienyl)acetylenes is studied starting from selenadiazole rings, β-chloro acroleins and substituted Ph or thienyl acetylenes.
 IT 204277-13-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 204277-13-4 CAPLUS
 CN Thiophene, 2-[(4-methoxyphenyl)ethynyl]-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

119 ANSWER 151 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 13998:62874 CAPLUS
 DOCUMENT NUMBER: 128:128566
 TITLE: High-Performance Polyquinolines with Pendent High-Temperature Chromophores for Second-Order Nonlinear Optics
 AUTHOR(S): Jen, Alex K-Y.; Wu, Xiaoming; Ma, Hong
 CORPORATE SOURCE: Department of Chemistry, Northeastern University, Boston, MA, 02115, USA
 SOURCE: Chemistry of Materials (1998), 10 (2), 471-473
 CODEN: CMATEX; ISSN: 0897-4756
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A simple, generally applicable synthetic approach to side-chain second-order nonlinear optical (NLO) polyquinolines is described. A series of side-chain NLO polyquinolines and their copolymers was prepared via direct polymerization of a bis(ortho-aminoketone) monomer with the chromophore-functionalized bis(ketomethylene) monomers. A series of high-temperature and chemical stable chromophores were covalently attached onto the polyquinoline backbones. These NLO side-chain polyquinolines possess high glass-transition temperature ($T_g > 200^\circ$), excellent processability, thermal stability, and electrooptical properties. Poling results of these polymers demonstrate large electrooptic coefficient (r_{33}) value (up to 10^4 pm/V measured at $0.83 \mu\text{m}$) and good temporal alignment stability of polymer films (the R_{33} value retained more than 80% of the original values at 100° for more than 3000 h).
 IT 201862-40-0P 201862-41-1P
 RI: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or Reagent)
 (in preparation of high-performance polyquinolines with pendent high-temperature chromophores for second-order nonlinear optics)
 RN 201862-40-0 CAPLUS
 CN Propanedinitrile,
 [[5-[4-[[2-(2,4-diethylphenoxy)ethyl]ethylamino]phenyl]-2-thienyl]-4-(4-(diethylamino)phenyl)methylene]- (9CI) (CA INDEX NAME)

$$\text{R}(\text{CH}_2)_n\text{X}-\text{C}_6\text{H}_4-\text{Y}-\text{C}_6\text{H}_4-(\text{CH}_2)_m\text{NB}$$
~~~~CCN(CC)c1ccc(cc1)C(=S)C2=CC=CC=C2C(=S)C3=CC=CC=C3C(=S)C4=CC=CC=C4C(=S)C5=CC=CC=C5C(=S)C6=CC=CC=C6C(=S)C7=CC=CC=C7C(=S)C8=CC=CC=C8C(=S)C9=CC=CC=C9C(=S)C10=CC=CC=C10C(=S)C11=CC=CC=C11C(=S)C12=CC=CC=C12C(=S)C13=CC=CC=C13C(=S)C14=CC=CC=C14C(=S)C15=CC=CC=C15C(=S)C16=CC=CC=C16C(=S)C17=CC=CC=C17C(=S)C18=CC=CC=C18C(=S)C19=CC=CC=C19C(=S)C20=CC=CC=C20C(=S)C21=CC=CC=C21C(=S)C22=CC=CC=C22C(=S)C23=CC=CC=C23C(=S)C24=CC=CC=C24C(=S)C25=CC=CC=C25C(=S)C26=CC=CC=C26C(=S)C27=CC=CC=C27C(=S)C28=CC=CC=C28C(=S)C29=CC=CC=C29C(=S)C30=CC=CC=C30C(=S)C31=CC=CC=C31C(=S)C32=CC=CC=C32C(=S)C33=CC=CC=C33C(=S)C34=CC=CC=C34C(=S)C35=CC=CC=C35C(=S)C36=CC=CC=C36C(=S)C37=CC=CC=C37C(=S)C38=CC=CC=C38C(=S)C39=CC=CC=C39C(=S)C40=CC=CC=C40C(=S)C41=CC=CC=C41C(=S)C42=CC=CC=C42C(=S)C43=CC=CC=C43C(=S)C44=CC=CC=C44C(=S)C45=CC=CC=C45C(=S)C46=CC=CC=C46C(=S)C47=CC=CC=C47C(=S)C48=CC=CC=C48C(=S)C49=CC=CC=C49C(=S)C50=CC=CC=C50C(=S)C51=CC=CC=C51C(=S)C52=CC=CC=C52C(=S)C53=CC=CC=C53C(=S)C54=CC=CC=C54C(=S)C55=CC=CC=C55C(=S)C56=CC=CC=C56C(=S)C57=CC=CC=C57C(=S)C58=CC=CC=C58C(=S)C59=CC=CC=C59C(=S)C60=CC=CC=C60C(=S)C61=CC=CC=C61C(=S)C62=CC=CC=C62C(=S)C63=CC=CC=C63C(=S)C64=CC=CC=C64C(=S)C65=CC=CC=C65C(=S)C66=CC=CC=C66C(=S)C67=CC=CC=C67C(=S)C68=CC=CC=C68C(=S)C69=CC=CC=C69C(=S)C70=CC=CC=C70C(=S)C71=CC=CC=C71C(=S)C72=CC=CC=C72C(=S)C73=CC=CC=C73C(=S)C74=CC=CC=C74C(=S)C75=CC=CC=C75C(=S)C76=CC=CC=C76C(=S)C77=CC=CC=C77C(=S)C78=CC=CC=C78C(=S)C79=CC=CC=C79C(=S)C80=CC=CC=C80C(=S)C81=CC=CC=C81C(=S)C82=CC=CC=C82C(=S)C83=CC=CC=C83C(=S)C84=CC=CC=C84C(=S)C85=CC=CC=C85C(=S)C86=CC=CC=C86C(=S)C87=CC=CC=C87C(=S)C88=CC=CC=C88C(=S)C89=CC=CC=C89C(=S)C90=CC=CC=C90C(=S)C91=CC=CC=C91C(=S)C92=CC=CC=C92C(=S)C93=CC=CC=C93C(=S)C94=CC=CC=C94C(=S)C95=CC=CC=C95C(=S)C96=CC=CC=C96C(=S)C97=CC=CC=C97C(=S)C98=CC=CC=C98C(=S)C99=CC=CC=C99C(=S)C100=CC=CC=C100C(=S)C101=CC=CC=C101C(=S)C102=CC=CC=C102C(=S)C103=CC=CC=C103C(=S)C104=CC=CC=C104C(=S)C105=CC=CC=C105C(=S)C106=CC=CC=C106C(=S)C107=CC=CC=C107C(=S)C108=CC=CC=C108C(=S)C109=CC=CC=C109C(=S)C110=CC=CC=C110C(=S)C111=CC=CC=C111C(=S)C112=CC=CC=C112C(=S)C113=CC=CC=C113C(=S)C114=CC=CC=C114C(=S)C115=CC=CC=C115C(=S)C116=CC=CC=C116C(=S)C117=CC=CC=C117C(=S)C118=CC=CC=C118C(=S)C119=CC=CC=C119C(=S)C120=CC=CC=C120C(=S)C121=CC=CC=C121C(=S)C122=CC=CC=C122C(=S)C123=CC=CC=C123C(=S)C124=CC=CC=C124C(=S)C125=CC=CC=C125C(=S)C126=CC=CC=C126C(=S)C127=CC=CC=C127C(=S)C128=CC=CC=C128C(=S)C129=CC=CC=C129C(=S)C130=CC=CC=C130C(=S)C131=CC=CC=C131C(=S)C132=CC=CC=C132C(=S)C133=CC=CC=C133C(=S)C134=CC=CC=C134C(=S)C135=CC=CC=C135C(=S)C136=CC=CC=C136C(=S)C137=CC=CC=C137C(=S)C138=CC=CC=C138C(=S)C139=CC=CC=C139C(=S)C140=CC=CC=C140C(=S)C141=CC=CC=C141C(=S)C142=CC=CC=C142C(=S)C143=CC=CC=C143C(=S)C144=CC=CC=C144C(=S)C145=CC=CC=C145C(=S)C146=CC=CC=C146C(=S)C147=CC=CC=C147C(=S)C148=CC=CC=C148C(=S)C149=CC=CC=C149C(=S)C150=CC=CC=C150C(=S)C151=CC=CC=C151C(=S)C152=CC=CC=C152C(=S)C153=CC=CC=C153C(=S)C154=CC=CC=C154C(=S)C155=CC=CC=C155C(=S)C156=CC=CC=C156C(=S)C157=CC=CC=C157C(=S)C158=CC=CC=C158C(=S)C159=CC=CC=C159C(=S)C160=CC=CC=C160C(=S)C161=CC=CC=C161C(=S)C162=CC=CC=C162C(=S)C163=CC=CC=C163C(=S)C164=CC=CC=C164C(=S)C165=CC=CC=C165C(=S)C166=CC=CC=C166C(=S)C167=CC=CC=C167C(=S)C168=CC=CC=C168C(=S)C169=CC=CC=C169C(=S)C170=CC=CC=C170C(=S)C171=CC=CC=C171C(=S)C172=CC=CC=C172C(=S)C173=CC=CC=C173C(=S)C174=CC=CC=C174C(=S)C175=CC=CC=C175C(=S)C176=CC=CC=C176C(=S)C177=CC=CC=C177C(=S)C178=CC=CC=C178C(=S)C179=CC=CC=C179C(=S)C180=CC=CC=C180C(=S)C181=CC=CC=C181C(=S)C182=CC=CC=C182C(=S)C183=CC=CC=C183C(=S)C184=CC=CC=C184C(=S)C185=CC=CC=C185C(=S)C186=CC=CC=C186C(=S)C187=CC=CC=C187C(=S)C188=CC=CC=C188C(=S)C189=CC=CC=C189C(=S)C190=CC=CC=C190C(=S)C191=CC=CC=C191C(=S)C192=CC=CC=C192C(=S)C193=CC=CC=C193C(=S)C194=CC=CC=C194C(=S)C195=CC=CC=C195C(=S)C196=CC=CC=C196C(=S)C197=CC=CC=C197C(=S)C198=CC=CC=C198C(=S)C199=CC=CC=C199C(=S)C200=CC=CC=C200C(=S)C201=CC=CC=C201C(=S)C202=CC=CC=C202C(=S)C203=CC=CC=C203C(=S)C204=CC=CC=C204C(=S)C205=CC=CC=C205C(=S)C206=CC=CC=C206C(=S)C207=CC=CC=C207C(=S)C208=CC=CC=C208C(=S)C209=CC=CC=C209C(=S)C210=CC=CC=C210C(=S)C211=CC=CC=C211C(=S)C212=CC=CC=C212C(=S)C213=CC=CC=C213C(=S)C214=CC=CC=C214C(=S)C215=CC=CC=C215C(=S)C216=CC=CC=C216C(=S)C217=CC=CC=C217C(=S)C218=CC=CC=C218C(=S)C219=CC=CC=C219C(=S)C220=CC=CC=C220C(=S)C221=CC=CC=C221C(=S)C222=CC=CC=C222C(=S)C223=CC=CC=C223C(=S)C224=CC=CC=C224C(=S)C225=CC=CC=C225C(=S)C226=CC=CC=C226C(=S)C227=CC=CC=C227C(=S)C228=CC=CC=C228C(=S)C229=CC=CC=C229C(=S)C230=CC=CC=C230C(=S)C231=CC=CC=C231C(=S)C232=CC=CC=C232C(=S)C233=CC=CC=C233C(=S)C234=CC=CC=C234C(=S)C235=CC=CC=C235C(=S)C236=CC=CC=C236C(=S)C237=CC=CC=C237C(=S)C238=CC=CC=C238C(=S)C239=CC=CC=C239C(=S)C240=CC=CC=C240C(=S)C241=CC=CC=C241C(=S)C242=CC=CC=C242C(=S)C243=CC=CC=C243C(=S)C244=CC=CC=C244C(=S)C245=CC=CC=C245C(=S)C246=CC=CC=C246C(=S)C247=CC=CC=C247C(=S)C248=CC=CC=C248C(=S)C249=CC=CC=C249C(=S)C250=CC=CC=C250C(=S)C251=CC=CC=C251C(=S)C252=CC=CC=C252C(=S)C253=CC=CC=C253C(=S)C254=CC=CCN(CC)c1ccc(cc1)-c2cc3c(cc2)sc(cc3C#N)C#Nc4ccc(cc4)N(CC)CCOC(=O)c5ccc(cc5)C(=O)CCc1ccc(cc1)C(C(F)(F)F)(C(F)(F)F)c2ccc(C)cc2

L19 ANSWER 151 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 201862-44-4 CAPLUS
 CN Propanedinitrile,
 [[5-[4-[(2-(2,4-diacetylphenoxy)ethyl)ethylamino]phenyl]-2-thienyl][4-(diethylamino)phenyl]methylene]-, polymer with
 [oxybis(6-amino-3,1-phenylene)]bis[phenylmethanone] (9CI) (CA INDEX NAME)

CM 1

CRN 201862-40-0


CMF C38 H38 N4 O3 S



CM 2


CRN 59827-14-4

CMF C26 H20 N2 O3



RN 201862-45-5 CAPLUS
 CN Propanedinitrile,
 [[5-[4-[(2-(2,4-diacetylphenoxy)ethyl)ethylamino]phenyl]-2-thienyl][5-[4-(diethylamino)phenyl]-2-thienyl]methylene]-, polymer with
 [oxybis(6-amino-3,1-phenylene)]bis[phenylmethanone] (9CI) (CA INDEX NAME)

L19 ANSWER 152 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:495177 CAPLUS
 DOCUMENT NUMBER: 127:149123
 TITLE: Studies on thiophene heterocycles. II. Synthesis and biological activity of some
 6-(5-aryl-2-thienyl)-7H-s-triazolo[3,4-b]-1,3,4-thiadiazines
 AUTHOR(S): Kalluraya, Bhalakrishna; Shetty, Suresh N.
 CORPORATE SOURCE: Department of Studies in Chemistry, Mangalore University, Mangalagangothri, 574 199, India
 SOURCE: Indian Journal of Heterocyclic Chemistry (1997), 6(4), 287-290
 CODEN: IJCHEI; ISSN: 0971-1627
 PUBLISHER: Lucknow University, Dep. of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Title compds. I [R = H, alkyl, aryl, (aryloxy)methyl, substituted anilinoethyl] were prepared from amino-1,2,4-triazolethiols and 2-(bromoacetyl)-5-(4-nitrophenyl)thiophene. I were screened for antibacterial and antifungal activity. The chlorine-containing compds.

were

significantly active against E. coli.

IT 193280-68-1P 193280-69-2P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial activity of)

RN 193280-68-1 CAPLUS

CN 7H-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazine,


3-[(2-chlorophenoxy)methyl]-6-[5-(4-nitrophenyl)-2-thienyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 151 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 201862-41-1


CMF C42 H40 N4 O3 S2



CM 2


CRN 59827-14-4

CMF C26 H20 N2 O3




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
 FORMAT

L19 ANSWER 152 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





RN 193280-69-2 CAPLUS
 CN 7H-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazine,
 3-[(4-chlorophenoxy)methyl]-6-[5-(4-nitrophenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




IT 193280-65-8P 193280-67-0P 193280-73-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 193280-65-8 CAPLUS
 CN 7H-1,2,4-Triazolo[3,4-b][1,3,4]thiadiazine,
 3-[(2-methylphenoxy)methyl]-6-[5-(4-nitrophenyl)-2-thienyl]- (9CI) (CA INDEX NAME)

L19 ANSWER 152 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 152 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 153 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:324316 CAPLUS
DOCUMENT NUMBER: 127:17609
TITLE: Directed Electrophilic Cyclizations: Efficient Methodology for the Synthesis of Fused Polycyclic Aromatics
AUTHOR(S): Goldfinger, Marc B.; Crawford, Khushrav B.; Swager, Timothy M.
CORPORATE SOURCE: Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
SOURCE: Journal of the American Chemical Society (1997), 119(20), 4578-4593
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:17609
AB A versatile method for the synthesis of complex, fused, polycyclic, aromatic systems in high chemical yield is described. Construction is achieved using a general two-step synthetic sequence. Pd-catalyzed Suzuki and Negishi type cross-coupling chemistries allow for the preparation of non-fused skeletal ring systems in yields consistently >80%. The critical ring-forming step, which generally proceeds in very high to quant. yield, utilizes (4-alkoxyphenyl)ethynyl groups and is induced by strong electrophiles such as trifluoroacetic acid and iodonium tetrafluoroborate. The reaction in essence produces phenanthrene moieties which are integrated into extended polycyclic aromatic structures. Fused polycyclic benzenoids as well as benzenoid/thiophene systems may be prepared by this methodol. The scope of the described cross-coupling/cyclization chemical including mechanistic insights and problematic side reactions are described.
IT 190371-95-0P 190372-07-7P 190372-10-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cross-coupling/cyclization chemical in preparation of fused polycyclic aroms.)
RN 190371-95-0 CAPLUS
CN Thiophene, 2,2'-[2,5-bis[[4-(dodecyloxy)phenyl]ethynyl]-1,4-phenylene]bis[5-methyl- (9CI) (CA INDEX NAME)


L19 ANSWER 153 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B




PAGE 1-B



L19 ANSWER 153 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 190372-11-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (cross-coupling/cyclization chemical in preparation of fused
 polycyclic aroms.)
 RN 190372-11-3 CAPLUS
 CN 2,2'-Bithiophene, 5-[5-bromo-2,4-bis[[4-(hexyloxy)phenyl]ethynyl]phenyl]-
 (9CI) (CA INDEX NAME)




REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L19 ANSWER 154 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:748862 CAPLUS
 DOCUMENT NUMBER: 126:59901
 TITLE: Studies on arylthiophene heterocycles. Part 1.
 Synthesis and biological activity of some
 2-aryl/arylamino-4-[5-(p-nitrophenyl)-2-thienyl]
 thiazoles
 AUTHOR(S): Kalluraya, Balakrishna; Shetty, Suresh N.
 CORPORATE SOURCE: Department Studies Chemistry, Mangalore University,
 Mangalagangothri, 574 199, India
 SOURCE: Oriental Journal of Chemistry (1996), 12(2), 141-144
 CODEN: OJCHEG; ISSN: 0970-020X
 PUBLISHER: Oriental Scientific Publishing Co.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The preparation of sixteen new 2-aryl/arylamino-4-[5-(p-nitrophenyl)-2-
 thienyl]thiazoles is described. The new compds. were screened for their
 antibacterial activity against both Gram-pos. and Gram-neg. bacteria.

The screening results indicates that compds. carrying the arylamino
 substituent at the 2-position are more active.
 IT 185315-68-8P 185315-71-3P 185315-72-4P
 185315-78-0P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation of bactericidal
 aryl/arylamino[(p-nitrophenyl)thienyl]thiazole
 s)
 RN 185315-68-8 CAPLUS
 CN Thiazole, 2-(3,4-dimethoxyphenyl)-4-[5-(4-nitrophenyl)-2-thienyl]- (9CI)
 (CA INDEX NAME)




RN 185315-71-3 CAPLUS
 CN 2-Thiazolamine, N-(4-methoxyphenyl)-4-[5-(4-nitrophenyl)-2-thienyl]-
 (9CI)
 (CA INDEX NAME)




L19 ANSWER 154 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 185315-72-4 CAPLUS
 CN 2-Thiazolamine, N-(2-methoxyphenyl)-4-[5-(4-nitrophenyl)-2-thienyl]-
 (9CI)
 (CA INDEX NAME)



RN 185315-78-0 CAPLUS
 CN 2-Thiazolamine, N-(4-ethoxyphenyl)-4-[5-(4-nitrophenyl)-2-thienyl]- (9CI)
 (CA INDEX NAME)




L19 ANSWER 155 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:718456 CAPLUS
 DOCUMENT NUMBER: 126:8858
 TITLE: Monomolecular Layers of Diarylethene-Containing
 Dendrimers
 AUTHOR(S): Karthaus, O.; Ijio, K.; Shimomura, M.; Hellmann, J.;
 Irie, M.
 CORPORATE SOURCE: Research Institute for Electronic Science, Hokkaido
 University, Sapporo, Japan
 SOURCE: Langmuir (1996), 12(26), 6714-6716
 CODEN: LANGD5; ISSN: 0743-7463
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Monolayers of dendrimers of the diarylethene chromophore bisphenol
 derivative
 were prepared by spreading the dilute benzene solution on a clear water
 surface.

The dendrimers showed an increasing surface pressure upon compression of
 a
 spread film at the air-water interface. The dendrimer films could be
 transferred to solid supports by the conventional vertical dipping
 (Langmuir-Blodgett) method.
 IT 184005-38-7P 184005-39-8P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and characterization of monomol. layers of
 diarylethene-containing
 dendrimers)
 RN 184005-38-7 CAPLUS
 CN Thiophene, 3,3'-(3,3,4,4,5,5-hexafluoro-1,2-cyclopentenediyl)bis[5-[4-
 [(3,5-bis(phenylmethoxy)phenyl)methoxy]phenyl]-2,4-dimethyl- (9CI) (CA
 INDEX NAME)

PAGE 1-A




L19 ANSWER 155 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 155 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-B

PAGE 2-A




RN 184005-39-8 CAPLUS
 CN Thiophene, 3,3'-(3,3,4,4,5,5-hexafluoro-1,2-cyclopentenediyl)bis[5-[4-
 [[3,5-bis[[3,5-bis(phenylmethoxy)phenyl]methoxy]phenyl]methoxy]phenyl]-2,4-
 dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A

—CH₂—Ph

PAGE 2-A




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L19 ANSWER 156 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:637056 CAPLUS
 DOCUMENT NUMBER: 125:275634
 TITLE: Preparation of phenylamidinothiophene derivatives as
 antiinflammatory agents
 INVENTOR(S): Tanaka, Kiyomi; Nishida, Tokiko; Nakano, Jun; Inoue,
 Mamoru; Nakamura, Tsutomu; Debuchi, Hayami
 PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9626204	A1	19960829	WO 1996-JP372	19960219
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2213537	A1	19960829	CA 1996-2213537	19960219
AU 9646771	A	19960911	AU 1996-46771	19960219
EP 811620	A1	19971210	EP 1996-902482	19960219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
CN 1176639	A	19980318	CN 1996-192134	19960219
US 6048890	A	20000411	US 1997-894627	19970822
PRIORITY APPLN. INFO.:			JP 1995-37043	A 19950224
			WO 1996-JP372	W 19960219

OTHER SOURCE(S): MARPAT 125:275634
 GI




AB Phenylamidinothiophene derivs. represented by general formula (I); R₁, R₂
 = H, halo, C1-4 alkyl or alkoxy) or pharmacol. acceptable salts thereof,
 which show antiinflammatory activity without digestive tract disorders
 (e.g stomach ulcer), and are useful for preventing and/or treating
 inflammatory diseases, collagen diseases, autoimmune diseases, other
 immune diseases, are prepared Thus, 300 mg
 5-cyano-2-(4-fluorophenyl)-3-(4-
 methanesulfonylphenyl)thiophene was dissolved in 1,1,2,2-
 tetrachloroethane, treated with 226 mg AlCl₃, stirred at room
 temperature for 1

L19 ANSWER 156 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 h, treated with 0.14 mL m-chloroaniline, and stirred at 100° for 8
 h to give, after workup and silica gel chromatog., 356 mg I (R₁ = 3-Cl,
 R₂ = H). The latter compd. at 10 mg/kg p.o. per day for 17 days in vivo
 inhibited 31.5% arthritis in rat paws which was induced by direct s.c.
 administration of an adjuvant vs. 28.3% for indomethcin. It in vitro did
 not inhibit cyclooxygenase at 10-4 M, but indomethcin dose-dependently
 inhibited cyclooxygenase and showed complete inhibition at 10-4 M.
 IT 182225-54-3P 182225-55-4P 182225-59-8P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylamidinothiophene derivs. as antiinflammatory
 agents)
 RN 182225-54-3 CAPLUS
 CN 2-Thiophenecarboximidamide, 5-(4-fluorophenyl)-N-(3-methoxyphenyl)-4-[4-
 (methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 182225-59-8 CAPLUS
 CN 2-Thiophenecarboximidamide, 5-(4-fluorophenyl)-N-(3,5-dimethoxyphenyl)-4-[4-
 (methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 182225-59-8 CAPLUS
 CN 2-Thiophenecarboximidamide, N-(3,5-dimethoxyphenyl)-5-(4-fluorophenyl)-4-[4-
 (methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)


L19 ANSWER 156 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 157 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:498196 CAPLUS
 DOCUMENT NUMBER: 125:233733
 TITLE: Recent development of high performance electro-optic materials for device applications
 AUTHOR(S): Jen, Alex K-Y.; Chen, Tian-An; Zhang, Yue; Liu, Yue-Jin; Zhang, XuanQi; Kenney, John T.; Dalton, Larry
 CORPORATE SOURCE: R.
 SOURCE: ROI Technology, Monmouth Junction, NJ, 08852, USA
 CODEN: FMSEDG; ISSN: 0743-0515
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A new series of highly efficient ($B_{11}=2000-3000 \times 10^{-48}$ esu) and thermally stable ($>300^\circ\text{C}$) nonlinear optical chromophores was developed.
 IT 181815-17-8P 181815-18-9P
 RL: DEV (Device component use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
 (recent development of high performance electro-optic materials for device applications)
 RN 181815-17-8 CAPLUS
 CN Propanedinitrile, [[5-[4-(diethylamino)phenyl]-2-thienyl][5-[4-[[2-(2,5-dinitrophenoxy)ethyl]ethylamino]phenyl]-2-thienyl]methylene]- (9CI) (CA INDEX NAME)



RN 181815-18-9 CAPLUS
 CN Propanedinitrile, [[5-[4-[[2-(2,5-diaminophenoxy)ethyl]ethylamino]phenyl]-2-thienyl][5-[4-(diethylamino)phenyl]-2-thienyl]methylene]- (9CI) (CA INDEX NAME)




L19 ANSWER 157 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 158 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:485780 CAPLUS
 DOCUMENT NUMBER: 125:142763
 TITLE: Heterocyclyl substituted hydroxyacetamide derivatives as fungicides
 INVENTOR(S): Doeller, Uwe; Braun, Peter; Sachse, Burkhard; Reissel, Willy; Ort, Oswald Peter Gerald; Hough, Thomas Lawley;
 PATENT ASSIGNEE(S): Simpson, Donald James; Lindner, Kerstin; Lindell, Stephen David
 SOURCE: Agrevo UK Ltd., UK
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9617840	A1	19960613	WO 1995-GB2849	19951206
W:	AU, BG, BR, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RO, RU, SD, SK, UA, US			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9642655	A	19960626	AU 1996-42655	19951206
PRIORITY APPLN. INFO.:			GB 1994-24553	A 19941206
			GB 1994-25971	A 19941222
			GB 1995-2865	A 19950214
			WO 1995-GB2849	W 19951206

OTHER SOURCE(S): MARPAT 125:142763
 AB Title compds. QZRICEWY (Q = optionally substituted heterocyclyl; Z = optionally substituted hydroxy or mercapto; E = CONR2, CSNR2, C(N)SR2; W = O, NR3, optionally substituted methylene or ethylene; R1, R2, R3 = Ph or alkyl, each of which is optionally substituted, or hydrogen; Y = Ph, heteroaryl or alkyl, each of which is optionally substituted, or hydrogen), useful as fungicides, were prepared Thus, reduction of 2-(3,5-dichloro-2-thienyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-oxoacetamide with NaBH4 gave 2-(3,5-dichloro-2-thienyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-hydroxyacetamide. N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-(2-bromo-3-thienyl)-2-hydroxyacetamide showed fungicidal activity against Pyricularia oryzae.
 IT 179758-57-7P 179759-31-OP
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclyl substituted hydroxyacetamide derivs. as fungicides)
 RN 179758-57-7 CAPLUS
 CN 2-Thiopheneacetamide, 5-(4-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-


L19 ANSWER 158 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 α -hydroxy- (9CI) (CA INDEX NAME)



RN 179759-31-0 CAPLUS
 CN 2-Thiopheneacetamide,
 5-(4-chlorophenyl)-N-[2-(4-ethoxy-3-methoxyphenyl)-1-
 methylethyl]- α -hydroxy- (9CI) (CA INDEX NAME)




L19 ANSWER 159 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:305482 CAPLUS
 DOCUMENT NUMBER: 125:11874
 TITLE: Processible aromatic polyamides derived from 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene and aromatic diacid chlorides
 AUTHOR(S): Lee, Won-Kyu; Lee, Kwang-Sup; Song, Hyun Hoon; Lee, Soo-Min
 CORPORATE SOURCE: Department Macromolecular Science, Han Nam University,
 SOURCE: Taejon, 300-791, S. Korea
 Polymers and Other Advanced Materials: Emerging Technologies and Business Opportunities, [Proceedings of the International Conference on Frontiers of Polymers and Advanced Materials], 3rd, Kuala Lumpur, Jan. 16-20, 1995 (1995), Meeting Date 1995, 385-392. Editor(s): Prasad, Paras N.; Mark, James E.; Tung, Joo
 Fail. Plenum: New York, N. Y.
 CODEN: 62SQAO
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB Structural characteristics of the title aromatic polythiophene-polyamides, prepared via low-temperature polymerization, are discussed. The results showed layer structures for these rigid polymers.
 IT 160362-93-6 177261-19-7 177261-21-1
 177261-24-4
 RL: PRP (Properties)
 (structural characterization of processible aromatic polyamides derived from bis(aminophenyl)diphenylthiophene and aromatic diacid chlorides)
 RN 160362-93-6 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl[2,5-bis(dodecyloxy)-1,4-phenylene]carbonylimino-1,4-phenylene] (9CI) (CA INDEX NAME)




RN 177261-19-7 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl[2,5-bis(octyloxy)-1,4-phenylene]carbonylimino-1,4-phenylene] (9CI) (CA INDEX NAME)


L19 ANSWER 159 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 NAME)



RN 177261-21-1 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl[2,5-bis(decyloxy)-1,4-phenylene]carbonylimino-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 177261-24-4 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl[2,5-bis(tetradecyloxy)-1,4-phenylene]carbonylimino-1,4-phenylene] (9CI) (CA INDEX NAME)




L19 ANSWER 160 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:200132 CAPLUS
 DOCUMENT NUMBER: 124:246135
 TITLE: Organic superlattice material, production thereof and device therefrom
 INVENTOR(S): Hamano, Koji; Kurata, Tetsuyuki; Fuchigami, Hiroyuki; Nobutoki, Ei-ji; Fukada, Che; Nakao, Yukiyasu
 PATENT ASSIGNEE(S): Mitsubishi Electric Corp, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
 CODEN: JKXKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07325329	A	19951212	JP 1994-120058	19940601
JP 2975530	B2	19991110	JP 1994-120058	19940601

PRIORITY APPLN. INFO.: JP 1994-120058 19940601


AB An organic material, suitable for use as nonlinear optical and electronic materials, is prepared by laminating ≥ 2 kind of organic thin films having a thickness 0.5-100 nm, wherein the organic thin film comprises π -conjugated linear oligomers.

IT 174896-19-6 174896-20-9
 RL: DEV (Device component use); USES (Uses)
 (organic superlattice material, production thereof and device therefrom)
 RN 174896-19-6 CAPLUS
 CN 2,2'-Bithiophene,
 5,5'-(2,5-dimethoxy-1,4-phenylene)bis[5'-(2,5-dimethoxy-4-(2-thienyl)phenyl)- (9CI) (CA INDEX NAME)




RN 174896-20-9 CAPLUS
 CN Thiophene, 2,5-bis[4'-(5-(2,5-dimethoxyphenyl)-2-thienyl)-2,2',5,5'-tetramethoxy[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

L19 ANSWER 160 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 161 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1996:54155 CAPLUS
 DOCUMENT NUMBER: 124:177567
 TITLE: Novel second-order nonlinear optical polyimides
 AUTHOR(S): Yu, Dong; Gharavi, Ali; Yu, Luping
 CORPORATE SOURCE: Department Chemistry, University Chicago, Chicago, IL, 60637, USA
 SOURCE: Proceedings of SPIE-The International Society for Optical Engineering (1995), 2527(Nonlinear Optical Properties of Organic Materials VIII, 1995), 127-36
 CODEN: PSISDG; ISSN: 0277-786X
 SPIE-The International Society for Optical Engineering
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A general approach to the synthesis of second-order nonlinear optical (NLO) polyimides exhibiting high thermal stability was developed. Several selected NLO chromophores were incorporated into the polyimide backbone. Phys. studies indicate that these polyimides exhibit long-term and high thermal stability in dipole orientation, relatively large electro-optic coeffs., and low optical loss. Although all of these properties are not optimized, the overall performances of these polyimides make them very attractive for practical applications. The synthetic approach is also versatile and will allow the syntheses of many other functional polymers.
 IT 171368-29-9P
 RL: PRP (Properties); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (preparation and characterization of second-order nonlinear optical polyimides with high thermal stability)
 RN 171368-29-9 CAPLUS
 CN 1,3-Isobenzofurandione, 5,5'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-, polymer with 2-[2-[ethyl[4-[5-(4-nitrophenyl)-2-thienyl]phenyl]amino]ethoxy]-1,4-benzenediamine (9CI) (CA INDEX NAME)
 CM 1
 CRN 171368-27-7
 CMF C26 H26 N4 O3 S



CM 2


L19 ANSWER 161 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 1107-00-2
 CMF C19 H6 F6 O6




L19 ANSWER 162 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:977840 CAPLUS
 DOCUMENT NUMBER: 124:102596
 TITLE: X-ray diffraction studies of the liquid crystal phases of certain 4-n-alkoxyphenyl 4-(5-n-alkyl-2-thienyl)benzoates
 AUTHOR(S): Bunning, John D.; Butcher, Jane L.; Byron, David J.; Matharu, Avtar S.; Wilson, Robert C.
 CORPORATE SOURCE: Mater. Res. Inst., Sheffield Hallam Univ., Sheffield, S1 1WB, UK
 SOURCE: Liquid Crystals (1995), 19(5), 693-8
 CODEN: LICRE6; ISSN: 0267-8292
 PUBLISHER: Taylor & Francis
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The Bu, octyl, decyl and dodecyl homologs of each of the 4-pentyloxyphenyl, 4-hexyloxyphenyl and 4-heptyloxyphenyl 4-(5-alkyl-2-thienyl)benzoates were prepared. All the homologs gives rise to liquid crystal phases and their transition temps. are reported. Phase identification was not straightforward, especially when distinguishing between some of the higher order smectic phases, and required a combination of thermal optical measurements of smectic layer spacings.
 IT 172800-62-3P, 4-Pentyloxyphenyl 4-(5-butyl-2-thienyl)benzoate
 172800-63-4P, 4-Pentyloxyphenyl 4-(5-octyl-2-thienyl)benzoate
 172800-64-5P, 4-Pentyloxyphenyl 4-(5-decyl-2-thienyl)benzoate
 172800-65-6P, 4-Pentyloxyphenyl 4-(5-dodecyl-2-thienyl)benzoate
 172800-66-7P, 4-Hexyloxyphenyl 4-(5-butyl-2-thienyl)benzoate
 172800-67-8P, 4-Hexyloxyphenyl 4-(5-octyl-2-thienyl)benzoate
 172800-68-9P, 4-Hexyloxyphenyl 4-(5-decyl-2-thienyl)benzoate
 172800-69-0P, 4-Hexyloxyphenyl 4-(5-dodecyl-2-thienyl)benzoate
 172800-70-3P, 4-Heptyloxyphenyl 4-(5-butyl-2-thienyl)benzoate
 172800-71-4P, 4-Heptyloxyphenyl 4-(5-octyl-2-thienyl)benzoate
 172800-72-5P, 4-Heptyloxyphenyl 4-(5-decyl-2-thienyl)benzoate
 172800-73-6P, 4-Heptyloxyphenyl 4-(5-dodecyl-2-thienyl)benzoate
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and liquid crystal properties of)
 RN 172800-62-3 CAPLUS
 CN Benzoic acid, 4-(5-butyl-2-thienyl)-, 4-(pentyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 172800-63-4 CAPLUS
 CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 4-(pentyloxy)phenyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 162 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172800-64-5 CAPLUS
CN Benzoic acid, 4-(5-decyl-2-thienyl)-, 4-(pentyloxy)phenyl ester (9CI)
(CA INDEX NAME)



RN 172800-65-6 CAPLUS
CN Benzoic acid, 4-(5-dodecyl-2-thienyl)-, 4-(pentyloxy)phenyl ester (9CI)
(CA INDEX NAME)




RN 172800-66-7 CAPLUS
CN Benzoic acid, 4-(5-butyl-2-thienyl)-, 4-(hexyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 172800-67-8 CAPLUS
CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 4-(hexyloxy)phenyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 162 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172800-72-5 CAPLUS
CN Benzoic acid, 4-(5-decyl-2-thienyl)-, 4-(heptyloxy)phenyl ester (9CI)
(CA INDEX NAME)




RN 172800-73-6 CAPLUS
CN Benzoic acid, 4-(5-dodecyl-2-thienyl)-, 4-(heptyloxy)phenyl ester (9CI)
(CA INDEX NAME)




L19 ANSWER 162 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172800-68-9 CAPLUS
CN Benzoic acid, 4-(5-decyl-2-thienyl)-, 4-(hexyloxy)phenyl ester (9CI) (CA INDEX NAME)



RN 172800-69-0 CAPLUS
CN Benzoic acid, 4-(5-dodecyl-2-thienyl)-, 4-(hexyloxy)phenyl ester (9CI)
(CA INDEX NAME)



RN 172800-70-3 CAPLUS
CN Benzoic acid, 4-(5-butyl-2-thienyl)-, 4-(heptyloxy)phenyl ester (9CI)
(CA INDEX NAME)




RN 172800-71-4 CAPLUS
CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 4-(heptyloxy)phenyl ester (9CI)
(CA INDEX NAME)

L19 ANSWER 163 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:938817 CAPLUS
DOCUMENT NUMBER: 124:30528
TITLE: Novel Aromatic Polyimides for Nonlinear Optics
AUTHOR(S): Yu, Dong; Gharavi, Ali; Yu, Luping
CORPORATE SOURCE: Department of Chemistry, University of Chicago, Chicago, IL, 60637, USA
SOURCE: Journal of the American Chemical Society (1995), 117(47), 11680-6
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English


AB A general approach to the synthesis of second-order nonlinear optical (NLO) polyimides exhibiting high thermal stability has been developed. Several selected NLO chromophores have been incorporated into the polyimide backbone. Detailed phys. studies showed that these polymers are very promising for practical applications. Three of these polyimides are soluble in common organic solvents, offering the ease of processing. High glass temps., around 230 °C, assure a long-term NLO stability at elevated temps., such as 150 °C. Low optical loss was observed for those soluble polymers. The synthetic approach is also versatile and will allow the syntheses of many other functional polymers.
IT 171368-27-7P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(monomer; preparation and characterization of novel aromatic polyimides for nonlinear optics)
RN 171368-27-7 CAPLUS
CN 1,4-Benzenediamine, 2-[2-[ethyl[4-[5-(4-nitrophenyl)-2-thienyl]phenyl]amino]ethoxy]- (9CI) (CA INDEX NAME)



IT 171368-29-9P
RI: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and characterization of novel aromatic polyimides for nonlinear optics)
RN 171368-29-9 CAPLUS
CN 1,3-Isobenzofurandione, 5,5'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-, polymer with 2-[2-[ethyl[4-[5-(4-nitrophenyl)-2-thienyl]phenyl]amino]ethoxy]-1,4-benzenediamine (9CI) (CA INDEX NAME)

CM 1


L19 ANSWER 163 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 171368-27-7
 CMF C26 H26 N4 O3 S



CM 2


CRN 1107-00-2

CMF C19 H6 F6 O6



L19 ANSWER 164 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:762771 CAPLUS
 DOCUMENT NUMBER: 123:270563
 TITLE: A dual-mode molecular switching device: bisphenolic diarylethenes with integrated photochromic and electrochromic properties
 AUTHOR(S): Kawai, Stephen H.; Gilat, Sylvain L.; Ponsinet, Rachel; Lehn, Jean-Marie
 CORPORATE SOURCE: Chem. Interactions Mol., Coll. France, Paris, 75005, Fr.
 SOURCE: Chemistry--A European Journal (1995), 1(5), 285-93
 Published in: Angew. Chem., Int. Ed. Engl., 34(15)
 CODEN: CEUJED; ISSN: 0947-6539
 PUBLISHER: VCH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Dual-mode optical-elec. mol. switching device was prepared in which all three states are stable species. The spectral and redox properties are very well suited to form the basis of an erasable optical data storage system with nondestructive readout capacity. While photochem. writing and erasing may be carried out as for any photochrome-based system, the redox behavior allows for the written data to be safeguarded or locked by oxidation to the quinonoid form. Not only does this prevent erasing during the read process with visible light, but it also represents an amplification of the stored data, since the quinone absorbs approx. twice as strongly as the colored, photochromic form. A reduction process would then be used to unlock the information and permit subsequent photochem. erasing. The complete process is thus a five-step write-lock-read-unlock-erase cycle. Such a system is also of interest in that it allows for both deep and shallow memory modes within the same medium, since locked data would remain unaffected during the course of writing and erasing of temporarily stored information based solely on the photochromic forms of the device.
 IT RL: DEV (Device component use); PNU (Preparation, unclassified); PRP (Properties); PREP (Preparation); USES (Uses)
 (bisphenolic diarylethenes with integrated photochromic and electrochromic properties for dual-mode mol. switching device)
 RN 169173-74-4 CAPLUS
 CN Thiophene,
 3,3'-(3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-diyl)bis[5-[3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)phenyl]-2-methyl- (9CI) (CA INDEX NAME)

L19 ANSWER 164 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 165 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:740932 CAPLUS
 DOCUMENT NUMBER: 123:127789
 TITLE: Mesomorphic compound, liquid crystal composition containing the compound, liquid crystal device using the composition, liquid crystal apparatus and display method.
 INVENTOR(S): Kosaka, Yoko; Takiguchi, Takao; Iwaki, Takashi; Toqano, Takeshi; Nakamura, Shinichi
 PATENT ASSIGNEE(S): Canon K. K., Japan
 SOURCE: Eur. Pat. Appl., 115 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 641850	A1	19950308	EP 1994-113906	19940905
EP 641850	B1	20000426		
R: CH, DE, ES, FR, GB, IT, LI, NL, SE				
JP 07072442	A	19950317	JP 1993-243579	19930906
JP 07076543	A	19950320	JP 1993-243578	19930906
US 5868960	A	19990209	US 1997-781062	19970109
PRIORITY APPLN. INFO.:			JP 1993-243578	A 19930906
			JP 1993-243579	A 19930906
			US 1994-300527	B1 19940906

OTHER SOURCE(S): MARPAT 123:127789
 AB A mesomorphic compound $C_mH_{2m+1}(CH_2)_nO(CH_2)_pO(CH_2)_qY_1-A_1-R_1$ [$R_1 = H$, halogen, CN, or a linear, branched or cyclized alkyl group having 1-30 C atoms capable of including at least one $-CH_2-$ group which can be replaced with $-O-$, $-S-$, $-CO-$, $-CH(Cl)-$, $-CH(CN)-$, $-C(CH_3)(CN)-$, $-CH=CH-$ or $-C.tplbond.C-$ provided that heteroatoms are not adjacent to each other and capable of including at least one H which can be replaced with F; m, n, p and q = 1-16 provided that m + n + p + q \leq 18; Y1 denotes a single bond, $-O-$, $-CO-$, $-COO-$, $-OCO-$, $-CH=CH-$ or $-C.tplbond.C-$; A1 = $-A_2-$, $-A_2-X_1-A_3-$ or $-A_2-X_1-A_3-X_2-A_4$ in which A2, A3 and A4 independently denote a divalent cyclic group; X1, X2 = a single bond, $-COO-$, $-OCO-$, $-CH_2O-$, $-OCH_2-$, $-CH_2CH_2-$, $-CH=CH-$ or $-C.tplbond.C-$ having \geq 2 ether groups between alkylene groups in a specific alkoxy perfluoroalkyl terminal group is suitable as a component for a liquid crystal composition providing improved response characteristics and a high contrast. A liquid crystal device is constituted by disposing the liquid crystal composition between a pair of substrates. The liquid crystal device is used as a display panel constituting a liquid crystal apparatus providing good display characteristics.
 IT 166440-86-4
 RL: MCA (Modifier or additive use); USES (Uses)
 (perfluoroalkyl mesomorphic compound for liquid crystal composition)
 RN 166440-86-4 CAPLUS
 CN Benzoic acid,
 4-[2-[3-[(9,9,10,10,10-pentafluorodecyl)oxy]propoxy]ethoxy]-

L19 ANSWER 165 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
, 4-(5-butyl-2-thienyl)phenyl ester (9CI) (CA INDEX NAME)




PAGE 1-B

L19 ANSWER 166 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:308776 CAPLUS
DOCUMENT NUMBER: 122:81404
TITLE: Preparation of N-aralkylpiperazines and -piperidines as antiischemics
INVENTOR(S): McCort, Gary; Pascal, Jean-Claude; Blondet, Dominique;
Gellibert, Francoise
PATENT ASSIGNEE(S): Syntex Pharmaceuticals Ltd., UK
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9424116	A1	19941027	WO 1994-EP1085	19940406
W:	AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, UZ, VN			
RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5428037	A	19950627	US 1993-45568	19930409
CA 2160113	A1	19941027	CA 1994-2160113	19940406
AU 9465660	A	19941108	AU 1994-65660	19940406
EP 693062	A1	19960124	EP 1994-913550	19940406
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
BR 9406209	A	19960206	BR 1994-6209	19940406
CN 1120838	A	19960417	CN 1994-191728	19940406
JP 08508741	T	19960917	JP 1994-522707	19940406
US 5545645	A	19960813	US 1995-401486	19950309
FI 9504718	A	19951004	FI 1995-4718	19951004
PRIORITY APPLN. INFO.:			US 1993-45568	A 19930409
			WO 1994-EP1085	W 19940406
OTHER SOURCE(S):		CASREACT 122:81404; MARPAT 122:81404		
GI				

L19 ANSWER 166 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB ACHR1(CH₂)mNR₂R₃ [A = aryl group Q, R₁R₂C₆H₃; R₁ = H, OH, alkyl; R₂ = alkyl; R₃ = XCHR₅(CH₂)nR₄; R₂R₃ = (CH₂CH₂)₂Y(CH₂)_pCHR₅(CH₂)_qR₄, CH₂CR₄R₅ZCH₂CH₂; R₄ = H, (cyclo)alkyl, (un)substituted Ph; R₅ = (un)substituted Ph; R₉ = alkyl, (un)substituted Ph; R₁₀ = H, alkyl; R₁₁ = alkyl, (un)substituted aryl; R₁₂ = H, alkyl(oxy), halo, CF₃; W = O, S, (alkyl)imino; X = (CH₂)_p, piperidine-1,4-diyl; Y = CH, CHO, CHS, N; Z = CH₂, NH, S, O; m, n, q = 0 or 1; p = 0-3] were prepared. Thus, prepared title compound I.2HCl gave 59% protection against exptl. ischemia in mice at 50µg/kg i.p. twice/day for 7 days.


IT 160416-79-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-aralkylpiperazines and -piperidines as antiischemics)

RN 160416-79-5 CAPLUS
CN Piperazine, 1-[(3-methyl-5-phenyl-2-thienyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L19 ANSWER 166 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 167 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:272673 CAPLUS
 DOCUMENT NUMBER: 122:56696
 TITLE: Novel thermotropic liquid crystalline polymers: rigid and semi-rigid polymers with flexible side chains
 AUTHOR(S): Lee, Kwang-Sup; Lee, Won-Kyu; Lee, Soo-Min; Kim, Hea-Ok; Le, Byung-Woon
 CORPORATE SOURCE: Dep. Macromol. Sci., Han Nam Univ., Taejon, 300-791, S. Korea
 SOURCE: Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals (1994), 254, 37-48
 CODEN: MCLCE9; ISSN: 1058-725X
 PUBLISHER: Gordon & Breach
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Two series of rigid and semi-rigid polyesters and polyamides with flexible side chains were prepared by solution, melt and interfacial polycondensation of 2,5-dialkoxypthaloyl chloride with various diols and diamines. The thermal behavior of the polymers were studied by DSC, TGA and polarizing microscopy. The results indicated that only rigid polymer systems form a nematic mesophase. However, none of the semi-rigid polymers formed nematic melts. The structures of both polyesters and polyamides were also examined by wide angle x-ray scattering. Anal. of sharp reflections, appearing at the lower angle of x-ray diffractograms of rigid polymers, suggested that rigid polymers crystallized to form a layered structure in the solid state.
 IT 160362-93-6P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation, characterization and properties of rigid and semi-rigid thermotropic liquid crystalline polymers with flexible side chains)
 RN 160362-93-6 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneimino]carbonyl[2,5-bis(dodecyloxy)-1,4-phenylene] (9CI) (CA INDEX NAME)






L19 ANSWER 168 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:252363 CAPLUS
 DOCUMENT NUMBER: 122:42692
 TITLE: Electrophotographic photoreceptor
 INVENTOR(S): Hanatani, Yasuyuki; Kadai, Mikio; Sakai, Hirotsuke
 PATENT ASSIGNEE(S): Mita Industrial Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06130699	A	19940513	JP 1992-278283	19921016
PRIORITY APPLN. INFO.:			JP 1992-278283	19921016

GI

L19 ANSWER 168 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title photoreceptor comprises a photosensitive layer(s) containing I
 [A = coupler residual; R1 = H, alkyl, aryl, heterocyclly; n = 0-1] as a charge generating material and II [R2-R5 = H, halo, alkyl, alkoxy; R6, R7 = alkyl, aryl, aralkyl; p = 1-3; q = 0-1; R6 and R7 may form ring each other] as a charge transporting material on a conductive support. The photoreceptor showed superior electrophotog. characteristics.
 IT 159716-81-1
 RL: DEV (Device component use); USES (Uses)
 (charge transporting material of electrophotog. photoreceptor)
 RN 159716-81-1 CAPLUS
 CN Benzaldehyde, 4-[5'-(diphenylamino)[2,2':5',2''-terthiophen]-5-yl]-, bis(4-methoxyphenyl)hydrazone (9CI) (CA INDEX NAME)

L19 ANSWER 169 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:545281 CAPLUS
 DOCUMENT NUMBER: 121:145281
 TITLE: High-sensitivity electrophotographic photoreceptor
 INVENTOR(S): Hatsutori, Yoshimasa; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05303222	A	19931116	JP 1992-105014	19920424
PRIORITY APPLN. INFO.:				
			JP 1992-105014	19920424


AB The title electrophotog. photoreceptor utilizes a carrier-generating material expressed as (CPA)-N:N-X-N:N-(CPB) [X = aromatic hydrocarbon or unsatd. heterocyclic group, the preceding groups linked via vinylene, O, CO, CH:N, NR (R = H, Aromatic hydrocarbon or aromatic heterocycle); CPA and CPB are specified coupler residues].

IT 157270-63-8
 RL: USES (Uses)
 (electrophotog. charge-generating compound)


RN 157270-63-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 4-[[[4-[5-[4-[[[3-[[[4-cyano-1-hydroxy-3-methylpyrido[1,2-a]benzimidazol-2-yl]amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]-2-thienyl]phenyl]azo]-3-hydroxy-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 169 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




L19 ANSWER 170 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:435005 CAPLUS
 DOCUMENT NUMBER: 121:35005
 TITLE: Substituted alkylamine derivatives
 INVENTOR(S): Takezawa, Hiroshi; Hayashi, Masahiro; Iwasawa, Yoshikazu; Hosoi, Masaaki; Iida, Yoshiaki; Tauchiya, Yoshimi; Horie, Masahiro; Kamei, Toshio
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
 SOURCE: U.S., 74 pp. Cont.-in-part of U.S. Ser. No. 533,532, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5234946	A	19930810	US 1991-753611	19910830
ZA 8808792	A	19890830	ZA 1988-8792	19881124
JP 03193746	A	19910823	JP 1988-296840	19881124
CN 1037141	A	19891115	CN 1988-109274	19881126
ZA 8908464	A	19910130	ZA 1989-8464	19891107
PRIORITY APPLN. INFO.:				
			JP 1987-299584	A 19871127

JP 1988-96286	A	19880419
JP 1988-113310	A	19880510
JP 1988-285381	A	19881111
US 1988-274972	B2	19881122
US 1990-465209	B2	19900308
US 1990-533532	B2	19900605

OTHER SOURCE(S): MARPAT 121:35005
 GI




AB The title compds. and their uses for the treatment of hypercholesteremia, arteriosclerosis and hyperlipemia are claimed. Specifically claimed is compound I. The title compds. are squalene epoxidase inhibitors.
 IT 155294-56-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiarteriosclerotic, anticholesteremic or hypolipemic)

L19 ANSWER 170 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 155294-56-7 CAPLUS
 CN Benzenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-ethyl-3-[[3-(5-methyl-3-thienyl)phenyl]methoxy]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L19 ANSWER 171 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:324460 CAPLUS
 DOCUMENT NUMBER: 120:324460
 TITLE: Diimide dicarboxylic acids and their polyamides
 INVENTOR(S): Yang, Chin Ping; Hsiao, Sheng Huei; Lin, Jiun Hung
 PATENT ASSIGNEE(S): National Science Council, Taiwan
 SOURCE: U.S., 11 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5268487	A	19931207	US 1993-44237	19930407
US 5414070	A	19950509	US 1993-162683	19931203
PRIORITY APPLN. INFO.:			US 1993-44237	A3 19930407


OTHER SOURCE(S): MARPAT 120:324460
 GI



AB Title acids I (R = arylene), useful for manufacture of poly(amide-imide)s with improved strength, heat resistance and processability, are prepared by condensing the appropriate aromatic diamines with trimellitic anhydride (II) in a polar solvent. Thus, reaction of 1,4-bis(4-aminophenoxy)benzene with II in DMF gave I (R = 1,4-phenylene), which was polymerized with 2,2-bis[4-(4-aminophenoxy)phenyl] sulfone to give a polymer with tensile strength 62 MPa and 10% weight loss temperature 525 and 521° in air and N, resp.
 IT 143780-00-1P
 RL: DMF (Industrial manufacture); PREP (Preparation) (manufacture of heat-resistant)
 RN 143780-00-1 CAPLUS
 CN Poly[(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-1,4-phenyleneoxy-1,4-phenyleneoxy-1,4-phenylene(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl)carbonylimino-1,4-phenylene(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl] (9CI) (CA INDEX NAME)

L19 ANSWER 172 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:299417 CAPLUS
 DOCUMENT NUMBER: 120:299417
 TITLE: New poly(amide-imide) synthesis. IX. Preparation and properties of poly(amide-imide)s derived from 2,7-bis(4-aminophenoxy)naphthalene and various bis(trimellitimide)s
 AUTHOR(S): Yang, Chin Ping; Chen, Wen Tung
 CORPORATE SOURCE: Dep. Chem. Eng., Tatung Inst. Technol., Taipei, Taiwan
 SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry
 Chemistry (1994), 32(6), 1101-11
 CODEN: JPACJC; ISSN: 0887-624X
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Eleven bis(phenoxy)naphthalene-containing poly(amide-imides) were synthesized by the direct polycondensation of 2,7-bis(4-aminophenoxy)naphthalene (DAPON) with various aromatic bis(trimellitimides) in N-methyl-2-pyrrolidone (I) using tri-Ph phosphite and pyridine as condensing agents. Poly(amide-imides) having inherent viscosities of 0.70-1.12 dL/g were obtained in quant. yields. The polymers containing p-phenylene of bis(phenoxy)benzene units exhibited crystalline x-ray diffraction patterns. Most of the polymers were readily soluble in various solvents such as I, N,N-dimethylacetamide (II), DMSO, n-cresol, o-chlorophenol, and pyridine, and gave transparent and flexible films cast from II solns. Cast films showed obvious yield points in the stress-strain curves and had strength at break up to 87 MPa, elongation to break up to 11%, and initial modulus up to 2.10 GPa. These poly(amide-imides) had glass transition temps. in the range of 255-321°, and the 10% weight loss temps. were recorded in the range of 529-586° in nitrogen. The properties of poly(amide-imides) were compared with those of the corresponding isomeric poly(amide-imides) prepared from 2,7-bis(4-trimellitimidophenoxy)naphthalene and aromatic diamines.
 IT 154929-77-8P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and properties of)
 RN 154929-77-8 CAPLUS
 CN Poly[(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-1,4-phenylene(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl)carbonylimino-1,4-phenyleneoxy-2,7-naphthalenediyl-1,4-phenyleneiminocarbonyl] (9CI) (CA INDEX NAME)




PAGE 1-A

L19 ANSWER 171 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



L19 ANSWER 172 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



L19 ANSWER 173 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:245918 CAPLUS
 DOCUMENT NUMBER: 120:245918
 TITLE: Synthesis and characterization of novel polyarylates from 2,5-bis(4-hydroxyphenyl)-3,4-diphenylthiophene and various aromatic dicarboxylic acids
 AUTHOR(S): Jeong, Hwa Jin; Iwasaki, Ken; Kakimoto, Masaaki; Imai, Yoshio
 CORPORATE SOURCE: Dep. Org. Polym. Mater., Tokyo Inst. Technol., Tokyo, 152, Japan
 SOURCE: Polymer Journal (Tokyo, Japan) (1994), 26(3), 379-85
 CODEN: POLJB8; ISSN: 0032-3896
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A new tetraphenylated heterocyclic diol, 2,5-bis(4-hydroxyphenyl)-3,4-diphenylthiophene, was synthesized in three steps starting from 4-methoxydeoxybenzoin. The tetraphenylthiophene-containing polyarylates having inherent viscosities of 0.29-0.84 dL g⁻¹ were prepared by the high temperature solution polycondensation of the diol with various aromatic dicarboxylic acid chlorides. All the polyarylates were crystalline or semicryst., and the crystalline polyarylates were quite insol. in organic solvents, while the others dissolved readily in a variety of solvents including N-methyl-2-pyrrolidone and sym-tetrachloroethane. These polymers had glass transition temps. in the range of 209-260°C, with no weight loss below 400°C in both air and nitrogen atmospheres.
 IT 154584-60-8P, 2,5-Bis(4-hydroxyphenyl)-3,4-diphenylthiophene-4,4'-oxydibenzoyl chloride copolymer, SRU
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and characterization of)
 RN 154584-60-8 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneoxycarbonyl-1,4-phenyleneoxy-1,4-phenylenecarbonyloxy-1,4-phenylene] (9CI) (CA INDEX NAME)

L19 ANSWER 173 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-B



L19 ANSWER 174 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:244491 CAPLUS
 DOCUMENT NUMBER: 120:244491
 TITLE: The synthesis of novel arylene-vinylene oligomers
 AUTHOR(S): Maud, J. M.; Thompson, N. J.; Hepburn, A. R.; Marshall, J. M.
 CORPORATE SOURCE: Dep. Chem., Univ. Coll. Swansea, Singleton Park/Swansea, SA2 8PP, UK
 SOURCE: Synthetic Metals (1993), 57(2-3), 4777-82
 CODEN: SYMEDE; ISSN: 0379-6779
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI


L19 ANSWER 174 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



AB The preparation of mixed arylene-vinylene oligomers with alkyl or alkoxy substituents situated on the 2 terminal aromatic units is described. Although the oligomers do not display the expected solubility in organic solvents, the success of the synthetic strategy in providing a wide range of materials, designed for the construction of oligomer structure - electronic property relations, is demonstrated. Coupling of (E)-1-(4-bromophenyl)-2-[4-(hexyloxy)phenyl]ethene gave the dimer I. Coupling of (E)-1-(4-bromophenyl)-2-(5-bromo-2-thienyl)ethene gave the dimer II.
 IT 154368-63-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 154368-63-5 CAPLUS
 CN Thiophene, 2,2'-(2,5-dimethoxy-1,4-phenylene)bis[5-[2-[4-(hexyloxy)phenyl]ethenyl]-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




L19 ANSWER 175 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:107926 CAPLUS
 DOCUMENT NUMBER: 120:107926
 TITLE: Synthesis and characterization of novel aromatic polyamides from 3,4-bis(4-aminophenyl)-2,5-diphenylthiophene and aromatic dicarboxylic acids
 AUTHOR(S): Jeong, HwaJin; Kobayashi, Atsushi; Kakimoto, Masaaki; Imai, Yoshio
 CORPORATE SOURCE: Dep. Organ. Polym. Mater., Tokyo Inst. Technol., Tokyo, 152, Japan
 SOURCE: Polymer Journal (Tokyo, Japan) (1994), 26(1), 99-103
 CODEN: POLYB8; ISSN: 0032-3896
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A new highly phenylated diamine, 3,4-bis(4-aminophenyl)-2,5-diphenylthiophene, was synthesized in 3 steps starting from 4'-nitrodeoxybenzoin. New aromatic polyamides containing the tetraphenylthiophene unit were prepared by low-temperature solution polycondensation of this diamine with various aromatic dicarboxylic acid chlorides. These polyamides had inherent viscosities of 0.20-0.35 dL-g⁻¹ and were generally soluble in various organic solvents such as AcNMe₂, N-methyl-2-pyrrolidone, and DMSO. The glass transition temps. of the polyamides were 285-327°, and the 10% weight loss temps. were >530° in N.
 IT 152834-78-1P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and solubility and thermal properties of)
 RN 152834-78-1 CAPLUS
 CN Poly[(2,5-diphenyl-3,4-thiophenediyl)-1,4-phenyleneiminocarbonyl-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)

L19 ANSWER 175 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




L19 ANSWER 176 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:55168 CAPLUS
 DOCUMENT NUMBER: 120:55168
 TITLE: New poly(amide imide) syntheses. V. Preparation and properties of poly(amide imides) based on the diimide-diacid condensed from 2,2-bis[4-(4-aminophenoxy)phenyl]propane and trimellitic anhydride
 AUTHOR(S): Yang, Chin Ping; Hsiao, Sheng Huei; Lin, Jiun Hung
 CORPORATE SOURCE: Dep. Chem. Eng., Tatung Inst. Technol., Taipei, Taiwan
 SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (1993), 31(12), 2995-3002
 CODEN: JPACEC; ISSN: 0887-624X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A dicarboxylic acid (I) bearing two pre-formed imide rings was prepared by the condensation of 2,2-bis[4-(4-aminophenoxy)phenyl]propane and trimellitic anhydride. A new family of poly(amide-imide)s having inherent viscosities 0.53-1.68 dL/g was prepared by P(OPh)₃-activated polycondensation of I with various aromatic diamines in a medium consisting of N-methyl-2-pyrrolidone (NMP), pyridine, and CaCl₂. Most of the resulting polymers showed an amorphous nature and were readily soluble in polar solvents such as NMP and AcNMe₂. All the soluble poly(amide-imide)s afforded transparent, flexible, tough films. The glass transition temps. of these poly(amide-imide)s were in the range 237-293°, and the 10% weight loss temps. were >508° in N.
 IT 152109-00-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and properties of films of)
 RN 152109-00-7 CAPLUS
 CN Poly[(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl)carbonylimino-1,4-phenylene(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-1,4-phenyleneoxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)

L19 ANSWER 176 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B



PAGE 1-A




L19 ANSWER 177 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:614339 CAPLUS
 DOCUMENT NUMBER: 119:214339
 TITLE: A study of homologation and the occurrence of an SA-SC-SA sequence of phases in the 4-alkoxy-3-fluorophenyl 4-(5-alkyl-2-thienyl)benzoates
 AUTHOR(S): Byron, D. J.; Matharu, A. S.; Shirazi, S. N. R.; Tajbakhsh, A. R.; Wilson, R. C.
 CORPORATE SOURCE: Dep. Chem. Phys., Nottingham Trent Univ., Nottingham, NG11 8NS, UK
 SOURCE: Liquid Crystals (1993), 14(3), 645-52
 CODEN: LICRE6; ISSN: 0267-8292
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Seventeen esters, derived from 4-alkoxy-3-fluorophenols and 4-(5-alkyl-2-thienyl)benzoic acids, were prepared and their liquid crystal transition temps. determined by thermal optical microscopy. On cooling the isotropic liquid, the SA-SC-SA sequence of phases reported for the octyloxy-octyl and octyloxy-nonyl esters was observed for certain other homologs, principally members of the 4-(5-nonyl-2-thienyl)benzoates. For these compds., the temperature range of occurrence of the intermediate SC phase decreases as the length of the alkoxy chain increases (for the hexyloxy-nonyl to dodecyloxy-nonyl esters) and the SC phase is absent for the tetradecyloxy-nonyl homolog.
 IT 150640-46-3P 150640-47-4P 150640-48-5P
 150640-49-6P 150640-50-9P 150640-51-0P
 150640-52-1P 150640-53-2P 150640-54-3P
 150640-55-4P 150640-56-5P 150640-57-6P
 150640-58-7P 150640-59-8P 150640-60-1P
 150640-61-2P 150640-62-3P
 RI: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (liquid crystal, preparation and properties of)
 RN 150640-46-3 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 3-fluoro-4-(pentyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 150640-47-4 CAPLUS
 CN Benzoic acid, 4-(5-heptyl-2-thienyl)-, 3-fluoro-4-(hexyloxy)phenyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 177 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 150640-48-5 CAPLUS
 CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 3-fluoro-4-(hexyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 150640-49-6 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 3-fluoro-4-(hexyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 150640-50-9 CAPLUS
 CN Benzoic acid, 4-(5-decyl-2-thienyl)-, 3-fluoro-4-(hexyloxy)phenyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 177 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 150640-51-0 CAPLUS
 CN Benzoic acid, 4-(5-heptyl-2-thienyl)-, 3-fluoro-4-(heptyloxy)phenyl ester (9CI) (CA INDEX NAME)



RN 150640-52-1 CAPLUS
 CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 3-fluoro-4-(heptyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 150640-53-2 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 3-fluoro-4-(heptyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 150640-54-3 CAPLUS
 CN Benzoic acid, 4-(5-decyl-2-thienyl)-, 3-fluoro-4-(heptyloxy)phenyl ester


L19 ANSWER 177 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 150640-55-4 CAPLUS
 CN Benzoic acid, 4-(5-heptyl-2-thienyl)-, 3-fluoro-4-(nonyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 150640-56-5 CAPLUS
 CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 3-fluoro-4-(nonyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 150640-57-6 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 3-fluoro-4-(nonyloxy)phenyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 177 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 150640-59-8 CAPLUS
 CN Benzoic acid, 4-(5-decyl-2-thienyl)-, 3-fluoro-4-(nonyloxy)phenyl ester (9CI) (CA INDEX NAME)



RN 150640-59-8 CAPLUS
 CN Benzoic acid, 4-(5-dodecyl-2-thienyl)-, 3-fluoro-4-(nonyloxy)phenyl ester (9CI) (CA INDEX NAME)



RN 150640-60-1 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 4-(decyloxy)-3-fluorophenyl ester (9CI) (CA INDEX NAME)




RN 150640-61-2 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 4-(dodecyloxy)-3-fluorophenyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 178 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:212876 CAPLUS
 DOCUMENT NUMBER: 118:212876
 TITLE: alkoxy-2-hydroxyphenyl 5-phenyl-2-thienyl ketones and their use as UV absorbers in photographic materials
 INVENTOR(S): Leppard, David G.; Burdeska, Kurt
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 521823	A1	19930107	EP 1992-810481	19920624
EP 521823	B1	19960117		
R: BE, DE, FR, GB, IT, NL				
US 5290952	A	19940301	US 1992-906607	19920630
JP 05194483	A	19930803	JP 1992-200323	19920703
JP 322386	B2	20010229		

PRIORITY APPLN. INFO.: CH 1991-1963 A 19910703

OTHER SOURCE(S): CASREACT 118:212876; MARPAT 118:212876
 GI




AB Some 4-alkoxy-2-hydroxyphenyl 5-phenyl-2-thienyl ketones are claimed. A process for the preparation of said compds. is claimed which comprises the

alkylation of 2,4-dihydroxyphenyl 5-phenyl-2-thienyl ketone with an alkyl halide or an epoxy compound. These compds. are UV absorbers for photog. materials. Photog. materials containing a transparent carrier, a layer consisting of said 2,4-dihydroxyphenyl 5-phenyl-2-thienyl ketone derivs. and layers of a silver halide emulsion are claimed. Treatment of 2,4-dihydroxyphenyl 5-phenyl-2-thienyl ketone with Bu glycidyl ether gave 4-(3-butoxy-2-hydroxypropoxy)-2-hydroxyphenyl 5-phenyl-2-thienyl ketone (I) in 73% yield.


IT 146950-92-7P 146950-93-8P 146950-94-9P
 146950-95-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)

RN 146950-92-7 CAPLUS
 CN Butanoic acid, 4-[3-hydroxy-4-[(5-phenyl-2-thienyl)carbonyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 177 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 150640-62-3 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 3-fluoro-4-(tetradecyloxy)phenyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 178 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 146950-93-8 CAPLUS
 CN Acetic acid, [3-hydroxy-4-[(5-phenyl-2-thienyl)carbonyl]phenoxy]-, 2-ethylhexyl ester (9CI) (CA INDEX NAME)



RN 146950-94-9 CAPLUS
 CN Methanone, [2-hydroxy-4-(3-butoxyphenyl)(5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 146950-95-0 CAPLUS
 CN Methanone, [2-hydroxy-4-(octyloxy)phenyl](5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)




IT 146950-87-0P 146950-88-1P 146950-89-2P
 146950-90-5P 146950-91-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as UV absorber for photog. materials)

RN 146950-87-0 CAPLUS
 CN Methanone, [4-(3-butoxy-2-hydroxypropoxy)-2-hydroxyphenyl](5-phenyl-2-


L19 ANSWER 178 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 146950-88-1 CAPLUS
CN Methanone, [4-[3-[(2-ethylhexyl)oxy]-2-hydroxypropyl]-2-hydroxyphenyl] (5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 146950-89-2 CAPLUS
CN Methanone, (2-hydroxy-4-methoxyphenyl) (5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 146950-90-5 CAPLUS
CN Methanone, [2-hydroxy-4-(2-propenyloxy)phenyl] (5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 179 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:572224 CAPLUS
DOCUMENT NUMBER: 117:172224
TITLE: New poly(amide-imide) syntheses. 4. Poly(amide-imides) derived from 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene and various bis(trimellitimides) Yang, Chin Ping; Hsiao, Sheng Huei; Lin, Jiun Hung Dep. Chem. Eng., Tatung Inst. Technol., Taipei, Taiwan
AUTHOR(S):
CORPORATE SOURCE: Makromolekulare Chemie (1992), 193(6), 1299-308
SOURCE: CODEN: MACEAK; ISSN: 0025-116X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Fifteen bis(trimellitimides) are prepared by condensation of the corresponding aliphatic or aromatic diamines with trimellitic anhydride.


A series of structurally new poly(amide-imides) are synthesized by the direct polycondensation of these bis(trimellitimides) with 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene using tri-Ph phosphite and pyridine as condensing agents in N-methyl-2-pyrrolidone (I). The resultant poly(amide-imides) have inherent viscosities 0.72-2.73 dL/g at 30° in N,N-dimethylacetamide (II). The polymers are amorphous and readily soluble in polar aprotic solvents such as II and I. Transparent

and tough films can be cast from their solns. Most aliphatic-aromatic poly(amide-imides) show a glass transition in 203-242° in their DSC traces, whereas the wholly aromatic poly(amide-imides) show no discernible

transition before decomposition. The thermal stability of the polymers is evaluated by thermogravimetry which shows the 10% weight-loss temps. at 414-459° in air and at 451-578° in a N atmospheric for the aliphatic-aromatic poly(amide-imides), and >500° in both air and N atmospheric for the wholly aromatic poly(amide-imides).

IT 143780-00-1P 143780-01-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and properties of)


RN 143780-00-1 CAPLUS
CN Poly[(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-1,4-phenyleneoxy-1,4-phenylene(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl) carbonylimino-1,4-phenylene(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl] (9CI) (CA INDEX NAME)




PAGE 1-A

L19 ANSWER 178 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 146950-91-6 CAPLUS
CN Methanone, [2-hydroxy-4-(phenylmethoxy)phenyl] (5-phenyl-2-thienyl)- (9CI) (CA INDEX NAME)




L19 ANSWER 179 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B

RN 143780-01-2 CAPLUS
CN Poly[(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-1,4-phenyleneoxy-1,3-phenyleneoxy-1,4-phenylene(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl) carbonylimino-1,4-phenylene(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneiminocarbonyl] (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-B

119 ANSWER 180 of 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:512535 CAPLUS
 DOCUMENT NUMBER: 117:112535
 TITLE: New poly(amide imides) syntheses. I. Soluble
 high-temperature poly(amide imides) derived from
 2,5-bis[4-(trimellitimidophenyl)]-3,4-diphenylthiophene
 and various aromatic diamines
 AUTHOR(S): Yang, Chin Ping; Yen, Yung Yu
 CORPORATE SOURCE: Dep. Chem. Eng., Tatung Inst. Technol., Taipei,
 Taiwan
 SOURCE: Chemistry
 Journal of Polymer Science, Part A: Polymer

DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel aromatic poly (amide-imides) with high inherent viscosities were prepared

by direct polycondensation of 2,5-bis(4-trimellitimidophenyl)-3,4-diphenylthiophene (I) and aromatic diamines using tri-Ph phosphite in the N-methyl-2-pyrrolidone/pyridine solution containing dissolved CaCl_2 . I

readily obtained by the condensation reaction of 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene with trimellitic anhydride. The obtained poly(amide-imides) showed high thermostability. Their decomposition temps. at

10% weight loss in N were >550° and the anaerobic char yield at 800° was 48-63%. Almost all the poly(amide-imides) showed high glass transition temps. (>300°) by DSC measurements. These polymers were readily soluble in various organic solvents and could be cast into transparent, tough, and flexible films. Their casting films showed obvious yield points in the stress-strain curves and had strength at break

break
 ≤ 74.2 MPa, elongation to break $\leq 70.1\%$, and initial modulus
 ≤ 4.56 GPa. The factors affecting the reaction of I and
4,4'-oxydianiline in view of monomer concentration, reaction
temperature, and amount of
CaCl₂ were also investigated.


IT 142956-33-0P 142956-39-6P 142987-71-1P
RL: PEP (Physical, engineering or chemical process); PRP (Properties);

(Synthetic preparation); PREP (Preparation); PROC (Process)
(preparation and properties of)


RN	142956-33-0	CAPLUS
CN	Poly(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-1,4-phenylene(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl)carbonylimino-3,4-phenyleneoxy-1,4-phenyleneiminocarbonyl (9CI) (CA INDEX NAME)	

L19 ANSWER 180 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 142956-39-6 CAPLUS


CN Poly(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)-1,4-phenylene(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl)carbonylimino-1,4-phenyleneoxy-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl) (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 180 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-B




RN 142987-71-1 CAPLUS

14298-11-1 CAPLOS
CN Poly([1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl]-1,4-phenylene(3,4-diphenyl(2,5-thiophenediyl)-1,4-phenylene(1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-diyl)carbonylimino-3,4-phenyleneoxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L19 ANSWER 181 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

L19 ANSWER 181 OF 250 CAPLUS COPYRIGHT 20
 ACCESSION NUMBER: 1992:417462 CAPLUS
 DOCUMENT NUMBER: 117:17462

TITLE: Mesomorphic compounds and liquid-crystal compositions and devices and display apparatus and method using them

INVENTOR(S): Iwaki, Takashi; Takiguchi, Takao; Togano, Takeshio;
Yamada, Yoko; Nakamura, Shinichi

PATENT ASSIGNEE(S):
SOURCE:

DOCUMENT TYPE: Patent

DOCUMENT TYPE: F
LANGUAGE: E
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 476567	A1	19920325	EP 1991-115683	19910916
EP 476567	B1	19960612		

JP 04124190	A	19920424	JP 1990-243712	19900917
-------------	---	----------	----------------	----------

UF 04124150	A	19920424	UF 1990-243712	19900317
US 5217645	A	19930608	US 1991-759442	19910913
AT 139235	T	19960615	AT 1991-115683	19910916

AI 139235	1	19980815	AI 1991-115883	19910918
PRIORITY APPLN. INFO.:			JP 1990-243712	A 19900917

OTHER SOURCE(S): MARPAT 117:17462
GI



AB The compds. have the general formula I, where R1 = C2-16 alkyl in which 1
a or 2 nonadjacent CH2 groups may be replaced by O, S, CO, COO, or OCO and

H may be replaced by F; A = Al or B; B2 = B3 or B3B4; A1,A2,B1,B3,B4 = 1,4-phenylene (optionally substituted with 1 or 2 F, Cl, Br, Me, CN, and/or CF3), 1,4-cyclohexylene, 5,2- or 2,5-pyrimidinylene, or 5,2- or 2,5-pyridinylene, and B1 may also be a single bond; Z1,Z2 = single bond, COO, COO, CH2O, or OCH2; Z3 = O, CO, COO, or OCO; Z2,R3,R4 = C1-16 alkyl in which 1 or 2 CH2 groups may be replaced by O, COO, or OCO; $l,m = 0$ or 1; $1 + n \neq 0$; $n = 1-12$; and X,Q = CH or N but are not N simultaneously.


IT 142051-31-8 142051-32-9 142051-34-1

142051-35-2 142051-36-3
RL: TEM (Technical or engineered material use); USES (Uses)
(liquid-crystal compns. containing, for display devices)


RN 142051-31-8 CAPLUS

142051-31-8 CAS#
CN Benzoic acid, 4-[[6-(hexyldimethylsilyl)hexyl]oxy]-, 4-(5-octyl-2-thienyl)phenyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 181 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 142051-32-9 CAPLUS
 CN Silane,
 [8-[4-[[4-(5-hexyl-2-thienyl)phenoxy]methoxy]phenoxy]octyl]trimethyl-
 1- (9CI) (CA INDEX NAME)



RN 142051-34-1 CAPLUS
 CN Benzoic acid, 4-[3-(butyldimethylsilyl)propoxy]-, 4-(5-hexyl-2-thienyl)phenyl ester (9CI) (CA INDEX NAME)




RN 142051-35-2 CAPLUS
 CN Silane,
 butyl[3-[4-[[4-(5-dodecyl-2-thienyl)phenyl]methoxy]phenoxy]propyl]dimethyl- (9CI) (CA INDEX NAME)



RN 142051-36-3 CAPLUS
 CN Benzoic acid, 4-[4-(ethyltrimethylsilyl)butoxy]-, 4-(5-decyl-2-thienyl)-2-

L19 ANSWER 181 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 182 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:265598 CAPLUS
 DOCUMENT NUMBER: 116:265598
 TITLE: Electrophotographic photoreceptor containing azo charge-generating agent
 INVENTOR(S): Yamada, Yasuyuki; Enomoto, Tsuyoshi; Ito, Naoto; Yamauchi, Teruhiro
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp. CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04020971	A	19920124	JP 1990-124094	19900516
JP 2895162	B2	19990524	JP 1990-124094	19900516

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 116:265598
 GI



AB The title photoreceptor consists of an elec. conductive substrate coated with a photosensitive layer containing ≥ 1 azo compound I [Z, R1 = (substituted) aromatic hydrocarbon group, aromatic heterocyclic group; R2 = alkyl, alkoxy; n = 2-4]. A photoreceptor having a charge-generating layer


containing I (Z = II, R1 = o-ClC6H4; R2 = OMe; n = 2) showed high photosensitivity and durability during repeating use.

IT 141624-30-8 141624-33-1
 RL: TEM (Technical or engineered material use); USES (Uses) (electrophotog. charge-generating agent)


RN 141624-30-8 CAPLUS
 CN Benzamide, 3,3',3'',3'''-[(1,1-dioxido-2,3,4,5-

thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-5-methoxy-N-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 182 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-A



PAGE 2-A

RN 141624-33-1 CAPLUS
 CN Benzamide, 3,3',3'',3'''-[(1,1-dioxido-2,3,4,5-



thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[N-(2,4-dinitrophenyl)-2-hydroxy-5-methoxy- (9CI) (CA INDEX NAME)

L19 ANSWER 182 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


L19 ANSWER 182 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A




PAGE 1-B



L19 ANSWER 183 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:224885 CAPLUS
 DOCUMENT NUMBER: 116:224885
 TITLE: Mesomorphic compounds and liquid-crystal compositions and devices containing them
 INVENTOR(S): Yamada, Yoko; Takiguchi, Takao; Iwaki, Takashi; Togano, Takeshi; Nakamura, Shinichi
 PATENT ASSIGNEE(S): Canon K. K., Japan
 SOURCE: Eur. Pat. Appl., 133 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 467260	A2	19920122	EP 1991-111755	19910715
EP 467260	A3	19920527		
EP 467260	B1	19961016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 04217973	A	19920807	JP 1990-326454	19901127
US 5244595	A	19930914	US 1991-729740	19910715
AT 144277	T	19961115	AT 1991-111755	19910715
PRIORITY APPLN. INFO.:			JP 1990-188490	A 19900716
			JP 1990-326454	A 19901127

OTHER SOURCE(S): MARPAT 116:224885
 GI




AB The comps. have the general formula I, where R1,R2 = C1-18 alkyl in which
 CH2 may be replaced by CO, O, CHF, CHCF3, CHCl, CHCN, or C(Me)(CN) and R2 may also be H, halogen, CN, or CF3; n = 0 or 1; A1 = single bond, 1,4-phenylene, 3-fluoro-, or 2-fluoro-1,4-phenylene; A2 = 1,4-phenylene or 1,4-cyclohexylene substituted with Z1 and Z2, 2,5- or 5,2-pyridinylene, thiophen-2,5-ylene; X1,X2,Z1,Z2 = H, halogen, CN, or CF3; and Y = COO, OCO, CH2O, OCH2, or single bond.
 IT 141113-21-5
 RL: TEM (Technical or engineered material use); USES (Uses)
 (Liquid-crystal comps. containing, for display devices)
 RN 141113-21-5 CAPLUS
 CN Benzoic acid, 2-fluoro-4-(5-octyl-2-thienyl)-, 2,5-difluorophenyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 183 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 184 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 AB R1COCH2CH2COR [I, R = C6H2(OCH2CO2H)Cl2-4,2,3, R1 = H, Me, RCOCH2CH2]
 ACCESSION NUMBER: 1992:194074 CAPLUS
 DOCUMENT NUMBER: 116:194074
 TITLE: Furans and thiophenes from etacrynic acid
 AUTHOR(S): Goerlitzer, Klaus; Boemeke, Michael
 CORPORATE SOURCE: Inst. Pharm. Chem., Tech. Univ. Braunschweig,
 Braunschweig, 3300, Germany
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1992),
 325(1), 9-12
 CODEN: ARPMAS; ISSN: 0365-6233
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 116:194074
 GI For diagram(s), see printed CA Issue.
 AB R1COCH2CH2COR [I, R = C6H2(OCH2CO2H)Cl2-4,2,3, R1 = H, Me, RCOCH2CH2]
 react with polyphosphoric acid (PPA) to yield the furans II (X = O) and
 with P2S5 to the thiophenes II (X = S). I (R1 = OH) cyclizes with PPA to
 form the α,β -unsatd. butyrolactone. I (R1 = OH) is reduced by
 NaBH4 chemo- and diastereoselectively to give the γ -hydroxy
 carboxylic acid (3RS, 4RS)-HOCHRCHECH2CO2H which is cyclized to III by
 dehydration with PPA. II (X = SO2) are obtained from II (X = S) by
 oxidation
 with magnesium monoperoxyphthalate. Under the same conditions II (X = O,
 R1 = Me) is cleaved to yield (Z)-MeCOCH:CEtCOR, which tautomerizes slowly
 forming (E)-MeCOCH2C(COR):CHMe.
 IT 139519-99-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 139519-99-6 CAPLUS
 CN Acetic acid, [4-[5-[2-[4-(carboxymethoxy)-2,3-dichlorobenzoyl]butyl]-3-
 ethyl-2-thienyl]-2,3-dichlorophenoxy]- (9CI) (CA INDEX NAME)



L19 ANSWER 185 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 compd. I [R = H, halo, (substituted) alkyl or aryl; Z = (substituted)
 arom. hydrocarbon, condensed polycyclic or heterocyclic ring]. The
 photoreceptors show good photosensitivity, durability, and provide high
 quality images. Thus, an Al vapor-deposited polyester film was coated
 with a compn. contg. II and 1-phenyl-3-(p-diethylaminostyryl)-5-(p-
 diethylaminophenyl)-2-pyrazoline to give a photoreceptor.
 IT 140131-14-2
 RL: USES (Uses)
 (charge-generating agent, electrophotog. photoreceptor using)
 RN 140131-14-2 CAPLUS
 CN 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6,6'-[(3,3'-dimethoxy[1,1'-
 biphenyl]-4,4'-diyl)bis(azo)]bis[5-hydroxy-2-[(5-phenyl-2-thienyl)methyl]-
 (9CI) (CA INDEX NAME)

PAGE 1-A


PAGE 1-B



L19 ANSWER 185 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:162533 CAPLUS
 DOCUMENT NUMBER: 116:162533
 TITLE: Electrophotographic photoreceptors using novel bisazo
 charge-generating agent
 INVENTOR(S): Amano, Masayo; Kuroda, Masami; Kozho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03255455	A	19911114	JP 1990-282465	19901019
JP 2833192	B2	19981209		
PRIORITY APPLN. INFO.:			JP 1990-8027	A1 19900117


GI

AB The photoreceptors comprise a photosensitive layer containing ≥ 1 bisazo

L19 ANSWER 186 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:619697 CAPLUS
 DOCUMENT NUMBER: 115:219697
 TITLE: Preparation of liquid crystal compositions
 INVENTOR(S): Mori, Yoshimasa; Takiguchi, Takao; Iwaki, Takashi;
 Tokano, Goji; Yamada, Yoko
 PATENT ASSIGNEE(S): Canon K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02255635	A	19901016	JP 1989-77060	19890328
PRIORITY APPLN. INFO.:			JP 1989-77060	19890328

OTHER SOURCE(S): MARPAT 115:219697
 GI




AB Liquid crystal compns. comprising I [R = (substituted) C1-16 alkyl,
 alkoxy,
 alkoxycarbonyl, acyloxy, alkoxycarbonyloxy; X = H, CF3, but at least one
 is CF3; Y = CO2, O2C, CH2O, OCH2; Z = 1,4-cyclohexylene, Q-Q4 wherein X1
 =
 H, F, Cl, Br, cyano, Me; Z1 = O, S] are prepared A mixture of
 m-CF3C6H4CO2H,
 a phenol derivative II (R1 = H), DCC, and pyrrolidinopyridine in CH2Cl2
 was
 stirred at room temperature to give 69% ester II (R1 = m-CF3C6H4CO),
 which
 showed crystalline-isotropic-smectic A-smectic C transition temperature

L19 ANSWER 186 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 77.8°, 68.4°, and 62.1°, resp.
 IT 132807-80-8
 RL: PRP (Properties)
 (liquid crystal composition containing)
 RN 132807-80-8 CAPLUS
 CN Biphenyl, 2-dodecyl-5-[4-[[2-(trifluoromethyl)phenoxy]methyl]phenyl]-
 (9CI) (CA INDEX NAME)



L19 ANSWER 187 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 1991:594830 CAPLUS
 DOCUMENT NUMBER: 115:194830
 TITLE: Unusual smectic polymorphism of 3-fluoro-4-octyloxyphenyl 4-(5-octyl-2-thienyl)benzoate
 AUTHOR(S): Butcher, Jane L.; Bunning, John D.; Byron, David J.; Tajbakhsh, Ali R.; Wilson, Robert C.
 CORPORATE SOURCE: Dep. Chem. Phys., Nottingham Polytech., Nottingham, NG11 8NS, UK
 SOURCE: Molecular Crystals and Liquid Crystals, Letters Section (1990), 7(3), 75-7
 CODEN: MCLLDZ; ISSN: 0888-7489
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The smectic liquid crystal phases formed by 3-fluoro-4-octyloxyphenyl 4-(5-octyl-2-thienyl)benzoate were investigated by thermal optical microscopy, differential scanning calorimetry, and x-ray diffraction.
 The phase sequence SA-Sc-S3-SE is observed on cooling the isotropic liquid
 The S3 phase is structurally similar to an SA phase and hence corresponds to a 3rd smectic phase with unstructured layers.
 IT 134831-47-3
 RL: PRP (Properties)
 (liquid crystal, smectic polymorphism of)
 RN 134831-47-3 CAPLUS
 CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 188 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 1991:546584 CAPLUS
 DOCUMENT NUMBER: 115:146584
 TITLE: Coating compositions for fabrication of electrophotographic photoconductors
 INVENTOR(S): Momotake, Hiroyuki; Sasaqawa, Tomoyoshi; Koide, Tetsuhiro; Sugawa, Hiroshi
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03024554	A	19910201	JP 1989-158299	19890622
JP 2815903	B2	19981027	JP 1989-158299	19890622


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 115:146584
 GI



AB The title coating comps. are dispersions of diazo dyes I (A = coupler group; k, m = 0, 1) in solvent solns. of poly(vinyl butyral). The invention includes similar dispersions in solvent solns. of vinyl chloride

L19 ANSWER 188 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 copolymers. These dispersions have high dispersed state and dispersion stability, and provide highly performing photoconductors. Thus, 2.5 g II was dispersed in 25 mL 10% soln. of Bakelite XYHL in THF, and mixed with 30 mL THF. An Al plate was coated with this dispersion and dried to form a 0.5-μm-thick charge-generating layer. A charge-transporting layer contg. III and polycarbonate was coated on the charge-generating layer, to obtain a photoconductor that showed high layer adhesion. The photoconductor was chargeable to -1010 V, which decayed to -930 V after 2 s, and showed residual voltage -5 V and sensitivity (lx-s required for half decay of charged voltage) 1.5. These values were -970 V, -900 V, -5 V and 1.5, resp., after 1000 charge-photodischarge cycles. The coating compn. showed no change on standing for 1 mo.
 IT 136208-42-9
 RL: USES (Uses)
 (charge-transporting agent, electrophotog. photoconductors containing)
 RN 136208-42-9 CAPLUS
 CN Benzenamine,
 N,N',N''-[(1,1-dioxido-4-phenyl-2,3,5-thiophenetriyl)tri-4,1-phenylene]tris[4-methoxy-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)




L19 ANSWER 189 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:482195 CAPLUS
 DOCUMENT NUMBER: 115:82195
 TITLE: Electrophotographic photoconductor with charge generating layer from bisazo compound
 INVENTOR(S): Kuroda, Masami; Amano, Masayo; Furusho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Ger. Offen., 107 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4018010	A1	19901220	DE 1990-4018010	19900605
DE 4018010	C2	19950427		
JP 03009365	A	19910117	JP 1989-143523	19890606
US 5087541	A	19920211	US 1990-530088	19900531
DE 4042455	C2	19931007	DE 1990-4042455	19900605
DE 4042454	C2	19960814	DE 1990-4042454	19900605
US 5198318	A	19930330	US 1991-799601	19911127
US 5266430	A	19931130	US 1992-982897	19921130
US 5275898	A	19940104	US 1993-15915	19930210
US 5286590	A	19940215	US 1993-74545	19930611
US 5292602	A	19940308	US 1993-74597	19930611
US 5292608	A	19940308	US 1993-75300	19930611
PRIORITY APPLN. INFO.:			JP 1989-143523	A 19890606
			US 1990-530088	A3 19900531
			DE 1990-4018010	A3 19900605
			US 1991-799601	A3 19911127
			US 1992-982897	A3 19921130
			US 1993-15915	A3 19930210

OTHER SOURCE(S): MARPAT 115:82195
 GI


L19 ANSWER 189 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title material contains a photosensitive layer containing a charge-generating agent from a disazo compound Z1CH:N-p-C6H4-N:CHZ1 (Z1 = I;
 Z = AN:N-p-C6H4-; A = coupling group), Z1-Z1, II (R4, R5 = H, halogen, alkyl, alkoxy; R6, R7 = H, alkyl, aryl), III (R8 = H, halogen, alkyl, aryl, cyano), Z1-CH:NN:CHZ1, IV (R9, R10 = H, halogen, alkyl, aryl), Z1CH:CHZ1, or V (n = 1-3). The photoconductor has improved decay properties.
 IT 134570-14-2 134570-51-7 134571-24-7
 134571-26-9 134596-53-5
 RL: USES (Uses)
 (electrophotog. photoconductor with charge generating agent from)
 RN 134570-14-2 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[[[(5-phenyl-2-thienyl)methyl]imino]bis(4,1-phenyleneazo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 189 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A


RN 134570-51-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[[[(5-phenyl-2-thienyl)methyl]imino]bis(4,1-phenyleneazo)]bis[3-hydroxy-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 189 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 134571-24-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[[1,2-ethenediylbis(5,2-thiophenediyl-4,1-phenyleneazo)]bis[3-hydroxy-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 134571-26-9 CAPLUS
 CN 11H-Benz[a]carbazole-3-carboxamide, 1,1'-[[1,2-ethenediylbis(5,2-thiophenediyl-4,1-phenyleneazo)]bis[2-hydroxy-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 189 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 134596-53-5 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[2,2'-bithiophene]-5,5'-diylbis(4,1-phenyleneazo)bis[2-hydroxy-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L19 ANSWER 190 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:439101 CAPLUS

DOCUMENT NUMBER: 115:39101

TITLE: An unusual sequence of smectic phases formed by members of the homologous series of 3-fluoro-4-octyloxyphenyl 4-(5-alkyl-2-thienyl)benzoates

AUTHOR(S): Butcher, J. L.; Byron, D. J.; Shirazi, S. N. R.; Tajbakhsh, A. R.; Wilson, R. C.; Bunning, J. D.

CORPORATE SOURCE: Dep. Chem. Phys., Nottingham Polytech., Nottingham, NG11 8NS, UK

SOURCE: Molecular Crystals and Liquid Crystals (1991), 199, 327-43

CODEN: MCLCA5; ISSN: 0026-8941

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Nine 4-(5-alkyl-2-thienyl)benzoic acids were converted into esters by reaction with 3-fluoro-4-octyloxyphenol. The liquid crystal properties of these esters were investigated by thermal optical microscopy, differential scanning calorimetry, and x-ray diffraction. For the octyl and nonyl homologs the properties of the 3rd smectic phase in the sequence SA-SC-S3-SE observed on cooling the isotropic liquid are unusual. The S3 phase is orthogonal with unstructured layers corresponding with a 2nd SA phase. The 4-(5-alkyl-2-thienyl)benzoic acids also form liquid crystals and, in addition to the Sc phase shown by other homologs, the octyl-decyl compds. give rise to a 2nd, unidentified smectic phase.

IT 134831-43-9P 134831-44-0P 134831-45-1P
 134831-46-2P 134831-47-3P 134831-48-4P
 134831-49-5P 134831-50-8P 134831-51-9P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (liquid crystal, preparation and transition temps. of)

RN 134831-43-9 CAPLUS
 CN Benzoic acid, 4-(5-butyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)

RN 134831-43-9 CAPLUS
 CN Benzoic acid, 4-(5-butyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)


RN 134831-43-9 CAPLUS
 CN Benzoic acid, 4-(5-butyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 134831-44-0 CAPLUS

CN Benzoic acid, 4-(5-pentyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)


L19 ANSWER 190 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 134831-45-1 CAPLUS
 CN Benzoic acid, 4-(5-hexyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)



RN 134831-46-2 CAPLUS
 CN Benzoic acid, 4-(5-heptyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 134831-47-3 CAPLUS
 CN Benzoic acid, 4-(5-octyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)




RN 134831-48-4 CAPLUS
 CN Benzoic acid, 4-(5-nonyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)

L19 ANSWER 190 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


(9CI) (CA INDEX NAME)




RN 134831-49-5 CAPLUS
 CN Benzoic acid, 4-(5-decyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)



RN 134831-50-8 CAPLUS
 CN Benzoic acid, 4-(5-dodecyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)



RN 134831-51-9 CAPLUS
 CN Benzoic acid, 4-(5-tetradecyl-2-thienyl)-, 3-fluoro-4-(octyloxy)phenyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 190 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 191 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:256929 CAPLUS
 DOCUMENT NUMBER: 114:256929
 TITLE: Electrophotographic photoreceptors
 INVENTOR(S): Yamada, Yasuyuki; Ito, Naoto; Nishizawa, Isao;
 Yamaguchi, Teruhiro
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02277072	A	19901113	JP 1989-97629	19890419
PRIORITY APPLN. INFO.:			JP 1989-97629	19890419

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The single-layer photosensitive layer of the photoreceptor contains azo compound I and tetraphenylthiophenes II [A = coupler groups; R1-2 = alkyl, aralkyl, aryl; R1/R2 may jointly form a part of N-containing ring; k, m, n = 0, 1 (k ≤ m ≤ n)]. These pos.-charging, single-layer photoreceptors have high performance. Thus, an Al plate was coated with a composition containing polycarbonate 7, I (A = III) 1, IV 7.7 g and solvent and dried to obtain a photoconductor, which was chargeable to 974 V. This voltage decayed to 930 V after 2 s, and the sensitivity (lux-s required for half-decay of voltage on exposure) was 2.4, and the residual voltage was 0.

IT 116372-83-9
 RL: USES (Uses)
 (charge-generating agent, pos.-charging and single-layer electrophotog. photoreceptor containing)


RN 116372-83-9 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-[(1,1-dioxido-2,3,4,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)]

L19 ANSWER 191 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




IT 123715-38-8 123715-39-9 134008-74-5
 RL: USES (Uses)
 (charge-transporting agent, pos.-charging and single-layer electrophotog. photoreceptor containing)

RN 123715-38-8 CAPLUS
 CN Benzenamine, 4,4'-(3,4-diphenyl-2,5-thiophenediyl)bis[N-(4-methoxy-2-methylphenyl)-N-phenyl- (9CI) (CA INDEX NAME)]




L19 ANSWER 191 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 123715-39-9 CAPLUS
 CN Benzenamine, 4,4'-(4-phenyl-2,3,5-thiophenediyl)tris[N-(4-methoxy-2-methylphenyl)-N-phenyl- (9CI) (CA INDEX NAME)]



RN 134008-74-5 CAPLUS
 CN Benzenamine, 4,4'-(3,4-diphenyl-2,5-thiophenediyl)bis[N-(2,4-dimethylphenyl)-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)]




L19 ANSWER 192 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:218086 CAPLUS
 DOCUMENT NUMBER: 114:218086
 TITLE: Electrophotographic photoconductors
 INVENTOR(S): Amano, Masayo; Kuroda, Masami; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02308170	A	19901221	JP 1989-129380	19890523
JP 2518392	B2	19960724		

PRIORITY APPLN. INFO.: JP 1989-129380 19890523

GI For diagram(s), see printed CA Issue.
 AB The photosensitive layer of the photoconductor contains bisazo dyes I, II, and/or III (A = coupler group; R1, R6 = H, halo, NO2, alkyl, alkoxy; R2, R5 = H, halo, alkyl, alkoxy; R3-4 = H, alkyl, aryl; R7 = H, halo, alkyl, aryl; n = 0, 1). Typically groups A are selected from IV to X (Z = aromatic or heterocyclic ring; X1 = H, COOR8, CONR9R10; R8-10 = H, alkyl, aryl, heterocyclyl; X2, X5 = alkyl, aryl, heterocyclyl; X3, X6 = H, cyano, carbamoyl, carboxyl, ester, acyl; X4, X11 = H, alkyl, cycloalkyl, alkenyl, aralkyl, aryl, heterocyclyl; X7, X8 = H, halo, NO2, alkyl, alkoxy; X9 = alkyl, aryl, carboxyl, ester; X10 = aryl, heterocyclyl; Y = heterocyclic ring). These charge-generating agents provide high sensitivity and stability in both pos. and neg. charging mode. Thus, an Al-coated polyester film was coated with a composition containing I (R1-6 = H, A = XI) 50, polyester 100, 1-phenyl-3-(p-diethylaminostyryl)-5-(p-diethylaminophenyl)-2-pyrazoline 100 parts and THF to obtain a photoconductor, which was charged to 650 V and showed sensitivity (lux-s required for half decay of voltage) 5.0, and residual voltage after discharging by irradiation 80 V.
 IT 133542-61-7
 RL: USES (Uses)
 (as charge generator, for electrophotog. photoconductors)
 RN 133542-61-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[[9-[(5-phenyl-2-thienyl)methyl]-9H-carbazole-3,6-diyl]bis(azo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


L19 ANSWER 192 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 193 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1991:218044 CAPLUS
 DOCUMENT NUMBER: 114:218044
 TITLE: Electrophotographic photoreceptor containing hydrazone
 INVENTOR(S): Yamada, Yasuyuki; Akahori, Hiroyuki; Enomoto, Katashi;
 PATENT ASSIGNEE(S): Itoh, Hisato; Nishizawa, Tsutomu; Yamaguchi, Akihiro
 SOURCE: Mitsui Toatsu Chemicals, Inc., Japan
 Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 392805	A1	19901017	EP 1990-303855	19900410
EP 392805	B1	19940615		
R: CH, DE, FR, GB, IT, LI, NL				
JP 02308861	A	19901221	JP 1989-130067	19890525
JP 02308862	A	19901221	JP 1989-130068	19890525
JP 03048254	A	19910301	JP 1990-88385	19900404
US 5132190	A	19920721	US 1990-505273	19900409
CA 2014298	A1	19901010	CA 1990-2014298	19900410
JP 03073961	A	19910328	JP 1990-96223	19900413
JP 03200972	A	19910902	JP 1990-211585	19900813
US 5235104	A	19930810	US 1992-879014	19920506
PRIORITY APPLN. INFO.:			JP 1989-88048	A 19890410
			JP 1989-107594	A 19890428
			JP 1989-130067	A 19890525
			JP 1989-130068	A 19890525
			JP 1989-262205	A 19891009
			US 1990-505273	A3 19900409


OTHER SOURCE(S): MARPAT 114:218044
 GI



AB An electrophotog. photoreceptor which exhibits high sensitivity and excellent durability comprises a photosensitive layer containing a charge-generating agent and a hydrazone having the general formula I (R1,R2 = aryl or R1 and R2 together may form a polycyclic group; R3 = H,


L19 ANSWER 193 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 halogen, alkyl, or Ph; R4, R5 = alkyl, aralkyl, or aryl, with the proviso that at least one of R4 and R5 is an aryl group) and obtained by condensing H2NNR4R5 with the corresponding aldehyde as a charge-transporting agent. The hydrazone thus obtained has sufficiently high ability to receive elec. charges generated by the charge-generating agent, ability to rapidly transport the elec. charges thus received, and ability to fully transport the elec. charges even in a low elec. field, so that no residual elec. charges remain.
 IT 116372-83-9
 RL: USES (Uses)
 (charge-generating agent, for electrophotog. photoconductor containing hydrazone charge-transporting agent)
 RN 116372-83-9 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-[(1,1-dioxido-2,3,4,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 193 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




L19 ANSWER 194 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

1991:196318 CAPLUS
 ACCESSION NUMBER: 114:196318
 DOCUMENT NUMBER: 114:196318
 TITLE: Electrophotographic photoconductor with tetrakisazo compound as charge-generating agent
 INVENTOR(S): Kuroda, Masami; Hattori, Yoshimasa; Furusho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Ger. Offen., 54 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4001351	A1	19900802	DE 1990-4001351	19900118
DE 4001351	C2	19950316		
JP 02189554	A	19900725	JP 1989-10801	19890119
JP 2629929	B2	19970716		
US 4971876	A	19901120	US 1990-466581	19900117
DE 4042427	C2	19940331	DE 1990-4042427	19900118
PRIORITY APPLN. INFO.:			JP 1989-10801	A 19890119
			DE 1990-4001351	A3 19900118

OTHER SOURCE(S): MARPAT 114:196318
 GI



AB An electrophotog. photoconductor is described comprising a photosensitive layer containing a charge-generating agent having the formula I, II, III, or IV [R = H, alkyl, aryl; R1 = AN:NC6H4-p-N:N; A = a coupler group; n =

L19 ANSWER 194 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

2,3]. The photoconductor has improved charging properties.

IT 133431-06-8 133431-27-3 133456-29-8


RL: USES (Uses)

(as charge-generating agent for electrophotog. photoconductor)

RN 133431-06-8 CAPLUS


CN 2-Naphthalenecarboxamide,

4,4'-[2,5-thiophenediylbis(4,1-phenyleneazo-4,1-phenyleneazo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 133431-27-3 CAPLUS


CN 2-Naphthalenecarboxamide, 4,4'-[(3,4-dimethyl-2,5-thiophenediyl)bis(4,1-phenyleneazo-4,1-phenyleneazo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 133456-29-8 CAPLUS

CN 2-Naphthalenecarboxamide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo-4,1-phenyleneazo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 194 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 195 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:621270 CAPLUS
 DOCUMENT NUMBER: 113:221270
 TITLE: Electrophotographic photoreceptor
 INVENTOR(S): Kitatani, Katsushi; Hoshi, Satoshi
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02108060	A	19900419	JP 1988-262201	19881018

PRIORITY APPLN. INFO.: JP 1988-262201 19881018


GI



AB The title electrophotog. photoreceptor contains ≥ 1 trisazo derivative, (AN:NAr1) (AN:NAr2)NAr3LAr4N:NA [Ar1,Ar2,Ar3,Ar4 = arylene, divalent condensed polycyclic aromatic group, divalent heterocyclic aromatic group; Ar1 and Ar2,Ar2 and Ar3,Ar3 and Ar1 may form a ring; L = NHCO, CONH, NHSO2, SO2NH; A = I, II, III, IV, C(COCH3)HCONR3R4, V, VI (X = aromatic ring, heterocyclic ring; Y = CONR4R5, CONHN:CR4R5, CO2R5; R1 = alkyl, phenyl; R2


L19 ANSWER 195 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 = H, lower alkyl, carbamoyl, carboxyl, alkoxy, carbonyl, aryloxy, carbonyl, amino; R3 = alkyl, arom., heterocyclic arom.; R4,R5 = H, alkyl, arom., heterocyclic arom.; R4 = R5 \neq H; when Y = CO2R5, R5 \neq H; B = divalent arom. hydrocarbon, divalent N-contg. heterocyclic ring)] as a charge carrier-generating material.
 IT 130558-10-0
 RL: USES (Uses)
 (charge carrier-generating material from, for electrophotog. photoreceptor)
 RN 130558-10-0 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[[[4-[5-[4-[4-[2-hydroxy-3-[[[4-methoxyphenyl]amino]carbonyl]-11H-benzo[a]carbazol-1-yl]azo]benzoyl]phenyl]-3,4-diphenyl-2-thienyl]phenyl]imino]bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 195 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




L19 ANSWER 196 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:572853 CAPLUS
 DOCUMENT NUMBER: 113:172853
 TITLE: Synthesis and characterization of aromatic-aliphatic polyamides containing tetraphenylthiophene units into the backbone
 AUTHOR(S): Mahajan, Sudhakar S.; Sarwade, Bhimrao D.; Maldar, Noormahmad N.
 CORPORATE SOURCE: Natl. Chem. Lab., Div. Polym. Chem., Pune, 411 008, India
 SOURCE: Polymer Bulletin (Berlin, Germany) (1990), 24(2), 143-9
 CODEN: POBUDR; ISSN: 0170-0839
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Aromatic-aliphatic polyamides were prepared from 2,5-bis[4-(carboxyethylcarbonyl)phenyl]-3,4-diphenylthiophene and aromatic diamines by using the Yamazaki phosphorylation reaction. The polymers were obtained in good yields and were characterized by solubility tests, viscosity measurements, IR spectroscopy, thermal anal., and x-ray diffraction studies. These polyamides had inherent viscosities 0.35-0.70 dL/g and were amorphous in nature. All the polyamides were readily soluble in solvents such as AcMe2, N-methyl-2-pyrrolidone, DMF, PhNO2, (Me2N)3PO, m-cresol, and H2SO4 and did not lose weight at <300° in air.
 IT 129709-67-7P, 2,5-Bis[4-[(2-carboxyethyl)carbonyl]phenyl]-3,4-diphenylthiophene-4,4'-oxydianiline copolymer, sru
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and characterization of heat-resistant)
 RN 129709-67-7 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene(1,4-dioxo-1,4-butanediyl)imino-1,4-phenyleneoxy-1,4-phenyleneimino(1,4-dioxo-1,4-butanediyl)-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 196 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L19 ANSWER 197 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:553169 CAPLUS

DOCUMENT NUMBER: 113:153169

TITLE: Novel synthesis of aromatic polyamides by nickel-catalyzed polycondensation of aromatic dibromides, an aromatic diamine, and carbon monoxide
Yoneyama, Masaru; Konishi, Toru; Kakimoto, Masaaki; Imai, Yoshio

AUTHOR(S):
CORPORATE SOURCE: Dep. Org. Polym. Mater., Tokyo, Inst. Technol., Tokyo,

SOURCE: 152, Japan
Makromolekulare Chemie, Rapid Communications (1990), 11(8), 381-6
CODEN: MCRCD4; ISSN: 0173-2803

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aromatic polyamides were prepared in the presence of Ni-containing catalysts

[NiCl₂, NiBr₂, dichloro(2,2'-bipyridyl)nickel(II), and 2,2'-bipyridyl/NiCl₂ complexes] by polymerization of bis(4-bromophenyl) ether (I)

and bis(4-bromophenyl) ether, m-dibromobenzene (II), or 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene, with CO, using aprotic polar

solvents and 1,8-diazabicyclo[5.4.0]-7-undecene as an HBr scavenger. Highest-viscosity (0.21 dL/g) I-II-CO copolymer was formed at 150°, while that prepared at 180° had viscosity 0.17 dL/g and no polymer was formed at 100°. No appreciable difference was in catalytic activity was observed with respect to the inherent viscosity of the resulting

aramids. IR and NMR spectra confirmed formation of amide linkages.

IT 97429-39-5P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, in presence of nickel catalysts)

RN 97429-39-5 CAPLUS

CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene-carbonylimino-1,4-phenyleneoxy-1,4-phenyleneimino-carbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 197 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L19 ANSWER 198 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:506394 CAPLUS

DOCUMENT NUMBER: 113:106394

TITLE: Electrochromic photoreceptors using a ladder-type

silicon polymer as a charge-transporting agent

Sugawa, Hiroshi; Momotake, Hiroyuki; Sasagawa, Tomoyoshi; Koide, Tetsuhiro; Kobayashi, Mineo; Ito, Masayoshi

PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02019853	A	19900123	JP 1988-168998	19880708
JP 2702160	B2	19980121	JP 1988-168998	19880708

PRIORITY APPLN. INFO.:

GI



AB The photoreceptors comprise a conductive support with a photosensitive layer containing an organic Si compound I (R, R1-9 = H, halo, ether group,

C₂₀ alkyl, alkenyl, aryl which may contain functional group such as CO₂H, NH₂, Cl, OH, etc.; n = 0, pos. integer). The photoreceptors

show increased photosensitivity and durability. Thus, an Al plate was coated with a charge-generating layer containing a disazo pigment and with a charge-transporting layer containing I (R, R1-3 = Cl, R4-9 = CHMe₂, n =

10) to give a photoreceptor.

IT 116372-51-1

RL: USES (Uses)

(charge-generating agent, electrophotog. photoreceptor containing organic


silicon polymer and)

RN 116372-51-1 CAPLUS


CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 198 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




L19 ANSWER 199 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:479265 CAPLUS
 DOCUMENT NUMBER: 113:79265
 TITLE: Manufacture of heat-resistant aromatic polyesters with good mechanical strength
 INVENTOR(S): Imai, Yoshio; Kakimoto, Masaaki; Yoneyama, Masaru
 PATENT ASSIGNEE(S): Tosoh Corp., Japan
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 355840	A2	19900228	EP 1989-115707	19890825
EP 355840	A3	19910814		
R: BE, DE, FR, GB, IT, NL				
JP 02060919	A	19900301	JP 1988-210590	19880826
JP 2638981	B2	19970806		
CA 1338594	C	19960910	CA 1989-609466	19890825
US 4948864	A	19900814	US 1989-400143	19890828
PRIORITY APPLN. INFO.:			JP 1988-210590	A 19880826


AB The title moderate mol. weight polyesters (OAr1O2CAR2CO)n (Ar1, Ar2 = bivalent aromatic residue; n = 10-100) are prepared in good yield from stable inexpensive reactants of aromatic diols HOAr1OH, aromatic dibromides BrAr2Br, and carbon monoxide, in presence of Pd catalysts and organic bases in organic solvents. Bis(4-bromophenyl) ether 2.5, bisphenol A 2.5, 1,8-diazabicyclo[5.4.0]undec-7-ene 5.5, dichlorobis(triphenylphosphine)paladium 0.10 mmol in 10 mL PhCl were heated 1.5 h at 115° in CO atmospheric, diluted with 40 mL PhCl, and poured into 450 mL MeOH to give a polyester with 99% yield.
 IT 104909-92-4P 128382-04-7P 128382-07-0P
 RL: PREP (Preparation)
 (preparation of, palladium catalysts for)
 RN 104909-92-4 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonyloxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxycarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

L19 ANSWER 199 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 128382-04-7 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonyloxy-1,3-phenyleneoxycarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

RN 128382-07-0 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonyloxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxycarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

L19 ANSWER 199 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

L19 ANSWER 200 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:414802 CAPLUS
 DOCUMENT NUMBER: 113:14802
 TITLE: Octazonium salt compounds and tetrakisazo compounds and manufacture thereof
 INVENTOR(S): Yamada, Yasuyuki; Ito, Naoto; Nishizawa, Isao; Yamaguchi, Teruhiro
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01230573	A	19890914	JP 1988-277303	19881104
JP 08026013	B	19960313		

PRIORITY APPLN. INFO.: JP 1987-290700 A1 19871119

GI



AB The title salts have the general formula Q(-p-C₆H₄N₂⁺ X⁻)₄ (Q = thiophene-1,1-dioxide-2,3,4,5-tetrayl; X⁻ = anion) which are coupled with I [at o-position with respect to OH, Z = (un)substituted carbo- or heterocycle member; Y = -CONR₁R₂, CONHN:CR₃R₄; R₁ = (un)substituted

carbo- or heterocycle group; R₂ = H, (un)substituted alkyl, phenyl; R₃ = (un)substituted carbocycle group; R₄ = H, alkyl, (un)substituted phenyl; R₃R₄ = ring member] to give the title tetrakisazo compds. Q(-p-C₆H₇N:NA)4 useful as charge generators in electrophotog. photoconductors.


IT 116372-83-9P 127637-34-7P
 RL: IMF (Industrial manufacture); PREP (Preparation) (manufacture and use of, as charge generator in electrophotog. photoconductors)

RN 116372-83-9 CAPLUS


CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-[(1,1-dioxido-2,3,4,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)]

L19 ANSWER 200 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 127637-34-7 CAPLUS


CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-[(1,1-dioxido-2,3,4,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-methoxy-2-nitrophenyl)- (9CI) (CA INDEX NAME)]

L19 ANSWER 200 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



L19 ANSWER 200 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 2-A



L19 ANSWER 201 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:243024 CAPLUS
 DOCUMENT NUMBER: 112:243024
 TITLE: Electrophotographic photoconductor with bisazo compound as charge generator
 INVENTOR(S): Hattori, Yoshimasa; Furusho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Ger. Offen., 44 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3918463	A1	19891214	DE 1989-3918463	19890606
DE 3918463	C2	19950316		
JP 02084660	A	19900326	JP 1989-50771	19890302
JP 2650403	B2	19970903		
US 4935323	A	19900619	US 1989-361660	19890602
PRIORITY APPLN. INFO.:			JP 1988-140874	A 19880608
			JP 1988-163018	A 19880630
			JP 1988-163020	A 19880630
			JP 1988-163021	A 19880630
			JP 1989-50771	A 19890302


OTHER SOURCE(S): MARPAT 112:243024
 GI



L19 ANSWER 201 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AB An electrophotog. photoconductor is described containing a charge-generating agent from 21 bisazo compound of the structure I, II, III, and/or CpN:NArAr2Ar1N:NCP [Cp = a coupling group; R1 = H, alkyl, alkoxy, carbamoyl; Ar1 = thienylene, thiazolylene; Ar2 = phenylene, thienylene; Ar1 and Ar2 are not thienyl simultaneously; R2 = H, alkyl, Ph; R3-R6 = H, alkyl, alkoxy, aromatic hydrocarbon group, aromatic heterocyclyl; m, n = 1-3].

The material has improved photosensitivity.
 IT 127296-55-3 127296-59-7 127296-60-0
 127297-45-4
 RL: USES (Uses)
 (as charge generator, for electrophotog. photoconductor)
 RN 127296-55-3 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[2,5-thiophenediylbis[(2-methyl-4,1-phenylene)azo]]bis[3-hydroxy-N-(2-methoxyphenyl)]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


RN 127296-59-7 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[2,5-thiophenediylbis[(2-methyl-

L19 ANSWER 201 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 4,1-phenylene)azo]]bis[2-hydroxy-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 127296-60-0 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[2,5-thiophenediylbis[(2-methyl-4,1-phenylene)azo]]bis[2-hydroxy-N-(4-methoxy-2-methylphenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 201 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 127297-45-4 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(2,5-thiazolidiylazo)]bis[2-hydroxy-N-(4-methoxy-2-methylphenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L19 ANSWER 202 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:207872 CAPLUS
 DOCUMENT NUMBER: 112:207872
 TITLE: Electrophotographic photoreceptor with photoconductive layer containing thienyl group-containing Schiff bases
 INVENTOR(S): Kuroda, Masami; Nakamura, Yoichi; Kosho, Noboru
 PATENT ASSIGNEE(S): Fujii Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01237554	A	19890922	JP 1988-64614	19880317

PRIORITY APPLN. INFO.: JP 1988-64614 19880317

AB In the electrophotog. photoreceptor, the photoconductive layer contains ≥ 1 thienyl group-containing Schiff base as a charge-transporting agent. The photoreceptor shows improved chargeability, durability, and sensitivity.


IT 126793-16-6 126793-17-7 126793-22-4

RL: USES (Uses)

(charge-transporting material, electrophotog. photoreceptor using)


RN 126793-16-6 CAPLUS

CN Benzenamine, 4,4'-(2,5-thiophenediyl)bis[N-[(4-methoxyphenyl)methylene]-2-methyl- (9CI) (CA INDEX NAME)



RN 126793-17-7 CAPLUS

CN Benzenamine, 4,4'-(2,5-thiophenediyl)bis[N-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




L19 ANSWER 203 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:188931 CAPLUS
 DOCUMENT NUMBER: 112:188931
 TITLE: Electrophotographic photoconductors containing charge-generating disazo pigments
 INVENTOR(S): Shiino, Yasuko; Umehara, Masashige; Matsumoto, Masakazu
 PATENT ASSIGNEE(S): Canon K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01100558	A	19890418	JP 1987-257375	19871014

PRIORITY APPLN. INFO.: JP 1987-257375 19871014

GI



AB The charge-generating layers of electrophotog. photoconductors contain unsym. disazo pigments of the formula I (R1, R2 = H, alkyl having optional substituents, alkoxy, halo; A1, A2 = coupler having phenolic OH; Ar = II, III, IV wherein X = O, S).

IT 126619-30-5 126619-35-0 126619-41-8


RL: TEM (Technical or engineered material use); USES (Uses)

(electrophotog. charge-generating agent)

RN 126619-30-5 CAPLUS


CN 2-Naphthalenecarboxamide, 4-[[[4-[5-[4-[[[3-[[[(2-fluorophenyl)amino]carbonyl]-2-hydroxyphenyl]azo]-3-methoxyphenyl]-2-thienyl]-2-methoxyphenyl]azo]-3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 202 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 126793-22-4 CAPLUS
 CN Benzenamine, 4,4'-(2,5-thiophenediyl)bis[N-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




L19 ANSWER 203 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 126619-35-0 CAPLUS


CN 11H-Benzo[a]carbazole-3-carboxamide, 1-[[[3-fluoro-4-[5-[2-fluoro-4-[[[3-[[[(2-fluorophenyl)amino]carbonyl]-2-hydroxy-11H-benzo[a]carbazol-1-yl]azo]phenyl]-2-thienyl]phenyl]azo]-2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 203 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 126619-41-8 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 4-[[2-ethyl-4-[5-[3-ethyl-4-[[3-[[2-(2-fluorophenyl)-2-phenylhydrazino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]-2-thienyl]phenyl]azo]-3-hydroxy-, 2-(3-methoxyphenyl)-2-phenylhydrazide (9CI) (CA INDEX NAME)

L19 ANSWER 203 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 126666-99-7 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1-[[4-[4-[[4-[[3-[[2-(2-fluorophenyl)amino]carbonyl]-2-hydroxy-1-dibenzofuranyl]azo]-3-methylphenyl]-2-thienyl]phenyl]azo]-2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 203 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L19 ANSWER 204 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:129095 CAPLUS
 DOCUMENT NUMBER: 112:129095
 TITLE: Preparation of bis-, tris- and tetrakisazo derivatives of tetraphenylthiophene-1,1-dioxide as charge-generating materials for electrophotographic receptors
 INVENTOR(S): Yamada, Yasuhiro; Nishizawa, Isao; Ito, Naoto; Yamaguchi, Teruhiro
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKXKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01107267	A	19890425	JP 1987-263704	19871021

PRIORITY APPLN. INFO.: JP 1987-263704 19871021


GI




AB Electrophotog. receptors containing at least one of tetraphenylthiophene-1,1-dioxide derivs. I (A = coupler residue; 1, m = 1, 0) in a photosensitive layer on an electroconductive support are described as well as preparation of I and imaging process for high durability, high sensitivity, and broad absorbance characteristic in visible region. Thus, diazotization of 5-bis(4-aminophenyl)-3,4-diphenylthiophene-1,1-dioxide by NaNO2 in aqueous H2SO4 gave a tetrazonium salt which was coupled with Naphthol AS in DMF

L19 ANSWER 204 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 the presence of AcONa to give 78.1% I (A = 4-Q, 1 = m = 0).
 IT 116372-66-8P 116372-83-9P 116372-98-6P
 124974-18-1P
 (I): SPN (Synthetic preparation); TEM (Technical or engineered material
 use); PREP (Preparation); USES (Uses)
 (Preparation of, as charge-generating material for electrophotog.
 receptors)
 RN 116372-66-8 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(1,1-dioxido-3,4-diphenyl-2,5-
 thiophenediyl)]bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 116372-83-9 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-[(1,1-dioxido-2,3,4,5-
 thiophenetetrayl)]tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-
 methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 204 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 116372-98-6 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 4,4'-[(1,1-dioxido-3,4-diphenyl-2,5-
 thiophenediyl)]bis(4,1-phenyleneazo)]bis[3-hydroxy-, bis[[4-
 methoxyphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

L19 ANSWER 204 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 124974-18-1 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[[5-[[4-[[2-hydroxy-3-[[4-
 methoxyphenyl]amino]carbonyl]-1-naphthalenyl]azo]phenyl]-1,1-dioxido-4-
 phenyl-2,3-thiophenediyl]]bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-
 methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 204 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



L19 ANSWER 205 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:118654 CAPLUS
 DOCUMENT NUMBER: 112:118654
 TITLE: Preparation of
 5,6-di(hetero)aryl-1,2-dihydro-2-oxo-3-
 pyridinecarboxylates as antibacterial agents
 INVENTOR(S): Biftu, Tesfaye; Heck, James V.; Thorsett, Eugene D.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 43 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 308020	A2	19890322	EP 1988-201974	19880909
EP 308020	A3	19901205		
R: CH, DE, FR, GB, IT, LI, NL				
JP 01128969	A	19890522	JP 1988-231505	19880917
PRIORITY APPLN. INFO.:			US 1987-98632	A 19870918

OTHER SOURCE(S): MARPAT 112:118654
 GI



AB The title compds. [I; R1 = H, C1-6 alkyl, C2-6 alkenyl, C7-14 aralkyl, etc.; R2, R3 = (substituted) aryl containing 6, 10, or 14 ring C atoms, heteroaryl, etc.; R4 = H, C1-6 alkyl, a prodrug ester group, a pharmaceutically acceptable cation], useful for treating bacterial infections, are prepared A mixture of ethanone derivative II (preparation given) and


L19 ANSWER 205 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (MeO)2CHNMe2 in DMF was heated at 25°, concd., NCH2CONH2 and MeOH added, the soln. was added to a slurry of NaH in DMF and heated at 95° to give III, which was heated in 6 M H2SO4 at 120° to give the acid I [R1 = R4 = H, R2 = 4-(Me2N)C6H4 R3 = p-MeOC6H4] (IV). Acid hydrolysis of IV with 48% HBr gave phenolic deriv. I (R3 = p-HOC6H4, other groups as in IV), which showed min. inhibitory concn. of 0.25 µg/mL against Staphylococcus aureus MB 2865.
 IT 124066-13-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of antibacterials)
 RN 124066-13-3 CAPLUS
 CN Ethanone, 1-(4-[2,2'-bithiophen]-5-ylphenyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 206 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:108568 CAPLUS
 DOCUMENT NUMBER: 112:108568
 TITLE: Electrophotographic photoreceptors containing a hydrazone charge-transporting agent
 INVENTOR(S): Kuroda, Masami; Nakamura, Yoichi; Kosho, Noboru
 PATENT ASSIGNEE(S): Fujii Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01164951	A	19890629	JP 1987-323237	19871221
PRIORITY APPLN. INFO.:			JP 1987-323237	19871221

GI




AB Electrophotog. photoreceptors exhibiting good sensitivity and cyclicability have a photosensitive layer containing ≥1 compds. selected from hydrazones I [R, R3 = OH, alkoxy; R1, R2 = H, halo, alkyl, alkoxy, NO2, allyl, (substituted) aryl, amino; R4 = (substituted) aryl; R5 = thiophenyl group Q, (substituted) aryl; R6 = H, halo, alkyl, alkoxy, NO2, allyl, (substituted) aryl, amino]. Thus, an Al-deposited polyester film was coated with a composition containing metal-free phthalocyanine, I (R = R3 = OMe; R1 = R2 = H; R4 = R5 = Ph), and Vylon 200 (polyester resin) to give a photoreceptor, which showed high sensitivity toward both white light and a light of 780 nm.
 IT 125582-27-6 125582-36-7
 RL: USES (Uses)
 (charge-transporting agent, for electrophotog. photoconductor, for repeated use)
 RN 125582-27-6 CAPLUS
 CN Benzaldehyde, 2-methoxy-4-[5-(3-methoxyphenyl)-2-thienyl]-, (4-methoxyphenyl) (phenylmethyl)hydrazone (9CI) (CA INDEX NAME)

L19 ANSWER 206 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 125582-36-7 CAPLUS
 CN Benzaldehyde, 2-ethoxy-4-[5-(3-ethoxyphenyl)-2-thienyl]-, phenyl[(5-phenyl-3-thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)



L19 ANSWER 207 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:108567 CAPLUS
 DOCUMENT NUMBER: 112:108567
 TITLE: Electrophotographic photoreceptors containing a
 hydrazone charge-transporting agent
 INVENTOR(S): Kuroda, Masami; Nakamura, Yoichi; Koshio, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01164950	A	19890629	JP 1987-323235	19871221
PRIORITY APPLN. INFO.:			JP 1987-323235	19871221

GI



AB Electrophotog. photoreceptors exhibiting good sensitivity and cyclability have a photosensitive layer containing ≥ 1 hydrazones I [R, R1, R2, R3 = H, halo, alkyl, alkoxy, OH, acyl, NO2, (substituted) aryl, (substituted) amino; R4 = (substituted) aryl; R5 = (substituted) alkyl, thiophene group Q; R6 = H, halo, alkyl, alkoxy, OH, acyl, NO2, (substituted) aryl, (substituted) amino; n = 1, 2]. Thus, an Al-deposited polyester film was coated with a composition containing metal-free phthalocyanine, I (R = R1 = R2 = R3 = H; R4 = R5 = Ph; n = 1), and Vylon 200 (polyester resin) to give a photoreceptor, which showed high sensitivity toward both white light and a light of 780 nm.

IT 125582-42-5
 RL: USES (Uses)
 (charge-transporting agent, for electrophotog. photoconductor, for repeated use)


RN 125582-42-5 CAPLUS

CN 2-Propenal, 3-[2-hydroxy-4-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]-, (4-methoxyphenyl) (phenylmethyl)hydrazone (9CI) (CA INDEX NAME)

L19 ANSWER 208 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:108503 CAPLUS
 DOCUMENT NUMBER: 112:108503
 TITLE: Electrophotographic photoconductor layer containing
 bisazo compound as charge-generating substance
 INVENTOR(S): Suzuki, Shinichi; Fukawa, Hiroko; Shibata, Toyoko;
 Takaqi, Takahiro; Sasaki, Osamu
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01179159	A	19890717	JP 1988-2037	19880108
PRIORITY APPLN. INFO.:			JP 1988-2037	19880108

GI




AB The photoconductor layer on an elec. conductive support contains a bisazo compound I (Cp = coupler residue; X1 = H, CN, halo; and X2 = NH, O, S) as a charge-generating substance.

IT 125501-91-9
 RL: USES (Uses)
 (charge-generating substance, electrophotog. photoconductor from)


RN 125501-91-9 CAPLUS

CN 11H-Benzo[a]carbazole-3-carboxamide, 1-[[4-[5-[2-chloro-2-[4-[[2-hydroxy-3-[[[4-methoxy-2-methylphenyl]amino]carbonyl]-11H-benzo[a]carbazol-1-yl]azo]phenyl]ethenyl]-2-thienyl]phenyl]azo]-2-hydroxy-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 207 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 208 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L19 ANSWER 209 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:45624 CAPLUS
 DOCUMENT NUMBER: 112:45624
 TITLE: Electrophotographic photoconductors containing bisazo compound charge carrier-generating agents
 INVENTOR(S): Kuroda, Masami; Hattori, Yoshimasa; Furusho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Ger. Offen., 100 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3841207	A1	19890629	DE 1988-3841207	19881207
DE 3841207	C2	19940224		
JP 01150147	A	19890613	JP 1987-310508	19871208
JP 2629752	B2	19970716		
JP 01150146	A	19890613	JP 1987-310509	19871208
JP 01167759	A	19890703	JP 1987-325962	19871223
JP 07038078	B	19950426		
JP 01180558	A	19890718	JP 1988-5138	19880113
JP 01183664	A	19890721	JP 1988-7681	19880118
JP 2643214	B2	19970820		
US 4929525	A	19900529	US 1988-283060	19881206
DE 3844602	C2	19921119	DE 1988-3844602	19881207
PRIORITY APPLN. INFO.:			JP 1987-310508	A 19871208
			JP 1987-310509	A 19871208
			JP 1987-325962	A 19871223
			JP 1988-5138	A 19880113
			JP 1988-7681	A 19880118


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Electrophotog. photoconductors, having a high photosensitivity and excellent characteristics in cyclic use, contain a bisazo compound of the structure I-V (R = a coupler moiety; R1-R4 = H, halogen, OH, alkyl, alkoxy, allyl, aryl, aralkyl, CO₂H, or an ester group; R5-R22 = H, CN, CO₂H, ester, acyl, halogen, alkyl, cycloalkyl, alkenyl, aryl, aromatic heterocyclyl; Ar = aromatic or aromatic heterocyclyl) as a charge-generating substance. Thus, an Al-coated PET film was overcoated with a mixture containing VI, 1-phenyl-3-(p-diethylaminostyryl)-5-(p-diethylaminophenyl)oxadiazole,

L19 ANSWER 209 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 of a polyester, and THF, dried, corona charged to show a surface potential of 550 V, and exposed with white light (25; 10 lx) to show a residual potential of 80 V, and an E1/2 sensitivity of 5.9 lx-s.
 IT 123110-46-3 123110-56-5
 RL: USES (Uses)
 (electrophotog. photoconductor containing charge carrier-generating agent from, for high photosensitivity and excellent characteristics in cyclic use)
 RN 123110-46-3 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[3,4-thiophenediylbis(4,1-phenyleneazo)]bis[7-bromo-3-hydroxy-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L19 ANSWER 209 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 123110-56-5 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[3,4-thiophenediylbis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L19 ANSWER 210 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:14238 CAPLUS
 DOCUMENT NUMBER: 112:14238
 TITLE: Electrophotographic photoconductor containing thiophene group-containing hydrozone as charge-transporting agent
 INVENTOR(S): Kuroda, Masami; Nakamura, Youichi; Furusho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Ger. Offen., 88 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3841391	A1	19890629	DE 1988-3841391	19881208
JP 01152466	A	19890614	JP 1987-311310	19871209
JP 01159659	A	19890622	JP 1987-317770	19871216
JP 01166053	A	19890629	JP 1987-326228	19871222
JP 01166054	A	19890629	JP 1987-326230	19871222
JP 01172960	A	19890707	JP 1987-332364	19871228
JP 01172961	A	19890707	JP 1987-332370	19871228
JP 01172965	A	19890707	JP 1987-332371	19871228
US 4956277	A	19900911	US 1988-281029	19881207
PRIORITY APPLN. INFO.:			JP 1987-311310	A 19871209
			JP 1987-317770	A 19871216
			JP 1987-326228	A 19871222
			JP 1987-326230	A 19871222
			JP 1987-332364	A 19871228
			JP 1987-332370	A 19871228
			JP 1987-332371	A 19871228

GI



AB Electrophotog. photoconductors which have a high photosensitivity and excellent characteristics in cyclic use, contain a thiophene group-containing hydrazone as a charge-transporting agent. Thus, an Al-coated PET film was overcoated with a mixture containing I, metal-free phthalocyanine, Nylon 200,


L19 ANSWER 210 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 and THF, dried, corona charged to show a surface potential of 660 V,
 exposed with white light to show a residual potential of 60 V and a
 sensitivity (Ey2) of 6.3 lx-s.
 IT 124196-98-1
 RL: USES (Uses)
 (electrophotog. photoconductor containing charge carrier-transporting
 agent from, for high sensitivity and excellent characteristics in cyclic
 use)
 RN 124196-98-1 CAPLUS
 CN 2-Propenal, 3,3-bis(4-methoxyphenyl)-, phenyl[(5-phenyl-2-
 thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)



L19 ANSWER 211 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:2625 CAPLUS
 DOCUMENT NUMBER: 112:2625
 TITLE: 2-Substituted ethynylthiophene pesticides
 INVENTOR(S): Eukart, Susan E.; Phillips, Richard B.; Roush, David M.
 PATENT ASSIGNEE(S): FMC Corp., USA
 SOURCE: U.S., 6 pp. Cont.-in-part of U.S. Ser. No. 889,040, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4826829	A	19890502	US 1988-169110	19880309
CN 87103400	A	19880406	CN 1987-103400	19870507
ZA 8705426	A	19880330	ZA 1987-5426	19870723
PRIORITY APPLN. INFO.:			US 1986-889040	A2 19860723

OTHER SOURCE(S): CASREACT 112:2625; MARPAT 112:2625
 GI




AB The ethynylthiophenes I [R, R2 = (un)substituted Ph, thienyl or naphthyl; R1 = H, Me] are prepared as acaricides and insecticides. A mixture of 5-formyl-2-phenylthiophene (preparation given) di-Et (4-chlorophenyl)chloromethylphosphonate (preparation given), DMF, and NaOMe was


stirred for 18 h, to give 1-(5-phenylthien-2-yl)-2-chloro-2-(4-chlorophenyl)ethene, which was refluxed with tert-BuOK in THF, to give 1-(5-phenylthien-2-yl)-2-(4-chlorophenyl)ethyne (II). Exposure to 50 ppm II was lethal to two-spotted spider mite (Tetranychus urticae). A wettable powder contained 1-[5'-methyl-(2,2'-bithien-5-yl)]-2-[4-(1-methylethyl)phenyl]ethyne 50.0, attapulgit 22.0, kaolin 220 and Na salt of sulfonated kraft lignin 6.04.

IT 115219-74-4P 115219-75-SP 124038-94-4P
 124038-99-9P 124039-03-8P 124039-05-0P
 124039-20-9P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as acaricide and insecticide)
 RN 115219-74-4 CAPLUS
 CN Thiophene, 2-[[4-(1-methylethoxy)phenyl]ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)


L19 ANSWER 211 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 INDEX NAME)




RN 115219-75-5 CAPLUS
 CN Thiophene, 2-[(4-phenoxyphenyl)ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 124038-94-4 CAPLUS
 CN Thiophene, 2-[(4-methoxyphenyl)ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 124038-99-9 CAPLUS
 CN Thiophene, 2-phenyl-5-[[4-(trifluoromethoxy)phenyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 124039-03-8 CAPLUS
 CN Thiophene, 2-[(4-ethoxyphenyl)ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 124039-05-0 CAPLUS
 CN Thiophene, 2-[[4-(2-fluoroethoxy)phenyl]ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 211 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 124039-20-9 CAPLUS
 CN Thiophene, 2-[(3-methoxyphenyl)ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)



L19 ANSWER 212 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:622064 CAPLUS
 DOCUMENT NUMBER: 111:222064
 TITLE: Tetraphenylthiophene derivative and electrophotographic photoreceptor containing same
 Tanaka, Eishi; Nishizawa, Tsutomu; Yamada, Yasuyuki; Itoh, Hisato; Yamaguchi, Akihiro; Nakatsuka, Masakatsu
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Eur. Pat. Appl., 68 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 317233	A2	19890524	EP 1988-310720	19881114
EP 317233	A3	19901205		
EP 317233	B1	19940504		
R: CH, DE, FR, GB, IT, LI, NL				
JP 01280764	A	19891110	JP 1988-266106	19881024
US 4963449	A	19901016	US 1988-272371	19881117
US 5023343	A	19910611	US 1990-553014	19900716
PRIORITY APPLN. INFO.:			JP 1987-288311	A 19871117
			JP 1987-316019	A 19871216
			JP 1988-2459	A 19880111
			JP 1988-3685	A 19880113
			US 1988-272371	A3 19881117


OTHER SOURCE(S): MARPAT 111:222064
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB A tetraphenylthiophene derivative [I; R₁, R₂ = alkyl, aralkyl; R₁ and R₂ may be linked together with the N atom to form a ring; l, m, n, = 0, 1; l ≥ m ≥ n], and an electrophotog. photoreceptor with a charge-transport agent from I and a selected charge-generating agent (preferably azo) are claimed. Thus, 2,5-bis(4-aminophenyl)-3,4-diphenylthiophene and iodobenzene were reacted to obtain II. A photoreceptor containing I (R₁, R₂ = Ph; l = 1; m = n = 0) and II had excellent elec. properties.
 IT 116372-66-8 116372-83-9 123715-41-3
 RL: USES (Uses)
 (as charge-generating agent in electrophotog. photoreceptor)

L19 ANSWER 212 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 123715-41-3 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4',4''-[(1,1-dioxido-4-phenyl-2,3,5-thiophenetriyl)tris(4,1-phenyleneazo)]tris[3-hydroxy-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

L19 ANSWER 212 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 116372-66-8 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(1,1-dioxido-3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 116372-83-9 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-[(1,1-dioxido-2,3,4,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

L19 ANSWER 212 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A




IT 123715-38-8 123715-39-9
 RL: USES (Uses)
 (as charge-transport agent in electrophotog. photoreceptor)
 RN 123715-38-8 CAPLUS
 CN Benzenamine, 4,4'-(3,4-diphenyl-2,5-thiophenediyl)bis[N-(4-methoxy-2-methylphenyl)-N-phenyl]- (9CI) (CA INDEX NAME)




L19 ANSWER 212 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 123715-39-9 CAPLUS
 CN Benzenamine, 4,4',4''-(4-phenyl-2,3,5-thiophenetriyl)tris[N-(4-methoxy-2-methylphenyl)-N-phenyl]- (9CI) (CA INDEX NAME)



IT 123715-32-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and use of, as charge-transport agent in electrophotog. photoreceptor)
 RN 123715-32-2 CAPLUS
 CN Benzenamine, N,N-bis(4-methoxyphenyl)-4-(3,4,5-triphenyl-2-thienyl)- (9CI)
 (CA INDEX NAME)




L19 ANSWER 213 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 213 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:605447 CAPLUS
 DOCUMENT NUMBER: 111:205447
 TITLE: Electrophotographic photoreceptors containing hydrazone compound as charge-transporting agent
 INVENTOR(S): Kuroda, Masami; Nakamura, Yoichi; Koshio, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01107262	A	19890425	JP 1987-265114	19871020
PRIORITY APPLN. INFO.:				
			JP 1987-265114	19871020

GI





AB Electrophotog. photoreceptors have a photosensitive layer containing, as a charge-transporting agent, a hydrazone compound of the structure I [R = (substituted) aryl; R1-R8 = H, halo, alkoxy, alkyl, NO2, OH, aryl, (substituted) amino]. The photoreceptors exhibit good sensitivity and cyclability. Thus, an Al-coated polyester film was coated with a composition containing metal-free phthalocyanine, I (R = Ph; R1-R8 = H), and Nylon 200 (polyester resin) to give a photoreceptor showing high sensitivity in both pos. and neg. charging.
 IT 123521-25-5
 RL: USES (Uses)
 (charge transporting agent, for electrophotog. photoreceptor)
 RN 123521-25-5 CAPLUS
 CN Benzaldehyde, 4-(5-phenyl-2-thienyl)-, (4-methoxyphenyl)(2-thienylmethyl)hydrazone (9CI) (CA INDEX NAME)

L19 ANSWER 214 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:544058 CAPLUS
 DOCUMENT NUMBER: 111:144058
 TITLE: Hydrazone charge carrier-transporting agents for electrophotographic in photoreceptors
 INVENTOR(S): Kuroda, Masami; Nakamura, Yoichi; Furusho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Ger. Offen., 62 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3835108	A1	19890427	DE 1988-3835108	19881014
DE 3835108	C2	19931028		
JP 01102469	A	19890420	JP 1987-260531	19871015
JP 05024507	B	19930408		
JP 01107263	A	19890425	JP 1987-265112	19871020
JP 01107261	A	19890425	JP 1987-265113	19871020
JP 01107264	A	19890425	JP 1987-265751	19871021
JP 01107265	A	19890425	JP 1987-265752	19871021
JP 01152467	A	19890614	JP 1987-311312	19871209
US 4957837	A	19900918	US 1988-257260	19881013
PRIORITY APPLN. INFO.:				
			JP 1987-260531	A 19871015
			JP 1987-265112	A 19871020
			JP 1987-265113	A 19871020
			JP 1987-265751	A 19871021
			JP 1987-265752	A 19871021
			JP 1987-311312	A 19871209

OTHER SOURCE(S): MARPAT 111:144058
 GI



AB Electrophotog. photoreceptors having a high photosensitivity and excellent

L19 ANSWER 214 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
characteristics for continuous use contain a hydrazone of the structure I
(R1 = aryl, that can have ≥ 1 substituent; R2-R6 = H, halogen,
alkyl, alkoxy, OH, NO₂, allyl, aryl, that can have ≥ 1 substituent,
or alkyl; n = 0 or 1) as a charge carrier-transporting agent. An
Al-coated polyester film was coated with a dispersion contg. milled
metal-free phthalocyanine, II, Nylon 200 (polyester), and THF, dried, and
tested in an electrostatically working recording paper testing app. to
show a white light photo sensitivity (E1/2 value) of 5.2 ex-s.

IT 122836-89-9 122836-99-1 122837-48-3
122837-80-3 122837-92-7 122852-22-6


RL: USES (Uses)

agent (electrophotog. photoreceptor containing charge carrier-transporting

from)

RN 122836-89-9 CAPLUS


CN Benzaldehyde, 4-(diethylamino)-2-methoxy-, (4-methylphenyl)[(5-phenyl-2-thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)



RN 122836-99-1 CAPLUS


CN Benzaldehyde, 4-(diethylamino)-, (4-methoxyphenyl)[(4-phenyl-3-thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)

L19 ANSWER 214 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122837-48-3 CAPLUS

CN Benzaldehyde, 3,4-dimethoxy-, phenyl[(5-phenyl-2-thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)



RN 122837-80-3 CAPLUS


CN [2,2'-Bithiophene]-5-carboxaldehyde, (4-methoxyphenyl)[(4-phenyl-2-thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)



RN 122837-92-7 CAPLUS


CN [2,2'-Bithiophene]-5-carboxaldehyde, (4-methoxyphenyl)[(5-phenyl-3-

L19 ANSWER 214 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)



RN 122852-22-6 CAPLUS

CN Benzaldehyde, 4-methoxy-, (4-methoxyphenyl)[(4-phenyl-3-thienyl)methyl]hydrazone (9CI) (CA INDEX NAME)



L19 ANSWER 215 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:458426 CAPLUS

DOCUMENT NUMBER: 111:58426

TITLE: Soluble high-temperature polymers containing a tetraphenylthiophene unit

AUTHOR(S): Imai, Yoshio; Kakimoto, Masaaki

CORPORATE SOURCE: Dep. Org. Polym. Mater., Tokyo Inst. Technol., Tokyo, 152, Japan

SOURCE: Polymer-Plastics Technology and Engineering (1989), 28(4), 371-414

CODEN: PPTEC7; ISSN: 0360-2559

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The title polymers were prepared using 4 types tetraphenylthiophene

monomers

- diamine, diisocyanate, diacyl chloride, and dibromide. Aromatic

polyimides

and copolyimides were prepared by reaction of tetraphenylthiophenediamine

(I) or tetraphenylthiophene diisocyanate (II) with tetracarboxylic

dianhydrides or dithioanhydrides. Aromatic polyamides and copolyamides

were

obtained by reaction of I with diacyl chlorides or

tetraphenylthiophenedicarboxylic acid chloride (III) with diamines.

Aromatic polyamide-imides were prepared by reaction of I with

4-chloroformylphthalic

anhydride and of II with trimellitic anhydride. The reaction of III with

bisphenols and aminophenols gave aromatic polyesters and

polyamide-esters,

resp. Aromatic polyazomethines were prepared by reaction of I and

aldehydes.

All the polymers had high mol. weight, were soluble in organic solvents,

and had

glass transition temps. of .apprx.300°.

IT 97429-39-5E 104909-92-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and solubility and glass transition temperature of)

RN 97429-39-5 CAPLUS

CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylene-carbonylimino-1,4-phenyleneoxy-1,4-phenyleneimino-carbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 215 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

]
 n

RN 104903-92-4 CAPLUS
 CN Poly[(3,3'-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonyloxy-1,4-phenylene-methylethylidene]-1,4-phenyleneoxycarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 1-B

]
 n

L19 ANSWER 216 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:222531 CAPLUS
 DOCUMENT NUMBER: 110:222531
 TITLE: Charge-generating azo photoconductor for electrophotographic plate
 INVENTOR(S): Nakamura, Yoichi; Kuroda, Masami; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63163369	A	19880706	JP 1986-313501	19861225
PRIORITY APPLN. INFO.:			JP 1986-313501	19861225
OTHER SOURCE(S):		MARPAT 110:222531		
GI				




AB The electrophotog. plate with improved sensitivity and stability has a photosensitive layer containing as a charge-generating photoconductor ≥

L19 ANSWER 216 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1 phenylthienylphenylazo deriv. of the formula I or phenylthienylphenyldisazo deriv. of the formula II (R1-R22 = H, halo, OH, alkyl, alkoxy, allyl, acyl, carbamoyl, amino, aryl, NO₂, CN, etc.; A = coupler residue which may be benzene deriv.; Z = [1,1'-biphenyl]-4,4'-diyl deriv.). The compd. (I; R1-R11 = H; A = 3-nitrophenyl) may be used as a charge-generating photoconductor for the electrophotog. plate.
 IT 120565-91-5 120565-98-2 120566-05-4
 RL: USES (Uses)
 (electrophotog. charge-generating photoconductor, for improved sensitivity)


RN 120565-91-5 CAPLUS
 CN Diazeno, (4-methoxyphenyl)[4-(5-phenyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)



RN 120565-98-2 CAPLUS
 CN Diazeno, (4-methoxyphenyl)[4-(4-methyl-5-phenyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)






RN 120566-05-4 CAPLUS
 CN Diazeno, (4-methoxyphenyl)[4-(3,4,5-triphenyl-2-thienyl)phenyl]- (9CI) (CA INDEX NAME)





L19 ANSWER 217 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:222530 CAPLUS
 DOCUMENT NUMBER: 110:222530
 TITLE: Charge-generating terthienylazo or terthienyldisazo photoconductor for electrophotographic plate
 INVENTOR(S): Nakamura, Yoichi; Kuroda, Masami; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63163368	A	19880706	JP 1986-313500	19861225
PRIORITY APPLN. INFO.:			JP 1986-313500	19861225
OTHER SOURCE(S):		MARPAT 110:222530		
GI				




AB The electrophotog. plate with improved sensitivity and stability has a photosensitive layer containing as a charge-generating photoconductor ≥ 1 terthienylazo derivative of the formula I or terthienyldisazo derivative of the formula II (R1-R14 = H, halo, OH, alkyl, alkoxy, allyl, acyl, carbamoyl, amino, aryl, NO₂, CN, etc.; A = coupler residue which may be benzene derivative; Z = [1,1'-biphenyl]-4,4'-diyl derivative). The compound (I; R1-R7 = H; A = 3-nitrophenyl) may be used as a charge-generating photoconductor for the electrophotog. plate.
 IT 120607-25-2
 RL: USES (Uses)
 (electrophotog. charge-generating photoconductor, for improved sensitivity)

L19 ANSWER 217 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 120607-25-2 CAPLUS
 CN Diazene, 1,1'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[2-(5''-phenyl[2,2':5',2''-terthiophen]-5-yl)- (9CI) (CA INDEX NAME)



L19 ANSWER 218 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:154135 CAPLUS
 DOCUMENT NUMBER: 110:154135
 TITLE: Preparation of acaricidal aryl(arylthien-2-yl)ethenes
 INVENTOR(S): Burkart, Susan E.; Rodriguez, Cesar; Roush, David M.; Phillips, Richard B.
 PATENT ASSIGNEE(S): FMC Corp., USA
 SOURCE: U.S., 6 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4792567	A	19881220	US 1987-60188	19870609
PRIORITY APPLN. INFO.:			US 1987-60188	19870609
OTHER SOURCE(S):			CASREACT 110:154135; MARPAT 110:154135	
GI				




AB The title compds. [I; R, R1 = H, halo, alkyl, alkoxy, carbonyl, N(CO2Et)CH2C6H11; R2, R3 = (un)substituted Ph, thienyl; 1 of R2, R3 ≠ Ph, alkylphenyl] were prepared 2-Bromothiophene was refluxed with PhMgBr in Et2O containing (Ph2PCH2)2CH2-NiCl2 to give 2-phenylthiophene which was stirred 2 h at -78° with BuLi in THF after which PhCHMeCHO was added and the mixture stirred 2 days at room temperature to give thienylpropanol II. The latter was refluxed 1.5 h with concentrated HCl to give I (R1 = Me, R2 = R3 = Ph) which gave 86 and 100% kill of phosphate-resistant and nonresistant Tetranychus urticae, resp., when sprayed at 50 ppm and maintained 48 h under UV light.

IT 119895-20-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as acaricide)

RN 119895-20-4 CAPLUS
 CN Thiophene, 2-[2-[4-(pentyloxy)phenyl]ethenyl]-5-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 218 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 219 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:144959 CAPLUS
 DOCUMENT NUMBER: 110:144959
 TITLE: Electrophotographic photoreceptors containing hydrazone as charge-transferring substance
 INVENTOR(S): Yamada, Yasuyuki; Ito, Naoto; Nishizawa, Isao; Yamauchi, Teruhiro
 PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63206758	A	19880826	JP 1987-39132	19870224
PRIORITY APPLN. INFO.:			JP 1987-39132	19870224

OTHER SOURCE(S): MARPAT 110:144959

AB Electrophotog. photoreceptors have, on a conductive support, a photo-sensitive layer containing a hydrazone of the formula $\text{PhN}(\text{C}_6\text{H}_4\text{CH}_2\text{NRR1-p})_2$ [I; R, R1 = (substituted) alkyl, (substituted) aralkyl, (substituted) aryl; 21 of them should be a (substituted) aryl] as a charge-transferring substance. The photoreceptors exhibit good sensitivity and durability. Thus, an Al substrate was coated with a composition containing a disazo compound and Vylon 200 (polyester resin) and overcoated with a composition containing I (R = Ph; R1 = Me) and Vylon 200 to give a photoreceptor which showed high sensitivity and excellent durability.


IT 116372-51-1
 RL: TEM (Technical or engineered material use); USES (Uses)
 (charge-generating agent, for electrophotog. photoreceptor)

RN 116372-51-1 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 219 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L19 ANSWER 220 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:104968 CAPLUS

DOCUMENT NUMBER: 110:104968

TITLE:

Electrophotographic photoreceptors with insulating layer and photosensitive layer on phenol resin substrate containing dispersed carbon

Asanuma, Tadashi; Takeda, Junko; Tokura, Yoshiko

Mitsui Toatsu Chemicals, Inc., Japan

Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:


LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63180963	A	19880726	JP 1987-11231	19870122
PRIORITY APPLN. INFO.:				
			JP 1987-11231	19870122

GI



AB Electrophotog. photoreceptors, having at least a charge-generating layer and a charge-transporting layer, are prepared by forming an insulating layer on a phenol resin substrate in which carbon is dispersed and then forming a charge-generating layer containing >50 weight% azo type pigment thereon. The

L19 ANSWER 220 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

photoreceptors exhibit good sensitivity and durability and are useful for copiers, laser printers and the like. Thus, a hardened resol type phenol resin substrate in which carbon (20 wt.%) was dispersed was first coated with casein, then coated with a compn. contg. azo pigment I and Vylon 200 (polyester resin) (2:1 wt. ratio), and finally coated with a compn.

contg. a hydrazone compd. and Vylon 200 to give an electrophotog. photoreceptor.


IT 116372-51-1

RL: USES (Uses)

(charge-generating agent, electrophotog. photoreceptor containing)

RN 116372-51-1 CAPLUS

CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



L19 ANSWER 221 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:104961 CAPLUS

DOCUMENT NUMBER: 110:104961

TITLE:

Electrophotographic photoreceptors with charge-generating layer prepared from dispersion of azo-type pigments in alkylglycol acetate media

Asanuma, Tadashi; Takeda, Junko; Tokura, Yoshiko

Mitsui Toatsu Chemicals, Inc., Japan

Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:


LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63172276	A	19880715	JP 1987-3354	19870112
PRIORITY APPLN. INFO.:				
			JP 1987-3354	19870112

GI



AB Electrophotog. photoreceptors comprise a charge-transporting layer and a charge-generating layer prepared by coating an azo-type pigment dispersion in an alkylglycol acetate medium. The photoreceptors exhibit high sensitivity and durability, and are useful for electrophotog. copiers, laser printers, etc. Thus, an Al substrate was coated with a composition containing I (diazo pigment), Rikemal S-100 (stearic acid monoglyceride), Vylon 200 (polyester resin), and cellosolve acetate and overcoated with a composition containing a charge-transporting material and Vylon

L19 ANSWER 221 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 200. The photoreceptor showed high sensitivity at a wide range in wavelength.
 IT 116372-51-1
 RL: TEM (Technical or engineered material use); USES (Uses)
 (charge-generating agent, for electrophotog. photoreceptor)
 RN 116372-51-1 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




L19 ANSWER 222 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:85429 CAPLUS
 DOCUMENT NUMBER: 110:85429
 TITLE: Organic electrophotographic photoconductors
 INVENTOR(S): Nakamura, Yoichi; Kuroda, Masami; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63158563	A	19880701	JP 1986-306872	19861223


PRIORITY APPLN. INFO.: JP 1986-306872 19861223

GI



AB The photosensitive layer of electrophotog. photoconductors contains azo bithiophene compd(s), (I) or (II) [R1-10 = H, halo, OH, alkyl, alkoxy, allyl, aldehyde, acyl, carboxy, ester group, carbamoyl, NH2, alkylamino, arylamino, aryl, aralkyl, NO2, cyano; N:NA1 = azo-containing group; N:NA2N:N = bisazo-containing group], as charge carrier-generating agent. The use of I provides high sensitivity and stability, and excellent performance when combined with varied charge carrier-generating agents. Thus, a dispersion containing I (R1-5 = H, A1 = 3-nitrophenyl) 50, 1-phenyl-3-(p-diethylaminostyryl)-(p-diethylaminophenyl)-2-pyrazoline 100, and polyester 100 parts was applied on an Al-coated polyester film. The obtained photoconductor showed sensitivity (irradiation required for half decay of charge voltage) 5.1 lx-s to white light.
 IT 119024-74-7
 RL: USES (Uses)
 (electrophotog. photoconductor containing, as charge carrier-generating

L19 ANSWER 222 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 agent)
 RN 119024-74-7 CAPLUS
 CN Diazene, 1,1'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[2-(5'-phenyl[2,2'-bithiophen]-5-yl)-(9CI) (CA INDEX NAME)




L19 ANSWER 223 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:85395 CAPLUS
 DOCUMENT NUMBER: 110:85395
 TITLE: Electrophotographic photoreceptor having photosensitive layer containing septithiophene structure-containing azo derivative
 INVENTOR(S): Nakamura, Yoichi; Kuroda, Masami; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63178246	A	19880722	JP 1987-10434	19870120




PRIORITY APPLN. INFO.: JP 1987-10434 19870120

GI





AB The title photoreceptor has a photosensitive layer containing ≥ 1 septithiophene structure-containing azo derivative I or II [R1-R30 = H, halogen, OH, alkyl, alkoxy, allyl, aldehyde, acyl, carboxyl, ester, carbamoyl, amino, alkylamino, arylamino, aryl, aralkyl, nitro, cyano; N:NA' = azo moiety; N:NA2N:N indicates a bisazo moiety]. An electrophotog. photoreceptor containing the azo derivative as a charge-generating material shows improved electrophotog. performance.
 IT 118155-16-1
 RL: USES (Uses)
 (charge-generating material, electrophotog. photoreceptor using)
 RN 118155-16-1 CAPLUS
 CN Diazene, 1,1'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[2-(5'-phenyl[2,2'-bithiophen]-5-yl)-(9CI) (CA INDEX NAME)

119 ANSWER 224 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:85392 CAPLUS
DOCUMENT NUMBER: 110:85392
TITLE: Electrophotographic photoreceptor having
photosensitive layer containing quinuethiophene azo
derivative
INVENTOR(S): Nakamura, Yoichi; Kuroda, Masami; Kozho, Noboru
PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:







AB The title photoreceptor has a photosensitive layer containing ≥ 1 quinquethiophene azo derivative of the structure I or II [R1-R22 = H, halogen, OH, alkyl, alkoxy, allyl, aldehyde, acyl, CO₂H, ester, carbamoyl, NH₂, alkylamino, arylamino, aryl, aralkyl, NO₂, CN; A1 = a coupler moiety; and

L19 ANSWER 224 OF 50 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
A2 = a divalent coupler moiety). This azo deriv. may be used as a
charge-generating material. An electrophotog. photoreceptor using this
azo deriv. shows both improved neg. and pos. chargeabilities with
improved sensitivity.
IT 118082-03-4
RL: USES (Uses)
(charge-generating material, electrophotog. photoreceptor using)
RN 118082-03-4 CAPLUS
CN Diazenyl[2,1'-(3,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[2-(5'''-
phenyl[2,2''',5'',2''',5''',2''',5''',2''',5'''-quinquethiophen]-5-yl)- (9CI) (CA
INDEX NAME




119 ANSWER 225 OF 250 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 1989:85391 CAPLUS
DOCUMENT NUMBER: 10:85391
TITLE: Electrophotographic photoreceptor having photosensitive layer containing terthiophene azo derivative
INVENTOR(S): Nakamura, Yoichi; Kuroda, Masami; Kosho, Noboru
PATENT ASSIGNEE(S): Fujii Electric Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



AB	The title photoreceptor has a photosensitive layer containing ≥ 1 terthiophene azo derivative of the structures I or II [R1-R18 = H, halogen, OH, alkyl, alkoxy, allyl, aldehydo, acyl, CO2H, ester, carbamoyl, NH2, alkylamino, arylamino, aryl, alkaryl; A1 = a coupler moiety; A2 = a divalent moiety]. This azo derivative may be used as a charge-generating material. An electrophotog. photoreceptor using this azo derivative
shows	both improved neg. and pos. chargeabilities with improved durability and sensitivity.
IT	118881-43-9 RL: USES (Uses) (charge-generating material, electrophotog. photoreceptor using)
RN	118881-43-9 CAPLUS



L19 ANSWER 225 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Diazene, 1,1'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[2-(5'''-phenyl[2,2':5',2'':5'',2'''-quaterthiophen]-5-yl)- (9CI) (CA INDEX NAME)



L19 ANSWER 226 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:66857 CAPLUS
 DOCUMENT NUMBER: 110:66857
 TITLE: Electrophotographic photoreceptor having photosensitive layer containing hydrazone derivative
 INVENTOR(S): Kuroda, Masami; Nakamura, Yoichi; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63183448	A	19880728	JP 1987-16764	19870127
US 4861691	A	19890829	US 1987-137212	19871222
PRIORITY APPLN. INFO.:				
				JP 1986-305652 A 19861222
				JP 1986-310176 A 19861229
				JP 1987-16764 A 19870127

OTHER SOURCE(S): MARPAT 110:66857
 GI



AB The title photoreceptor has a photosensitive layer containing ≥ 1 hydrazone derivative XCH:NNR1R2 [R1,R2 = (substituted) alkyl, (substituted) aryl, (substituted) aralkyl; X = I or II (R3-R15 = H, halogen, OH, alkyl, alkoxy, allyl, carboxyl, acyl, ester, aryl, cyano, nitro, amino, alkylamino, arylamino; n = 1-5)]. This hydrazone derivative is suited for use as a charge-transferring material. An electrophotog. photoreceptor using this hydrazone derivative shows improved pos. and neg. chargeability with improved sensitivity and durability.




L19 ANSWER 226 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 118163-66-9
 RL: USES (Uses)
 (charge-transferring material, electrophotog. photoreceptor using)
 RN 118163-66-9 CAPLUS
 CN Benzaldehyde, 4-(3,4-dimethyl-5-phenyl-2-thienyl)-, (4-methoxyphenyl)methylhydrazone (9CI) (CA INDEX NAME)



L19 ANSWER 227 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:31369 CAPLUS
 DOCUMENT NUMBER: 110:31369
 TITLE: Electrophotographic photoreceptor having photosensitive layer containing sexithiophene structure-containing azo derivative
 INVENTOR(S): Nakamura, Yoichi; Kuroda, Masami; Kosho, Noboru
 PATENT ASSIGNEE(S): Fuji Electric Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63178245	A	19880722	JP 1987-10433	19870120
PRIORITY APPLN. INFO.:				
				JP 1987-10433 19870120



OTHER SOURCE(S): MARPAT 110:31369
 GI



AB The title photoreceptor has a photosensitive layer containing ≥ 1 sexithiophene structure-containing azo derivative I or II [R1-R22 = H, halogen, OH, alkyl, alkoxy, allyl, aldehyde, acyl, carboxyl, ester, carbamoyl, amino, alkylamino, arylamino, aryl, aralkyl, nitro, cyano; N:NA' = azo residue; N:NA2N:N = bisazo residue]. An electrophotog. photoreceptor containing the azo derivative shows improved sensitivity and durability.

IT 118154-28-2
 RL: USES (Uses)
 (charge-generating material, electrophotog. photoreceptor using)
 RN 118154-28-2 CAPLUS
 CN Diazene, 1,1'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[2-(5'''-phenyl[2,2':5',2'':5'',2'''-sexithiophen]-5-yl)- (9CI) (CA INDEX NAME)

L19 ANSWER 227 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:519596 CAPLUS

DOCUMENT NUMBER: 109:119596

TITLE: Electrophotographic photoreceptor containing azo compound with tetraphenylthiophene or tetraphenylthiophene-1,1-dioxide skeleton

INVENTOR(S): Yamada, Yasuyuki; Itoh, Hisato; Nishizawa, Tsutomu; Yamaguchi, Akihiro

PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8707736	A1	19871217	WO 1987-JP353	19870604
W: JP, KR, US				
RW: CH, DE, FR, GB, IT, NL				
EP 270685	A1	19880615	EP 1987-903740	19870604
EP 270685	B1	19940907		
R: CH, DE, FR, GB, IT, LI, NL				
CA 1302767	C	19920609	CA 1987-538844	19870604
JP 05057581	B	19930824	JP 1987-503388	19870604
US 4808503	A	19890228	US 1987-110757	19870828
JP 04211266	A	19920803	JP 1991-48644	19910222
JP 05053266	B	19930809		
PRIORITY APPLN. INFO.:			JP 1986-129082	A 19860605
			WO 1987-JP353	W 19870604

GI



AB An electrophotog. photoreceptor having high sensitivity and excellent durability is comprised of a photosensitive layer containing 21 of azo compds. having a tetraphenylthiophene or tetraphenylthiophene-1,1-dioxide skeleton as a charge-generating substance. The preferable azo compds. are

represented by I [A = coupler moiety; Q = S, SO₂; l, m = 1, O].

IT 116352-36-4 116352-45-5 116372-87-3

116372-93-1 116372-98-6 116373-01-4



L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RL: USES (Uses)

(charge-generating substance, for electrophotog. photoreceptor)

RN 116352-36-4 CAPLUS

CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1''-[(4-phenyl-2,3,5-thiophenemethyl)tris (4,1-phenyleneazo)]tris[2-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 116352-45-5 CAPLUS


CN 2-Naphthalenecarboxylic acid, 4,4',4'',4'''-[2,3,4,5-thiophenemethyltetrakis (4,1-phenyleneazo)]tetrakis[3-hydroxy-, tetrakis[(4-methoxyphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B

OMe


RN 116372-87-3 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[3-hydroxy-, bis[(4-methoxyphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




RN 116372-93-1 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[N-(2,4-dimethoxyphenyl)-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




RN 116372-98-6 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[3-hydroxy-, bis[(4-methoxyphenyl)methylene]hydrazide] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 116373-01-4 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4',4'-[(4-phenyl-2,3,5-

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 thiophenediyl)tris(4,1-phenyleneazo)]tris[3-hydroxy-N-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 108041-53-8P 116372-51-1P 116372-55-5P
 116372-58-8P 116372-66-8P 116372-70-4P
 116372-78-2P 116372-83-9P 116400-56-7P
 116400-58-9P 116400-59-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and use of, as charge-generating substance for electrophotog.

photoreceptor)
 RN 108041-53-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PAGE 1-A




PAGE 2-A




RN 116372-51-1 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




RN 116372-55-5 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 116372-58-8 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-butoxyphenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 116372-66-8 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(1,1-dioxido-3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 116372-70-4 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4',4''-[(4-phenyl-2,3,5-thiophenetriyl)tris(4,1-phenyleneazo)]tris[2-hydroxy-N-(2-ethoxyphenyl)]-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 116372-78-2 CAPLUS

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-(1,1-dioxido-4-phenyl-2,3,5-thiophenetriyl)tris(4,1-phenyleneazo)]tris[2-hydroxy-N-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-A



PAGE 1-B

RN 116372-83-9 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-(1,1-dioxido-2,3,4,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B


RN 116400-56-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4',4''-(4-phenyl-1,1-dioxido-2,3,5-thiophenetriyl)tris(4,1-phenyleneazo)]tris[N-(2-ethoxyphenyl)-3-hydroxy-(9CI) (CA INDEX NAME)

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 116400-58-9 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4',4''-(4-phenyl-1,1-dioxido-2,3,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[3-hydroxy-N-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 116400-59-0 CAPLUS
 CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1'',1'''-(2,3,4,5-thiophenetetrayl)tetrakis(4,1-phenyleneazo)]tetrakis[2-hydroxy-N-(4-

L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methoxyphenyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 228 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

PAGE 1-A



PAGE 1-B




L19 ANSWER 229 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1988:483322 CAPLUS
DOCUMENT NUMBER: 109:83322
TITLE: Composite organic electrophotographic photoconductor
INVENTOR(S): Takiguchi, Takao; Matsumoto, Masakazu; Kikuchi, Norihiro
PATENT ASSIGNEE(S): Canon K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62264055	A	19871117	JP 1986-106752	19860512
JP 07120054	B	19951220		

PRIORITY APPLN. INFO.: JP 1986-106752 19860512

GI



AB A durable electrophotog. plate is claimed which comprises a composite layer consisting of a carrier-generating sublayer and a carrier-transporting sublayer, wherein the carrier-transporting layer contains a compound I (R1, R2, R3, R4 = (ar)alkyl, aryl, heterocyclic group);

X = O, S, N bonded to (ar)alkyl, aryl, heterocyclic group).

IT 114527-43-4 114527-45-6


RL: USES (Uses)

(carrier-transporting layer containing, for electrophotog.

photoconductor)

RN 114527-43-4 CAPLUS


CN Benzenamine, 4-[5-[4-[bis(4-ethoxyphenyl)aminophenyl]-2-thienyl]-N-(4-ethoxyphenyl)-N-octyl]- (9CI) (CA INDEX NAME)



RN 114527-45-6 CAPLUS


CN Benzenamine, N,N-bis(4-ethoxyphenyl)-4-[5-[4-(4-morpholinyl)phenyl]-2-

L19 ANSWER 229 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
thienyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 230 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1988:455343 CAPLUS
 DOCUMENT NUMBER: 109:55343
 TITLE: Synthesis and characterization of aromatic polyesters containing tetraphenylthiophene unit
 AUTHOR(S): Negi, Y. S.; Imai, Y.; Kakimoto, M.
 CORPORATE SOURCE: Cent. Mater. Sci. Technol., Indian Inst. Technol., Delhi, 110 016, India
 SOURCE: Journal of Polymer Materials (1988), 5(1), 67-71
 CODEN: JOPME8; ISSN: 0970-0838
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Tetraphenylthiophene-based polyesters were prepared by phase-transfer polycondensation of 2,5-bis(4-chloroformylphenyl)-3,4-diphenylthiophene with 3-(4-hydroxyphenyl)-1,1,3-trimethyl-5-indanol, 4,4'-sulfonyldiphenyl, or 4,4'-biphenol. The polymers were characterized by IR, NMR, and inherent viscosity measurements. All polymers showed high decomposition temps. (>400°) as determined by TGA.
 IT 115489-93-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and characterization of)
 RN 115489-93-5 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarboxyloxy-1,4-phenylenesulfonyl-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 230 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-B

L19 ANSWER 231 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1988:433870 CAPLUS
 DOCUMENT NUMBER: 109:33870
 TITLE: Preparation of 2-substituted ethynylthiophene acaricides and insecticides
 INVENTOR(S): Burkart, Susan Ellen; Phillips, Richard Benton; Roush,
 PATENT ASSIGNEE(S): David Michael
 SOURCE: FMC Corp., USA
 PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8800467	A1	19880128	WO 1987-US846	19870414
W: AU, BR, DK, JP, KR				
RW: CH, DE, FR, GB, NL				
AU 8775446	A	19880210	AU 1987-75446	19870414
CN 87103400	A	19880406	CN 1987-103400	19870507
ZA 8705426	A	19880330	ZA 1987-5426	19870723
PRIORITY APPLN. INFO.:			US 1986-889040	A 19860723
			WO 1987-US846	A 19870414


OTHER SOURCE(S): MARPAT 109:33870
 GI




AB The 2-ethynylthiophene derivs. I [R = phenylthienyl, (un)substituted Ph; R1 = H, alkyl; R2 = (un)substituted thienyl, (un)substituted Ph] are prepared as acaricides and insecticides. A solution of 5-formyl-2-phenylthiophene (preparation given) and di-Et (4-chlorophenyl)chloromethylphosphonate (preparation given) in DMF was treated with NaOMe to give 1-(5-phenylthien-2-yl)-2-chloro-2-(4-chlorophenyl)ethene, which was refluxed for 4 h with tert-BuOK in THF, to give I (R = 4-ClC6H4, R1 = H, R2 = Ph) (II). II (50 ppm) totally controlled Tetranychus urticae on bean leaf segments.

IT 115219-74-4P 115219-75-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as acaricide)
 RN 115219-74-4 CAPLUS
 CN Thiophene, 2-[[4-(1-methylethoxy)phenyl]ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)

L19 ANSWER 231 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 115219-75-5 CAPLUS
 CN Thiophene, 2-[(4-phenoxyphenyl)ethynyl]-5-phenyl- (9CI) (CA INDEX NAME)




L19 ANSWER 232 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1987:524534 CAPLUS
 DOCUMENT NUMBER: 107:124534
 TITLE: Disazo and/or tetrakisazo compounds for electrophotography and laser-sensitive optical recording
 INVENTOR(S): Horie, Seiji; Makino, Naomori; Sato, Hideo
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62047053	A	19870228	JP 1985-187095	19850826
JP 05049104	B	19930723		

PRIORITY APPLN. INFO.: JP 1985-187095 19850826

GI




AB The disazo compds. have the formula I and the tetrakisazo compds. have the formula II (R = coupler residue having OH group; L1, L2 = H, electron-withdrawing group; Z = NR6, O, S, Se, Te; m = H, low alkyl, aryl, etc.; Ar = arylene, heteroarylene; B1, B2 = H, halo, low alkyl; n, m = 0, 1, 2). Electrophotog. photoconductors contain ≥ 1 of the disazo and tetrakisazo charge-generating compds. show improved sensitivity and durability. A laser disk with a recording layer containing nitrocellulose and a disazo compound of the formula I shows improved sensitivity and storage stability.


L19 ANSWER 232 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L19 ANSWER 232 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 110308-50-4
 RL: USES (Uses)
 (electrophotog. photoreceptors containing)
 RN 110308-50-4 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4',4'',4'''-[2,3,4,5-thiophenetetrayltetrakis(2,1-ethenediyl-4,1-phenyleneazo)]tetrakis[N-(2-ethoxyphenyl)-3-hydroxy- (9CI) (CA INDEX NAME)]

PAGE 1-A



PAGE 2-A




L19 ANSWER 233 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1987:157084 CAPLUS
 DOCUMENT NUMBER: 106:157084
 TITLE: Polyesters containing tetraphenylthiophene groups
 INVENTOR(S): Imai, Yoshio; Kakimoto, Masaaki; Negi, Yuvraj Singh
 PATENT ASSIGNEE(S): University of Tokyo, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61207430	A	19860913	JP 1985-45730	19850309
JP 03063972	B	19911003		

PRIORITY APPLN. INFO.: JP 1985-45730 19850309

AB Polyesters [COZCOZ₂10]_n (at least some of Z are tetraphenylthiophene residues; Z1 = arylene; n = 10-2000), soluble in organic solvents and having high glass-transition temps., are prepared by treating Z(COX)₂ (X = halo) with dihydric phenols Z1(OH)₂ in organic solvents or in organic solvent-aqueous alkali 2-phase media. Thus, treating (4-HOC6H4)₂CMe₂ with 2,5-bis[4-(chloroformyl)phenyl]-3,4-diphenylthiophene in aqueous NaOH-PhNO₂ in the presence of PhCH₂NEt₃+ Cl⁻ at room temperature for 1 h gave 92% white polymer with inherent viscosity 0.45 dL/g (0.5 g/dL o-C₆H₄Cl₂, 30°), 10% weight-loss temperature 470° in air and 485° in N₂, and solubility at room temperature in CHCl₃, C₆H₆, pyridine, and o-ClC₆H₄OH.
 IT 104909-92-4P
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (manufacture of solvent-soluble, heat-resistant)
 RN 104909-92-4 CAPLUS
 CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenyleneoxycarbonyloxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxycarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 233 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


] n

L19 ANSWER 234 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1986:573279 CAPLUS
DOCUMENT NUMBER: 105:173279
TITLE: Polyamide resins
INVENTOR(S): Imai, Yoshio; Kakimoto, Masaaki; Negi, Yuvraj Shingh
PATENT ASSIGNEE(S): Tokyo Institute of Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXKAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61062523	A	19860331	JP 1984-183831	19840904
JP 01049377	B	19891024		

PRIORITY APPLN. INFO.: JP 1984-183831 19840904

AB Polyamides are prepared from derivs. of tetraphenylthiophene and diamines.
The polyamides are soluble in organic solvents and have good heat resistance.
Thus, a solution of 0.10 g 4,4'-oxydianiline in 1.5 mL AcNMe2 was cooled to 0°, treated with 0.257 g 2,5-bis[4-(chloroformyl)phenyl]-3,4-diphenylthiophene and 0.2 mL AcNMe2, and stirred in an ice bath for 1.5 h to give a polyamide (97% yield) which was soluble in N-methyl-2-pyrrolidone and AcNMe2, had intrinsic viscosity (0.5 g/dL in H2SO4 at 30°) 0.90, and had 10% weight loss at 520° in air or 515° in N.
IT 97429-39-5P
RL: PREP (Preparation)
(preparation of soluble, heat-resistant)
RN 97429-39-5 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneimino-1,4-phenylene] (9CI) (CA INDEX NAME)




L19 ANSWER 234 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

] n

L19 ANSWER 235 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1986:573152 CAPLUS
DOCUMENT NUMBER: 105:173152
TITLE: Synthesis and characterization of aromatic polyesters and poly(amide esters) from bisphenols and aromatic aminophenols, and 2,5-bis(4-chloroformyl)-3,4-diphenylthiophene
AUTHOR(S): Kakimoto, Masaaki; Negi, Yuvraj Singh; Imai, Yoshio
CORPORATE SOURCE: Dep. Text. Polym. Mater., Tokyo Inst. Technol., Tokyo, 152, Japan
SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry
(1986), 24(7), 1511-17
CODEN: JPACEC; ISSN: 0887-624X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Polycondensation of 2,5-bis[4-(chloroformyl)phenyl]-3,4-diphenylthiophene (I) with various bisphenols afforded tetraphenylthiophene-containing aromatic polyesters by the interfacial or solution polycondensation method. Polyamide-esters were obtained from I and aminophenols by the interfacial technique. These polymers had inherent viscosities of 0.4-0.8 dL/g. All the polymers were readily soluble in various organic solvents, and could be cast into transparent and flexible films. Their glass transition temps. were in the range of 235-335°. These polymers did not lose weight below 400° in either air or N.
IT 104909-92-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 104909-92-4 CAPLUS
CN Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonyloxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxy-1,4-phenylene] (9CI) (CA INDEX NAME)



L19 ANSWER 235 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

L19 ANSWER 236 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1986:534489 CAPLUS
DOCUMENT NUMBER: 105:134489
TITLE: Tetraphenylthiophenedicarboxylic acid derivatives
INVENTOR(S): Imai, Yoshio; Kakimoto, Masaaki; Negi, Yuvraj Singh
PATENT ASSIGNEE(S): Tokyo Institute of Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61063672	A	19860401	JP 1984-183832	19840904
JP 01024151	B	19890510		

PRIORITY APPLN. INFO.: JP 1984-183832 19840904

AB Title compds. (acid, acid halide, or ester derivs.) useful as materials for heat resistant resins with excellent moldability, are prepared by treating tetraphenylthiophene (II) with carboxylic acid halides over Friedel-Crafts reagents. Thus, treating II with AcCl in nitrobenzene

over

AlCl₃ at room temperature for 2 h with stirring gave 61% 2,5-bis(4-acetylphenyl)-3,4-diphenylthiophene, which was then heated with NaOCl at 70° for 18 h to give 94% tetraphenylthiophenedicarboxylic acid.

IT

97429-39-5P
RL: IMF (Industrial manufacture); PREP (Preparation)


RN

97429-39-5 CAPLUS

CN

Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 236 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

L19 ANSWER 237 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:454526 CAPLUS
DOCUMENT NUMBER: 103:54526
TITLE: Synthesis and characterization of soluble aromatic polyamides derived from
2,5-bis(4-chloroformylphenyl)-3,4-diphenylthiophene and aromatic diamines
AUTHOR(S): Kakimoto, Masaaki; Negi, Yuvraj Singh; Imai, Yoshio
CORPORATE SOURCE: Dep. Text. Polym. Mater., Tokyo Inst. Technol., Tokyo,
152, Japan
SOURCE: Journal of Polymer Science, Polymer Chemistry Edition (1985), 23(6), 1787-95
CODEN: JPLCAT; ISSN: 0449-296X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 2,5-Bis(4-carboxyphenyl)-3,4-diphenylthiophene [97483-30-2], was synthesized either by the Friedel-Crafts reaction of tetraphenylthiophene (I) [1884-68-0] with oxalyl chloride, or by the Friedel-Crafts acetylation of I followed by oxidation. The low temperature solution polycondensation

of 2,5-bis(4-chloroformylphenyl)-3,4-diphenylthiophene [97463-89-3] with various aromatic diamines in N,N-dimethylacetamide (II) afforded I-containing aromatic polyamides with inherent viscosities of 0.5-1.0 dL/g.

Copolyamides were obtained from a mixture of the diacid chloride and isophthaloyl or terephthaloyl chloride. All except 2 of the polyamides were readily soluble

in amide-type solvents including II and were cast into transparent and flexible films. These polymers had glass transition at approx. 300°. Thermal stability of the polymers was evaluated by thermogravimetry, which showed no weight loss below 390° in both air and N atms.

IT

97429-39-5P
RL: SPN (Synthetic preparation); PREP (Preparation)


RN

97429-39-5 CAPLUS

CN

Poly[(3,4-diphenyl-2,5-thiophenediyl)-1,4-phenylenecarbonylimino-1,4-phenyleneoxy-1,4-phenyleneiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A




L19 ANSWER 237 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

L19 ANSWER 238 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1985:157989 CAPLUS
 DOCUMENT NUMBER: 102:157989
 TITLE: Electrophotographic photoreceptor
 PATENT ASSIGNEE(S): Canon K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59185341	A	19841020	JP 1983-59332	19830406
JP 04075497	B	19921201		
PRIORITY APPLN. INFO.:			JP 1983-59332	19830406


GI



AB The electrophotog. photoreceptor contains a hydrazone derivative having the general formula I (R, R1 = alkyl, aralkyl, aryl that may be substituted, but not alkyl simultaneously; R2 = alkyl, aryl, substituted alkyl, alkoxy or aryl, halo) as a charge-transport substance. Thus, a casein-coated Al plate was coated with EtOH solution of a bisazo dye II 5 and butyral resin 29, to form the charge-generating layer. The charge-transport layer was formed by coating a composition containing III 5 and poly(4,4'-dioxydiphenyl-2,2-propanecarbonate) 5 g in CH2Cl2. Obtained photoreceptor was charged to -575 V, of which 99% was retained after 10 s. Sensitivity (for half decay of voltage) was 7.3 lx-s.

L19 ANSWER 238 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 95897-32-8 CAPLUS
 RL: USES (Uses)
 (electrophotog. charge-transport agents)
 RN 95897-32-8 CAPLUS
 CN 2-Thiophenecarboxaldehyde, 5-[4-(diethylamino)phenyl]-, bis(4-ethoxyphenyl)hydrazone (9CI) (CA INDEX NAME)



L19 ANSWER 239 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1983:558117 CAPLUS
 DOCUMENT NUMBER: 99:158117
 TITLE: Aminocyclopentane esters and their pharmaceutical formulation
 INVENTOR(S): Collington, Eric W.; Hallett, Peter; Wallis, Christopher J.; Wadsworth, Alan; Hayes, Norman F.; Bradshaw, John; Carter, Malcolm
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Eur. Pat. Appl., 74 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 74861	A1	19830323	EP 1982-304886	19820916
EP 74861	B1	19860827		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DK 8204138	A	19830317	DK 1982-4138	19820916
AU 8288459	A	19830324	AU 1982-88459	19820916
AU 561140	B2	19870430		
JP 58074659	A	19830506	JP 1982-161554	19820916
ZA 8206805	A	19830727	ZA 1982-6805	19820916
ES 515761	A1	19831001	ES 1982-515761	19820916
US 4410521	A	19831018	US 1982-418975	19820916
CA 1190926	A1	19850723	CA 1982-411565	19820916
AT 21695	T	19860915	AT 1982-304886	19820916
IL 67041	A	19880331	IL 1982-67041	19821021
FI 8203690	A	19830430	FI 1982-3690	19821028
FI 77242	B	19881031		
FI 77242	C	19890210		
US 4482549	A	19841113	US 1984-578014	19840208
PRIORITY APPLN. INFO.:			GB 1981-27982	A 19810916
			GB 1981-32675	A 19811029
			GB 1982-12489	A 19820429
			GB 1982-13069	A 19820506
			EP 1982-304886	A 19820916
			US 1982-418976	A1 19820916
			US 1983-510969	A1 19830705

OTHER SOURCE(S): MARPAT 99:158117
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Approx. one-hundred and forty I (R = saturated 5-8 membered N heterocycle,

L19 ANSWER 239 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
optionally contg., e.g., O, S, NH; R1, R2 = groups assocd. with
prostaglandins; X = O or H, β -OH; A = C1-7 alkylene; Q = CH:CH,
CH2CH2) were prepd. from known prostaglandin analogs or intermediates.
Typical of compds. prepd. were II-IV.

IT 87204-10-2P
RL: R1 (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or Product)
(preparation and oxidation of)

RN 87204-10-2 CAPLUS
CN 4-Heptenoic acid, 7-[3-hydroxy-2-(4-morpholinyl)-5-[(5-phenyl-3-
thienyl)methoxy]cyclopentyl]-, 4-methylphenyl ester,
[1 α (Z),2 β ,3 α ,5 α]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 87214-29-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 87214-29-7 CAPLUS
CN 4-Heptenoic acid, 7-[2-(4-morpholinyl)-3-oxo-5-[(5-phenyl-3-
thienyl)methoxy]cyclopentyl]-, 4-methylphenyl ester,
[1 α (Z),2 β ,5 α]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.


L19 ANSWER 240 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1979:137601 CAPLUS
DOCUMENT NUMBER: 90:137601
TITLE: Thiophene derivatives. IV. α,β -
Unsaturated ketones of the phenylthiophene series
Fisera, L.; Kovac, J.; Hrabovsky, J.
Zb. Pr. Chemickotechnol. Fak., Slov. Vys. Sk. Tech.,
Bratislava, Czech.
SOURCE: Zbornik Prac Chemickotechnologickej Fakulty SVST
(1978), Volume Date 1975-1976 91-6
CODEN: ZPCTA7; ISSN: 0524-2185
DOCUMENT TYPE: Journal
LANGUAGE: Slovak
OTHER SOURCE(S): CASREACT 90:137601
GI



AB Chalcone analogs I [R = Ph, 3,4-(MeO)2C6H3, R1C6H4; R1 = 4-Br, 4-Cl,
4-Me2N, 4-H2N, 3- and 4-O2N and -MeO] were prepared in 20.5-69.7% yield
by acetylating 2-(4-chlorophenyl)thiophene with Ac2O containing H3PO4 to
give 52.6% 2-acetyl-5-(4-chlorophenyl)thiophene, and condensing the latter
with the corresponding RCHO in EtOH containing NaOH. I exist as mixts. of
s'-trans-*s*-cis and *s'*-cis-*s*-trans conformers, according to their IR
spectra. The C=O stretching frequencies of I correlated with the Hammett
 σ^+ consts. of the substituents.


IT 69512-75-0P 69512-77-2P 69512-78-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, IR spectrum and conformation of)

RN 69512-75-0 CAPLUS
CN 2-Propen-1-one, 1-[5-(4-chlorophenyl)-2-thienyl]-3-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 69512-77-2 CAPLUS
CN 2-Propen-1-one, 1-[5-(4-chlorophenyl)-2-thienyl]-3-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)


L19 ANSWER 239 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L19 ANSWER 240 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





RN 69512-78-3 CAPLUS
CN 2-Propen-1-one, 1-[5-(4-chlorophenyl)-2-thienyl]-3-(3,4-dimethoxyphenyl)-
(9CI) (CA INDEX NAME)



L19 ANSWER 241 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1977:484804 CAPLUS
 DOCUMENT NUMBER: 87:84804
 TITLE: 1-(2-Thienyl)-2-aminoethanols
 INVENTOR(S): Bagli, Jehan F.; Ferdinandi, Eckhardt
 PATENT ASSIGNEE(S): American Home Products Corp., USA
 SOURCE: U.S., 10 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4024156	A	19770517	US 1975-569509	19750418
CA 1030146	A1	19780425	CA 1974-197896	19740418
PRIORITY APPLN. INFO.:			CA 1974-197896	A 19740418


OTHER SOURCE(S): MARPAT 87:84804
 GI




AB Approx. thirty title compds., useful as β -sympatholytics and antihypertensives, were prepared Thus, I with 3,4-(MeO)2C6H3CH2CH2NH2 gave

II.
 IT 59160-37-1P 59160-55-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for use as antihypertensive and β -sympatholytic)
 RN 59160-37-1 CAPLUS
 CN 2-Thiophenemethanol, α -[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-5-phenyl-, hydrochloride (9CI) (CA INDEX NAME)


L19 ANSWER 241 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 59160-55-3 CAPLUS
 CN 2-Thiophenemethanol, α -[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-5-phenyl- (9CI) (CA INDEX NAME)




L19 ANSWER 242 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1976:428483 CAPLUS
 DOCUMENT NUMBER: 85:28483
 TITLE: Synthesis and antihypertensive activity of some thienylethanolamines
 AUTHOR(S): Bagli, Jehan F.; Mackay, Walter D.; Ferdinandi, Eckhardt; Cayen, Mitchell N.; Vavra, Ivan; Pugsley, Thomas; Lippmann, Wilbur
 CORPORATE SOURCE: Dep. Chem., Ayerst Res. Lab., Montreal, QC, Can.
 SOURCE: Journal of Medicinal Chemistry (1976), 19(7), 876-82
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 85:28483
 GI




AB Synthesis of a series of thienylethanolamines (I) having varying substituents on the thiophene ring and on the N atom is described using the general procedure reported earlier. Some of the derivs. showed marked antihypertensive activity in the spontaneously hypertensive rat model. Some of these derivs. also antagonized α - and β -adrenoreceptor activities. The ability of this class of compds. to inhibit catecholamine-induced release of free fatty acids by adipose tissue was demonstrated. Structure-activity relationships are discussed.

IT 59160-37-1P
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation and pharmacol. of)
 RN 59160-37-1 CAPLUS
 CN 2-Thiophenemethanol, α -[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-5-phenyl-, hydrochloride (9CI) (CA INDEX NAME)


L19 ANSWER 242 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 59160-55-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 59160-55-3 CAPLUS
 CN 2-Thiophenemethanol, α -[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-5-phenyl- (9CI) (CA INDEX NAME)



L19 ANSWER 243 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1971:448795 CAPLUS
 DOCUMENT NUMBER: 75:48795
 TITLE: Potential antituberculous compounds. XVII. Thiosemicarbazones and a Schiff's base of α -phenyl- α' -formylthiophene
 AUTHOR(S): Misra, Vinay S.; Khare, Anakshi
 CORPORATE SOURCE: Dep. Chem., Lucknow Univ., Lucknow, India
 SOURCE: Journal fuer Praktische Chemie (Leipzig) (1970), 312(6), 1188-90
 CODEN: JPCEAO; ISSN: 0021-8383
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB 5-Phenyl-2-thiophenecarboxaldehyde (I) is treated with thiosemicarbazides H2NNHCSNHR to give the corresponding I thiosemicarbazones (II). Thus, I is treated with H2NNHCSNHPh to give I 4-phenylthiosemicarbazone. Similarly prepared are II (R = substituted phenyl, 2-ClOH7, cyclohexyl).
 I acylhydrazones (III) are prepared by the treatment of I with AcCONHNH2 (Ar = Ph, substituted phenyl). I is treated with p-toluidine to give a Schiff base.
 IT 32973-27-6P 32973-33-4P 32973-34-5P
 32973-35-6P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 32973-27-6 CAPLUS
 CN 2-Thiophenecarboxaldehyde, 5-phenyl-, 4-(p-ethoxyphenyl)-3-thiosemicarbazone (8CI) (CA INDEX NAME)



RN 32973-33-4 CAPLUS
 CN 2-Thiophenecarboxaldehyde, 5-phenyl-, 4-(p-methoxyphenyl)-3-thiosemicarbazone (8CI) (CA INDEX NAME)



RN 32973-34-5 CAPLUS
 CN 2-Thiophenecarboxaldehyde, 5-phenyl-, 4-(m-methoxyphenyl)-3-thiosemicarbazone (8CI) (CA INDEX NAME)

L19 ANSWER 244 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1968:478434 CAPLUS
 DOCUMENT NUMBER: 69:78434
 TITLE: Fluorescent whiteners
 INVENTOR(S): Maeder, Erwin; Liechti, Peter; Siegrist, Adolf E.
 PATENT ASSIGNEE(S): CIBA Ltd.
 SOURCE: Patentschrift (Switz.), 8 pp.
 CODEN: SWXXAS
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 442216		19680131	CH 1963-14122	19631118

GI For diagram(s), see printed CA Issue.
 AB I are useful for incorporation in polyester or polyamide melts before spinning into fibers. Thus, a mixture of 5-phenylthiophene-2-carboxylic acid 51, 3,4-H2N(HO)C6H3CO2Me 40, and H3BO3 2 parts was stirred with 150 vols. (EtOCH2CH2)2O under N, heated to 185-90° in 1 hr. (dark solution evolves H2O), stirred for 1-2 hrs. at 185-90°, slowly evaporated, the dark melt stirred for 2 hrs. at 260°, cooled, dissolved in 1000 parts hot HCONMe2, clarified, concentrated, and precipitated with MeOH to give 50 parts

I (X = Y = Z = H, R = OMe) (II), small colorless needles, m. 194-5° (dioxane). Similarly were prepared other I (R = OMe) (X, Y, Z, appearance, and m.p. given): MeO, H, H, small light yellow needles, 184-5° (Me2CO, vacuum sublimation) (intermediate o-hydroxyanilide m. 258-60°); Me, H, H, colorless needles, 175-6° (PhMeMeOH) (intermediate o-hydroxyanilide m. 274-6°); Cl, OMe, OMe, yellow needles, 228-9° (dioxane). A mixture of II 33.5, NaOH 40, H2O 100, and EtOH 400 parts was boiled under reflux for 24 hrs., diluted with 500 parts H2O, the alc. evaporated in vacuo, and the solution acidified to precipitate I (X = Y = Z = H, R = OH) (III), yellowish powder, m. 281-3.5° (C6H4Cl2) (Ca salt m. >320°). Similarly was prepared I (X = MeO, Y = Z = H, R = CO2H), m. 293-4° (Me2CO, vacuum sublimation). A mixture of 9.6 parts III and 30 vols. SOCl2 was refluxed for 12 hrs., excess SOCl2 evaporated


in vacuo, the solid residue suspended in 30 vols. dry pyridine, treated dropwise with 4.5 parts morpholine, boiled for 3 hrs., cooled, and diluted

with 50 vols. MeOH to give 7.2 parts I (X = Y = Z = H, R = morpholino), yellowish glittering crystals, m. 189.5-90.5° (EtOH). Similarly were prepared other I (X = Y = Z = H) (R and m.p. given): NHPh, 240-1° (dioxane); NHC6H2(OMe)2Cl-2,5,4, 200-1° (C6H6); NHCH2CH2OH, 217.5-18° (EtOH); NHCH2CH:CH2, 222-3° (dioxane); NH2, 239-41° (dioxane-AcOEt); OCH2CH:CH2, 155.5-6.5° (cyclohexane); OCH2Ph, 167-8° (Me2CO); OC6H4Me-4, 207.5-8.5° (PhCl-EtOH); OCMe2, 141.5-2°; OCH2CH2tBu, 147-8°; O(CH2)15Me, 106-8°; O(CH2CH2O)2tBu, - (waxy precipitate from CH2Cl2-petroleum ether).


IT 2493-15-4P 2493-21-2P
 RL: IMP (Industrial manufacture); PREP (Preparation) (preparation of)

RN 2493-15-4 CAPLUS
 CN 5-Benzoxazolecarboxylic acid, 2-(5-phenyl-2-thienyl)-, p-tolyl ester (7CI,


L19 ANSWER 243 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 32973-35-6 CAPLUS
 CN 2-Thiophenecarboxaldehyde, 5-phenyl-, 4-(o-methoxyphenyl)-3-thiosemicarbazone (8CI) (CA INDEX NAME)



L19 ANSWER 244 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 8CI) (CA INDEX NAME)



RN 2493-21-2 CAPLUS
 CN 5-Benzoxazolecarboxylic acid, 2-(5-phenyl-2-thienyl)-, p-tolyl ester (7CI, 8CI) (CA INDEX NAME)



L19 ANSWER 245 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1965:91539 CAPLUS
 DOCUMENT NUMBER: 62:91539
 ORIGINAL REFERENCE NO.: 62:16423f-h,16424a-c
 TITLE: Thienyl benzoxazole optical brighteners
 PATENT ASSIGNEE(S): Ciba Soc.
 SOURCE: Patent
 DOCUMENT TYPE: 21 pp.
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 641607		19640622	BE	19631220
FR AD84935			FR	
GB 1016365			GB	
NL 302367			NL	
PRIORITY APPLN. INFO.:				19621221

GI For diagram(s), see printed CA Issue.
 AB Comps. of the general formula I, useful for brightening polyamide and polyester fibers, are prepared by the H₃BO₃-catalyzed ring closure under

N of an o-hydroxyarylamide derived from the reaction of a 5-aryl-2-thiophenecarboxylic acid chloride with 2,5-HO(MeO₂C)C₆H₃NH₂

(II). When W = X = Y = H, II is treated with the carboxylic acid directly to effect amide formation and ring closure in one step. The Me esters can

be hydrolyzed to the carboxylic acids and from the latter, via the acid chloride in situ, a series of esters and amides is prepared. Thus, a mixture

of 5-phenyl-2-thiophenecarboxylic acid 51, II 40 and H₃BO₃ 2 parts in (EtOCH₂CH₂)₂O 150 vols. is heated under N to 185-90° over 1 hr. and, after 1-2 hrs., the solvent is slowly distilled and the residue

heated 2 hrs. at 260°. After cooling, the whole is dissolved in HCONMe₂ 1000 parts, the solution filtered, diluted with MeOH and cooled to precipitate I (X =

Y = W = H, Z = OMe) (III), colorless needles, m. 194-5° (dioxane). III 33.5 is refluxed for 24 hrs. in H₂O 100 parts and EtOH 400 vols. containing NaOH 40 parts to yield, after the EtOH is distilled and the

remaining solution filtered and neutralized, 27 parts I (W = X = Y = H, Z = OH)

(IV), yellow powder, m. 281-3.5° (o-Cl₂C₆H₄). Also prepared are the I given in the table. The following V were isolated (X, color, and m.p. given): MeO, beige, 258-60°; Me, brown, 274-6°. Also given is the preparation of the Ca salt of IV, yellow powder, m. >320°. W, X, Y, Z, m.p.; H, MeO, H, Ome, 184-5° (distilled); H, MeO, H, OH, 293-4° (sublimed); H, Me, H, Ome, 175-6° (PhMe-MeOH); MeO, Cl, MeO, Ome, 228-9° (dioxane); H, H, H, N-morpholinyl, 189.5-90.5° (EtOH); H, H, H, PhNH, 240-1° (dioxane); H, H, H, 4,2,5-Cl₃MeO₂C₆H₂NH, 200-1° (C₆H₆); H, H, H, HOCH₂CH₂NH,

L19 ANSWER 246 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1963:475802 CAPLUS
 DOCUMENT NUMBER: 59:75802
 ORIGINAL REFERENCE NO.: 59:14145d-h,14146a-c
 TITLE: 2-Phenyl-5-(2-benzimidazolyl)thiophenes and 2-phenyl-5-(2-benzoxazolyl)thiophenes as optical brighteners
 PATENT ASSIGNEE(S): CIBA Ltd.
 SOURCE: 65 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 620372		19630118	BE	
CH 405223			CH	
FR 1335174			FR	
GB 990397			GB	
US 3264315		19660802	US 1963-328112	19631204
PRIORITY APPLN. INFO.:				19610719

GI For diagram(s), see printed CA Issue.

AB 2-Phenyl-5-thiophenecarboxylic acids are treated with o-aminophenols and 1,2-diaminobenzenes in the presence of H₃BO₃ to give the title compds. which can be used as optical brighteners for synthetic fibers and plastics. Thus, a mixture of 5-phenyl-2-thio-phenecarboxylic acid 51, 3,4-(H₂N)C₆H₃Me 35, and H₃BO₃ 3 parts is heated at 230° under N for 1.5 hrs., 70 parts HCONMe₂ is added slowly, and 2N HCl is added to give a precipitate. The precipitate is filtered, washed with H₂O, suspended in 500 parts


HCONMe₂, treated with excess NH₃, and precipitated with H₂O to give 58 parts

2-(5-methyl-2-benzimidazolyl)-5-phenylthiophene, beige powder, m. 196.5-7° (C₆H₆). Similarly prepared are compds. of general formula I (R, R₁, R₂, R₃, R₄, R₅, m.p. given): Ph, H, H, Me, Me, H, 235-6° (C₆H₆); Ph, H, H, H, Me, 143.5-4° (EtOAc); Ph, H, H, H, H, H, 255-6° (EtOH); Ph, H, H, MeO, H, H, 205-6° (EtOH); 2,5-Cl₂C₆H₃, H, H, Me, H, 130-1.5° (EtOH-EtOAc); p-ClC₆H₄, H, H, Me, H, H, 262-3° (EtOAc); p-tolyl, H, H, Me, H, H, 257-7.5° (EtOH-C₆H₆); 2,5-Me₂-C₆H₃, H, H, Me, H, H, 223-4° (C₆H₆); 3,4-Cl₂C₆H₃, Me, Ph, Me, H, H, 213-14° (EtOH); 4,2-Cl(Me)C₆H₃, H, H, H, H, 248-8.5° (EtOH-EtOAc); 4,2,6-Cl(MeO)₂C₆H₂, H, H, H, H, H, 249-50° (MeOH-EtOAc); 2-ClOH₇, H, H, H, H, 251.5-2.5° (EtOAc); Ph, H, H, H, H, (CH₂)₂CN, 159-9.5° (EtOH); Ph, H, H, H, H, p-MeOC₆H₄CO, 160-1° (EtOH-EtOAc); Ph, H, H, H, H, PhCH₂, 218-19° (EtOH-H₂O). Compds. of the general formula II are prepared similarly from o-aminophenols (R, R₁, R₂, R₃, R₄, R₅, R₆, m.p. given):


Ph, H, H, H, Me, H, H, 152.5-3° (C₆H₆-EtOH); Ph, H, H, H, H, Me, H, 154-4.5° (EtOH); Ph, H, H, Me, H, H, H, 105-5.5° (EtOH); Ph, H, H, H, tert-Bu, H, H, 136-7° (MeOH); Ph, H, H, H, tert-BuCH₂Me₂, H, H, 115.5-16.5° (C₆H₆-EtOH); Ph, H, H, H, C₉H₁₉, H, H, -; Ph, H, H, H, Cl₂H₂₅, H, H, -; Ph, H, H, H, PhCMe₂, H, H, 111-12° (EtOH-EtOAc); Ph, H, H, H, cyclohexyl, H, H, 151.5-2° (C₆H₆-EtOH); Ph, H, H, H, Ph, H, H, 204-5.5° (HCONMe₂); Ph, H, H, H, H, (CH₂)₂CN, H, H, 151-2° (EtOAc); Ph, H, H, H, MeO, H, H, 133.5-5° (EtOH); Ph, H, H, H, F, H, H, 182.5-3° (EtOH-dioxane); Ph, H, H, H,

L19 ANSWER 245 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 217.5-18° (EtOH); H, H, H, CH₂CHCH₂NH, 222-3° (dioxane); H, H, H, NH₂, 239-41° (EtOAc-dioxane); H, H, H, CH₂CHCH₂O, 155.5-6.5° (cyclohexane); H, H, H, PhCH₂O, 167-8° (acetone); H, H, H, 4-MeOC₆H₄O, 207.5-8.5° (PhCl-EtOH); H, H, H, iso-PrO, 141.5-2°; H, H, H, Me(CH₂)₃CH(Et)CH₂O, 147-8°; H, H, H, Me(CH₂)₄CH₂O, 106-8°; H, H, H, Me(CH₂)₃O(CH₂CH₂O)₂, -; 2493-15-4F, 5-Benzoxazolecarboxylic acid, 2-(5-phenyl-2-thienyl)-, p-tolyl ester 2493-21-2F, 5-Benzoxazolecarboxanilide, 4'-chloro-2',5'-dimethoxy-2-(5-phenyl-2-thienyl)-
 RL: PREP (Preparation)
 (preparation of)

RN 2493-15-4 CAPLUS
 CN 5-Benzoxazolecarboxylic acid, 2-(5-phenyl-2-thienyl)-, p-tolyl ester (7CI, 8CI) (CA INDEX NAME)



RN 2493-21-2 CAPLUS
 CN 5-Benzoxazolecarboxanilide, 4'-chloro-2',5'-dimethoxy-2-(5-phenyl-2-thienyl)- (7CI, 8CI) (CA INDEX NAME)




L19 ANSWER 246 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Cl, H, H, 184-5° (EtOH-PhCl); Ph, H, H, H, H, H, H, 146.5-7° (EtOH); Ph, H, H, H, Me, Me, H, 173.5-4° (dioxane-EtOH); Ph, H, H, H, tert-Bu, H, tert-Bu, -; Ph, H, H, Me, tert-Bu, H, tert-Bu, 153-4° (C₆H₆-EtOH); Ph, H, H, H, Pr, H, H, 89-9.5° (EtOH); Ph, H, H, H, H, sec-Bu, -; Ph, H, H, H, (CH₂)₂CO₂Me, H, H, 109-10° (MeOH); Ph, H, H, H, (CH₂)₂CO₂H, H, H, 199-200° (EtOH); 2,5-Cl₂C₆H₃, H, H, H, Ph, H, H, 135-7° (EtOAc-EtOH); 4,2-Cl(Me)C₆H₃, H, H, Ph, H, H, 140-1° (EtOH-EtOAc); p-ClC₆H₄, H, H, H, Ph, H, H, 202-2.5° (dioxane); p-MeOC₆H₄, H, H, H, Ph, H, H, 178-9° (EtOAc-EtOH); p-tolyl, H, H, H, Ph, H, H, 179-80° (EtOAc); 3,4-Cl₂C₆H₃, Me, Me, H, Ph, H, H, 218-19° (C₆H₆-EtOH); 3,4-Cl₂C₆H₃, Me, Et, H, Ph, H, H, 124-5° (EtOH); 3,4-Cl₂-C₆H₃, Me, Ph, H, Ph, H, H, 167-7.5° (HOAc-EtOH); 4,2,6-Cl(MeO)₂C₆H₂, H, H, H, tert-Bu, H, H, 165-6° (MeCl-EtOH); 3,4-Cl₂C₆H₃, H, H, Me, H, H, 163-4° (dioxane); 2-ClOH₇, H, H, H, Ph, H, H, 216-17° (EtOAc). Also prepd. are 2-(1H-naphth [2,3-d] imidazol-2-yl)-5-phenylthiophene, 228-9° (EtOAc); 3-ethyl-2-(5-phenyl-2-thienyl)benzimidazolium

p-toluenesulfonate, m. 270-1° (HCONMe₂); 2-(6,7,8,9-tetrahydro-2-naphth-[1,2-d]oxazolyl)-5-phenylthiophene, m. 131.5-3° (EtOAc-EtOH); 2-(2-naphth [1,2-d]oxazolyl)-5-phenylthiophene, m. 151-1.5° (dioxane-EtOH); and 2-(2-benzothiazolyl)-5-phenyl-thiophene, m. 152-3° (EtOH). Polyacrylonitrile cloth (50 parts) is treated in a bath contg. H₂O 1500, 85% HCO₂H 2, and 2-(5-methyl-2-benzimidazolyl)-5-phenylthiophene 0.01 part at 85-95° for 30 min. to give a cloth which is brighter than material not treated with the thiophene compd.

IT 96586-98-0P, Ketone, p-methoxyphenyl 2-(5-phenyl-2-thienyl)-1-benzimidazolyl
 RL: PREP (Preparation)
 (preparation of)

RN 96586-98-0 CAPLUS
 CN Ketone, p-methoxyphenyl 2-(5-phenyl-2-thienyl)-1-benzimidazolyl (7CI)
 (CA INDEX NAME)




L19 ANSWER 247 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1962:67387 CAPLUS
 DOCUMENT NUMBER: 56:67387
 ORIGINAL REFERENCE NO.: 56:13047b-g
 TITLE: Red azabenzanthrone dyes. 1-Substituted 2-oxo-3-alkyl-6-alkylamino-3-azabenzanthrones
 AUTHOR(S): Simon, Myron S.; Rogers, Jean B.
 CORPORATE SOURCE: Polaroid Corp., Cambridge, MA
 SOURCE: Journal of Organic Chemistry (1961), 26, 4352-9
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB cf. CA 51, 3673b. 1-Alkoxy derivs. were prepared from N-chloroacetyl-1,4-bis(isopropyl-amino)anthraquinone (I), 1-chloro-2-oxo-3-isopropyl-6-isopropylamino-3-azabenzanthrone (II), and 1-pyridino-2-oxo-3-isopropyl-6-isopropylamino-3-azabenzanthrone chloride (III). The 1-alkoxy dyes are hydrolyzed by alkali to 1-hydroxy derivs. and are converted by NH₃ to 1-amino derivs. They are stable to concentrated HCl.
 1,4-Bis(isopropylamino)-anthraquinone (IV) was acetylated with Ac₂O and NaOAc to give 84% of the N-Ac derivative (V), m. 161-2° (PhMe-petr. ether b. 90-120°). Chloroacetylation of IV in C₆H₆ gave 76% I, m. 167-8° (alc.) V was refluxed 1/2 hr. in Me Cellosolve with KOH to give 87.5% 2-oxo-3-isopropyl-6-isopropylamino-3-azabenzanthrone (VI), m. 261-3° (alc.). Treatment of I with alkali gave different products depending on conditions. In acetone or BuOH, aqueous alkali at 60° for 3/4 hr. gave 90-100% II m. 184-6°. When the solvent was a water-miscible alc. the Cl was replaced (at 60°) by the alkoxy group of the alc. giving 1-alkoxy derivs. At 100° the 1-hydroxy derivative was formed. Thus, I heated 1/2 hr. at 60° with NaOH in EtOH gave 65% 1-EtO derivative (VII), m. 174-5°, of VI. VII was also prepared in 61% yield from II. Similarly, I and BuOH gave 79% BuO analog (VIII), m. 181-2°, of VII. I and Me Cellosolve gave 83% of the MeOCH₂CH₂O analog (IX), m. 158-9°, of VII. Spectra of VIII and IX were almost identical to that of VII. I, NaOH, and Me Cellosolve at reflux gave 97% of the 1-HO analog (X), m. 273-5° (acetone) of VII. X was also prepared in 94.5% yield from II. I was refluxed 1 hr. in Me Cellosolve


with NaNO₂ to give 41% yield of the 1-NO₂ analog (XI), m. 239-9.5°, of VII. V was refluxed with pyridine 1/2 hr. to give 76% III m. 235-5.5°. I heated 1 hr. at 125° with KCN in 90% HOCH₂CH₂OAc gave 59% of the 1-CN analog, m. 275-5.5°, of II. II treated with NH₃ and Cu in EtOH at 100° gave 22% VI. In acetone the products were 2% IV, 2% 1-amino-4-isopropylaminoanthraquinone, and 7% of the 1-NH₂ analog (XII), m. 201-2°, of II. XII was prepared in 100% yield (crude) by heating II and NH₃ in EtOH for 18 hrs. at 100°. The 1-alkoxy derivs. and pyridinium salts are unstable in alkali or NH₃. Heating HI with NaOEt for 1 hr. at 60° (in alc.) gave 7% VI and 65% VII. Refluxing III 1/2 hr. in water with Na₂S₂O₄ gave 93% VI. Refluxing III in PhNO₂ gave 54% II. XI was reduced catalytically with PtO₂ to give 76% XII. XI was refluxed 21 hrs. in alc. with KOH to give 96% (crude) X. VII refluxed 1/2 hr. with alc. NaOH gave 53.5% X. IX heated 24 hrs. at 100 with NH₃ in alc. gave 71.5% XII.

L19 ANSWER 247 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 108041-54-9P, 2-Naphth-p-anisidide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(p-phenyleneazo)]bis[3-hydroxy-(7), S,S-dioxide
 RL: PREP (Preparation)
 (preparation of)
 RN 108041-54-9 CAPLUS
 CN 2-Naphth-p-anisidide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(p-phenyleneazo)]bis[3-hydroxy-, S,S-dioxide (7CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L19 ANSWER 248 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1962:67386 CAPLUS
 DOCUMENT NUMBER: 56:67386
 ORIGINAL REFERENCE NO.: 56:130451,130461,13047a-b
 TITLE: Utilization of polystyrene residues. VI. Azoic dyes from thionessal and thionessal 1,1-dioxide
 AUTHOR(S): Fortina, Luigi; Montaudou, Giorgio
 CORPORATE SOURCE: Univ. Catania, Italy
 SOURCE: Annali di Chimica (Rome, Italy) (1961), 51, 95-9
 CODEN: ANCRAI; ISSN: 0003-4592
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB cf. CA 55, 9370E. Thionessal derivs. are prepared which are fast dyes for cotton, rayon, and nylon. 2,5-Bis(4-aminophenyl)-3,4-diphenylthiophene (I), 2-(4-aminophenyl)-3,4,5-triphenylthiophene 1,1-dioxide (II), and the 1,1-dioxide (III) of I were diazotized or tetrazotized and coupled with naphthalene derivs. [amine, coupler, m.p. (PhCl). λ_{maximum} in m μ , and log ϵ in PhNO₂ given]: I, 2-naphthol (IV), 267° (C₆H₆-EtOH), 520, 4.74; I, 2-naphthylamine, 255°, 500, 4.70; I, naphthol ACNA C (V), 324°, 572, 4.82; I, naphthol ACNA PC (VI), 239°, 570, 4.76; I, naphthol ACNA R (VII), 235° (xylene), 568, 4.76; I, naphthol ACNA F (VIII), 308°, 573, 4.78; III, IV, >330°, 537, 4.76; III, V, 275°, 565, 4.75; III, VI, 235°, 563, 4.75; III, VII, 224°, 563, 4.79; III, VIII, 254°, 565, 480; II, IV, 246°, 518, 4.45; II, V, 280°, 545, 4.53; II, VI, 246°, 543, 4.52; and II, VIII, 295°, 544, 4.52.
 IT 108041-53-8P, 2-Naphth-p-anisidide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(p-phenyleneazo)]bis[3-hydroxy-(7) 108041-54-9P, 2-Naphth-p-anisidide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(p-phenyleneazo)]bis[3-hydroxy-(7), S,S-dioxide
 RL: PREP (Preparation)
 (preparation of)
 RN 108041-53-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 248 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 108041-54-9 CAPLUS
 CN 2-Naphth-p-anisidide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(p-phenyleneazo)]bis[3-hydroxy-, S,S-dioxide (7CI) (CA INDEX NAME)

L19 ANSWER 248 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




L19 ANSWER 249 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1962:67385 CAPLUS
 DOCUMENT NUMBER: 56:67385
 ORIGINAL REFERENCE NO.: 56:13046h
 TITLE: Ink for graphic reproduction containing a wetting element
 INVENTOR(S): Boillet, Emile
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IT 599682		19591116	IT	
PRIORITY APPLN. INFO.:			CH	19571026


AB An ink is prepared, which is especially useful for offset printing, and eliminates a sep. wetting operation since it contains all necessary ingredients in a single product; i.e. a wetting agent, especially glycerol, a binder, a coloring material which is H₂O-insol., and an emulsifier. Thus, a pigment 161 is mixed with glycerol 249, linseed-oil varnish 586, and triethanolamine 4 parts.
 IT 108041-53-8
 (Derived from data in the 7th Collective Formula Index (1962-1966))
 RN 108041-53-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 4,4'-[(3,4-diphenyl-2,5-thiophenediyl)bis(4,1-phenyleneazo)]bis[3-hydroxy-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 249 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L19 ANSWER 250 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1939:11340 CAPLUS
 DOCUMENT NUMBER: 33:11340
 ORIGINAL REFERENCE NO.: 33:1724c-i,1725a
 TITLE: Highly arylated compounds. VIII. Derivatives of tetraphenylthiophene. 2
 AUTHOR(S): Diltthey, W.; Graef, Emmi
 SOURCE: Journal fuer Praktische Chemie (Leipzig) (1938), 151, 257-78
 CODEN: JPCEAO; ISSN: 0021-8383
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB cf. C. A. 33, 579.3. Tetraphenylthiophene (I) (4. g.) and 1.5 g. KNO₃ in 80 cc. AcOH, heated on a boiling water bath and treated (with shaking) with a little more than the calculated amount of H₂SO₄, give 60% of the 2-(4-nitrophenyl) derivative (II), yellow, m. 179-80°; oxidation gives p-O₂N₂C₆H₄CO₂H, thus showing the position of the NO₂ group in the Ph nucleus. The position of the nitrophenyl group in I (i. e., α or β) cannot be determined directly but is inferred from the color reaction of the sulfones of the various derivs. with MeONa in C₅H₅N. Reduction of II with SnCl₂ and gaseous HCl in AcOH gives the 2-(4-aminophenyl) derivative (III), m. 204-5°; the EtOH solution shows a blue fluorescence; concentrated H₂SO₄ gives an orange-yellow solution, changing to blue and (after 24 h.) to violet. The diazo solution from III with HClO₄ gives α-4-tetraphenylthiophenediazonium perchlorate, golden yellow. III in C₅H₅N gives an Ac derivative, m. 258°, which gives a deep orange solution in concentrated H₂SO₄; with p-MeOC₆H₄CHO III yields the α-4-anisalmino derivative of I, pale yellow, m. 201°; the halochromy in concentrated H₂SO₄ is red-yellowish brown (unstable). II in sulfoacetic acid (from Ac₂O and concentrated H₂SO₄ at 80°) with H₂O₂-Ac₂O-AcOH gives the 1-dioxo derivative (IV), golden-yellow, m. 250°; this shows an intensive violet-red halochromy with MeONa in C₅H₅N. The production of the red color is dependent upon the presence of a NO₂ and a SO₂ group in the mole. The significance of this color reaction in relation to the constitution of these derivs. is discussed at some length. With O₃ IV gives only BrOH and the p-NO₂ derivative I (5 g.) in 100 cc. AcOH, treated on a boiling water bath during 1 h. with 10 cc. HNO₃ and 10 cc. AcOH, gives a mixture of 60-5% of the α,α'-4,4'-di-NO₂ derivative (V), m. 217-18°, and from the mother liquor 13-16% of the yellow α,β-4,4'-di-NO₂ derivative (VI), m. 169-70°; oxidation gives only p-O₂N₂C₆H₄CO₂H. V is reduced by SnCl₂ to 50-5% of the di-NH₂ derivative, m. 273°; concentrated H₂SO₄ gives an orange-red color, changing quickly to pale yellow and (after 24 h.) to violet. Di-Ac derivative, m. 324-5°, di-Bz derivative, m. 320°; dianisal derivative, yellow, m. 243°. The diazo compound with β-C₁₀H₇OH gives a dark red compound, C₄₈H₃₂O₂N₄S, m. 267°; concentrated H₂SO₄ gives a dark blue color. H₂O₂ oxidizes V to the 1-dioxo derivative (VII), yellow, m. 294°; MeONa in C₅H₅N gives a red-violet color, stable to the addition of a little H₂O but precipitating VII on addition of

L19 ANSWER 250 OF 250 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 excess of H₂O; Et₂O ppts. from the C₅H₅N soln. the compd. VII.MeONa. VI
 is reduced to the α,β -4,4'-di-NH₂ deriv., m. 220°; H₂SO₄
 gives a pale yellow-orange soln., changing through pale yellow to violet
 (24 h.). 1-Dioxo deriv. of VI, m. 194°; MeONa in C₅H₅N gives a
 violet-red color. I with fuming HNO₃ at 0° yields a hexa-NO₂
 deriv., m. 284° (Fleischer, Ann. 144, 192 (1867), believed this to
 be a tetra-NO₂ deriv.). Nitration of II gives a mixt. of V and VI in
 about the same proportions as obtained from I. V with fuming HNO₃ in

AcOH
 gives a small yield of a tetra-NO₂ deriv., m. 302°. Nitration of
 the sulfone of I gives a small yield of IV. (p-O₂NC₆H₄CH₂)₂S with H₂O₂
 yields a sulfone, m. 259°; this gives a violet color with MeONa in
 C₅H₅N.

IN 860532-72-5P, Aniline, N-anisylidene-p-(3,4,5-triphenyl-2-thienyl)-

RL: PREP (Preparation)

(preparation of)

RN 860532-72-5 CAPLUS

CN Aniline, N-anisylidene-p-(3,4,5-triphenyl-2-thienyl)- (4CI) (CA INDEX
 NAME)

